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Abstract 
Pandemic influenza viruses are responsible for many deaths and much 
suffering as well as large costs accumulated through healthcare provision and 
lost productivity. The swine-origin H1N1 influenza virus that was at the root of 
the pandemic in 2009, although considered mild, in the UK alone caused the 
deaths of 361 people, subjected 1,700 to critical care and led to hospital 
admission of 7,879, before summer 2010.  This virus is now embedded in the 
human population and will remain there, inducing further mortality, morbidity, 
and cost until it is replaced by a new pandemic influenza virus and the cycle 
repeats. However, if we improve our understanding of the characteristics of 
virus/host interactions that support transmission, we may be able to identify 
potentially problematic strains, improve our preparedness and ultimately 
prevent future pandemics.   
The ability of an influenza virus to transmit from host to host is multifactorial.  
One role proven to be important because its inhibition by drugs prevents 
replication is the ability of neuraminidase (NA) to cleave sialic acid (SA). NAs 
of recently circulating influenza viruses were analysed with the aim of 
identifying characteristics that might support new or previous pandemic 
influenza virus strains. NA stalk truncation, induced by influenza virus 
transmission through gallinaceous poultry, was found to hinder transmission 
through the air of an otherwise transmissible virus. While this genetic ablation 
did not directly affect sialidase activity, when measured using a small soluble 
substrate, it did reduce the ability of virions to release complex tethered 
substrates, separate from one another and penetrate through mucus.  This 
work suggests that the next pandemic virus is unlikely to have a short stalk 
NA.  
Previously, loss of the ability of NA to haemabsorb (Hb) chicken red blood 
cells (CRBSs) was associated with the adaptation of an influenza virus from 
avian to human hosts and a single amino acid mutation was shown to 
reinstate the haemabsorption ability of an NA from a prototypic pandemic 
H2N2 virus of avian-origin.  This thesis shows that the human-adapted 2009 
pandemic N1 NA, which arose from the introduction of an avian influenza 
virus into swine, did not Hb CRBCs, as expected. However, unexpectedly, 
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many back mutations to make the 2009 N1 resemble an NA that did Hb also 
did not alter this characteristic.  Further investigations showed that some NAs 
from both avian and swine influenza viruses also did not Hb, despite the fact 
that NA haemabsorption increased viral growth in airway culture cells. Thus 
we conclude that loss of Hb occurs within birds, before a virus can cross the 
species barrier into mammals and this may be due to a reduction, rather than 
a gain, in activity.  
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1 Chapter 1: Introduction 
1.1 Historical origin, present immunity and future 
diversity of influenza viruses 
1.1.1 Evolutionary perspective on influenza viruses 
Humans suffer after infection by many RNA viruses. Interactions between 
RNA viruses and hosts are highly likely to have begun when life originated in 
the sea 4,000 million years ago (mya) (Lane, 2010). However, phylogenetic 
molecular clock analysis of RNA virus origins, which assumes that the rate of 
nucleotide substitution is about 10-3 per site per year, point to the appearance 
of RNA viruses 50,000 years ago (Holmes, 2003). The differentiation of codon 
preference between species is a further argument for viral pressure 
throughout evolution (Shackelton and Holmes, 2008). Considering the 
evolutionary timeline of mammals, which evolved about 200 mya, and birds 
which evolved about 150 mya, then their speciation into anseriformes (~60 
mya) (Clarke et al., 2005; Feduccia, 1999; Shields and Wilson, 1987) and 
homo sapiens (at least 150,000 years ago) (Mellars, 2006) we can start to 
narrow down the time-frame in which the ancestors of Orthomyxoviridae may 
have interacted with these two species.  It is likely that humans and birds 
were in close contact through shared fresh water sources and as hunter and 
prey since prehistoric times (Duncan et al., 2002). However, it should be 
noted that levels of human infection with avian influenza viruses through 
shared water seem negligible in current times (Van Kerkhove et al., 2011). As 
shown by the host specificity of MxA and NP interactions (Mänz et al., 2013; 
Mitchell et al., 2012), barriers to transmission of ancestors of 
orthomyxoviruses to hominoids were probably being selected within the 
Miocene era (23-5 million years ago). 
A measurable notch on the timeline of co-existence that marked a change in 
the frequency and mode of interaction between humans and hosts of 
ancestors of the modern day human influenza viruses was the domestication 
of animals. The definition of domestication is controversial as it is a long-term, 
multistage process (Larson and Burger, 2013). Therefore designating a time 
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of domestication is not precise, but it can help us align knowledge of viral 
evolution with increased probability of zoonoses. Dogs were domesticated 
from wolves around 13,000 BCE (Gentry et al., 2004). Pigs were 
domesticated from wild boars, which were managed by humans in Cyprus as 
early as 9,400 BCE (Vigne et al., 2009). Remains of domesticated pigs were 
found in Southwest Asia dating back to around 8,500 BCE (Conolly et al., 
2011). Chickens were domesticated from Red Junglefowl of Southern China 
and first transported North. The earliest, undisputed, domestic chicken 
remains, found in the Northern Chinese Provence Hebei, are from 5,400 BCE 
(Miao et al., 2013; Underhill, 1997; West and Zhou, 1988). Red junglefowl 
were exploited by humans in the Ganges region of India as early as 5,000 
BCE (Fuller, 2006; Lawler, 2012; Storey et al., 2012). Later, horses were 
domesticated. The earliest domestic horse was found in China to be from 
about 1,700 BCE (Jing, 2010). Compared to dogs, pigs, chickens and horses, 
ducks have a much shorter history of domestication (Liu et al., 2008). The 
earliest report of domesticated ducks was of large-scale duck farms in the 
Eastern Zhou dynasty around 514-495 BCE (Qu et al., 2009). 
Humans currently support transmission of three different types of human 
influenza virus: C, B, and A. An estimate by Suzuki and Nei suggests that the 
ancestor of influenza C virus entered the human population around 8,000 
years ago and that the ancestor of influenza B virus entered around 4,000 
years ago (Suzuki and Nei, 2002). This timeframe would mean that the 
ancestor of influenza C emerged in humans around 6,000 BCE, when 
domestication of swine was widespread and in the early days of chicken 
domestication. It also indicates that the ancestor of influenza B emerged in 
humans around 2,000 BCE, a time near the beginning of horse domestication. 
Suzuki and Nei also calculated that influenza A subtypes diverged into two 
groups 2,000 years later, around the beginning of the common era (CE). 
Furthermore, they calculated that influenza A HAs branched into four 
subtypes at some point between 270 and 800 CE. Gatherer concluded that 
the divergence of influenza A occurred a little later, between 517 and 1497 CE 
(95% CI), with four subtypes present at some point between 996 and 1781 CE 
(Gatherer, 2010, 2009). Taubenberger and Morens speculate that there could 
have been influenza A pandemics in Europe in 1293, 1323, 1357, 1386 
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(Morens and Taubenberger, 2011; Taubenberger and Morens, 2009), which 
due to their proximity in time (about 30 years apart) and haemagglutinin (HA) 
cycling requirements (see below), could indicate that those pandemics 
presented at least two different serotypes. The regularity of influenza 
pandemics is difficult to discern. Gatherer suggests that the frequency of 
pandemics increased after HA subtype divergence (Gatherer, 2010), but this 
conclusion is biased by the improved reporting of pandemics since 1500 CE. 
Influenza C, B, and A have genetically diverged away from each other so 
much that now they do not exchange genetic material (Webster et al., 1992). 
The main species that hosts influenza C and B is humans. There are some 
reports of influenza C or B in seals and swine (Guo et al., 1983; White, 2013). 
Other Othromyoviridae include ISA viruses, which are hosted by salmon and 
thogotoviruses, which are hosted by ticks and mosquitos (refs). Many animals 
support the enzootic transmission of influenza A viruses. Birds support the 
most diverse genetic pool (refs- same as reservoir below). Mammals, 
including bats, dogs, horses, pigs and humans also support a limited genetic 
pool of influenza A viruses (Forrest and Webster, 2010)(Figure 1.1). Because 
of the genetic diversity within birds and the ability to link the origins of many 
mammalian influenza virus genes to those found in birds, they are considered 
the ‘reservoir’ of influenza A viruses. Sequences from the last four pandemic 
viruses has proven that zoonosis of influenza A viruses from animals to 
humans can create viruses that cause human pandemics. 
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Figure 1.1. Zoonosis diagramme. This figure shows the transmission of various HA 
and NA subtype viruses between different hosts. Adapted from (Forrest and Webster, 
2010). 
 
The definition of “pandemic influenza” draws controversy because declaration 
of a pandemic implies a shift from ‘normal’ political activity and healthcare 
service, which occurs during periods of endemic influenza virus circulation, to 
increased activity (Doshi, 2011). The WHO recently shifted away from 
defining “pandemic influenza” to define “pandemic influenza phases”. WHO 
Phases 4, 5, and 6 can be summarised to cover what makes a virus a 
pandemic virus. Taken together they indicate that a pandemic virus is an 
animal or human-animal influenza reassortant virus that is able to 
spread from human-to-human [on a large scale]. WHO define what is 
paraphrased here as “on a large scale” more specifically as spread in 
“community-level outbreaks achieved in two or more WHO defined regions” 
(World Health Organisation, 2009). The WHO defined regions are shown in 
Figure 1.2. Noticeably, the WHO’s definition of pandemic phases has avoided 
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describing any requirements for reaching a specific level of disease severity. 
The WHO also exchanged the word “new” for “animal or human-animal 
reassortant” to describe the virus (Doshi, 2011). Although not stated discretely, 
it is understood that in order to cause “community-level outbreaks” a 
substantial percentage of people within those communities must lack pre-
existing protective immunity to the virus. Potter and Jennings state this 
requirement by concluding that one condition of a pandemic is that “there is 
significant lack of immunity in the population against the emergent virus” 
(Potter and Jennings, 2011). Inherent in these definitions is the message that 
pandemics occur when the human population lacks adaptive immunity to a 
virus that can transmit from person-to-person. 
 
 
Figure 1.2. WHO pandemic phases (A) and regions (B). Permission for reprinting 
granted by WHO.  
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1.1.2 Pandemics are different 
Pandemic influenza warrants alternative analysis compared to seasonal 
influenza for a number of reasons. Pandemic viruses can induce higher 
morbidity in the middle aged (Andreasen and Simonsen, 2011; Taubenberger 
and Morens, 2006). The unpredictability of when an influenza pandemic might 
occur and associated morbidity and mortality rates leads to difficulties in 
preparing appropriate healthcare services. Finally, pandemic influenza virus 
strains go on to become seasonal influenza virus strains that circulate within 
the human population for many years after they become established. 
Therefore, predicting the genetic make-up of future pandemic influenza 
viruses would provide extremely useful information that could be used to 
prepare for or prevent future pandemics. 
 
1.1.3 Pandemics and immunity 
1.1.3.1 Pandemic viruses have HAs that do not instigate protective 
immunity in the majority of the population 
The clearest correlate of protection from infection is the presence in serum of 
neutralising antibodies directed against the haemagglutinin (HA) protein. The 
presence of anti-H3 HA antibodies in serum collected from the elderly before 
1968 indicates that humans had previously been infected with an influenza 
virus of the H3 serotype and spurned a theory of “recycling” (Dowdle, 1999). 
The fact that both the 1918 and 2009 HA proteins were of the H1 serotype 
gives further credence to this theory. Rather than calling this theory “recycling”, 
a term that implies circular lineage from humans back into birds, the term 
“cycling” suits better, as it can imply a cycle between population immunity 
(that will wane as the population ages) and HA subtype emergence. Given the 
examples of H1 and H3, it can be concluded that the level of immunity in the 
human population dropped to low enough levels to allow a pandemic with the 
same HA subtype of a previous pandemic 79 and 91 years later, respectively. 
Co-circulation of two strains of influenza virus is a phenomenon only known to 
exist since 1977. Introduction of the 2009 H1N1 pandemic strain without 
displacing the human seasonal H3N2 strain reinforced the understanding that 
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co-circulation is the new norm. The ability of the human population to support 
two co-circulating strains might relate to population growth in numbers and 
density over the last century. It might also be because the elderly act as a 
reservoir for the older strain while the young support transmission of new 
pandemic strains. 
The strong protective activity of anti-HA antibodies present from the cycling of 
HA subtypes is likely responsible for the reduced excess death observed in 
the elderly during the 1918, 1968, 2009 and some older pandemics. During 
the 2009 pandemic, it was observed that those born before or just after 1918 
had antibodies that neutralised the 2009 pandemic H1N1 virus (Itoh et al., 
2009) and mortality data from Copenhagen clearly showed that the 2009 
pandemic did not cause excess mortality in the elderly (Andreasen and 
Simonsen, 2011). With an understanding of the link between HA cycling and 
excess death in the elderly, it can be extrapolated that, since low excess 
mortality was observed in the elderly during the 1918 pandemic 
(Taubenberger and Morens, 2006), the 1847 pandemic virus probably also 
had an H1 HA. Observations that the 1830 pandemic spared persons over 45 
could be taken to imply that the pandemic that pre-dated it by 45 years, the 
1780 pandemic, might have also had an HA of the same subtype. Decreased 
attack rates in the elderly were also reported in relationship to the 1510 and 
1693 possible pandemics, thus giving further weight to the HA subtype cycling 
hypothesis (Taubenberger and Morens, 2009). Moreover, the presence of H2 
and apparent cycling of H1 and H3 HA subtypes in past pandemic indicates 
that some HAs were better poised to cross the species barrier than others and 
that when the population’s immunity level drops humans will again be 
susceptible to the HA subtypes that have been involved in past pandemics. 
Neutralising antibodies that bind strongly to the HA receptor binding site or 
block fusion correlate with vaccine efficacy and reduced viral replication and 
disease in vivo (Chen et al., 2013; Tan et al., 2012; Wong and Webby, 2013). 
Non-neutralising antibodies including some that bind to other areas of HA are 
associated with enhanced disease. For example weakly binding antibodies 
were associated with immune complex mediated disease (Monsalvo et al., 
2010). Influenza patients who required mechanical ventilation had a higher 
ratio of titres of antibodies detected by ELISA over neutralising antibody titres 
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compared to patients with less severe disease (To et al., 2012). In swine, 
antibodies to a specific epitope in HA2, which were stimulated by vaccination, 
were shown, upon subsequent challenge with a different strain, to enhance 
viral fusion and disease (Khurana et al., 2013). In contrast, there is some 
evidence that antibodies that do not block replication still play a role in 
containing replication by binding to HA on infected cells and triggering NK cell 
driven apoptosis (Jegaskanda et al., 2013). It is not clear why non-neutralising 
antibodies reduce disease in some cases and enhance it in others, but it is 
clear that non-neutralising antibodies cannot prevent a pandemic. 
1.1.3.2 Pandemic viruses can have NAs that circulated among 
humans just before a pandemic 
Despite neuraminidase (NA) being expressed on the surface of virions and 
therefore a target for antibodies, protection due to anti-NA antibodies is more 
controversial than protection induced by anti-HA antibodies. Antibodies that 
bind NA can inhibit activity, reduce viral replication, and reduce disease 
severity, but have not yet conclusively been shown to prevent infection (Chen 
et al., 2000; Johansson et al., 1993, 1989). Therefore, lack of population 
immunity to NA is not a prerequisite for a pandemic virus. This point was 
proven by the 1968 H3N2 pandemic virus, which gained its NA gene from an 
endemic H2N2 virus circulating in the human population during the 
emergence of the 1968 pandemic strain. However, it should be noted that 
while the pandemic N2 NA was from the dominant H2N2 lineage in 1968, 
H3N2 viruses that circled the year after carried an N2 NA that had previously 
existed in only a minority of H2N2 viruses. It is likely that this was selected to 
evade host immunity to the dominant N2 NA (Lindstrom et al., 2004; 
Scholtissek et al., 1978; Webster and Laver, 1972). The NA of 1918 and 2009 
were both N1s (Smith et al., 2009b; Taubenberger et al., 1997), which 
confirms that, like HA serotypes, NA serotypes have also been cycled in the 
past. NA inhibition assays suggest that the 1889 NA was not an N2 (Webster, 
1969), but instead may have been of the N8 serotype (Fedson et al., 1972; 
Kendal et al., 1973). Therefore, past pandemics indicate that N1, N2, and 
maybe N8 NAs can each support transmission of a pandemic virus and while 
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the population must have limited immunity to the HA, the permissible level of 
immunity to NA is still debatable (Couch et al., 2013). 
1.1.3.3 Pandemic viruses are affected by T cell immunity 
Pandemics occur in the presence of population-wide T cell immunity to many 
epitopes of influenza virus proteins. While it is clear that T cell recognition of 
peptides from influenza virus proteins play a role in reducing infectivity, 
duration of viral shedding, and disease (Wilkinson et al., 2012), emergence of 
the 1957 and 1968 pandemic strains, which retained all internal genes but 
PB1 show that T cell immunity to proteins from five or six of eight genes 
cannot prevent a pandemic. Recently a vaccine that stimulates T cell 
responses to NP and M1 was shown to reduce infection and duration of viral 
shedding upon challenge (2/11 vaccinated versus 5/11 unvaccinated humans 
shed virus)(Lillie et al., 2012). Furthermore, CD8+ T cells specific for epitopes 
of pandemic influenza were shown to correlate with protection from symptoms 
post influenza virus infection (Sridhar et al., 2013).  
It is possible that natural influenza virus infection does not stimulate as strong 
a T cell response as that which could be achieved through vaccine design. 
Therefore, in the future, it may be possible to stimulate adaptive T cell 
immunity that can prevent infection. 
In summary, population-wide anti-HA neutralising immunity can prevent 
influenza viruses of the same subtype from causing pandemics. Meanwhile, 
concurrently stimulated adaptive immunity to other influenza proteins likely 
plays a role in reducing viral infectivity and disease, but does not prevent the 
reuse of genes from human seasonal viruses in new pandemic strains. 
 
1.2 Zoonoses of avian viruses within the past few 
decades 
If adaptive immunity was the only barrier that prevents influenza viruses from 
causing pandemics then all zoonotic infections by influenza viruses with an 
HA of a subtype to which humans were naïve would lead to pandemics. 
Humans have experienced known zoonoses of avian influenza viruses of HA 
subtypes H5, H6, H7, H9, and H10. Cases of H7N7 zoonosis occurred in 
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three separate countries. The first incidence, in 1980, and second, in 1995, 
clinically affected a total of four people. The third, in 2003, was a significant 
outbreak, which clinically affected 89 people in the Netherlands and led to one 
fatality. H7N2 and H7N3 viruses infected one or two individuals in five 
incidents over six years and none died. Nine people were clinically affected by 
H9N2 infection on four separate occasions and none died; the H9N2 zoonotic 
events occurred in 1998, 1999, 2003, and 2007. The first outbreak of H5N1 
was in Hong Kong in 1997: 18 people were clinically affected and six died. 
Additional outbreaks of H5N1 have occurred every year from 2003 to present 
(Katz et al., 2009; Peiris, 2009; Suarez, 2010). From 2004 through 2012 
between 32 and 115 people were clinically affected each year and the 
mortality rate has stabilised around 60% (World Health Organisation, 2012). 
Of the avian influenza viruses the H5N1 serotype seemed most likely to cause 
a pandemic, since it infected humans more regularly than the others and was 
prevalent in higher numbers than any other subtype. Furthermore, the 
possibility of an H5N1 pandemic was most frightening, since its mortality rate 
is so high. 
Serological studies indicate that human-to-human transmission of H5N1 
viruses is limited, but detectable. For example one study found that 0%, 4%, 
and 12% of social-, healthcare-, and household- contacts of index cases from 
the 1997 H5N1 outbreak were seropositive, respectively (Van Kerkhove et al., 
2012). Other limited human-to-human transmission of H5N1 viruses has also 
been documented (Aditama et al., 2012). Among patients visiting hospital in 
Vietnam, 13% were seropositive for anti-H5 HA antibodies, which is less than 
the frequency of seropositivity to H9 or H7 HAs (Boni et al., 2013). 
Viruses with H7 HAs have caused two major outbreaks and a few sporadic 
infections in humans. The first major outbreak was an H7N7 in 2003 in the 
Netherlands and the second is H7N9 and is currently underway in China. 
Sporadic zoonoses were detected in the UK, Canada, and New York. 
Although active infections have not been detected in some Asian countries, 
seroprevalence to H7 viruses is higher than it is to H5 viruses.  
During the H7N7 outbreak, virus was detected by PCR and infection was 
culture confirmed for 86 poultry workers and three close contacts of poultry 
workers. There was one fatal case. Over 87% of those confirmed to be 
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infected with H7N7 had conjunctivitis. Sample swabs were more likely to be 
positive if they were from the eye rather than the throat. Only two individuals 
who were H7 positive had influenza like illness without conjunctivitis and one 
of these was a fatal case (Fouchier et al., 2004; Koopmans et al., 2004). 
Serology collected after the outbreak showed that the virus had stimulated 
seroconversion in about 50% of poultry workers and 64% of family and friends 
exposed to infected poultry workers (Fouchier et al., 2004; Koopmans et al., 
2004; Meijer et al., 2006). It is possible that out of all the close contacts that 
seroconverted, more than the three detected shed virus, but the outbreak did 
not lead to sustained human transmission and died out within a few months. 
Therefore, it can be concluded that the human-to-human transmission events 
did not lead to selection of a virus with an Ro>1.    
Other incursions of H7 into humans have resulted in only a handful of cases. 
One individual with conjunctivitis was found to have an H7 virus infection in 
the UK and others in Canada (Belser et al., 2008; Nguyen-Van-Tam et al., 
2006). Another H7 virus was isolated from a man in NY (NY107) who had 
respiratory disease without any record of conjunctivitis (Belser et al., 2008). 
These were all isolated cases.  
The H7N9 virus has infected over 100 people in China this year (2013) (Gao 
et al., 2013). Serology samples collected between 2010 and 2012 revealed 
that 19% of people who attended a main hospital in two main cities in Vietnam 
for unreported reasons had antibodies that specifically bound to the HA of the 
2003 outbreak in the Netherlands (Boni et al., 2013) implying that an H7 virus 
may have zoonosed undetected in this region. On the other hand, the 
exposure of poultry workers in Italy to H7 viruses was much lower despite 
many outbreaks in their poultry, only 3.8% were seropositive in 2003 (Puzelli 
et al., 2005).  
In comparison to H7 and H5 HA antibodies, serology against H9 HAs is 
highest among hospital patients in Vietnam with 23% showing anti-H9 HA 
specific antibodies (Boni et al., 2013) suggesting that this subtype is more 
likely to zoonose than the others. 
Reports of seroprevalence and limited outbreaks show that in many cases 
host range barriers prevent currently circulating avian influenza viruses from 
infecting humans and when they do not block infection they do prevent 
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efficient human-to-human spread and thus pandemics. Therefore, it is 
pertinent that we identify the barriers that prevent viruses with HAs of these 
subtypes from transmitting among humans. 
Putting aside adaptive immunity, other host range barriers can be divided into 
two categories: physiological barriers and innate immunity. The barriers that 
influenza viruses must overcome to replicate and transmit are numerous and 
complex. When one barrier is overcome by a virus’ ability to use an alternative 
pathway, it is likely another barrier will still block transmission. The 
accumulation of abilities to overcome many physiological and innate immune 
barriers allows an influenza virus to cause a pandemic. The diversity of 
influenza A viruses within the avian virus reservoir inevitably means that 
different viruses may use different mechanisms to overcome or evade host 
barriers.  
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1.3 Influenza virology 
1.3.1 Influenza virus genome, structure, and morphology 
1.3.1.1 The genome 
The influenza A virus genome is encoded in negative sense by eight 
segments of single stranded RNA (ssRNA). It contains about 13,000 
nucleotides of coding sequence and can encode up to 17 known proteins 
(Wise et al., 2012). The most common length of coding sequence for each of 
the eight segments and the size of the proteins that they encode are shown in 
Table 1.1. Over half of the proteins are incorporated into virions.  
1.3.1.2 Virion structure 
1.3.1.2.1  Membrane associated proteins 
Haemagglutinin (HA), Neuraminidase (NA), and Matrix 2 (M2) are the three 
integral membrane viral proteins that have surface exposed domains (Figure 
1.3). HA and NA are glycosylated and although M2 contains a potential 
glycosylation site, evidence indicates that it is not glycosylated (Zebedee et al., 
1985). There are about 300 HA trimers on a spherical virion and about 50 NA 
tetramers, so for each NA tetramer on the surface there are 6 or 7 HA trimers 
(Harris et al., 2006; Inglis et al., 1976). M2 tetramers are less abundant on a 
spherical virion (Noda and Kawaoka, 2010) about 12 ± 34(SD) (personal 
communication with Edward Hutchinson). (Concentrations of HA, NA, and M2 
in the cellular membrane are covered in Leser and Lamb, 2005.) The outer tip 
of HA spikes on virions of the human influenza virus A/Aichi/68 are about 14 
Angstroms from the membrane surface, while the outer tip of NA spikes are 
about 16 Angstroms (Harris et al., 2006). Therefore, on the viral and cellular 
surface, NA is normally about 2 Angstroms taller than HA. Matrix protein 1 
(M1) binds to the cytoplasmic tails of the glycoproteins and forms a sheet that, 
bar a few gaps, covers the inside of the membrane (Harris et al., 2006).  
1.3.1.2.2 vRNP 
Viral RNA (vRNA) is stored inside the virion encased in viral proteins. Each of 
the eight vRNA gene segments have a central open reading frame, flanked by 
an untranslated region (UTR) at each end that are between 19 and 58 
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nucleotides (nts) long (Fournier et al., 2012). At the 3’ distal end of each UTR 
there are 12 nts and at the 5’ distal end there are 13 nts that are highly 
conserved and specific relative to their gene segment (Desselberger et al., 
1980; Fournier et al., 2012). These sequences contain the promoter elements, 
which initiate transcription and replication. The promoter elements are also 
partially complementary in a way that instigates RNA-RNA interactions (Hsu 
et al., 1987). Two conformations for the RNA secondary structure have been 
proposed, a “panhandle” and a “corkscrew”. The corkscrew configuration has 
been shown to relate more closely to levels of promoter activity than a 
panhandle configuration (Flick et al., 1996; Neumann et al., 2004). The rest of 
the RNA forms a twisted rod-like structure with inter-linked NP along its length 
and a hairpin loop at the opposite end (Coloma et al., 2009; Hsu et al., 1987). 
Each vRNA gene segment has a heterotrimeric viral RNA dependent RNA 
polymerase complex (RdRp, vPol or 3P), which includes polymerase basic 1 
(PB1), polymerase basic 2 (PB2), and polymerase acidic (PA) proteins bound 
to the 5’ and 3’ ends of vRNA. Each vRNA is also bound by nucleoprotein 
(NP), together the whole complex is called viral ribonucleoprotein (vRNP) 
(Figure 1.3) (Arranz et al., 2012; Martín-Benito and Ortín, 2013; Moeller et al., 
2012).  
1.3.1.3 Virion morphology 
Virions usually assume one of two morphologies, either spherical with a 
diameter of about 100nm or filamentous, which can be hundreds of nm longer 
(Reviewed by Rossman and Lamb, (2011)). 
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Gene 
Segment 
Gene 
Nucleotide 
Length 
(including 
ncrs) 
Nucleotide 
Coding 
Sequence 
length 
(excludes 
ncrs) 
Protein 
Protein 
length 
(aa) 
1 PB2 2,341 2,280 Polybasic protein 2 (PB2) 759 
2 PB1 2,341 2,274 
Polybasic protein 1 
(PB1) 757 
PB1-F2 87 
PB1-N40 718 
3 PA 2,233 2,151 
Polyacidic Protein 
(PA) 716 
PA-N155 (11th AUG) 562 
PA-N182 (13th AUG) 535 
PAX 252 
4 HA 1,760 1,659 Haemagglutinin (HA) 552 
5 NP 1,565 1,494 Nucleocapsid Protein (NP) 497 
6 NA 1,466 1,341 Neuraminidase (NA) 446 
7 M 1,027 982 
Matrix Protein 1 (M1) 252 
M2 Matrix Protein 2 
(M2) 97 
M42 splice variant 99 
8 NS 890 823 
Non Structural 
Protein 1 (NS1) 230 
Nuclear Export 
Protein (NS2 or NEP) 121 
Total   13,004   
Table 1.1. Influenza virus genes and proteins.  
Nucleotide lengths from (Fournier et al., 2012). 
CDS lengths from Influenza Research Database (Squires et al., 2012) or PB1-N40 
(Wise et al., 2009), PA-N155 and PA-N182 (Muramoto et al., 2013), M42 (Wise et al., 
2012). 
Ncrs = non coding regions 
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1.3.2 Influenza virus replication cycle 
1.3.2.1 Receptor binding, endocytosis and fusion 
 Human seasonal and pandemic influenza viruses primarily infect and 
replicate in human respiratory epithelial cells in vivo and ex vivo (Guarner et 
al., 2006; Shieh et al., 2010; van Doremalen et al., 2011; Yu et al., 2011). 
Infection of macaques, ferrets, mice, and swine with swine, human seasonal 
or pandemic viruses and detection of them in the respiratory tract confirms 
that influenza viruses target the respiratory epithelium in mammals (Itoh et al., 
2009; Van Poucke et al., 2010).  
The HA protein binds to terminal SA on N-linked glycans attached to cell 
surface proteins (Chu and Whittaker, 2004). Virions are internalised into 
endosomes by endocytosis, for spherical influenza virions this is mainly 
clatherin-mediated. Clatherin-coated pit formation begins about three minutes 
after a virus binds to a cell. The clatherin-coat on a vesicle persists for about 
one minute then the clatherin disassembles, leaving an uncoated vesicle. 
About one third of spherical virions are concurrently endocytosed by a 
clatherin-independent, caveolin-indepentent pathway, which is likely 
macropinocytosis, since it is the main endocytic pathway for filamentous 
virions (Rossman et al., 2012). Influenza carrying endosomes move in three 
stages. They first move slowly along actin in the cell periphery, then quickly 
along microtubules from the cell periphery to the perinuclear region, then they 
have intermittent bi-direction movement along microtubules near the nucleus 
(Lakadamyali et al., 2003). The acidification of influenza virus infected 
endosomes to pH 6 occurs about 30 seconds after the endosome arrives in 
the perinuclear region. The M2 protein channels protons into the virion, which 
leads to the disassociation of vRNP complexes from M1 (Helenius, 1992). 
Fusion of the viral and host endosomal membranes occurs significantly later, 
presumably in the late endosomes, which are closer to pH 5. HA 
conformational change and fusion of viruses from different hosts are triggered 
at a slightly different, but always low pH (Galloway et al., 2013; Reed et al., 
2010; Stegmann et al., 1990). Fusion within late endosomes of MDCK and 
CHO cells was found to occur about 10 minutes post infection (Lakadamyali 
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et al., 2003; Schmid et al., 1989; Yoshimura and Ohnishi, 1984). Rab proteins, 
in particular Rab5, Rab7, and Rab10 play important roles in influenza virus 
trafficking from the early through to the late endosomes (Brass et al., 2009; 
Hao et al., 2008). (The above steps in endocytosis, vesicle trafficking and 
fusion are reviewed in Lakadamyali et al. (2004).) 
1.3.2.2 Nuclear import of vRNP 
The nuclear pore complex (NPC) acts as a gatekeeper for the nucleus. Since 
influenza viruses replicate in the nucleus many proteins (specifically PB2, PB1, 
PA, NP, M1, NS1 and NS2/NEP) have nuclear localisation signals (NLSs) and 
have been shown to interact with nuclear import machinery. vRNP complexes, 
which are 10-15 nm wide and 30-120 nm long, are actively transported into 
the nucleus through nuclear pores (Reviewed by Hutchinson and Fodor, 
2012). However, there is still much to be determined as to which NLSs are 
important for vRNP import versus import of viral proteins in the absence of 
vRNA. Interestingly, vRNPs remain co-localised until they are on the inside of 
the nucleus, indicating that all eight segments arrive at the nuclear pore 
together (Chou et al., 2013). Subunits of importin-α have been shown to bind 
to nuclear localisation sequences of influenza virus proteins: importin-a1/a2 
binds NP (O’Neill et al., 1995; Wang et al., 1997); importin-5 (RanBP5) binds 
PB1-PA dimers (Deng et al., 2006); and the importin-a1/importin-a5 
heterodimer binds PB2 (Gabriel et al., 2008; Resa-Infante et al., 2008; 
Tarendeau et al., 2008, 2007). Importin-α, in complex with vRNP, then binds 
importin-β and all are transported through the nuclear pore complex. Other 
nuclear pore complex proteins that, through RNAi screens, were deemed 
important in flu replication include Nup98, Nup153 and the KPNβ1 subunit of 
importin (Watanabe et al., 2010). Nuclear import is a host range determinant 
(Resa-Infante and Gabriel, 2013). 
1.3.2.3 Transcription (vRNA !  mRNA) 
The viral RdRp that is bound to the promoter of each vRNA segment in 
influenza virions can synthesize viral mRNA in vitro in the absence of cells if 
given an mRNA primer and nucleotides (Vreede and Brownlee, 2007). The 
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sequence of both the 3’ and 5’ ends of vRNA are important for transcription 
(Fodor et al., 1994).  
Transcription of host mRNA and viral RNA both occur in the nucleoplasm (not 
in the nucleoli) in insoluble fractions called ‘nuclear cages’ (Jackson et al., 
1982, 1981; López-Turiso et al., 1990). Eukaryotic transcription of mRNA is 
performed by RNA polymerase II (Pol II) (Lee and Young, 2000). The c-
terminal domain (CTD) of the largest subunit of Pol II consists of 52 repeats of 
7 aas with the consensus sequence YSPTSPS and a short C-terminal 
extension. The repeats can be extensively and differentially phosphorylated. 
Phosphorylation status serves as a marker for the stage of transcription. 
Initiation of transcription leads to phosphorylation of Serine 5 of the CTD 
repeats. The viral polymerase interacts with host Pol II when the fifth serines 
of Pol II’s CTD repeats are phosphorylated. This particular phosphorylation 
occurs after host mRNA transcription has been initiated, thus it indicates the 
presence of 5’capped mRNA (Engelhardt and Fodor, 2006; Patturajan, 1998). 
Inhibition of Pol II inhibits viral transcription (Mark et al., 1979). Interestingly, 
influenza viruses prefer to attach to cells in G1-phase, likely because cells in 
this phase express more SA (Ueda et al., 2013). During G1-phase cellular 
contents (excluding chromosomes) are duplicated, presumably leading to a 
plentiful supply of capped mRNA primers. Binding of vPol to Pol II leads to 
ubiquitylation of Pol II and its degredation (Vreede and Fodor, 2010; Vreede 
et al., 2010). This indicates that capped primers would only be available for a 
short period post infection. 
A primer that is a short segment of mRNA initiates viral mRNA transcription. 
The primer has a 7-methylated guanine nucleotide connected to its 5’ end by 
a 5’ to 5’ triphosphate linkage that is ‘snatched’ from host pre-mRNA. The 5’ 
cap mRNA primer is bound by PB2 and two aromatic residues (Phe-357 & 
Phe-404) are essential for the binding (Fechter et al., 2003). PB2 only binds 
the 5’ cap when PB1 is bound to the 5’ end of vRNA (Cianci et al., 1995). PA 
is responsible for the endonuclease activity that cleaves the host mRNA and 
this only occurs when PB1 is bound to both the 5’ and the 3’ ends of vRNA 
(Cianci et al., 1995; Hagen et al., 1994). The mRNA cap can be as short at 7 
nt and as long as 15nts and most often ends in an A (Beaton and Krug, 1981; 
Ulmanen et al., 1981). The endonuclease activity is in the N-terminus of PA. 
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Single aa mutations in PA can knock out endonuclease activity and thus 
mRNA production while maintaining vRNA synthesis activity in a polymerase 
assay. Endonuclease activity is enhanced by bivalent metal ions, including 
Mn2+, Co2+ or Mg2+ (Dias et al., 2009; Doan et al., 1999; Yuan et al., 2009). A 
2’-O-methyl on the penultimate base of the mRNA primer seems important for 
PB2 binding and likely aids in nuclear export of mRNA (Bouloy et al., 1980; 
Krug et al., 1976; York and Fodor, 2013). PB2 remains bound to the cap for 
about 11-15 nt of viral mRNA growth, then it disassociates (Braam et al., 
1983). The cap ensures that viral mRNA is exported from the nucleus, 
protected from degradation and translated as though it were host mRNA 
(Kapp and Lorsch, 2004). The N-terminus of PA clamps around a short and 
highly conserved sequence of the C-terminus of PB1 (González et al., 1996; 
He et al., 2008; Obayashi et al., 2008; Perez and Donis, 2001). The N-
terminus of PB2 binds to the C-terminus of PB1, the middle binds the 5’ cap 
and the C-terminus has a RNA binding domain followed by a NLS domain 
(Kuzuhara et al., 2009; Resa-Infante et al., 2011). The RNA binding domain of 
PB2 contains residue 627, which is a strong host determinate (Subbarao et al., 
1993).   
PB1 binds vRNA, stimulates cap binding and cleavage and holds the enzyme 
activity responsible for elongation of mRNA, as well as cRNA and vRNA. 
Except for the N- and C-termini, PB1 has not been crystalised, but the central 
location of the elongation domain is predicted from the presence of a 
conserved S-D-D motif, which is characteristic of segmented negative-strand 
RNA-dependent polymerases (Biswas and Nayak, 1994; Müller et al., 1994; 
Poch et al., 1989). Interaction between PB1 and PB2 is essential for 
nucleotide polymerization (Poole et al., 2007). PB1 extends viral mRNA from 
the 5’ capped host mRNA primer through the 3’ poly-adenine (polyA) tail 
(Biswas and Nayak, 1994; Robertson et al., 1981; Ulmanen et al., 1981). 
Transcription of vRNA to make mRNA starts with the addition of a guanine (G) 
nt that pairs with the second nt of vRNA, which is a cytosine (C) for all vRNA 
segments (Beaton and Krug, 1981). Despite not having a polyA tail, the 3’ end 
and other sections of vRNA must avoid degradation during transcription for a 
successful infection (Houseley and Tollervey, 2009). According to a model 
proposed by Moeller et al. this could be because an NP protein that sits above 
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the 3P might protect the 3’ end or sterically hinder other proteins from entering 
the area during the beginning of elongation. Their model suggests that, after 
an unknown number of nucleotides are added, the 3’ end loops back around 
and becomes re-attached to PB1. As the vRNA is unwound and re-wound, 
NPs detach from the vRNA before it is read and reattach after it has been 
read. This model proposes a way that allows very little vRNA to become 
exposed during transcription (Moeller et al., Science, 2012). 
Elongation ends at the a string of 5-7 uridines (U) about 17-22 nts from the 5’ 
end of each vRNA and these are transcribed to make the polyA tail of viral 
mRNA (Robertson et al., 1981). The 5’ end of the vRNA template is proposed 
to remain associated with the viral polymerase throughout transcription (Tiley 
et al., 1994). Binding of the 5’ end and base-pairing of the 3’ and 5’ ends of 
vRNA is important for both transcription initiation and polyadenylation. This 
requirement led to the proposal of a stuttering mechanism for elongation of 
the polyA tail (Luo et al., 1991; Poon et al., 1998). Interestingly, the splicing 
factor SFPQ/PSF was found to increase the efficiency of viral mRNA 
polyadenylation (Landeras-Bueno et al., 2011).  
In vitro, in MDCK cells, synthesis of mRNA occurs within the first few hours 
post infection. The quantity of viral mRNA reaches a maximum by 2.5 hpi and 
declines to 5% of the maximum by 4.5 hpi. Once synthesized, viral mRNA can 
continue to be translated. Therefore, synthesis of viral proteins is not affected 
by the reduction of mRNA synthesis between 3 and 5 hpi (Shapiro et al., 
1987). 
 
1.3.2.4 Splicing of mRNA 
Transcription, splicing and mRNA export are all coupled (Reed, 2003). Both 
full length and spiced variants of influenza viral mRNA exist for segments 7 
and 8. Two important influenza proteins, M2 and NS2/NEP, are translated 
from spliced mRNA (Inglis and Brown, 1981; Lamb et al., 1980; Selman et al., 
2012; Shih et al., 1998). Splicing of viral mRNA is performed by host cellular 
machinery. Splicing factors (including UAP56, PTBP1, NHP2L1, SNRP70, 
SF3B1, SF3A1, P14, and PRPF8) have been shown to be important for 
influenza virus replication (Reviewed by Watanabe et al., 2010). Splicing of 
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viral mRNAs is regulated by viral proteins and RNA (Garaigorta and Ortín, 
2007; Lamb and Horvath, 1991; Robb and Fodor, 2012; Robb et al., 2010). 
For example, NS1, through an interaction with NS1-binding protein and 
hnRNP K, regulates the amount of M2 mRNA produced (Tsai et al., 2013). 
NS2/NEP accumulation is timed by the inefficient production of spliced 
segment 8 mRNA (Chua et al., 2013).  
1.3.2.5 Export of mRNA from nucleus to cytoplasm 
The role of host factors in nuclear export is well studied. Most (95%) of host 
mRNAs are spliced and 5% of mRNAs are intronless (Shabalina et al., 2010). 
Currently, five types of mRNA have been identified and the mechanisms of 
five nuclear export pathways are becoming more detailed. Mature host mRNA 
that has had its introns spliced can exist as long or longer units. Meanwhile 
intronless mRNA exists in either long (<200nts) or short (<200nts) forms and 
the long form can further be characterised as a histone transcript.  
Factors involved in nuclear export of spliced and unspliced mRNAs have been 
identified. Spliced mRNA that is not too long is exported through the nuclear 
pore, while longer spliced mRNA is exported from the nucleus through 
budding of the nuclear envelope. Export of spliced host mRNA is via a 
heterodimeric export receptor (Reed and Hurt, 2002). Factors known to be 
involved in nuclear pore trafficking of spliced mRNAs include CBC, the exon 
junction complex (EJC), SR-proeins, UAP56-interacting factor (UIF), the 
TRanscription EXport complexes (TREX) 1 or 2, Cleavage and 
Polyadenylation Specficity Factor 6 (CPSF6), PolyA Binding Protein 2 
(PABP2) and Nuclear eXport Factor 1 (NXF1). RNA binding proteins and their 
adaptors recruit NXF1. It then chaperones the mRNP through the nuclear 
pore (Müller-McNicoll and Neugebauer, 2013). Less is known about nuclear 
export of intronless mRNA. Long intronless mRNA has a polyA tail and export 
is via the alternative pathway which still utilizes CBC, TREX1 and NXF1, but 
not splice-related factors. 9G8 and SRp20 proteins, which are members of the 
SR (serine/arginine-rich) family, which is normally associated with splicing, 
have been shown to promote export of intronless cellular mRNAs by directly 
interacting with NXF1 (Huang et al., 2003). Short intronless mRNA is exported 
via the CBC, PHosphorylated Adaptor for RNA eXport (PHAX), CRM1 and 
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RAN pathway, which is utilised by small nuclear RNA. For histone mRNA, the 
Negative ELongation Factor (NELF) binds to CBC of the mRNA of histone 
transcripts and recruits Stem-Loop Binding Protein (SLBP), which binds to a 
stem-loop at the 3’ end of the mRNA. SLBP both prevents polyadenylation 
and aids nuclear export (Müller-McNicoll and Neugebauer, 2013). Although 
adaptor proteins that recruit TREX and NXF1 to host intronless mRNAs have 
not been identified, specific sequences within intronless mRNA, which are 
important for polyadenylation and nuclear export, have been identified 
(Grzybowska, 2012; Guang and Mertz, 2005; Huang and Carmichael, 1997; 
Kimura et al., 2004; Lei et al., 2013, 2011). Interestingly, due to the lack of 
binding to the exon junction complex, human intronless mRNA transcripts 
seem to be insensitive to nonsense mediated decay (Brocke et al., 2002; 
Maquat and Li, 2001). 
Some viruses encode proteins that assist in nuclear export of their mRNA. For 
example HIV Rev binds to the host protein Rev Responsive Element, which 
induces binding of unspliced or partially spliced viral mRNA by CRM1 and 
RanGTP (Yarbrough et al., Traffic, 2013). When not bound to RNA, the N-
terminus of NP interacts with UAP56 (a component of the mRNA export 
complex TREX1)(Momose et al., 2001). Therefore, NP could play a role in 
influenza mRNA nuclear export. 
Different mRNA segments of influenza viruses are exported via different 
routes. Influenza mRNA fall into three categories, intronless (3PNP, HA, NA), 
intron containing, but unspliced (M1 and NS1) and spliced (M2 and NEP). 
Host factors that play a role in mRNA expression and thus likely nuclear 
export of specific influenza mRNAs have been identified. Influenza virus NA, 
M1 and M2 mRNAs are exported from the nucleus via a CRM-1 independent 
pathway. Viral NA, M1 and M2 mRNA co-localised with host NXF1 (aka TAP) 
and the mRNAs were co-immunoprecipitated in an anti-NXF1 pull down (W. 
Wang et al., 2008). Influenza NA and NP mRNA co-immunopreciptated with 
the 20 kDa subunit of CBC (NCBP2) and Ref/Aly (another part of the TREX1 
complex)(Bier et al., 2011). NXF1 knockdown by RNAi reduced expression of 
the M2 protein the most (to less than 10%), compared to other influenza virus 
proteins. HA, M1, NS1 and NS2 expression were also significantly reduced (to 
around 20%) with knockdown of NXF1. In the same assay expression of PB2 
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and NP were not significantly altered. A similar pattern was detected when 
UAP56 was knocked down, except that NS2 was not as affected as with 
knockdown of NXF1. Knockdown of Aly left expression of most proteins tested 
unaffected except for M2, which was knocked down by about 50% (Read & 
Digard, JGV, 2010). Interestingly, the interaction of viral mRNAs with NXF1 
can be inhibited by the omega-3 fatty acid derived lipid mediator Protectin D1 
(PD1) (Morita et al., 2013). NFX1 binds Nucleoporins (Nups) that contain FG 
(phenylalanine-glycine) repeats (Hoelz et al., 2011). Knockdown of FG-Nup62, 
but not FG-Nup98 or FG-Nup214, reduced cytosolic expression of NP mRNA 
(Morita et al., 2013). The 3’ exon of M2 is bound by splice factors SF2/ASF, 
which regulate M2 expression (Shih and Krug, 1996). As technology improves, 
the exact location along the mRNA processing pathway of these interactions 
will become clearer. 
 
1.3.2.6 Translation 
Specific host factors are involved in translation of influenza virus mRNAs. 
Elongation Initiation Factor 4E (eIF4E) was co-immunoprecipitated with both 
NP and NA mRNAs (Bier et al., 2011). eIF4E recruits ribosomes that 
transcribe both host and viral mRNA to make proteins. Nuclear export factors 
will dictate location of translation and thus subsequent processing. 
 
1.3.2.7 Post translational modification of influenza virus proteins 
Influenza virus proteins are processed through cellular activities according to 
their sequence and structure. Glycosylation of HA and NA are covered in the 
discussion (Section 6.4.3.2). HA and M2 are palmitoylated (s-acylated). The 
S-acylation of HA is important for fusion and association with lipid rafts. The 
importance of S-acylation for M2 is more elusive, but virus lacking the M2 S-
acylation site are attenuated in mice (Grantham et al., 2009)(Reviewed by 
Veit et al., 2013). 
Bioinformatics has led to the identification of sequences that indicate 
posttranslational modifications. All influenza virus proteins are predicted to 
have putative phosphorylation sites (Hutchinson et al., 2012). Phosphorylation 
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likely regulates their activities. For example, at early time points post infection, 
phosphorylated M1 activates antiapototic genes (Halder et al., 2013). 
Influenza virus HA has a predicted Y-sulfation site at residue 105 (H3 
numbering) and the surrounding sequence is more conserved than the 
average for aas of HA (Lin et al., 2003). PB2 of an H9N2 from 2004 is 
predicted to have a N-myristoylation domain. A myristoyl group is a lipid chain 
that allows a protein to bind to membranes in a non-permanent fashion. The 
binding domain is indicated by the sequence GGvrTV, which was found at 
residues 290-295 of the H9N2 PB2 (Danishuddin and Khan, 2008). 
USP11, a ubiquitinating enzyme, can inhibit influenza virus replication. It 
interacts with PB2, PA, and NP of vRNP, specifically it ubiquitinates residue 
K184 on NP (Liao et al., 2010) Sumoylation is the conjugation of a small 
ubiquitin-like modifier (SUMO) to a protein (reviewed in Flotho and Melchior, 
2013). NS1, M1, NP, PB1 and NEP are targets for sumoylation and all but 
NEP have been shown to become sumoylated post infection (Pal et al., 2011, 
2010). NS1 interacts with Ubc9, a conjugating enzyme, and SUMO1, 2 and 3. 
NS1 is sumoylated on residues K70, K219 and K221. Sumoylation may 
enhance NS1 stability in cell culture and/or affect its ability to regulate IFN 
(Santos et al., 2013; Xu et al., 2011). M1 is sumoylated at residue K242. 
Mutation of this residue abrogated binding between M1 and vRNP, thus 
leading to build-up of vRNP in the nucleus and reduced numbers of viable 
virions (Wu et al., 2011).  
 
1.3.2.8 Trafficking of influenza virus proteins and their interactions 
with each other 
Nuclear import of influenza virus proteins (PB1, PB2, PA, NP, NS1, NEP, M1) 
has been reviewed by (Boulo et al., 2007) and (Hutchinson and Fodor, 2012). 
As mentioned above in nuclear import (Section 1.3.2.2), many influenza virus 
proteins have NLSs. Newly synthesized polymerase subunits are transcribed 
in the cytoplasm then transported into the nucleus (Huet et al., 2010). The C-
terminal region of PA binds a short N-terminal peptide of PB1 in a manner that 
has been described as like ‘the jaws of a dragon’ (González et al., 1996; He et 
al., 2008; Obayashi et al., 2008; Perez and Donis, 2001). PB1 has a bipartite 
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NLS between residues 180-252 (Nath & Nayak, Molec Cell Biol, 1990). 
Interaction with RanBP5 (a member of the importin-β family) is important for 
nuclear import of PB1 and the sequence involved in the interaction is 
conserved between viruses isolated from different host species (Deng et al., 
2006; Hutchinson et al., 2011). PA has two NLS regions (Nieto et al., 1994). 
Due to the clenched jaw interaction between PB1 and PA, they are thought to 
import into the nucleus as a dimer, but when expressed alone each imports 
into the nucleus.  
PB2 is imported into the nucleus separately (Huet et al., 2010). The C-
terminus of PB2 (aas 678-759), which is adjacent to the 627-domain, has a 
nuclear localization signal that binds to importin-α. PB2 has been co-
crystalised with importin-a5 (Resa-Infante et al., 2008; Tarendeau et al., 2008, 
2007). Importins are host range and cell tropism determinants (Gabriel et al., 
2011; Resa-Infante and Gabriel, 2013). Humanised PB2-627K uses importin-
α1 & α7 (Hudjetz and Gabriel, 2012) whereas, avian PB2-627E did not bind 
human importins very well (Resa-Infante et al., 2008). Hsp90 and CCT also 
play a role in nuclear import of PB2 (Fislová et al., 2010; Naito et al., 2007b). 
Once inside the nucleus PB2 binds to the other polymerase proteins. An 
interaction between PA N-term 100 aas and PB2 was detected in both the 
cytoplasm and nucleus by bimolecular fluorescence complementation post 
transfection (Hemerka et al., 2009). The first 86 aas of the PB1 C-terminus 
interacts with the last 37 aas of the N-terminus of PB2 as a bunch of α-helices 
(Poole et al., 2007). The interacting α-helical domains are conserved through 
all avian and human influenza virus strains (Sugiyama et al., 2009).  
NP is also imported into the nucleus via a NLS and interaction with importin-α 
(Cros et al., 2005; Gabriel et al., 2008). The NP crystal structure shows a 
head domain, a body domain and a tail loop/linker region (Ng et al., 2008; Ye 
et al., 2012). Insertion of NP “tail-loop” into body of another NP is crucial for 
oligomerisation (Chan et al., 2010). Phosphorylation sites on and near the tail-
loop region of NP (Hutchinson et al., 2012) indicate oligomerisation may be 
highly regulated (Fodor, 2013). NP binds to vRNA and cRNA with high affinity, 
but not sequence specificity (Yamanaka et al., 1990). NP is likely incorporated 
into vRNPs as dimers (Ortega et al., 2000). NP makes direct contact with 
polymerase proteins. Biochemistry and EM methods indicate interactions 
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between NP and PB1 and/or PB2. There are 3 aas (R204, W207, R208) in 
the head region of NP that are required for its interaction with vPol and for 
vRNA synthesis (Biswas et al., 1998; Coloma et al., 2009; Marklund et al., 
2012; Poole et al., 2004). The interaction between 3P and NP seems to 
involve a host factor, since binding of avian 3P to avian NP is impaired in 
human cells (Rameix-Welti et al., 2009). UAP56 and Tat-SF1 act as 
chaperones for NP (Momose et al., 2001; Naito et al., 2007a).  
M1, NEP, and NS1 also play important roles in the nucleus and have NLSs. 
The NLS of M1 is aas 101-105 which encode the sequence RKLKR (Ye et al., 
1995). A NLS for NEP has not been identified. NEP residue W78 with nearby 
E residues interact with the NLS of M1 for nuclear export (Akarsu et al., 2003). 
Two NLSs of NS1 exist at positions 34-38 and 216-221 (Greenspan et al., 
1988)(Reviewed in Boulo et al., 2007). 
The influenza virus transmembrane proteins M2, NA, and HA are trafficked 
from the ER through the golgi to the plasma membrane in vesicles. M2 
trafficking is highly dependent upon Rab11a/b (Rossman et al., 2010b). HA is 
stabilised by M2, which maintains a higher than normal pH in the late Golgi, 
thus preventing premature HA conformational change during trafficking to the 
plasma membrane (Harvey et al., 2004; Ohuchi et al., 1994; Takeuchi and 
Lamb, 1994). Aas in the transmembrane domain of HA are important for 
targeting it to the apical plasma membrane (Lin et al., 1998). Tsg101 is also 
important for trafficking of HA to plasma membrane and it is regulated by IFN 
(Sanyal et al., 2013). Sphingomyelin is essential for transportation of HA and 
NA from the trans-golgi to the cell surface (Tafesse et al., 2013). 
1.3.2.9 Synthesis of cRNA and vRNA 
Synthesis of cRNA is initiated by polymerase binding to GTP as directed by 
the second nucleotide from the 3’ end of vRNA, which is a cytosine. It then 
either makes a phosphodiester bond with ATP (Vreede et al., 2008) or a host-
specific ribonucleotidyltransferase (such as polyA polymerase) adds an 
adenine to the first nt position of cRNA (Zhang et al., 2010). Vreede et al. 
showed that cRNA could be produced from purified vRNPs, therefore, they 
suggested that cRNA was synthesized by the attached polymerase. However, 
since they found that cRNA could only be detected in a cell in the presence of 
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the three polymerase proteins and NP, they suggested that cRNA was 
degraded in the absence of protection by its coating proteins. The attached 
polymerase is commonly referred to as the “cis-polymerase” (Vreede and 
Brownlee, 2007; Vreede et al., 2004; York et al., 2013). Residues in the C-
terminal region of PB1 bind vRNA and residues in the central region bind 
cRNA. cRNA and vRNA compete for binding to the N-terminal region of PB1 
(González and Ortín, 1999). 
Synthesis of vRNA is initiated with synthesis of AG at nt positions 4 and 5 on 
cRNA after that the polymerase pauses and shifts to the 3' end, using the AG 
as a primer that pairs with the UC at the first and second cRNA nt positions 
(Deng et al., 2006). Synthesis of vRNA can only occur when the cis-
polymerase is activated by a second, “trans-activating” polymerase. In vitro 
experiments showed that synthesis still occurred when the trans-activating 
polymerase was replication incompetent, thus indicating that it is possible for 
the cis-polymerase to synthesize vRNA (Jorba et al., 2009; Moeller et al., 
2012; York et al., 2013). The finding that the synthesis activity of the trans-
activating polymerase is not required for synthesis does not rule out the 
possibility that it contributes to overall synthesis when it is replication 
competent. New PB1 proteins first bind to the 5’ end of vRNA centered 
around the arginines at positions 571 and 572. Then they bind to the 3’ end of 
vRNA using aas 249-256, which includes two phenylalanines at positions 251 
and 254 (Li et al., 1998). 
NP allows for elongation of cRNA and vRNA. The first NP dimer is recruited 
by the viral polymerase complex, possibly stimulated by 3P binding to the 5’ 
end of either RNA. Second and later NP dimers are recruited by previous NPs 
binding to the tail-loop of new NPs (Resa-Infante et al., 2011; Turrell et al., 
2013). 
NEP regulates synthesis of vRNA (Mänz et al., 2012; Robb et al., 2009). 
Specifically, NEP may promote the synthesis of small viral RNAs, which have 
been proposed to promote vRNA synthesis possibly through binding to PA 
and activating trans-activating polymerases (Perez et al., 2012, 2010).  
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1.3.2.10 Export of vRNA through nuclear pores 
vRNPs are exported from the nucleus, while cRNPs are not. This is likely due 
to specific, directionally sensitive sequences. It is possible that these 
differences are in the promoters sequences (Tchatalbachev et al., 2001). 
vRNPs are exported from the nucleus via the Crm1-RanGTP pathway. Crm1 
is a β-importin (reviewed in Paterson and Fodor, 2012). Nuclear vRNPs (but 
not cRNPs) bind host chromatin. This puts them into contact with Rcc1. Rcc1 
generates RanGTP, which drives Crm1-dependent nuclear export. Immuno-
precipitation of Rcc1 pulled down vRNP components (NP, PA and M1, but not 
NEP), thus showing that there is a direct interaction between host proteins 
involved in the export pathway and proteins of the viral genome complex 
(Chase et al., 2011). M1 is thought to directly bind single stranded RNA 
(Wakefield and Brownlee, 1989). NEP binds to M1 and PB2 (Akarsu et al., 
2003; Mänz et al., 2012). NEP’s nuclear export signal is bound by Crm1 
(Boulo et al., 2007; Elton et al., 2001; Iwatsuki-Horimoto et al., 2004; 
Neumann et al., 2000). NP also directly interacts with CRM1 (Elton et al., 
2001). Other proteins that have also been shown to have roles in nuclear 
export are heat shock cognate 70 (Hsc70) and MAPK (Pleschka et al., 2001; 
Watanabe et al., 2006).  
1.3.2.11 Transport of vRNP through cytosol to plasma 
membrane and packaging 
Packaging of vRNPs occurs in Rab11+ recycling endosomes. Rab11 is 
involved in the trafficking of host cell proteins to the apical membrane of 
polarized cells (reviewed by Jing & Prekeris, 2009). Different vRNAs on these 
endosomes co-localise independently of M2 and HA. Movement of the 
endosomes requires actin and is microtubule independent (Chou et al., 2013).  
Electron microscopy and tomography have shown that the eight vRNPs form 
an ordered set of seven vRNP rods surrounding a central rod in a parallel 
configuration suspended from the tip of a virion (Fournier et al., 2012). Each 
vRNA gene segment contains packaging sequences that form base-pairs with 
packaging sequences on other segments, which leads to a network of 
interactions and specific arrangement of the vRNP rods in a virion (Fournier et 
al., 2012). New research suggests that short lengths of RNA may stick out, 
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away from NP and form “kissing loops” with short RNA lengths of other vRNA 
segments (Essere et al., 2013; Gavazzi et al., 2013a, 2013b). Recently, it was 
shown that an extra NP is located at the top of vRNP rods with the 3P 
proteins (Moeller et al., 2012). vRNP have been shown to interact with M1 
and/or the cytoplasmic tail of HA or NA at the tip of each virion (Noda and 
Kawaoka, 2010). The precise protein-protein interactions between the 3PNP 
proteins and M1, HA and NA tails are yet to be determined.  
The influenza gene segment packaging mechanism is fallible and sometimes 
virions are found with either more or less than eight unique gene segments 
(Bancroft and Parslow, 2002; Enami et al., 1991; Harris et al., 2006). 
Replication of the viral genome can lead to deletions in the coding regions of 
gene segments. Since the packaging sequences are maintained, this can lead 
to virions that lack the genetic code for a part of a protein. Virions with coding 
deletions are called defective interfering particles. They can infect cells and 
stimulate an immune response, but do not produce viable progeny 
(Hutchinson et al., 2010).  
1.3.2.12 Budding and release 
Studies of virus like particles (VLPs) in vitro show the basic ability of proteins 
to stimulate budding. HA, NA, and M2 can all support budding of VLPs on 
their own from a lipid bilayer (Chen et al., 2007; Lai et al., 2010). Expression 
of M1 on its own does not initiate budding of VLPs from a lipid bilayer, but it 
does enhance release of VLPs from lipid membranes that contain HA, NA, M2 
or any combination of these proteins (D. Wang et al., 2010).  
There are more restrictions on budding in cells. HA and NA are concentrated 
in patches throughout lipid rafts (Takeda et al., 2003). HA palmitoylation of 
three cysteine residues in transmembrane and cytoplasmic tail is important for 
lipid raft formation (Chen et al., 2005; Scheiffele et al., 1997). Influenza virus 
lipid raft formation can be antagonised by expression of viperin (Wang et al., 
2007). HA has been found at higher concentrations at the apical end of virions. 
Often at the opposite end of the virion the NA is enriched. Though both HA 
and NA can be found interspersed in random locations (Calder et al., 2010a; 
Harris et al., 2006). HA and NA cytoplasmic tails are important for virion 
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shape and recruitment of vRNA (Jin et al., 1997; Zhang et al., 2000). vRNP is 
often found at the head of filamentous virions (Calder et al., 2010b).  
M2 proteins congregate around the outer fringe of the lipid rafts. M2 clusters 
with HA located at edge of rafts. This attraction is dependent upon lipid raft-
targeting signals of HA & actin (Rossman et al., 2010a; Thaa et al., 2010). M2 
cytoplasmic tail binds caveolin-1 (Cav-1). This binding likely mediates 
localization of M2 from the perinuclear region to the plasma membrane (Zou 
et al., 2009). A peptide with a putative Cav-1 binding domain from M2’s 
cytoplasmic tail (residues 43-59) bound Cav-1 in a pull down assay, while a 
mutant did not. Furthermore antibody against GFP-M2 and Cav-1 co-
immunoprecipitated the other from transfected and infected cells (L. Sun et al., 
2010).  
M1 forms an interlocking sheet along the inside of the plasma membrane 
before budding and inside the virion. Crystalised sheets of M1 can interact in 
a straight or bent manner (Arzt et al., 2001; Harris et al., 2001)(Arzt et al., 
2001; Harris et al., 2001). Hydrophobic residues of M1 fall on the membrane 
associated side while negative residues are located on the other (Sha and 
Luo, 1997; Shishkov et al., 1999). Recruitment of M1 to the plasma 
membrane is dependent upon the cytoplasmic tail of M2 (B. J. Chen et al., 
2008; McCown and Pekosz, 2006; D. Wang et al., 2010).  
M1 binds RNA without any sequence specificity via its negatively charged 
NLS (Elster et al., 1997; Wakefield and Brownlee, 1989). M1 has a zinc finger 
motif and binds zinc, but Zinc does not inhibit RNA binding (Elster et al., 1994). 
Middle domain of M1 binds to NP (Noton et al., 2007). M1 also binds to the 
ESCRT-1 complex, which is involved in trafficking vesicles, but ESCRT-1 is 
not necessary for trafficking of vRNA to the plasma membrane (Bruce et al., 
2009). 
The M2 amphipathic helix induces negative membrane curvature that leads to 
scission, in a cholesterol dependent manner. In the absence (or at low 
concentrations) of cholesterol, M2 induces positive membrane curvature. A 
few M2s, that induce negative curvature may balance HA & M1’s positive 
curvature & lead to filamentous virions. M1 and M2 are both implicated in 
formation of filamentous virions (Rossman et al., 2010a). M2 cytoplasmic tail 
has two partial, overlapping, cholesterol recognition amino acid consensus 
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(CRAC) motifs and binds cholesterol, but only in presence of other viral 
proteins (Rossman et al., 2010b; Schroeder et al., 2005). The interaction 
between M2 and cholesterol relates to virulence (Stewart et al., 2010). M2 can 
block fusion between autophagosomes and lysosomes, thus steering cells 
down the apoptosis route to cell death (Gannagé et al., 2009). Furthermore, 
M2 ion channel activity activates inflamasomes in primed macrophages and 
DCs (Ichinohe et al., 2010). (Budding of influenza viruses is reviewed in 
Rossman and Lamb, 2011). 
Influenza virus NA performs the final step in virion release by cleaving SA 
from host cell and virion associated glycoproteins. The mechanism is covered 
in more detail below in Section 1.4.2.  
Influenza virus replication is summarised in Figure 1.3. 
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Figure 1.3. The influenza virus and its replication cycle. The influenza virion has 
three integral membrane proteins: HA, NA, and M2. M1 lines the inside of the 
membrane. Virions generally hold eight segments of negative sense ssRNA (red). 
Each vRNA segment has a promoter region, which is bound by the RdRp proteins 
PB1, PB2, and PA. NP binds the rest of the vRNA in a coiled configuration. Infection 
is initiated when HA binds to the surface of an epithelial cell and virions are 
internalised via endocytosis or macropinocytosis. The late endosome acidifies and 
HA fuses with the membrane of the vesicle. This releases vRNPs and they are 
transported into the nucleus. vRNA is transcribed into mRNA which are in turn 
translated into proteins. vRNA is also used as a template for replication which uses a 
cRNA intermediate. Integral membrane proteins and vRNP meet at the apical surface 
of infected cells and bud into new virions, which are pinched off by M2 and released 
from surface receptors by NA. The images in this figure were adapted from (Flint et 
al., 2008) and (Resa-Infante et al., 2011). 
  
1.3.2.13 Immune regulation 
Regulation of the host response to infection has been touched on in other 
sections. Influenza viruses stimulate immune responses in epithelial cells and 
immune cells through an array of signals. Pattern recognition receptors on 
scavenger cells like macrophages can recognise sugars on viral glycoproteins. 
Macrophages have TLR7, which detects vRNA in endosomes while epithelial 
cells do not. Both cells have RIG-I, which detects the 5’ triphosphate end of 
vRNA in the cytosol (Pichlmair et al., 2006). Some viral proteins have 
functions that counteract stimulation of the host’s immune response. 
This section will mainly focus on the roles of NS1 and PB1-F2. Neither protein 
is included in the virion. NS1 and PB1-F2 are sometimes truncated in a host 
dependent manner (NS1 reviewed in Hale et al., 2008)(PB1-F2 analysed by 
Zell et al., 2007).  
1.3.2.13.1 NS1 
NS1 is the main protein antagonist of the host immune response. NS1 has 
two main domains that crystallise as dimers (Bornholdt and Prasad, 2008). 
The N-terminal binds to double stranded RNA (dsRNA) and the C-terminal is 
the effector domain. R35, R46 and R38 are crucial and S42 is important for 
dsRNA binding (Cheng et al., 2009). NS1 binds vRNA in a structure 
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dependent manner (Marc et al., 2013). The effector domains dimerize through 
a conserved helix-helix interaction (Kerry et al., 2011). 
NS1 prevents (dsRNA)-mediated activation of transcription factors like IRF-3, 
NFkb, and c-Jun/ATF-2 (Talon et al., 2000; Wang et al., 2000). Retinoic acid 
inducible Gene I (RIG-I) binds to dsRNA and binding is enhanced by terminal 
5’-phosphorylation of the RNA (Kowalinski et al., 2011; Luo et al., 2011). The 
concentration of the co-precipitated RIG-I/NS1 complex increases with more 
vRNA and is almost totally wiped out when vRNA is de-phosphorylated 
(Pichlmair et al., 2006). dsRNA-activation of RIG-I can lead to ubiquitination 
by the E3 ligase TRIM25, but influenza NS1 binds to the coiled-coil domain of 
TRIM25 and prevents its multimerization, thus preventing ubiquitination of 
RIG-I. NS1 residues R38/K41 and E96/E97 are important for inhibition of 
TRIM25 activity (Gack et al., 2009). The activity of Riplet, another E3 ligase 
that can add ubiquitin to RIG-I, is also blocked by NS1. The interaction 
between Riplet and NS1 is virus and host species specific (Rajsbaum et al., 
2012). NS1 also binds protein kinase receptor (PKR). PKR can be activated 
by dsRNA or PACT (Nanduri et al., 2000; Peters et al., 2009). Active PKR 
deactivates eukaryotic translation initiation factor 2a (eIF2a) by 
phosphorylating it. Phosphorylation of eIF2a leads to a reduction in synthesis 
of both cellular and viral proteins (Reviewed by García et al., 2006). Binding of 
PKR by NS1 inhibits its activity (Li et al., 2006). Mutations I123A/M124A or 
D126A/N127A in Ud72 NS1 severely reduced binding to PKR in a pull-down 
assay (Min et al., 2007). Through these interactions, NS1 inhibits the 
formation of anti-viral stress granules that normally contain RIG-I and PKR 
(Onomoto et al., 2012). NS1 can also prevent the targeting of NP to cellular 
processing bodies (P-bodies) and stress granules by interacting with RNA-
associated protein 55 (RAP55) (Mok et al., 2012). 
NS1 also binds directly to p85b, a regulatory subunit of PI3K. This activates 
PI3K signalling (Hale et al., 2006). Structures of the effector domain of NS1 in 
complex with p85b and p110 show NS1 binds to the inter-SH2 coiled-coil of 
p85b. This could prevent binding of PI3K inhibitors (Hale et al., 2008a; Li et al., 
2008). NS1 residues important for p85b binding include Y89/M93, P164/P167, 
and L141/E142 (Hale et al., 2006; Li et al., 2008; Shin et al., 2007b). 
Mutations of these residues block Akt phosphorylation and lead to earlier 
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apoptosis (Hale et al., 2006; Shin et al., 2007a). NS1 also has contacts with 
the C2/kinase domains of p110. Mutations that change the charge of the NS1 
loop that is near the C2/kinase domains of p110 render PI3K inactive (Hale et 
al., 2010a). NS1 activation of PI3K signaling is strain specific (Ayllon et al., 
2012). 
dsRNA also activates 2’5’-oligoadenylate synthetase (OAS). In turn, OAS 
activates RNase L, which can degrade vRNA (Reviewed by (Silverman, 2007). 
Since a direct interaction between NS1 and OAS has not been detected, NS1 
is thought to prevent OAS from binding dsRNA by binding more strongly 
through its dsRNA binding domain (Min and Krug, 2006). 
The above activities of NS1 require its presence in the cytosol. PDZ domain-
containing proteins are often membrane bound. They are involved in short-
term cellular activation of trafficking, signaling, apoptosis, and more 
(Reviewed in Javier and Rice, 2011; Lee and Zheng, 2010; Romero et al., 
2011). The C-terminus of most influenza NS1 proteins contains a PDZ-
domain binding motif (PDM). The PDM sequence most common in avian NS1 
is ESEV; in human NS1 it is RSKV. Short peptides containing PDM 
sequences of avian NS1s bound to PDZ-domain containing proteins 
disheveled (Dsh) and postsynaptic density protein 95 (PSD-95) more strongly 
than peptides with PDM sequences of human NS1s (Obenauer et al., 2006). 
The PDM sequence of NS1 affects virulence in mice (Jackson et al., 2008). 
The interaction between full avian NS1 protein is also stronger than that of 
human NS1 for PDZ-domain containing proteins human Scribble or Dlg-I 
(Golebiewski et al., 2011; Thomas et al., 2011). The interaction of avian NS1 
PDM with Scribble delays apoptosis in infected cells (H. Liu et al., 2010). The 
presence of a human Scribble-binding PDM reduces STAT phosphorylation in 
response to IFNa stimulation (Thomas et al., 2011). Interaction of a PDM 
containing NS1 with MAGI-1 post transfection increases IFNb induction. 
However, it is likely that in the presence of infection other viral activities would 
suppress IFNb production (Kumar et al., 2012).  
NS1 is also active in the nucleus. It can prevent post-transcriptional 
processing of pre-mRNA by blocking mRNA splicing and nuclear export 
(Fortes et al., 1994; Lu et al., 1994; Qiu and Krug, 1994). CPSF30 has two 
zinc-finger regions through which it binds, cleaves, and polyadenylates host 
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mRNA. NS1 binds to the two zinc finger regions F2F3 and blocks CPSF30 
activity (Nemeroff et al., 1998). Binding requires NS1 C-terminal residues 
F103, M106, L144, and residues 184-188 (Kochs et al., 2007; Li et al., 2001; 
Twu et al., 2007, 2006). E96 may also be functionally significant (Shimizu et 
al., 1999). Importantly, NS1 binding of CPSF30 suppresses the host antiviral 
response to infection (Noah et al., 2003). NS1s of viruses including H3N2 
A/Udorn/72, H1N1 A/BM/1/1918, A/Texas/36/91 and A/WSN/33, H7N1 
FPV/Rostock/34, H5N1 Gs/Gd/96 can all bind CPSF30, but PR8 and 
pandemic 2009 NS1s do not bind it (Hale et al., 2010c; Kochs et al., 2007; Ma 
et al., 2010; Nemeroff et al., 1998; Twu et al., 2006). 
NS1 can also block export of polyadenylated mRNA through interactions with 
poly(A)-binding protein II (PABII or PABPII). PABPII elongates polyA tails and 
aids in export of pre-mRNA. Binding by NS1 of Ud72 prevents PABPII from 
localising to nuclear speckles (Chen et al., 1999). Binding of NS1 to PABPII 
requires C-terminal NS1 residues 223–237 (Li et al., 2001). Pandemic 2009 
NS1 lacked PABII binding domain (Tu et al., 2011). Interestingly, export of 
vRNA seems to require PABPI, which also interacts with NS1, but in a 
positive manner (Bier et al., 2011; Burgui, 2003).  
As mentioned in the section about nuclear export of mRNA, NS1 binds to 
other export factors (specifically NXF1, TAP/p15, Rae1, E1B-AP5 and Nup98). 
These interactions seem to also inhibit export of host mRNA (Satterly et al., 
2007; W. Wang et al., 2008). NS1 also inhibits transcription of host mRNA by 
acting as a histone mimic (Marazzi et al., 2012). 
1.3.2.13.2 PB1-F2 
PB1-F2 was discovered in 2001 and is encoded from an alternative start 
codon, AUG4 of segment 2. PB1-F2’s mRNA is not spliced (Chen et al., 2001; 
Wise et al., 2011) and the protein is usually greater than 78 aas long, but can 
be truncated. The truncated forms (less than 58 aas long) are more often 
found in human and swine influenza viruses, but also in some viruses isolated 
from poultry (Zell et al., 2007). Full length PB1-F2 localizes to the 
mitochondria and induces cell death (Zamarin et al., 2005). In the nucleus, 
PB1-F2 can interact with PB1 and regulate polymerase activity (Mazur et al., 
2008). PB1-F2 affects viral virulence and host immune response. Mice 
 58 
infected with PB1-F2-66S virus had a higher viral titres than those infected 
with PB1-F2-66N. They also had a delayed, but more severe inflammatory 
immune response (Conenello et al., 2011). PB1-F2 inhibits RIG-I/MAVS 
induced IRF3 activition which leads to suppressed expression of IFNb and 
IFN stimulated genes in infected epithelial cells (Dudek et al., 2011)(Dudek et 
al., Biol Chem, 2011). 
Since 2001 expression of seven proteins, including PB1-F2, have been 
discovered. Like PB1-F2, the others also have characteristics including virus 
and host specificity as well as the ability to regulate viral replication and 
immune response, but details await further exploration (Reviewed by Vasin et 
al., 2014). 
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1.4 Functions of influenza virus HA and NA proteins 
1.4.1 HA 
Evolutionarily the HA subtypes form two groups. HA has five antigenic sites 
recognised by antibodies with neutralising activity (Figure 1.4)(Caton et al., 
1982). The HA protein has two main functions: to bind receptors and fuse 
membranes. Receptor binding is mediated through the receptor binding site 
(RBS). The HA RBS consists of three main structural features, which play 
different roles in stabilising sialated glycans (SAGs). The first is the 130-loop, 
(usually depicted along the right side of images), against which both α2,3- and 
α2,6-linked Sia-1 settle and make hydrogen bonds between the carboxylate or 
acetamido substituents and hydroxyls of the amino acid R-groups or 
backbone. The second is the 220-loop, which is usually displayed on the left 
and holds residues that interact with Gal-2. The third is the 190-α-helix, which 
spirals along the top in most figures. The interactions of its residues vary 
depending on HA subtype and the SA-linkage of the receptor. Amino acids in 
the 190-helix can interact with Sia-1, Gal-2, GlcNAc-3, and Gal-4. α2,3-SAGs 
bind to HA in an extended form, which involves the glycosidic linkage between 
Sia-1 and Gal-2 taking on a “trans” conformation. α2,6-SAGs bind to HA in a 
folded form and the glycosidic linkage takes on a “cis” conformation (Eisen et 
al., 1997; Liu et al., 2009; Xu et al., 2012a).  
HA receptor binding is a major determinant for host range. HAs from avian 
influenza viruses preferentially bind α2,3-SAGs, while those of human 
influenza viruses preferentially bind α2,6-SAGs (Rogers and Paulson, 1983). 
In differentiated primary human airway epithelial cell cultures this means that 
human influenza viruses more often bind to receptors on non-ciliated rather 
than ciliated cells (Matrosovich et al., 2007; Thompson et al., 2006). 
To support transmission in humans it is likely that HA needs to bind SAGs that 
are present on cells in the URT, but new pandemic viruses often also bind to 
receptors in the LRT and are capable of replicating there (Itoh et al., 2009; 
Munster et al., 2009). HA binding to decoy receptors in the mucus on mucins 
or innate immune modulators can reduce viral replication (Matrosovich and 
Klenk, 2003; Ramos and Fernandez-Sesma, 2012).  
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Fusion is mediated through a conformational change, brought on by a 
decrease in pH along the endosome/lysosome pathway. Fusion requires 
proteolytic cleavage between HA1 and HA2 so that the small fusion peptide 
located at the new N terminus of HA2 can be inserted into the endosomal 
membrane to initiate fusion (Böttcher-Friebertshäuser et al., 2012; Chaipan et 
al., 2009) (Figure 1.4). HA must undergo fusion at the appropriate pH so that 
it fuses the viral membrane with the membrane of an endosome after 
internalisation. If HA fusogenic change is triggered outside of the cell due to 
the extracellular environment associated with the ecology of a particular host 
then replication and transmission are inhibited (Galloway et al., 2013; Imai et 
al., 2012; Reed et al., 2010; Shelton et al., 2013).  
 
 
Figure 1.4. HA strucutre showing antigenic sites, conformations pre and post 
fusion, and phylogenetic tree of HA subtypes. Images adapted from (Elsevier, 
2006) and (Russell et al., 2008).  
 
1.4.2 NA 
1.4.2.1 NA structure and function 
Influenza virus NAs are distinguished by their antigenicity and their structure 
and separated into two groups: Group 1 includes N1, N4, N5, N8 and Group 2 
contains N2, N3, N6, N7, N9 (Figure 1.5D). NA is a type II membrane 
glycoprotein (N. Wang et al., 2008). The N-terminus holds a short cytoplasmic 
domain, which leads to a transmembrane domain, a stalk domain, and an 
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enzymatic ‘head’ domain at the C-terminus (Figure 1.5B). The heads of N1, 
N2, N4, N5, N8, N9, and N10 subtypes have been characterised by X-ray 
crystallography and have similar morphology (Baker et al., 1987; Colman et 
al., 1983; Li et al., 2012; Q. Li et al., 2010; Russell et al., 2006; Wang et al., 
2011; Zhu et al., 2012b). NA is expressed as a homotetramer and the heads 
form a propeller-like arrangement. Each head has six four-stranded 
antiparallel β-sheets (Xu et al., 2008). The tetrameric structure has the overall 
dimensions of 94 by 94 by 54 Angstroms cubed (10 angstroms are equal to 
1nm in length). The major difference between Group 1 and Group 2 NAs is 
the position of the carbon atoms along the 150-loop, which stretches from aa 
147 to 151 (Xu et al., 2008).  
 
Figure 1.5. NA domains and phylogenetic relationships of subtypes. (A) A three 
dimensional space fill image of the outward-facing surface of an NA tetramer adapted 
from (Uhlendorff et al., 2009). (B) A depiction of the full NA tetramer with labelled 
domains. (C) Electron micrograph of negatively stained NA rosettes where the stalk 
is full length in the left panel and truncated by 18 aas in the right panel adapted from 
(Els et al., 1985). (D) Phylogenetic tree of NA subtypes adapted from (Russell et al., 
2006).  
 
The main function of NAs 1-9 is to cleave SA. N10 does not cleave SA 
(García-Sastre, 2012). SA is bound and cleaved in the enzyme pocket of NA. 
The enzyme active site is located on the membrane-distal surface and tilted 
approximately 25° away from the axis of the tetramer (Xu et al., 2008). NA 
activity levels are governed by amino acids located throughout the head 
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region of NA (Kobasa et al., 2001). Influenza virus NA subtypes 1-9 have 8 
conserved “catalytic” aas (R118, D151, R152, R225, E277, R293, R368, 
Y402), which are located in the enzyme pocket (coloured red in Figure 1.6 
and 1.7) and interact with SA in order for the sialidase reaction to occur (Air 
and Laver, 1989; Colman, 1994; Colman et al., 1983; Reid et al., 2000; 
Varghese et al., 1992; Xu et al., 2008). Aas that are not directly involved in the 
enzymatic reaction, but interact with the catalytic residues are called 
“framework” aas. The N1 consensus framework aas are: E119, R156, W179, 
S180, D199, I223, E228, H275, E278, N295, E425 (coloured blue in Figure 
1.6 and 1.7). Although they do not directly interact with glycans, mutations of 
the framework aas as well as other aas have often led to changes in enzyme 
activity, receptor preference, drug resistance and the ability to transmit in a 
new host.   
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Figure 1.6. 3D image overlay of NAs from H2N2 A/Tokyo/3/1967 and H1N1 
A/California/04/2009. Backbones are coloured green and gold, catalytic residues 
coloured red and pink and framework residues coloured dark and light blue, 
respectively. SA is shown with thin lines for carbons (grey lines) oxygens (red lines) 
and nitrogen (blue lines). Structure created using Pymol and PDB structures 2BAT 
(Tok67) and 3NSS (CA04).  
 
 
64  
Figure 1.7. A
lignm
ent of N
A
s from
 H
2N
2 A
/Tokyo/3/1967 and H
1N
1 A
/C
alifornia/04/2009. C
A
/04/09 N
A
 has the sam
e sequence as 
E
195/09 N
A
. C
atalytic residues are highlighted in red and fram
ew
ork residues are highlighted w
ith blue. A
m
ino acids are coloured by polarity. 
A
as that have a negative charge are coloured red, those w
ith a positive charge are blue, green are polar and yellow
 are nonpolar. 
 
 65 
 
 
 
(This page intentionally left blank) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 66 
Four steps are involved in the NA’s sialidase reaction (Zhu et al., 2012a). First 
NA binds SA, this involves SA’s carboxylate group moving into an equatorial 
position creating three salt bridges with the catalytic residues R118, R293, 
and R368. When HA binds SA the carboxylate group is bound in the axial 
position (Gamblin and Skehel, 2010). Second, a transition state intermediate 
is formed by a proton donation from the solvent. Catalytic residues D151 and 
R152 and framework residue E278 stabilize the intermediate (Taylor and von 
Itzstein, 1994). The third step is the formation of SA and the fourth is the 
release of SA, at which point it returns from a boat to a chair conformation.  
Cleavage of SA destroys receptors that HA might have bound. When 
surrounded by SA receptors, the HAs of an influenza virion will bind to them 
unless the binding avidity of numerous HA-SA interactions drops below a 
certain level. SAs are usually found as the terminal sugar on N- and O-linked 
glycans on glycoproteins and glycosphingolipids (gangliosides) and 
occasionally on side chains of glycosylphosphatidylinositol (GPI) anchors 
(Varki et al., 2009). SA expressed on mucins can retain virus in the mucus, 
whereas efficient NA cleavage of mucus decoy receptors allows virus to 
penetrate through mucus quickly (Matrosovich and Klenk, 2003; Matrosovich 
et al., 2004; McCrea, 1948).  
Binding to cell surface receptors after a new virion has formed inhibits virion 
release after replication. NA activity plays an important role in removing SA 
from cell surface receptors so that virions are released (Barrère et al., 1997; 
Compans et al., 1969; Griffin et al., 1983; Griffin and Compans, 1979; 
Lakdawala et al., 2011; Palese and Compans, 1976; Palese et al., 1974; Seto 
and Chang, 1969; Wagner et al., 2002b; Yen et al., 2011). Like cell surface 
glycoproteins, the glycans on viral surface glycoproteins HA and NA, have 
terminal SA and if the SAs are not removed HA will bind them, thus linking 
virions together. NA cleavage of these SAs is important in preventing virion 
aggregation (Compans et al., 1969; Griffin et al., 1983; Griffin and Compans, 
1979; Kaverin et al., 1998; Lakdawala et al., 2011; Palese and Compans, 
1976; Palese et al., 1974; Rudneva et al., 1993; Seto and Chang, 1969; 
Wagner et al., 2002b; Yen et al., 2011).  
As well as occurring on the cell surface, SA cleavage is thought to occur in 
the acidic environment of the late endosomes/lysosomes as well as less 
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acidic in the golgi. Avian and pandemic influenza NAs from 1918, 1957, and 
1968 retain sialidase activity at low pH, while human seasonal influenza NAs 
are unstable at low pH. However, the NA of an early 2009 pandemic virus 
isolate was less active at pH 5 than later isolates. NA enzymes that function at 
low pH cleave SA while in endosomes and replicate to higher titres than 
mutants that are inactive at low pH (Suzuki et al., 2005, 2004; Takahashi et al., 
2013, 2010, 2001).  
As well as being regulated by pH stability, NA activity can be also regulated 
by cell surface expression. Expression levels affect the density of the enzyme 
on the surface of virions and can also be adjusted through single aa mutations 
that are related to stability. For example, human seasonal H1N1 viruses were 
able to support reduced enzyme activity conferred by the drug resistant 
mutation H275Y by adopting mutations R222Q and V234M which increased 
NA stability and surface expression (Bloom et al., 2010). 
SAs on glycans attached to HA can partially inhibit HA’s ability to bind to SA. 
This was shown by a reduction in HA haemadsorption and fusion as NA 
presence or activity was diminished (Luo et al., 1999; Su et al., 2009). NA can 
cleave SA from HA once virions have formed, but it may also cleave these 
terminal SAs during export of glycoproteins to the cell surface. In COS cells, 
but not MDCK cells, the NA of an influenza B virus was shown to cleave SA 
from viral glycoproteins in the trans-Golgi network (Luo et al., 2002).  
Models of receptor binding to the NA protein indicate that some amino acids 
of some NAs interact with the Gal-2 and GlcNAc-3 sugars of α2,3- and α2,6-
SAGs (Jongkon and Sangma, 2012). Like HA receptor binding, NA sialidase 
activity has been shown to be sensitive to the terminal linkage of SA (Baum 
and Paulson, 1991; Kobasa et al., 1999).  
In specific viral strains, NA was shown to recruit proteases. In the mouse 
adapted WSN strain recruitment of plasmin aided in cleavage of HA and thus 
allowed HA activation in specific tissues (Goto and Kawaoka, 1998).  
Furthermore, cleavage of SA is known to play a role in regulation of the host’s 
immune response. For example some NAs can activate TGFβ and this may 
affect pathogenicity (Carlson et al., 2010).  
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1.5 HA NA Balance 
The paradigm is that infection is initiated when HA binds to SA on a cell’s 
surface and completed when NA cleaves SA from the surface of the same cell, 
thus allowing progeny particles to be released from one cell or host and 
spread to the next. Studies of different HA and NA pairings with and without 
mutations has led to the conclusion that HA:NA balance is crucial for virus 
replication and transmission (Lakdawala et al., 2011; Mitnaul et al., 2000; 
Wagner et al., 2002b; Xu et al., 2012b; Yen et al., 2011). 
There are many examples of HA:NA misbalance and re-balance in vitro. 
Kaverin was the first to underscore the importance of the HA:NA balance 
when he demonstrated that an imbalance between HA avidity and NA activity 
post reassortment led to virus attenuation and that such viruses showed virion 
aggregation (Kaverin et al., 1998; Rudneva et al., 1993). Comparison of an 
HA with and without glycans on its head showed that the HA without glycans 
had enhanced receptor binding strength and virus only replicated efficiently in 
cell culture when reassorted with a more active NA (Wagner et al., 2000). 
Mutations that make NA drug resistant usually also reduce NA sialidase 
activity and compensatory mutations that alter HA receptor binding, including 
the addition of a glycosylation site, are often detected in HA (Baigent et al., 
1999; Ginting et al., 2012; McKimm-Breschkin et al., 2013; Mishin et al., 2005). 
Recent studies have suggested that the segmented nature of the influenza 
genome allows sufficient plasticity such that the HA NA balance can be 
rapidly sampled and reset as HA evolves in response to antigenic pressure 
(Das et al., 2013). In addition guinea pig transmission studies have shown 
how adaptation of the virus to a new host selects for mutations that reset the 
NA HA balance even by epistatic mutation in other genes (Ince et al., 2013).  
In the last three pandemics the pairing between HA and NA was slightly 
different. In 1957 an avian-origin HA was paired with an avian-origin NA; in 
1968 an avian-origin HA was paired with a human-origin NA; in 2009 a swine-
origin HA was paired with a swine-origin NA. Yet they all managed to adapt to 
support transmission between humans. Xu et al. measured HA avidity and NA 
enzyme activity for these pandemic strains (including 1918) and found a 
correlation between the two activities. In comparison, they found that two of 
three swine virus HA and NA pairs did not fall within the correlation and 
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therefore declared that viruses with pandemic capability required a fine 
HA:NA balance that was not always present in swine viruses (Xu et al., 
2012b). This simple analysis used an NA enzyme activity assay that 
overlooks the role of SAG specificity and has other issues, but if methods 
were further refined, the results could be useful for preliminary predictions 
about the pandemic potential of new viruses as they emerge. 
Two experiments that compared ferret transmission of swine influenza viruses 
with prototypic 2009 pandemic viruses and reassortants showed that 
characteristics of the pandemic NA were important for transmission of virions 
through the air between ferrets. Lakdawala et al. showed that higher NA 
enzyme activity associated with increased frequency of virions in respiratory 
droplets that were smaller than 1um in diameter. Yen et al. showed that 
increased NA enzyme activity associated with a reduction in virion 
aggregation. The viruses used in these studies were from both the classical 
swine and Eurasian swine lineages, which gives credence to the conclusion of 
Xu et al. that not all swine viruses have HA:NA pairs that would support 
efficient transmission between other mammals.  
Given the inherent differences in the host species of viral genetic origin, it is 
likely that each pandemic NA followed a different evolutionary path to support 
its pandemic HA. Recognising these differences, this thesis aims to explore 
some specific NA characteristics and their effect on the ability of either avian 
or swine NAs to support transmission in a model relevant for understanding 
the role of NA in human-to-human transmission. Two known characteristics of 
NA that are associated with avian or swine viruses but not present in human 
adapted NAs are deletions within the stalk domain and the ability to 
haemeabsorb RBCs. 
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1.6 Receptors and receptor binding of pandemic and 
zoonotic influenza HAs and the effect on 
transmission of viruses 
1.6.1 Different hosts have differentially linked SA and thus 
vary in the receptor they present for influenza 
attachment. 
The receptors by which influenza viruses attach to target cells are glycans 
with terminal SA. The SA can be linked to the rest of the glycan chain in one 
of three linkages: α2,3, α2,6 and α2,8. Early research found that duck and 
equine influenza viruses have stronger affinity to glycan receptors with α2,3-
terminally linked SA, while human and swine viruses bind more strongly to 
α2,6-sialated glycans (SAGs) (Rogers and Paulson, 1983). It is presumed that 
the differential expression of SAGs between host species is a driver for 
evolution of the different binding preferences and this work has continued to 
be refined over the years. 
Many groups have used lectins to characterise the distribution of differentially 
linked SA in tissues of animals. In addition more detailed analysis has been 
performed by mass spectrometry, which allows not only determination of the 
terminal few sugars but also characterization of longer sugar chains. 
Generally, waterfowl are thought to express much more α2,3-SA than α2,6 
SA.This definitely seems to be the case in the enteric tract. However, ducks 
were found to express varying – from absent to equal – amounts of α2,6 SA in 
their trachea, bronchi, bronchioles (Costa et al., 2012; Kimble et al., 2010; 
Kuchipudi et al., 2009). 
Terrestrial birds express both α2,3- and α2,6-SA. In chicken enteric tract, α2,6 
SA dominated in goblet cells and lymphocytes, but was not detected on the 
main epithelium which was dominated by α2,3-SAGs. Chicken trachea was 
found to express both α2,6 SA and α2,3 SA. The α2,3 SA was specifically 
detected by MAAI and not MAAII, indicating that the third sugar, GlcNAc had 
a 1,4-linkage, rather than 1,3 (Kuchipudi et al., 2009). While α2,3 SA 
expression was found to be higher in the upper and lower respiratory tract of 
chickens, α2,6 was expressed at higher concentrations in the glands of the 
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nasal cavity and at equal levels in the bronchial epithelial cells (Costa et al., 
2012).  
Turkeys and quails were found to have higher α2,6 SA expression on 
bronchial epithelial cells and, in one study, quails had particularly clear 
dominance of α2,6 SA on the ciliated and non-ciliated cells of their nasal 
cavity (Costa et al., 2012). A different study showed that quail had equal 
amounts of α2,3 and α2,6 SA in their lungs and trachea, with more α2,3 SA in 
their large intestine (Kimble et al., 2010). 
Horse nasal and tracheal airway epithelium was found to express both α2,3- 
and α2,6-SAGs in high quantities (Scocco and Pedini, 2008). Interestingly, 
one study was only able to detect lectin staining with SNA and MAL-II after 
removal of O-linked oligosaccharides (Parillo et al., 2009).  
An initial report on expression of SAGs in swine trachea using lectin staining 
suggested that swine express both α2,3- and α2,6-SAGs (Ito et al., 1998). 
However, later reports showed that SNA staining dominated the respiratory 
tract in swine nasal, tracheal, and bronchial epithelium, but it was mixed with 
MAA-I or MAL-II staining in the bronchioles and alveoli (Nelli et al., 2010; Van 
Poucke et al., 2010). Mass spectrometry confirmed that α2,6-SAGs were 
more abundant than α2,3 in primary swine respiratory epithelial cells. 
Furthermore, Bateman et al. showed that NeuAc was more abundant than 
NeuGc in these cells (Bateman et al., 2010).  
Lectin staining of human respiratory tissues showed that α2,6-SAGs 
dominated over α2,3 in the nose, bronchi, and bronchioles. Many cells in the 
alveoli expressed α2,3-SAGs and thus stained with MAA (Shinya et al., 2006). 
Glycomic analysis of human lung and bronchus samples revealed that a wide 
spectrum of both α2,3- and α2,6-SAGs were present. Furthermore, Walther et 
al. showed that bi-, tri-, and tetra-antennary N-glycans with varying lengths of 
polyLacNAc extensions existed (Walther et al., 2013). Ciliated cells from 
human primary airway epithelial cells and tissues express abundant α2,6-
SAGs on both ciliated and non-ciliated cells. Ciliated cells expressed more 
α2,3-SAGs, but some was also found on non-ciliated cells (Ibricevic et al., 
2006; Thompson et al., 2006; Wan and Perez, 2007). 
Animal models for influenza virus studies also have specific SA distributions. 
Ferret trachea and hilar region lung tissues stained with SNA, but not with 
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MAL-II, confirming α2,6-SAGs are dominant in the glycocalyx. Staining with 
SNA and MAL-II of the submucosal glands in the trachea indicated that they 
had mixed expression (Jayaraman et al., 2012). In guinea pigs, lectin staining 
showed that both α2,3- and α2,6-SAGs were presented at high frequency in 
nasal and tracheal tissue, while α2,3-SAGs were the main receptor in the lung 
(Y. Sun et al., 2010). Primary airway epithelial cells grown from mice were 
only MAA positive, indicating that they only express α2,3-SAGs (Ibricevic et 
al., 2006).  
In summary, waterfowl mainly express α2,3-SAGs in their enteric tract. 
Terrestrial birds have a more mixed expression, especially along their 
respiratory tract. Humans, swine, and ferrets express α2,6-SAGs at higher 
densities than α2,3-SAGs along most of their respiratory tract, with 
bronchioles and alveoli expressing a more evenly mixed population. Therefore, 
based on their expression of differentially linked SAGs, it might be the case 
that terrestrial birds can support viruses that bind to both α2,3- and α2,6-
SAGs and thus act as intermediates hosts between waterfowl and hosts 
where α2,6-SAGs are more prevalent such as pigs and humans.  
 
1.6.2 Amino acids in or near the RBS of HA affect SA binding 
and transmission of past pandemic viruses  
1.6.2.1 Binding pocket and sugar conformations 
Amino acids in the receptor binding site of each pandemic HA (since 1918) 
have been identified as important for a binding phenotype that prefers α2,6- 
over α2,3-SAG, which is believed to be an important determinant of the virus’ 
ability to transmit between humans. These residues were identified by 
comparing the HA sequences of avian versus human viruses. Then, using 
reverse genetics, prototypic pandemic HA sequences were back mutated to 
match an avian sequence and the effect of the mutations on receptor binding 
specificity and transmission in mammalian models were studied.  
The HA receptor binding pocket consists of three main features, which play 
different roles in stabilising α2,3- and α2,6-SAGs. The first is a the 130-loop, 
(usually depicted along the bottom of images), against which both α2,3- and 
α2,6-linked Sia-1 settle and make hydrogen bonds between the carboxylate or 
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acetamido substituents and hydroxyls of the amino acid R-groups or 
backbone. The second is the 220-loop, which is usually displayed on the left 
and holds residues that interact with Gal-2. The third is the 190-α-helix, which 
spirals along the top in most figures. The interactions of its residues vary 
depending on HA subtype and the SA-linkage of the receptor. Amino acids in 
the 190-helix can interact with Sia-1, Gal-2, GlcNAc-3, and Gal-4. α2,3-SAGs 
bind to HA in an extended form, which involves the glycosidic linkage between 
Sia-1 and Gal-2 taking on a “trans” conformation. α2,6-SAGs bind to HA in a 
folded form, where the glycosidic linkage takes on a “cis” conformation (Eisen 
et al., 1997; Liu et al., 2009; Xu et al., 2012a). 
 
1.6.2.2 Receptor binding assays and their limitations  
 Taken together, the results from a few types of experiments give a 
good picture of the SA preference of specific HAs. Structural analyses of the 
interactions between HA proteins and synthetic glycans shed light on the 
stabilising bonds between amino acids and sugars. Binding assays quantify 
the overall strength of the interactions between different HAs and receptors. 
Glycan arrays show the variety of glycans that different HAs can bind. Binding 
to ex-vivo tissues or primary epithelial cell cultures shows when receptors for 
specific HAs are present. The ability of viruses to replicate in ex-vivo tissues 
or specific cell types of primary cultures can highlight permissive cells with low 
receptor expression. 
However, all of these assays have limitations. Crystal structures do not 
portray the dynamic kinetics that are involved in temporary bonds. Availability 
of synthetic glycans that accurately reflect the structure of those found in 
nature has improved over the years, but their diversity is not yet 
representative of the diversity presented by nature. Binding of viruses or HA 
proteins to formalin fixed ex-vivo tissue and binding to primary epithelial cells 
may only reveal receptors with strong interactions or those present at high 
densities. The ability of viruses to replicate ex vivo or in vitro may not 
accurately reflect their replication in vivo. Nonetheless, there is a plethora of 
data obtained using such techniques that can give important clues as to the 
effect that mutations in the RBS of HA have on receptor binding and thus 
pandemic emergence. 
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1.6.2.3 Experimental transmission between mammals 
Ferrets became the model for the study of influenza virus transmission when 
Smith, Andrewes & Laidlaw inoculated many different species with filtered 
throat-washings of patients with influenza-like illness during the 1933 
epidemic and found that ferrets were the only ones to develop observable 
infection. Furthermore, they found that the virus transmitted between ferrets 
housed in the same cage and that a swine influenza virus had the same ability 
to infect and transmit between ferrets (Smith et al., 1933). To this day, ferrets 
remain the gold standard for studying influenza virus transmission. 
Transmission studies between ferrets infected with human and avian 
influenza viruses closely reflect the transmission patterns observed in humans. 
Where ferret aerosol transmission experiments have been reported, human 
seasonal and pandemic strains always transmit to at least 1/3 ferrets (Table 
1.2). Most avian or avian-origin zoonotic viruses do not induce aerosol 
exposed ferrets to seroconvert or shed virus. In some cases the barrier to 
aerosol transmission between ferrets has been overcome through engineered 
reassortment or amino acid mutations of avian viruses. The text below will 
cover many of these H5, H7 and H9 viruses. However, it is important to note 
that two wild type viruses stick out as having the ability to transmit through the 
air between ferrets, while they have not achieved sustained human-to-human 
transmission. The H7N9 zoonotic virus of 2013 transmits through the air 
between ferrets (Belser et al., 2013a; Watanabe et al., 2013; H. Zhu et al., 
2013) as does an avian H1N1 from a shorebird (Koçer et al., 2012). Therefore, 
although the ferret is the gold standard animal model for studying barriers that 
avian viruses must overcome before they can transmit between humans, it is 
recognised that ferrets and humans differ. 
Some swine viruses transmit via aerosol between ferrets, while others do not 
(Table 1.2). In general, swine viruses that have recently (within the last 
decade) reassorted with genes from human viruses can transmit through the 
air between ferrets. The efficient aerosol transmission between ferrets of 
swine H3N2 variant (H3N2v) in the absence of sustained human transmission, 
indicates that herd immunity is the barrier that protects humans from an H3N2 
pandemic (Biggerstaff et al., 2013; Gambhir et al., 2013).  
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A major downfall of transmission studies in animals is the lack of prior 
immunity due to repeated infection throughout life as is common in humans. 
Some groups have studied transmission with primary infection followed by 
secondary challenge and have shown that primary infection can indeed 
protect or reduce disease from challenge via exposure to another animal 
infected with an antigenically distinct virus (Ellebedy et al., 2011; Lowen et al., 
2009).  
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Type of 
virus 
Sub 
type Strain Name 
DC 
sero 
DC 
shed 
RD 
sero 
RD 
shed References 
        
Human 
Pandemic H1N1 A/South Carolina/1/1918   3/3 3/3 
(Tumpey et 
al., 2007) 
Human 
Pandemic H1N1 A/California/04/2009  ND  3/3 
(Itoh et al., 
2009) 
Human 
Pandemic H1N1 A/California/04/2009 3/3 3/3 2/3 2/3 
(Maines et 
al., 2009) 
Human 
Pandemic H1N1 A/California/04/2009 ND 2/2  ND 
(Cline et al., 
2011) 
Human 
Pandemic H1N1 A/California/04/2009   3/3 3/3 
(Imai et al., 
2012) 
Human 
Pandemic H1N1 A/California/04/2009   2/2 2/2 
(Hale et al., 
2010b) 
Human 
Pandemic H1N1 A/California/04/2009  1/1  1/1 
(Seibert et 
al., 2010) 
Human 
Pandemic H1N1 A/California/04/2009  3/3  3/3 
(Yen et al., 
2011) 
Human 
Pandemic H1N1 A/California/04/2009    3/3 
(Watanabe 
et al., 2013) 
Human 
Pandemic H1N1 A/California/07/2009 3/3 3/3 3/3 3/3 
(H. Zhu et 
al., 2013) 
Human 
Pandemic H1N1 A/Texas/15/2009 3/3 3/3 2/3 2/3 
(Maines et 
al., 2009) 
Human 
Pandemic H1N1 A/Mexico/4482/2009 3/3 3/3 2/3 2/3 
(Maines et 
al., 2009) 
Human 
Pandemic H1N1 A/England/195/2009    3/3 
(van 
Doremalen 
et al., 2011) 
Human 
Pandemic H1N1 A/Netherlands/602/2009    4/4 
(Munster et 
al., 2009) 
Human 
Pandemic H1N1 A/Netherlands/602/2009    4/4 
(Herfst et 
al., 2010) 
Human 
Pandemic H1N1 A/Denmark/524/09 2/2 2/2 2/2 1/2 
(Duan et 
al., 2010) 
Human 
Pandemic H1N1 A/Quebec/141447/09 5/5 5/5   
(Hamelin et 
al., 2010) 
Human 
Pandemic H1N1 A/Québec/147023/2009  4/4  4/4 
(Hamelin et 
al., 2011) 
Human 
Pandemic H1N1 A/Kawasaki/UTK-4/09  ND  1/2 
(Itoh et al., 
2009) 
Human 
Pandemic H1N1 A/Osaka/164/2009    3/3 
(Kiso et al., 
2010) 
Human 
Pandemic H1N1 A/Vietnam/HCM9727/2009    3/3 
(Kiso et al., 
2010) 
Human 
Pandemic H1N1 A/Korea/CJ01/2009   2/2 2/2 
(Song et al., 
2010) 
Human 
Pandemic H1N1 A/Hong Kong/415742/09  3/3  2/3 
(Yen et al., 
2011) 
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Type of 
virus 
Sub 
type Strain Name 
DC 
sero 
DC 
shed 
RD 
sero 
RD 
shed References 
        
Human 
Pandemic H2N2 A/El Salvador/2/57 1/3 0/3 1/3 1/3 
(Pappas et 
al., 2010) 
Human 
Pandemic H2N2 A/Albany/6/58 3/3 3/3 3/3 3/3 
(Pappas et 
al., 2010) 
        
Human 
Seasonal H1N1 A/Texas/36/91   3/3 3/3 
(Tumpey et 
al., 2007) 
Human 
Seasonal H1N1 A/Brisbane/59/2007 4/4 4/4   
(Ellebedy et 
al., 2011) 
Human 
Seasonal H1N1 A/Brisbane/59/2007 3/3 3/3 3/3 3/3 
(Maines et 
al., 2009) 
Human 
Seasonal H1N1 A/Brisbane/59/2007 (oc) ND ND 1/3 1/3 
(Belser et 
al., 2012) 
Human 
Seasonal H1N1 A/Brisbane/59/2007 (in) ND ND 1/3 1/3 
(Belser et 
al., 2012) 
Human 
Seasonal H1N1 A/Netherlands/26/07    4/4 
(Munster et 
al., 2009) 
Human 
Seasonal H1N1 A/Panama/2007/09 ND ND 3/3 3/3 
(Maines et 
al., 2006) 
Human 
Seasonal H1N1 A/Panama/2007/09 (oc) ND ND 1/3 1/3 
(Belser et 
al., 2012) 
Human 
Seasonal H1N1 A/Quebec/15230/08 4/4 4/4 ND ND 
(Abed et al., 
2011) 
        
Human 
Seasonal H3N2 A/Victoria/03/75    2/2 
(Itoh et al., 
2009) 
Human 
Seasonal H3N2 A/Victoria/3/75 ND ND 3/3 3/3 
(Maines et 
al., 2006) 
Human 
Seasonal H3N2 A/Victoria/3/75  6/6   
(Roberts et 
al., 2011) 
Human 
Seasonal H3N2 A/LA/1/87  2/2   
(Herlocher 
et al., 2001) 
Human 
Seasonal H3N2 A/Wuhan/359/95  2/2   
(Yen et al., 
2005) 
Human 
Seasonal H3N2 A/Wuhan/359/95 2/2 2/2 ND ND 
(Yen et al., 
2007) 
Human 
Seasonal H3N2 A/Wuhan/359/95  3/3  2/3 
(Yen et al., 
2011) 
Human 
Seasonal H3N2 A/Sydney/5/97  2/2   
(Herlocher 
et al., 2001) 
Human 
Seasonal H3N2 A/Memphis/14/98 2/2 2/2 2/2 2/2 
(Wan et al., 
2008) 
Human 
Seasonal H3N2 A/Panama/2007/1999    2/2 
(Gustin et 
al., 2011) 
Human 
Seasonal H3N2 A/Wyoming/3/03    2/2 
(Jackson et 
al., 2009) 
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Type of 
virus 
Sub 
type Strain Name 
DC 
sero 
DC 
shed 
RD 
sero 
RD 
shed References 
        
Human 
Seasonal H3N2 A/Fukui/20/2004  2/2   
(Hurt et al., 
2010) 
Human 
Seasonal H3N2 A/Bethesda/NIH12–0/2008  3/4   
(Memoli et 
al., 2010) 
Human 
Seasonal H3N2 A/Perth/16/2009    2/3 
(Houser et 
al., 2013) 
Human 
Seasonal H3N2 A/Texas/50/2012 3/3 3/3 3/3 3/3 
(Belser et 
al., 2013a) 
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virus 
Sub 
type Strain Name 
DC 
sero 
DC 
shed 
RD 
sero 
RD 
shed References 
        
Avian H1N1 A/duck/Alberta/35/76   0/3 0/3 (Tumpey et al., 2007) 
Avian H1N1 A/duck/Alberta/35/76 1/3 1/3 ND ND 
(Van 
Hoeven et 
al., 2009) 
Avian H1N1 A/duck/Alberta/35/76    0/3 (Itoh et al., 2009) 
Avian H1N1 A/duck/NewYork/15024-21/96 1/3 1/3 0/3 0/3 
(Van 
Hoeven et 
al., 2009) 
Avian H1N1 A/shorebird/DE/300/2009  2/2  2/2 (Koçer et al., 2012) 
Avian H1N1 A/mallard/MN/Sg-00627/2008  0/2  0/2 (Koçer et al., 2012) 
        
Avian H1N9 A/Ruddy Turnstone/DE/1171/02 0/3 0/3 ND ND (Driskell et al., 2012) 
        
Avian H2N2 A/Mallard/New York/6750/78 1/3 1/3 0/3 0/3 (Pappas et al., 2010) 
        
Avian H5N1 A/Hong Kong/213/03 1/4 0/4 ND ND (Yen et al., 2007) 
Avian H5N1 A/Hong Kong/213/03 ND ND 0/3 0/3 (Maines et al., 2006) 
Avian H5N1 A/Vietnam/1203/04 0/4 0/4 ND ND (Yen et al., 2007) 
Avian H5N1 A/Vietnam/1203/04 1/3 0/3 0/3 0/3 (Maines et al., 2011) 
Avian H5N1 A/Turkey/65-596/06 0/2 0/2 ND ND (Yen et al., 2007) 
Avian H5N1 A/Vietnam/JP36-2/05 1/3 2/4 ND ND (Yen et al., 2007) 
Avian H5N1 A/Hong Kong/486/97  1/2 2/3 0/3 (Maines et al., 2006) 
Avian H5N1 A/Hong Kong/486/1997 2/2 1/2 2/3 0/3 (Maines et al., 2011) 
Avian H5N1 A/Vietnam/HN30408/05  0/3 0/3 0/3 (Maines et al., 2006) 
Avian H5N1 A/Indonesia/5/05  0/3 0/3 0/3 (Maines et al., 2006) 
Avian H5N1 A/Indonesia/5/2005   0/2 0/2 (Munster et al., 2009) 
Avian H5N1 A/Thailand/16/04    0/3 (Jackson et al., 2009) 
Avian H5N1 A/egret/Egypt/1162/2006 0/2 0/2 0/2 0/2 (Chen et al., 2011a) 
Avian H5N1 A/duck/Guangxi/35/2001     (Y. Zhang et al., 2013) 
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Type of 
virus 
Sub 
type Strain Name 
DC 
sero 
DC 
shed 
RD 
sero 
RD 
shed References 
        
Avian H6N1 A/Ruddy Turnstone/DE/892/02 3/3 3/3 ND ND (Driskell et al., 2012) 
        
Avian H6N5 A/Aquatic Bird/Korea/CN5/2009 ND 1/2   (Nam et al., 2011) 
        
Avian H7N2 A/Tky/VA/4529/02 0/3 0/3 0/3 0/3 (Belser et al., 2008) 
Avian H7N2 A/NY/107/03 3/3 3/3 0/3 0/3 (Belser et al., 2008) 
Avian H7N2 A/NY/107/03 (oc) 3/3 2/3 ND ND (Belser et al., 2012) 
Avian H7N2 A/Ck/Conn/260413–2/03 1/3 1/3 0/3 0/3 (Belser et al., 2008) 
Avian H7N3 A/Canada/504/04 0/3 0/3 0/3 0/3 (Belser et al., 2008) 
Avian H7N3 A/mallard/Albetera/24/01 2/3 2/3 0/3 0/3 (Song et al., 2009) 
Avian H7N7 A/ Netherlands /219/03 0/3 0/3 0/3 0/3 (Belser et al., 2008) 
Avian H7N7 A/Netherlands/230/03 2/3 2/3 0/3 0/3 (Belser et al., 2008) 
Avian H7N7 A/Netherlands/230/03 (oc) 3/3 3/3 ND ND (Belser et al., 2012) 
Avian H7N9 A/duck/Gunma/466/2011    0/3 (Watanabe et al., 2013) 
Avian H7N9 A/Anhui/1/2013    1/3 (Watanabe et al., 2013) 
Avian H7N9 A/Anhui/1/2013 4/4 4/4 2/6 2/6 (Belser et al., 2013a) 
Avian H7N9 A/Shanghai/1/2013 4/4 4/4 1/3 1/3 (Belser et al., 2013a) 
Avian H7N9 A/Shanghai/2/2013 3/3 3/3 2/3 1/3 (H. Zhu et al., 2013) 
        
Avian H9N2 A/guinea fowl/Hong Kong/WF10/99 5/5 5/5 0/2 0/2 
(Wan et al., 
2008) 
Avian H9N2 A/dk/Hong Kong/Y280/97 1/2 1/2 ND ND (Wan et al., 2008) 
Avian H9N2 A/quail/Hong Kong/A28945/88 0/2 0/2 ND ND (Wan et al., 2008) 
Avian H9N2 A/ck/Hong Kong/SF3/99 0/2 0/2 ND ND (Wan et al., 2008) 
Avian H9N2 A/ck/Jordan/554/03 0/2 0/2 ND ND (Wan et al., 2008) 
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DC 
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RD 
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Swine H1N1 A/sw/Korea/SCJ01/2009 PN   2/2 2/2 (Song et al., 2010) 
Swine H1N1 A/swine/Korea/CAN01/04 EA   1/2 1/2 (Song et al., 2010) 
Swine H1N1 A/Ohio/2/07 TR (no seq) 3/3 3/3 1/3 0/3 (Belser et al., 2011a) 
Swine H1N1 A/Texas/14/08 TR (neighbour seq) 3/3 3/3 2/3 0/3 
(Belser et 
al., 2011a) 
Swine H1N1 A/Sw/HK/4167/99 CL  3/3  0/3 (Yen et al., 2011) 
Swine H1N1 A/Sw/HK/NS29/09 EA  2/3 2/3 1/3 0/3 (Yen et al., 2011) 
Swine H1N1 A/Sw/HK/201/10 EA+TR  3/3  0/3 (Yen et al., 2011) 
Swine H1N1 A/sw/Italy/3169-7/1994 EA (no seq) 1/2 1/2 0/2 0/2 
(Barman et 
al., 2012) 
Swine H1N1 A/sw/NC/47834/2000 TR   2/2 0/2 0/2 (Barman et al., 2012) 
Swine H1N1 A/sw/NC/18161/2002 TR 1/2  1/2 0/2 0/2 
(Barman et 
al., 2012) 
Swine H1N1 A/sw/MN/6998/03 TR  2/2 1/2 1/2 (Barman et al., 2012) 
Swine H1N1 A/sw/NC/38448-1/2005 TR+huHANA  2/2  2/2 
(Barman et 
al., 2012) 
        
Swine H1N2 A/Sw/HK/915/04 CL+EA+TR  5/5  1/5 (Yen et al., 2011) 
Swine H1N2 A/Sw/Arkansas/2976/02 TR (no seq)  3/3  0/3 
(Yen et al., 
2011) 
Swine H1N2 A/sw/IN/9K035/99 TR+huNA  2/2 1/2 1/2 (Barman et al., 2012) 
Swine H1N2 A/sw/MN/1192/01 TR+huNA  2/2  2/2 (Barman et al., 2012) 
Swine H1N2 A/sw/MN/5763/03 TR+huNA  2/2 1/2 1/2 (Barman et al., 2012) 
Swine H1N2 A/sw/OK/011521-5/2008 TR+huHANA  2/2  2/2 
(Barman et 
al., 2012) 
Swine H1N2 A/Sw/Korea/1130/2009 TR   0/3 0/3 (Pascua et al., 2012) 
Swine H1N2 A/Sw/Korea/1204/2009 TR   1/1 3/3 (Pascua et al., 2012) 
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Swine H2N3 A/swine/Missouri/2124514/2006 av+TR 3/3 3/3   
(Ma et al., 
2007) 
        
Swine H3N2 A/sw/OK/011506/2007 TR+huHANA  2/2  2/2 
(Barman et 
al., 2012) 
Swine H3N2 A/Sw/Korea/CY05/2007 TR   0/3 0/3 (Pascua et al., 2012) 
Swine H3N2 A/Sw/Korea/CY07/2007 TR   1/3 0/3 (Pascua et al., 2012) 
Swine H3N2v A/Indiana/08/11    3/3 3/3 (Pearce et al., 2012) 
Swine H3N2v A/Minnesota/11/10 (no seq)   3/3 3/3 (Pearce et al., 2012) 
Swine H3N2v A/Pennsylvania/14/10 (no seq)   3/3 3/3 (Pearce et al., 2012) 
Swine H3N2v A/Kansas/13/2009   2/3 2/3 (Pearce et al., 2012) 
Swine H3N2v A/Indiana/08/11     3/3 (Houser et al., 2013) 
        
Table 1.2. Ferret transmission. This table includes all wild type viruses, with which ferret transmission 
experiments have been undertaken, and their results.  
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1.6.2.4 Receptor binding and transmission of the 1918 H1N1 
pandemic virus 
There are now available 17 sequences that described the receptor binding 
site of HA from the 1918 H1N1 ‘Spanish’ influenza pandemic. They were 
obtained from lung tissue samples that were formalin fixed, paraffin 
embedded, and archived by the military or exhumed from a mass grave 
preserved by permafrost (Reid et al., 1999, 2003; Sheng et al., 2011; 
Taubenberger et al., 1997). The sequences show minimal variation except at 
residue 225 where there is a mixed population of 10 Ds, 6 Gs, and 1 N. The 
consensus of avian H1 HA sequences available when this comparison was 
done showed that G dominated at position 225 (Glaser et al., 2005). 
Comparison with the avian consensus sequence also showed that H1 HA of 
viruses isolated from birds had 190E, while all pandemic 1918 HAs had 190D. 
Interestingly, analysis of avian H1 HA sequences currently available in 
Genbank (accessed 27/06/2013) shows that the consensus of sequences 
from ducks (N=101) gives the avian consensus, 190E/225G, while the 
consensus from terrestrial birds (N=22) is 190D/225G. (In terrestrial birds, at 
position 190, there are 14Ds and 8Es. One H1 HA virus isolated from a 
Turkey has 190D/225D). The consensus sequence of swine H1 HAs (not 
including recent 2009 pandemic sequences) is 190D/225G.  
The 1918 influenza virus was reconstructed to match the sequence obtained 
from a formalin fixed tissue using reverse genetics (Tumpey et al., 2007). 
Following this, derivative viruses were generated with changes in the HA RBS 
and the binding preference for resialated RBCs was established. In addition a 
number of groups expressed the HA using recombinant baculovirus and 
probed glycan arrays to investigate the SAG preference. In general these 
studies demonstrate that 1918 H1 HA with 190D/225D bound strongly to α2,6-
SAGs and almost did not bind at all to α2,3-SAGs (Maines et al., 2009; 
Srinivasan et al., 2008; Stevens et al., 2006a; Tharakaraman et al., 2013b; Xu 
et al., 2012b; W. Zhang et al., 2013b). Furthermore, the binding affinity of 
1918 HA with 190D/225D was similar to HAs of human seasonal H1N1 
viruses (Srinivasan et al., 2008). 
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On the other hand, mutation at residue 225 to create 1918 H1 HA with 
190D/225G resulted in an HA that bound preferentially to α2,6-SAGs, but 
retained significant ability to bind to α2,3-SAGs (Stevens et al., 2006a; W. 
Zhang et al., 2013b). Using slightly different length glycans, Srinivasan et al. 
concluded that the same 1918 HA with 190D/225G bound to 3’SLN–LN better 
than 6’SLN-LN at low concentrations and equally at high concentrations 
(Srinivasan et al., 2008). Preference aside, the data showed that the binding 
affinity of 1918 HA 190D/225G to 6’SLN-LN was clearly lower than the affinity 
of a similar 1918 HA with 225D and other HAs of human seasonal H1N1 
viruses (Srinivasan et al., 2008). Furthermore, mutation of residue 190 from 
the human consensus, D, to the waterfowl consensus, E, when accompanied 
by 225G, switched receptor binding preference more completely, such that 
the HA strongly preferred to bind α2,3-SAGs (Glaser et al., 2005; Srinivasan 
et al., 2008; Stevens et al., 2006a).  
Experiments using ferrets showed that a 1918 H1N1 virus with 190D/225D 
residues in the HA transmitted efficiently through the air, as it was shed by 
three out of three naïve ferrets in adjacent cages from those infected. A 
waterfowl H1N1 virus with 190E/225G was not shed by any of the three 
ferrets exposed in the same way. The 1918 H1N1 virus with two back 
mutations to the α2,3-SAG preferring HA sequence, 190E/225G, also did not 
transmit as determined by both absence of virus in the exposed ferret nasal 
washes and absence of antibodies in serum three weeks after exposure. 
However, a 1918 H1N1 mutant with HA 190D/225G did transmit through the 
air, albeit with low efficiency. This virus was shed by one of three ferrets and 
another ferret seroconverted (Tumpey et al., 2007). This body of work was the 
first to link receptor binding preference with transmission through the air in the 
ferret model, and illustrated that viruses with intermediate receptor preference 
might be pandemic precursors. 
1.6.2.5 Receptor binding and transmission of the 2009 H1N1 
pandemic virus 
Sequencing of swine influenza viruses improved in 1976 with the “Swine Flu” 
scare at Fort Dix. Dependent upon the availability of plentiful sequences, 
phylogenetic analysis of the 2009 H1 HA clearly shows that it originated from 
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the classical swine lineage. Therefore, we can be reasonably certain that this 
HA has been circulating in swine for over a century (Smith et al., 2009a, 
2009b). This new round of ‘Swine Flu’ stimulated further collection of 
thousands of sequences from humans and swine and their deposition in 
sequence databanks. Therefore, we can also be certain that the 2009 H1 HA 
had a relatively consistent sequence through its receptor binding domain. The 
only amino acid that showed high variability (similar to that of aa 225 in 1918) 
among sequences collected in the early part of the pandemic outbreak was 
residue 206. Of sequences collected before July 2009, 67% of HAs had the 
swine consensus amino acid, S, at this position and the other 33% had T. 
This residue is located along the side of the HA head region where it interacts 
with another HA head to form a trimer. Therefore it may play a role in 
stabilising the trimer. 
 
1.6.2.5.1 225 
One major difference between viruses sequenced from 1918 and 2009 is the 
location of their isolation. 1918 virus sequences were obtained from 
pathological specimens of lung tissue, while 2009 virus sequences were more 
often obtained from nasopharyngeal swabs. As stated above, of the few 
human H1N1 HA sequences available from 1918 about 60% had 225D and 
35% had 225G. In contrast, more than 98% of 600 pandemic H1N1 HA 
sequences from viruses isolated before July 2009 had 225D. 2009 H1N1 
viruses with 225G have been associated with severe disease, but were more 
often found in BAL or endotracheal aspirate samples than in nasopharyngeal 
samples (H. Chen et al., 2010; Piralla et al., 2011). The effect of the D/G 
amino acid at position 225 on receptor preference of 1918 H1 HA was more 
profound than in the 2009 HA. By ELISA, biacore assay, and glycan array the 
2009 HA with 225G was shown to increase α2,3-SAG binding, but retain a 
preference for α2,6-SAGs (Belser et al., 2011b; Y. Liu et al., 2010; W. Zhang 
et al., 2013b) 
The effect of this polymorphism on transmission has been studied in both the 
ferret and the guinea pig model. In the genetic background of a 2009 H1N1 
Netherlands strain (NL602), both HA-225D and -225G transmitted via aerosol 
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to 4/4 guinea pigs (Chutinimitkul et al., 2010a). In the California strain (CA04) 
background, both HA-225D and -225G transmitted via aerosol to 2/3 ferrets. 
Virus with HA-225G was shed by exposed ferrets a day or two earlier after 
exposure than virus with HA-225D. Unexpectedly, the titres of both viruses 
were reported as similar in the URT and LRT, but this may have been 
because samples were collected every other day rather than daily (Belser et 
al., 2011b). 
The 2009 pandemic virus was reintroduced to swine and has circulated in 
them since. The swine HA consensus sequence is 225G, but about 4% of 
swine H1N1 isolates have 225D. It is possible that the virus population that 
initially led to the 2009 pandemic had both 225D and G. Indeed, Yasugi et al. 
suggested that 225G may have been a minor population from the early phase 
of the pandemic and that the 225D virus population was favourably selected 
over time with continued human transmission (Yasugi et al., 2012). It is also 
possible that humans pre-disposed to severe infection might be more tolerant 
of expanding populations of virus with HA-225G.  
 
1.6.2.5.2 226 
Tissue tropism, glycan array, and transmission experiments have also been 
used to characterise other amino acid differences between swine consensus 
and 2009 pandemic HA sequences. Although most pandemic virus isolates 
had HA-Q226, a few less than 2% (isolated before 2011) had 226R. HA-
Q226R mutation was shown to switch receptor binding preference to favour 
α2,3-SAGs. This mutation abolished RD transmission between guinea pigs 
and decreased the efficiency of transmission to ferrets as indicated by 
shedding by ferrets exposed to the mutant virus being lower and later. This 
study also analysed the effect of the Q226R mutation in combination with a 
polymerase mutation in the PB2 gene. The PB2 gene of the pandemic virus 
was part of the TRIG internal gene constellation and had originated from an 
avian virus PB2. The overwhelming majority of 2009 pandemic viruses have 
the mammalian-adapting PB2 motif A271 and only one had the avian virus 
consensus 271T. A at position 271 of PB2 was shown to increase polymerase 
activity in mammalian cells (Bussey et al., 2010). On its own, the mutation 
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PB2-A271T in the pH1N1 2009 virus abolished RD transmission between 
guinea pigs, despite replicating to similar titres obtained by wild type virus. In 
ferrets, the same mutation led to impaired viral replication, but transmission 
levels were sustained albeit with with a slight delay. Interestingly, the double 
mutation HA-Q226R and PB2-A271T abolished transmission via RD between 
ferrets (Zhang et al., 2012). This study shows that the same virus can have 
different transmission capabilities in ferrets and guinea pigs.  
 
1.6.2.5.3 227 and other mutations 
A number of studies have investigated the role of residue 227 in pH1N1 2009 
HA in receptor binding and virus transmissibility. Van Doremalen et al. (2011) 
found that back mutation of a prototypic pandemic HA (E195/09) from 227E to 
the swine consensus 227A increased HA binding to and virus infection of 
ciliated cells over non-ciliated cells in HAE cultures. This has been previously 
shown to indicate a difference is SAG linkage preference (Ayora Talavera, 
Shelton et al. 2008; Shelton et al. 2009).  The E227A mutation in a 2009 
pandemic H1N1 virus reduced its ability to grow in primary human airway 
epithelial cells. However, the mutant virus still transmitted by respiratory 
droplet to the same number of exposed ferrets as the wild type virus. Although, 
it is interesting to note that donors infected with the mutant virus shed over 
half a log more virus than donors infected with the wild type, yet two out of 
four ferrets exposed to the mutant virus started shedding virus much later 
(van Doremalen et al., 2011).  In contrast to the results of van Doremelan et al, 
Xu et al. showed that the E227A mutation of a another prototypic 2009 
pandemic HA (CA04/09) had the opposite effect and increased its binding 
affinity to 6’SLNLN and more specifically to α2,6-SAGs with sulphated 
GlcNAc-3, a glycan that had three LacNAcs, or one with two LacNAcs plus an 
extra branch with α2,6-linked SA (Xu et al., 2012b).  In conjunction with the 
227A mutation, a K133R back mutation from the human pandemic sequence 
to the swine consensus sequence, further increased the diversity of α2,6-
SAGs that could be bound by the pandemic HA and increased its binding to 
two branched α2,3-SAGs. The double mutant reflects HA sequences 
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commonly found in swine (Xu et al., 2012b). It would be interesting to know 
the effect of E227A in conjunction with K133R on transmission.  
Further evidence that supports the idea that viruses that initiate a pandemic 
are not yet fully switched in SAG preference comes from data showing that 
HAs isolated later than CA04 during the 2009 pandemic, such as 
A/Netherlands/602/2009 and A/New York/06/2009, which showed increased 
affinity for α2,6-SAGs compared with prototype pandemic outbreak viruses 
(Xu et al., 2012a).  
In 95% of classical swine H1 HAs residue 200 is A. H1 HA of CA04/09 had 
200T, while over 99% of other 2009 pandemic H1 HAs had A. De Vries et al. 
showed that the sole mutation T200A in CA04/09 HA did not significantly 
affect this HA’s ability to bind fetuin, but did increase binding to 6’SLNLNLN 
on a glycan array.   Furthermore, in the same way that K133R influenced the 
effect of the E227A mutation, they found that in the presence of T200A/E227A 
increased binding to fetuin and binding to a more diverse set of glycans in an 
array (de Vries et al., 2011). T200A may account for the difference in receptor 
binding affinity of CA04/09 as compared to NL602/09 and NY06/09, which 
both have 200A. 
Taken together, these studies suggest a possibility that the mutations A227E, 
R133K, and T200A were present in the seed virus that zoonosed from a pig to 
a human or that they became dominant in early human-to-human 
transmission events, since they are present in over 99% of human 2009 
pandemic HA sequences. 
 
1.6.2.5.4 2009 H1N1 Summary 
2009 marked the first pandemic where phylogenetics indicate a swine virus as 
a direct precursor. Sampling and sequencing without egg passage was widely 
employed and sequences of viruses that caused infections within a few 
months of the predicted zoonotic event are available. Therefore, it is tempting 
to speculate that the low α2,6-SAG receptor binding affinity of early isolated 
pandemic virus HAs may portray a characteristic necessary for a strain to 
initiate a pandemic.   
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Human seasonal H1N1 viruses from recent years bind strongly to an array of 
α2,6-SAGs and proportionally very much less, almost undetectably to α2,3-
SAGs (Walther et al., 2013; Yang et al., 2010a). Similar patterns of strong 
α2,6-SAG preference are observed with most swine H1 HAs. Using glycan 
arrays, swine H1 HAs almost always show recognition of a broad display of 
α2,6-SAGs. Occasionally they show binding peaks for one to two α2,3-SAGs, 
which are about a third of the height of the α2,6-SAG peaks. Less commonly, 
glycan arrays indicate a more precise recognition by swine virus H1 HAs of 
only a few α2,6-SAGs (Bradley et al., 2011; Chen et al., 2011b; de Vries et al., 
2011; Walther et al., 2013; Xu et al., 2012b). 
In summary, it seems highly likely that initial human-transmissible H1 HA 
pandemic viruses had HAs with a preference for α2,6-SAGs, but the overall 
affinity for α2,6-SAGs was much lower than later pandemic isolates and 
human seasonal H1 HAs.   
1.6.2.6 Receptor binding and transmission of the 1957 H2N2 
pandemic virus 
1.6.2.6.1 The genetic origin or the H2N2 1957 pandemic virus 
Smith et al. suggest that the avian MRCAs of human 1957 pandemic NA, HA, 
and PB1 existed between 1945 and 1957. More precisely, their Baysian 
Confidence Interval suggests that the avian MRCA of HA existed between 
1952 and 1957. They also show that the other five genes descended directly 
from the human seasonal H1N1 lineage. Furthermore, they raise the 
possibility that the three avian-origin genes could have sequentially been 
introduced into the same virus through reassortment within a mammal, which 
would have begun some time in or after 1945. For example, co-infection of a 
mammal (human or swine), with an avian and human virus may have led to 
reassortment and transmission of a virus with an avian N2 NA and seven 
other genes from the human virus. Further reassortment during a second co-
infection of another mammal with the previous virus and another avian virus 
could have given rise to double and triple reassortants, adding a new avian 
virus gene each time (Smith et al., 2009a). This step-wise reassortment 
pattern would allow genes of viruses from one host to adapt to another one at 
a time and thus likely be less restrictive on transmission. 
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A common assumption is that the mammals that supported the reassortments 
were most likely swine because they are thought of as a ‘mixing vessel’ (Ito et 
al., 1998). However, a multi-country survey of serum from swine indicated that 
the H2N2 virus was not present in swine before the pandemic and did not 
transmit from humans to swine during outbreaks in the human population. 
This study did find that some horse serum collected before or during 
pandemic outbreaks in humans was HAI positive for a prototypic 1957 H2N2 
virus, but less so after the pandemic passed, so the results are questionable 
(Kaplan and Payne, 1959). Combined with the facts that only H3N8, H7N7, 
and H7N1 viruses have ever been isolated from horses and the fact that these 
viruses preferentially bind sulphated α2,3-SAGs and furthermore prefer 
NeuGca2-3Gal over NeuAca2-3Gal, it seems unlikely that horses were the 
mammal that mixed human and avian viruses to make the 1957 pandemic 
strain (Gambaryan et al., 2012; Yamanaka et al., 2010). Scarcity of H2 HA 
viruses in swine is similar to that in horses. Only two swine viruses with H2 
HAs have been detected since the first swine strain was detected in 1930 
(Shope, 1931)(database accessed on 27/07/2013) and these likely signify a 
transient zoonosis from terrestrial birds in 2006. Therefore, it seems most 
likely that the reassortment events between the human and avian viruses that 
led to the 1957 H2N2 pandemic strain occurred in humans.  
Early isolates of 1957 were passaged in eggs and have some variability in 
sequence. The sequences that lead to inefficient replication and transmission 
in mammals may shed light on amino acids that changed during the transition 
from an avian to a mammalian host. Isolates collected from later years, after 
human adaptation, confirm which mutations supported efficient human-to-
human transmission.    
1.6.2.6.2 Amino acids important for a switch in receptor binding of 1957 
H2 HA  
The key amino acids that determine the RBS specify of H2 HA appear to differ 
from those of H1 HA. Sequences from avian H2 HAs, of both duck and 
terrestrial birds, have 190E/225G and all human H2N2 HAs retained 
190E/225G through 1964. Instead amino acids 226 and 228 appear to be key 
in switching receptor binding preference of H2 HAs. Sequences of H2 HAs 
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from both duck and terrestrial birds have 226Q/228G, while sequences of H2 
HAs of viruses isolated from humans in 1957 and 1958 are mixed, but those 
from 1959 and later almost consistently have 226L/228S (Matrosovich et al., 
2000).  
Human H2 HAs from 1957 and 1968 viruses with either natural or engineered 
amino acids 226L/228S or 226L/228G have a clear preference for α2,6-SAGs. 
Those with 226L/228G have lower binding avidity than those with 226L/228S. 
When one pandemic H2 HA was mutated to have 226Q/228S, its receptor 
binding was undetectable, indicating that this pair of amino acids was not 
viable and indeed it is not found in nature. The avian consensus, 226Q/228G, 
in human pandemic H2 HAs led to a clear α2,3-SAG binding preference and 
this binding profile was similar to an H2 HA isolated from a chicken. HAs with 
226L/228S bound to some or many cells on human tracheal tissue, depending 
on which HA they were in, while tracheal tissue binding by HAs with 
226Q/228G was undetected. Binding of the single mutant to tracheal sections 
was not done (Matrosovich et al., 2000; Pappas et al., 2010; Viswanathan et 
al., 2010; Xu et al., 2010). In conclusion, the single aa change Q226L from 
avian consensus to human consensus could switch receptor binding 
preference of pandemic H2 HA isolates. 
Other sequence changes in the H2 HA of the 1957 pandemic virus mat have 
supported its ability to accommodate receptor switching: A crystal structure 
overlay of a duck H2 HA with a human 1957 pandemic HA shows that Y98, 
W153, S136, E190, and N186 all have slightly different locations compared to 
the residues of the human pandemic HA. They were all located at positions 
that make the RBS wider (Liu et al., 2009). Presumably, the mutations 
allowed the binding pocket to widen so that the HA bound more favourably to 
α2,6-SAGs and less favourably to α2,3-SAGs. 
  Ferret transmission experiments clearly showed that the mutation 
Q226L was important in achieving respiratory droplet transmission. A 
pandemic virus with the avian consensus 226Q/228G only transmitted via RD 
when it acquired the mutation Q226L, which occurred naturally in 1/3 
inoculated ferrets. Interestingly and probably due to low dose exposure, DC 
exposed ferrets only seroconverted and did not shed virus with 226Q/228G or 
Q226L. The research team diligently showed that 0/12 plaques picked from 
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the NW of the donor ferrets six days post infection had the 226L mutant, thus 
proving its occurrence was relatively rare. Virus with the single HA-226L 
mutation was shown to transmit to 3/3 RD exposed ferrets after inoculation of 
donors, but with delayed and lower shedding compared to virus with HA-
226L/228S (Pappas et al., 2010). Presumably a chain of transmission 
between hosts that predominantly express α2,6-SAG in their respiratory tract 
would select 228S. In summary, these experiments show how mutations that 
support transmission of a virus with an avian HA might evolve into a pandemic.  
 
1.6.2.7 Receptor binding and transmission of the 1968 H3N2 
pandemic virus 
1.6.2.7.1 The genetic origin or the H3N2 1968 pandemic virus 
The virus that sparked the 1968 H3N2 influenza pandemic apparently 
retained six genes from previously circulating H2N2 human influenza strains 
and acquired two genes of avian virus origin: HA and PB1. Smith et al. 
suggest that the avian HA gene might have been introduced into the viral 
backbone before the PB1 gene (Smith et al., 2009a). If reassortment occurred 
sequentially, then the evolutionary pathway to the 1968 pandemic H3N2 virus 
would have taken two reassortments and relied on two co-infections. The 
Bayesian confidence interval for the MRCA of the H3 HA ranges from 1959 to 
1966. Therefore, the HA may have been circulating in a mammalian 
population for a maximum of nine years or a minimum of two years before it 
was officially proclaimed to be part of a pandemic virus. 
There is no record of a heroic collection of swine serum from around the world 
at the beginning of the 1968. However, some H3N2 viruses of the pandemic 
lineage were isolated from swine and some swine were found to be 
seropositive for H3N2 viruses in the years following the 1968 pandemic 
(Chapman et al., 1978; Cuneo-Crovari et al., 1976; Harkness et al., 1972; 
Schild et al., 1972; Tũmová et al., 1976; Webster et al., 1977). Therefore, the 
possibility that the 1968 pandemic virus arose through reassortment of human 
and avian viruses in swine is much more feasible than it is for the 1957 virus.  
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1.6.2.7.2 Amino acids important for a switch in receptor binding of 1968 
H3 HA  
The mutations that switch receptor preference of H3 HAs from α2,3- to α2,6-
SAGs are similar to those of H2 HA, amino acid residues 226 and 228 again 
play a big role, but some differences exist. Like H2 HAs, over 99% of the H3 
HA sequences of viruses isolated from ducks and terrestrial birds have 
190E/225G. Human H3 HAs from 1968 through 1980 retained 190E/225G. 
Unlike H2 HAs that have 222K, the human H3 HA has 222W. In the pandemic 
1957 H2 HA and 1918 and 2009 H1 HAs, the amino group of K222 hydrogen 
bonds with the 3-hydroxyl of Gal-2 of α2,6-SAGs, thus stabilising the folded 
form (Liu et al., 2009; Stevens et al., 2006a; Xu et al., 2012a). Therefore, the 
stabilisation of Gal-2 in the receptor binding pocket of H3 HA differs from 
previous pandemic HAs. 
In ducks, like H2 HA, the consensus for H3 HA is 226Q/228G. However, while 
those two residues remain consistent in H2 HAs of terrestrial birds, the H3 
HAs of terrestrial bird viruses seem to have split into a chicken and a turkey 
lineage. The chicken lineage H3 HA consensus is 226Q/228G, while the 
turkey lineage consensus is 226V/228S. In human H3 HAs, from 1968 
through 1980, 226L/228S were by far the dominant amino acids, but while 
228S is present in 100% of isolated viruses within this timeframe, a few virus 
isolates have 226Q. Therefore, H3 HA can tolerate 226Q/228S, whereas H2 
HA could not.     
The single amino acid mutation L226Q switched receptor binding preference 
of human viruses with H3 HAs isolated between 1968 and 1977 from α2,3- to 
α2,6-SAGs (Rogers et al., 1983). This switch was associated with a switch 
from binding of non-ciliated cells to ciliated cells and reduced replication in 
primary human airway cell cultures (Matrosovich et al., 2000). The switch is 
further confirmed by a glycan array of an HA from a 1968 pandemic H3N2 
virus showed relatively strong binding to a wide array of α2,6-SAGs and 
weaker binding to an equally wide array of α2,3-SAGs (Xu et al., 2012b). The 
double mutant, from the human to duck consensus, L226Q/S228G in a 1975 
H3N2 virus abrogated transmission from inoculated ferrets to ferrets exposed 
via direct contact (Roberts et al., 2011). Therefore, the only difference 
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between pandemic H3 and H2 HAs is that the amino acid combination 
226Q/228S was tolerated in H3, but not in H2 HA.  
Since H3N2 viruses have circulated in humans for so long in the virological 
era, they provide an interesting example of how a virus with an α2,6-SAG 
preference can evolve over time. Walther et al. showed that seasonal H3N2 
HAs from 1996 to 2010 have taken on all sorts of binding fingerprints and Lin 
et al. have shown the structural basis for the effect of amino acid changes on 
H3 HA receptor binding avidity (Lin et al., 2012; Walther et al., 2013). This 
continual alteration in the receptor binding site of human HAs also occurs in 
swine and birds, albeit at a slower rate (Nerome et al., 1995), and clearly 
plays a role in the evolution of new pandemic strains.  
 
1.6.2.8 Patterns in receptor binding reflect the host origin of 
pandemic viruses 
In summary, the sequences and characteristics of the HAs of the last four 
pandemic viruses illustrate the importance of binding to α2,6-SAGs and 
provide examples of how the switch from α2,3-SAGs can be achieved through 
genetic drift. These four examples indicate that zoonotic HAs with very low 
affinity for both receptor linkages may be poised to achieve a first human-to-
human transmission event that could lead to a pandemic.  
The evolutionary pathways that led to pandemic H1 HAs seem to be different 
from those that led to pandemic H2 and H3 HAs. The positions of LSTc, a 
synthetic pentasaccharide with α2,6-terminally linked SA, when bound to 
pandemic H1 HAs from 1918 and 2009 are very similar as are the positions of 
the same synthetic glycan when bound to pandemic H2 and H3 HAs. 
However, an overlay of the X-ray crystal structures of pandemic H1, H2, and 
H3 with bound LSTc shows that the positioning of the three penultimate 
sugars is different for H1 HAs versus H2 and H3. When bound to a pandemic 
H1 HA, Gal-2 of LSTc is closer to the 220-loop and Gal-4 is twisted so that its 
plane is perpendicular to the 190-helix and its position is closer to the 190 
residue on the left, rather than the 193 residue on the right of the α-helix. 
When LSTc is bound to H2 or H3 HA, Gal-2 is further from the 220-loop. Also, 
the planes of GlcNAc-3 and Gal-4 are parallel to the 190-helix and Gal-4 is 
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closer to the 193 residue, rather than the 190 residue (Liu et al., 2009; Xu et 
al., 2012a). One could speculate that this difference in the way HA has 
accommodated human like SAG binding is because H1 pandemic HAs 
zoonosed from swine to humans while H2 and H3 pandemic HAs zoonosed 
directly from birds.  
 
1.6.3 Amino acids in or near the RBS of HA affect SA binding 
and transmission of avian zoonotic viruses  
The receptor binding preferences of H5, H7, and H9 HAs have been studied 
and found to be quite variable. For example, H9 HA often shows motifs 
associated with α2,6-SAG preference (Matrosovich et al., 2001). However, so 
far, none of these subtype HAs have been incorporated in a human pandemic 
virus. Since viruses with these HAs are hosted by terrestrial birds, as well as 
waterfowl, and are only rarely found in swine it is reasonable to assume that a 
switch in receptor binding preference leading to the emergence of a pandemic 
virus would follow evolutionary pathways more similar to H2 and H3 rather 
than H1 pandemic HAs.  
Phylogenetics shows that the different HA subtypes are evolutionarily related 
as shown in Figure 1.4. Evolutionary closeness leads to similar overall 
structural configurations, but structures of certain areas that are important for 
host-virus interaction, such as the RBS, are more likely determined by a virus’ 
host rather than its evolutionary origins. Shorter branches may indicate closer 
RBS relationships. For example, H5 HAs are relatively closely related to H1 
and H2 HAs, but the evolutionary links from H7 and H10 HAs to H3 HA – and 
H9 HA to H1 and H2 HAs – are relatively long (Russell et al., 2008).  
 
1.6.3.1 Receptor binding and transmission of viruses with H5 HA 
1.6.3.1.1 Receptor binding of viruses with H5 HA 
Due to the perceived pandemic threat posed by H5N1 viruses that have a 
wide host range and geographical spread, receptor binding preference of H5 
HAs has been a focus of influenza virus research for over a decade. Early 
crystal structure observations indicated that human H3 and swine H9 HAs had 
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wider binding pockets than an avian H5 HA (Ha et al., 2001). The shape taken 
by an α2,3-SAG when bound to HA has been described as a ‘cone’, whereas 
the shape taken on by bound α2,6-SAGs has been termed ‘umbrella’ since 
α2,6-SAGs take up more space and therefore require an increased diameter 
of HA receptor biding site to fit (Chandrasekaran et al., 2008). Indeed, 
receptor binding assays indicate that H5 HAs have a strong preference for 
α2,3-SAGs. Most HAs of H5N1 viruses isolated from birds and humans have 
higher affinities and bound to more types of α2,3- than α2,6-SAGs (Ayora-
Talavera et al., 2009; Chandrasekaran et al., 2008; Gambaryan et al., 2006, 
2008; Oshansky et al., 2011; Shinya et al., 2005; Stevens et al., 2008; 
Watanabe et al., 2011; Zhou et al., 2012). A few human isolates of H5N1 
viruses had equal affinities for synthetic α2,3- and α2,6-glycopolymers 
(Yamada et al., 2006), none of them showed patterns reminiscent of human 
HAs.  
Mutations that increase α2,6-SAG binding by H5 HA have been identified 
through mutagenesis. Some mutations (Q192R/S223N, G193R/N182K, and 
L129V/A134V) made binding of H5 HA to α2,3- and α2,6-SAGs equal 
(Auewarakul et al., 2007; Yamada et al., 2006). Other mutations (H3 
numbering unless otherwise indicated:  N158S/Q226L/N248D, 
T160A/Q226L/G228S, E190D/K193S/Q226L/G228S, Q196R/Q226L/G228S, 
N182K/Q222L/G224S (N1 numbering)) made an H5 HA prefer binding to 
α2,6-SAGs, bind to or infect non-ciliated cultured cells more frequently than 
ciliated ones, or increased binding to human or ferret URT tissues (Ayora-
Talavera et al., 2009; Chen et al., 2011a; Chutinimitkul et al., 2010b; Ilyushina 
et al., 2008; Maines et al., 2011; Stevens et al., 2008; Tharakaraman et al., 
2013b; Xiong et al., 2013a; W. Zhang et al., 2013a). Both N158S and A160T 
lead to loss of a glycosylation site near the receptor binding domain, which is 
thought to improve binding to α2,6-SAGs due to a decrease in steric 
hindrance. Interestingly, bearing in mind the proposed structural relationship 
between H5 and H1 HAs, mutations that matched those required for H1 HA to 
support efficient transmission (E190D/G225D) abolished binding to α2,3- and 
α2,6-SAGs altogether in one H5 HA (Stevens et al., 2006b). 
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1.6.3.1.2 Transmission of viruses with H5 HA 
H5N1 viruses, with one to eight genes of avian-virus origin have been tested 
for transmission in guinea pigs and ferrets. The two different species have 
sometimes shown different profiles underscoring that they might have 
different levels of stringency for avian virus transmission or might present 
slightly different mammalian specific barriers. However it is also important to 
note that in some cases the starting strain of H5N1 was also different, 
complicating comparison of the studies. 
Guinea pigs can support DC transmission of natural H5N1 viruses, but 
mutations were required to achieve aerosol transmission between them. Two 
H5N1 viruses were shed by 3/3 guinea pigs exposed to inoculated guinea 
pigs through DC. One of the HAs was shown to have a preference for binding 
α2,3-SAGs, with slightly lower, but significant binding affinity for α2,6-SAGs. 
When a switch in receptor binding preference was engineered through 
mutations Q226L/G228S the number of DC exposed guinea pigs that shed 
virus was reduced by one (Gao et al., 2009). Another natural H5N1 virus was 
shed by 3/4 DC exposed guinea pigs. Transmission efficiency of this H5N1 
virus was reduced by a polymerase mutation from the human to avian 
consensus sequence, PB2-K627E, which itself could be compensated for by a 
different mammalian-adapting polymerase mutation, D701N (Steel et al., 
2009). Guinea pigs exposed through the air to donors infected with one of the 
above H5N1 viruses did not shed virus or seroconvert. However, engineered 
reassortant 7+1 viruses with seven genes from the H5N1 virus and a PA or 
NS gene from a prototypic pandemic H1N1 2009 virus both transmitted 
efficiently and were shed by 6/6 aerosol exposed guinea pigs. Other 
reassortants that retained the avian H5 HA also achieved varying levels of RD 
transmission between guinea pigs. Interpretation of these results led to the 
conclusion that the avian NS and PA genes, from this particular H5N1 virus, 
play major roles in inhibiting mammalian transmission. Furthermore, M and 
NA genes of this particular virus were also shown to play significant roles (Y. 
Zhang et al., 2013).  
The barriers to transmission of H5N1 viruses are evidently higher in ferrets 
than guinea pigs. Most groups reported that ferrets exposed to donors 
infected with avian H5N1 viruses even by direct contact did not become 
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infected. Some groups reported detection of H5N1 viruses in nasal wash or 
rectal swabs of direct contact exposed ferrets, but viral titres were hardly 
detectable and were only reported for a single day (Cline et al., 2011; Maines 
et al., 2006; Yen et al., 2007). Transmission to DC ferrets was achieved with 
three different H5N1 viruses containing three or four HA mutations chosen to 
alter the receptor binding preference to favour α2,6-SAGs, remove the 
glycosylation site at residue 158, and reduce its pH of fusion, but these 
viruses did not transmit via aerosol (Chen et al., 2011a; Maines et al., 2011; 
Shelton et al., 2013).   
Transmission of H5N1 virus between ferrets through the air required further 
adaptations in addition to those adaptations that allowed viruses with H5 HAs 
to transmit via direct contact. This was achieved with three different H5 HA 
genes. Chen et al. achieved RD transmission to 50% of exposed ferrets with a 
reassortant virus that had three HA mutations, which switched its receptor 
binding preference, an N2 NA from a human seasonal strain, and six internal 
genes from an H5N1 virus, different from the HA, that had PB2-627K (Chen et 
al., 2011a). Imai et al. achieved RD transmission to 33% of exposed ferrets 
with a 7+1 reassortant virus that had three HA mutations, which switched its 
receptor binding preference and removed a glycosylation site from its head 
region and seven genes from a prototypic 2009 pandemic strain. A single 
additional amino acid mutation, one that reduced the pH of fusion, increased 
the transmission efficiency of the above 7+1 virus to 67% (Imai et al., 2012). 
The HA used in the reassortant virus transmission had K193, but still bound 
α2,6-SAG in the folded conformation (Xiong et al., 2013a). Herfst et al. 
achieved RD transmission with an avian H5N1 virus that had two HA 
mutations, which switched receptor binding preference and a PB2-E677K 
mutation and was passaged ten times between ferrets. Ferret passage of the 
mutated H5N1 virus led to the acquisition of a large number of extra mutations 
throughout the genome. Two of the additional mutations in the HA were 
shown to further increase binding affinity to α2,6-resialated RBCs. One 
through loss of the 158 glycosylation site. The other was located at the 
interface of two HAs and therefore likely stabilised the trimer (Herfst et al., 
2012). The rest of the acquired mutations await characterisation. A further 
mutation in the 190-helix, R193T/S, may have further increased binding 
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affinity to α2,6-SAGs (W. Zhang et al., 2013a). The phenotypic alterations that 
were required for RD transmission of virus with H5 HA included a switch in 
receptor binding preference, which in all cases was aided by mutation Q226L, 
loss the a glycosylation site on the head region of HA near the RBS, and 
increased stability. Even with all these changes to HA, the transmission 
experiments show that the viruses did not transmit until barriers faced by 
other genes were also overcome. 
 
1.6.3.1.3 H5N1 in humans 
Some of the mutations known to alter receptor binding preference and ferret 
transmissibility have been found in the quasispecies of HA RNA isolated from 
NPS of infected humans. The most frequent of these is the mutation N158D, 
which leads to loss of the glycosylation site, but mutations E190D, G225R, 
N224S/D/H, G228E, and S227N, have also been reported in human samples. 
Q226L was not observed (Kongchanagul et al., 2008). At least one 
(Tharakaraman et al., 2013b) and maybe a few more H5 HAs in nature 
require only one mutation to switch receptor preference. Therefore, it seems 
that the receptor binding barrier in conjunction with many other barriers to 
mammalian transmission have so far prevented H5N1 viruses from gaining 
the ability to cause a human pandemic or an enzootic in pigs. 
 
1.6.3.2 Receptor binding and transmission of viruses with H7 HA 
1.6.3.2.1 Unique features related to receptor binding by H7 HAs  
Comparison of crystal structures of H7 HAs to H1, H3, H5, and H9 HAs 
showed that the 150-loop of H7 HAs is unique in that it extends six angstroms 
inward toward the receptor binding pocket possibly occluding the space 
required for α2,6-SAG binding. A singular H7 HA isolate, the virus NY107, had 
a deletion in the 220-loop. Other H7 HAs do not have this feature (Yang et al., 
2010b).  
The association of H7 viruses with conjunctivitis led researchers to 
hypothesise that the H7 HAs of viruses that zoonosed into humans had a 
specific binding tropism that associated with glycans present in the ocular 
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epithelium. Belser et al. showed that human eye cells expressed high levels of 
α2,3-SAGs detected by MAAI & MAAII and lower levels of α2,3-SAGs as 
detected by SNA (Belser et al., 2009). Gambaryan et al. screened about 70 
H7 HAs from viruses isolated from ducks, terrestrial poultry and horses. They 
found that they all had a23SAG preference with stronger binding to sulphated 
α2,3-SAGs (Su-3’SLN and Su-Slex) in comparison to their binding of 3’SLN, 
Slex, Slec, and Slea. They went on to show that amino acids 185 to 189 in 
HA’s RBS are important for strong binding affinity to Su-3’SLN and Su-SLex. 
Furthermore, they show that K193 interacts with the sulphate group and that 
since Q222 is shorter than K222, which is present in many other HA subtypes, 
it does not clash with the fucose residue (Gambaryan et al., 2012, 2008). 
However, there has been no assessment as to whether or not similarly 
branched α2,3-glycans are present on the human ocular epithelium.  
 
1.6.3.2.2 Receptor binding preference of viruses with H7 HA 
Whole genome sequencing of three viruses and partial genome sequencing of 
20 more isolates collected during the 2003 H7N7 Netherlands outbreak 
showed that the fatal case “FC219” had 14 aa mutations including some in HA, 
and one other case had a HA-D264N mutation, whereas all others had the 
same consensus aa sequence as the chicken virus isolate (Fouchier et al., 
2004). Glycan arrays showed that the HA from FC219 bound to a tertiary 
branched α2,6-SAG, with more affinity than the representative H7 HA. 
However, in general, they both had a strong preference for α2,3-SAGs, similar 
to that of an H5 from 1997. The Canadian H7N3 isolates also preferred α2,3-
SAGs, but bound more α2,6-SAGs than those from the Netherlands outbreak. 
The NY107 isolate with the 220-loop deletion had increased α2,6- and 
decreased α2,3-SAG binding with no clear preference on glycan arrays 
(Belser et al., 2008; Walther et al., 2013; Yang et al., 2010b). However, a solid 
phase binding assay showed that the NY107 HA retained much higher affinity 
for 3’SLNLN than 6’SLNLN. Q226L/G228S mutations of both HAs from a 
conjunctivitis case and the fatal case from the 2003 H7 Netherlands outbreak 
resulted in increased binding to 6’SLNLN, but the HAs retained a preference 
for 3’SLNLNLN (Srinivasan et al., 2013a).  
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The recently emerged H7N9 virus in Eastern China has a number of 
mutations that differentiate it from other H7 viruses. Human isolates vary at 
residue 226. Most have the human consensus L226, but at least one has the 
avian consensus Q226 and another has I226. Avian isolates of H7N9 in 
outbreak areas were found to retain 226Q. Glycan arrays showed that an HA 
with 226Q to preferred α2,3-SAGs, while and HAs with 226L/I bound most 
strongly to α2,6-SAGs (Watanabe et al., 2013). However, a solid phase 
binding assay using an HA with 226L showed a preference for 3’SLN over 
6’SLN (Xiong et al., 2013b). An H7N9 HA with 226L/226G was shown to bind 
with low intensity to cells on formaldehyde fixed ex-vivo human trachea. 
Mutation of the adjacent residue G228S resulted in stronger binding 
(Tharakaraman et al., 2013a). A crystal structure of H7N9 HA with a bound 
α2,6-SAG shows that a bulky G186V residue to the left of the 190-helix in the 
RBS pushes Gal-2 and GlcNAc-3 further away from the 190-helix compared 
to how an α2,6-SAG bound to H2 and H3 pandemic HAs (Xiong et al., 2013b). 
Since H7 HAs have 222Q, rather than 222K like the pandemic H2 HA or 
222W like the pandemic H3 HA, as well as other amino acid differences, it 
remains to be seen if and how stabilisation of the Gal-2 and other sugars of 
α2,6-SAGs might be supported to quantitatively switch receptor preference. 
 
1.6.3.2.3 Transmission of viruses with H7 HA 
Transmission of H7 viruses varies in animal models. The FC219 H7N7 
Netherlands virus was not transmitted from inoculated donor ferrets to any of 
the three DC exposed ferrets. The exposed ferrets did not even seroconvert. 
However, the virus representative of the other cases with conjunctivitis did 
transmit and was shed by two out of three direct contact ferrets. RD exposed 
ferrets did not shed viruses or seroconvert. This result accurately reflects what 
was observed in the community and confirms that a virus with an HA that 
strongly prefers α2,3-SAGs can transmit via direct contact to ferrets and to 
close contacts of humans. Other human H7 isolates had varying rates of 
transmission via direct contact between ferrets and also did not transmit to RD 
ferrets: The NY107 virus transmitted to 3/3 DC ferrets but the Canadian 
isolate did not transmit to any. None of these H7 viruses transmitted to RD 
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exposed ferrets (Belser et al., 2008). An H7N3 poultry virus with preference 
for α2,3-SAGs transmitted via DC to two out of three ferrets with delayed 
shedding kinetics, but robust shedding titres. This virus only infected ciliated 
primary human airway cells at six hours post infection, but at 60 hours post 
infection non-ciliated cells had become infected. It did not transmit to exposed 
ferrets via RD. Interestingly, this virus also transmitted between quails, but not 
between chickens (Song et al., 2009). 
Three very recent studies looking at transmission of wild type H7N9 virus in 
ferrets have all shown some degree of RD transmission, with varying 
efficiency that may reflect the slightly different conditions used by the different 
groups that performed these studies (Belser et al., 2013a; Watanabe et al., 
2013). Inoculation of pigs with a wild type H7N9 virus led to viral shedding by 
the pigs, but only led to seroconversion of 1/4 DC exposed pigs (H. Zhu et al., 
2013). Interestingly, there was a report of an individual who was co-infected 
with an H7N9 and a human seasonal H3N2 viruses, but not reported 
reassortment between the two (Y. Zhu et al., 2013). Given the number of 
humans infected during this outbreak and the receptor binding profile of this 
zoonotic virus it seems the closest to human adaptation of all avian HA 
zoonotic subtypes documented over the last 30 years. 
 
1.6.3.3 Receptor binding and transmission of viruses with H9 HA 
1.6.3.3.1 Receptor binding of viruses with H9 HA 
H9 HAs have variable preference for different SAGs but can clearly 
accommodate mutations that confer preference for α2,6-SAG binding such as 
Q226L. Selection of H9 HAs with 226L has been detected in many avian 
viruses isolated since 1997. Natural isolates with 226Q bound preferentially to 
ovomucoid, which presents α2,3-SAGs and those with 226L bound 
preferentially to pig α2-macroglobulin, which has α2,6-SAGs (Matrosovich et 
al., 2001). Mutation of HA of natural isolates by either Q226L or L226Q 
reversed SAG preference as expected (Srinivasan et al., 2013b; Wan and 
Perez, 2007). Glycan arrays showed that a chicken, quail, and three human 
H9N2 viruses bound to α2,6-SAGs stronger than α2,3-SAGs. Those with 
sequences available had HA-226L (Walther et al., 2013).   
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H9 HAs have 222L, so like H7s binding of α2,6-SAGs will be different from 
that seen with pandemic H2 and H3 HAs. Ha et al. crystallised a swine H9 HA 
with LStc, which shows the Gal-4 and Glc-5 fold over toward the 130-loop, 
rather than extending over the 190-helix, as SAGs to for past pandemic HAs 
(Ha et al., 2001).  
 
1.6.3.3.2 Transmission of viruses with H9 HA 
H9N2 viruses are capable of transmitting between mammals. In guinea pigs, 
three H9N2 viruses from 2007 and 2008 were incapable of transmitting via 
direct contact (Y. Sun et al., 2010). In a separate study, a 2009 and a 2010 
H9N2 virus were both shown to transmit via direct contact between guinea 
pigs, but neither transmitted through the air. Both viruses had 226L (Lv et al., 
2012).  
More H9N2 virus transmission studies have been performed in ferrets. In an 
early study, three wild type H9N2 viruses did not transmit from two inoculated 
ferrets to two exposed ferrets via DC and none of the ferrets seroconverted. 
One of the viruses had 226Q and two had 226L. Two other wild type H9N2 
viruses were shed by one or more ferrets that were exposed to inoculated 
ferrets via DC and these both had 226L. One was from a waterfowl. Q226L 
mutation of the 226Q virus that did initially transmit increased its 
transmissibility so that one of two DC exposed ferrets shed virus. The back 
mutation HA-L226Q of the waterfowl virus that was initially transmissible 
abrogated contact transmission. A reassortant virus containing the HA and NA 
of the waterfowl virus with six internal genes from a human seasonal H3N2 
also transmitted via direct contact. However, none of these viruses 
transmitted through the air between ferrets (Wan et al., 2008). 
In a later study, Sorrell et al. passaged the H9N2/H3N2 reassortant virus ten 
times through ferrets and this led to a virus stock that, when inoculated into 
donor ferrets, transmitted to four out of four RD exposed ferret. Virus was 
detected in their nasal wash with similar titres and kinetics as the human 
seasonal H3N2 virus itself. When the ferret transmissible H9N2 reassortant 
viruses were sequenced, the HA, NA, M and PB2 genes all carried amino acid 
mutations. Sorrell et al. then engineered recombinant viruses that had either 
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just the H9 HA and N2 NA genes or the six internal genes with sequences 
from the transmissible virus. The virus with the ferret-adapted HA and NA 
genes transmitted via RD and was shed by 3/4 exposed ferrets. The fourth 
ferret seroconverted. Virus with six internal ferret-adapted genes and un-
adapted waterfowl HA and NA also transmitted via RD but was shed by only 
1/4 exposed ferrets (Sorrell et al., 2009). This indicated that the HA and NA 
mutations were more important for the ferret-transmissible phenotype. 
However, in the context of six internal genes from a prototypic 2009 pandemic 
virus, both the wild type and the ferret passaged H9N2 HA NA pair supported 
RD transmission. When paired with the 2009 pandemic NA, the wild type 
waterfowl H9 HA did not support transmission whereas the ferret adapted H9 
HA was shed by both ferrets exposed via RD (Kimble et al., 2011).  
Interestingly one of the mutations in the ferret adapted H9 HA was in the HA 
stalk region and likely also affected the pH stability of the HA as has been 
reported for the two independent H5 ferret transmission adaptation 
experiments. Taken together this body of work suggests that viruses with 
avian H9N2 HA and NA and human influenza internal genes might require 
only a few mutations to become transmissible in a humans. 
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1.7 Physiological aspects of influenza virus 
transmission  
In order to understand the barriers an influenza virus has to overcome to 
transmit from animals to people and then from one person to another, it is 
important to understand the routes of transmission, the anatomical location of 
productive infection, and infectious dose. 
1.7.1 Routes of transmission 
Human infection is thought to occur through the landing of water-containing 
respiratory particles on a mucosal surface – delivered either through the air or 
by hand – to the eyes, nose, mouth or airways. Respiratory particles, which 
range in size from less than 1um to greater than 100um in diameter are 
formed during breathing, talking, coughing, sneezing, and spitting. As soon as 
a respiratory particle is exposed to room air desiccation, a process of extreme 
drying occurs. Although desiccation can vary, dependent upon the salt 
concentrations of respiratory fluids and the relative humidity (RH) of the air, it 
can be assumed that it causes the diameter of respirated particles to shrink by 
half as long as RH is below 75% (Holmgren et al., 2011). Therefore, 
desiccation reduces the total volume of a respiratory particle by three quarters, 
concurrently increasing their salt concentration. Respiratory particles of 
different sizes fall out of the air at different rates. Stoke’s Law has been used 
to calculate the amount of time it takes for a respiratory particle of a specific 
diameter to fall three meters, about the height of the ceiling in an average 
room. Particles of diameter <3um will essentially remain suspended in the air 
forever, while 5um particles will fall after about an hour, 10um particles will 
settle by about 20 minutes, and 20um particles in about 5 minutes. Some 
groups differentiate between “aerosols” as particles with diameters <5um and 
“droplets” as particles with diameters >5um (Reviewed by Tellier, 2009). In 
this thesis I use respiratory particles to refer to all expired particle sizes and 
specifically state sizes when they are known. Respiratory particles that land 
on surfaces are called fomites. 
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1.7.2 Transmission from fomites 
Viruses in the larger particles that fall out of the air and become fomites are 
possible sources of infection. When people infected with influenza virus 
sneeze or cough, fomites can fall onto their hands, which can then wipe the 
virions onto other surfaces in a room, or droplets can fall directly onto 
surfaces. One study of survival of influenza virus on household items showed 
that while RNA copy numbers only dropped slightly after 24 hours, infectious 
virions had fallen below the level of detection. Infectious virions were detected 
after application of 3,000 pfu onto items made of different materials, including 
stainless steel, soft toys, plastic and wood. After four hours infectious virions 
were still detected on stainless steel, soft toy material, and light switch 
material, albeit with 2-4 log pfu/ml reduction in concentration (Greatorex et al., 
2011). Influenza virus RNA has been detected on fingers of infected 
individuals and on doorknobs and telephones in their houses. However, viral 
RNA on fingers of nasal/pharyngeal culture positive individuals was only 
detected on 5/20 (25%) of participants and concentration on their fingers was 
low, equivalent to 21.5-29.4 TCID50/ml. Also, viral RNA was not detected 
consistently for longer than 10 minutes (Mukherjee et al., 2012). An 
experiment using guinea pigs looked at the efficiency of transmission via 
fomites. Using two different strains of guinea pigs, Hartley and Strain 13, 
Mubareka et al. housed guinea pigs for 24 hours in cages that had been 
inhabited by inoculated guinea pigs for the previous 48 hours. They found that 
2/12 Hartley and 1/4 Strain 13 guinea pigs became infected through this route 
of exposure, indicating about 12.5-25% transmission efficiency. In parallel 
experiments they found that exposure of naïve guinea pigs to air from guinea 
pigs inoculated with the same amount of the same human seasonal H3N2 
A/Panama/2007/1999 virus led to transmission with 50-75% efficiency. The 
first experiment did not completely remove the possibility that virus particles 
may have remained in the air. Mubareka et al. also exposed 6 guinea pigs to 
cages that had 5 x 105 pfu virus in 30ul volumes deposited on 5 surfaces in 
each cage, including the water bottle and an area the animals normally 
burrowed into, but none of the exposed guinea pigs shed virus or 
seroconverted (Mubareka et al., 2009). Therefore, while transmission via 
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fomites occurs, animal models indicate that it is not as efficient as 
transmission through the air. However, a recent study on hand washing 
concluded that 50% of human-to-human transmission was through the air and 
50% was transmitted by hand (Cowling et al., 2013). 
1.7.3 Transmission via the ocular route 
Large respiratory particles might be inhaled or land directly on the eyes of 
individuals. During an outbreak of human infections with H7N7 avian influenza 
virus a high level of conjunctivitis was noted (Fouchier et al., 2004). Along with 
avian influenza viruses, many other human respiratory viruses have been 
documented to cause ocular complications during infection, including human 
seasonal influenza viruses, adenoviruses, paramyxoviruses (respiratory 
syncial virus (RSV)) and metapneumovirus, corona viruses (SARS and HCoV-
NL63), and picornaviruses (rhino virus) (Belser et al., 2013c). Ocular 
inoculation of mice and ferrets led to infection of the respiratory tract (Belser 
et al., 2013b, 2009). However, ocular infection of ferrets with human seasonal 
viruses led to reduced transmission efficiency via the aerosol route compared 
to intranasal inoculation (Belser et al., 2012). Therefore, while a primary 
infection can occur through the eyes and ocular infection can lead to 
transmission, it is not the most efficient mode for onwards transmission of 
influenza viruses.  
1.7.4 Transmission through the air: volume of air inhaled and 
possible sites of deposition 
Since fomite and ocular transmission are less efficient than transmission 
achieved during co-housing or neighbour-housing of experimentally exposed 
animals, transmission must occur more efficiently through a different route. 
Therefore, inhalation of expired particles is likely. During regular (aka tidal 
(Wanger et al., 2005)) breathing, humans inhale and exhale 12-20 breaths per 
minute (Lindh et al., 2009). Each breath takes in about 0.5 litres (L) of air 
(Barrett et al., 2009), so the tidal volume exchange is 6 to 10 L per minute 
(min). An average room in a house is about 100 m3 and thus holds about 
100,000 L of air. Assuming the higher tidal breathing rate of 10 L/min, it would 
take about 167 minutes or 7 days to breath in all of the air in one room. 
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Obviously this calculation does not account for re-inhalation of exhaled air and 
movement of the individual or particles around the room, which would affect 
the percentage of particles inhaled.  
The respiratory tract offers a large surface area onto which respiratory 
particles can deposit. Understanding where different sized particles land might 
provide insight into influenza virus transmission. At the end of inspiration the 
RH in the trachea ranges from 27.4 - 67.6% and it increases to 85 - 95% by 
the end of expiration (Liener et al., 2006). Breathing in particles can lead them 
to take on water, increase in diameter, and deposit more readily. Modelling of 
airflow in the lungs during breathing has led to the understanding that there 
are “hot spots” or areas where the concentration of particle deposition is 
higher than others. During inhalation the nodes at points where bronchioles 
bifurcate are hotspots for particle deposition. Hot spots for particle deposition 
during expiratory flow were observed on the tip and bottom of parent tubes. A 
typical human lung has 23 bifurcations per extension. Counting starts with the 
first bifurcation where the two bronchi that lead to the right and left lobes 
branch from the end of the trachea (Kleinstreuer et al., 2008; Soni and 
Thompson, 2012). Respiratory droplets of different sizes have different, but 
overlapping, patterns of deposition within the lung. Lambert et al. showed, 
using a mathematical model, that particles of 2.5um deposit in the nasal 
turbinates, pharynx, larynx, trachea and in the upper bronchioles (Figure 
1.8)(Lambert et al., 2011). Reviews agree that particles with diameters greater 
than 20um essentially do not penetrate below the trachea and also that 
particles >6um mainly deposit in the URT. However, reviews give conflicting 
messages about the location of deposition of small sized particles. One says 
deposition at deeper locations within the airways becomes possible, but only 
30% of particles with diameters <5um are deposited there. Another says 
particles 2-6um in diameter land mainly in the central and small airways while 
particles <2um mainly deposit in the alveolar region (Darquenne, 2012; 
Heyder, 2004; Tellier, 2009). Figure 1.8 serves as a reminder that although 
smaller particles can penetrate deeper into the lung, they also land in the 
upper respiratory tract. Therefore, determining the size of respiratory particles 
that contain influenza viruses will only give an understanding of relative 
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probabilities in relation to their location of deposition within an individual’s 
airways.   
 
 
Figure 1.8. Distribution of small particle deposition modelled onto a scan of 
human upper airways. The blue dots in each image show the relative concentration 
of particles as they would deposit in the upper airways at the end of an inspiratory 
period. Particle sizes are indicted on top of each image. The airway tree geometry 
was acquired using a Siemens Sensation 64 multi-detector row computed 
tomography scanner. (This image is adapted from Lambert et al., 2011). 
 
1.7.5 Characterizing what comes out 
During normal tidal breathing humans exhale respiratory droplets of 0.3-
0.8um in diameter (Schwarz et al., 2010). Collection of exhaled human breath 
condensate for 1 minute led to collection of 71ul of liquid (Liu and Thomas, 
2007). Proteins in exhaled breath indicate that the liquid originates in the 
distal airways. The most abundant protein found was SP-A. Interestingly, 
particles in exhaled air were not contaminated with amylase, the most 
abundant protein in saliva, despite participants breathing though their mouth 
(Bredberg et al., 2012). Although it is not known how breath aerosols are 
created, there is one theory that they are created by “Bronchiole Bursts,” 
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which release small <2um particles due to a thin liquid film breaking during 
inhalation when small bronchioles open to let air through (Almstrand et al., 
2010; Johnson and Morawska, 2009). Schwarz et al. found that the number of 
respiratory particles exhaled by people can vary by over two orders of 
magnitude between individuals. However, this seemed insignificant when 
compared to the variation within an individual. The average exhaled number 
of particles ranged from 5 to 5,000 particles per litre from tidal breathing, 
which was relatively non-productive up through deep breathing, which was 
extremely productive. During a study of exhaled particles during normal tidal 
breathing among adults, older age correlated with increased concentration of 
respirated particles (Schwarz et al., 2010). Bearing in mind a proposed role 
for children in transmitting influenza, similar studie on children would be very 
important. Individuals who exhale higher concentrations of respiratory 
particles have been labelled as possible “superspreaders” (Fabian et al., 
2011; Lloyd-Smith et al., 2005). However, it is unclear whether or not 
breathing out higher numbers of respiratory droplets is correlated with 
releasing higher numbers of virus particles into the air. 
1.7.6 How do respiratory particles get out? 
Talking and coughing create respiratory droplets of around 0.8 um that 
originate from different locations within the respiratory tract including the 
bronchioles and larynx (Morawska et al., 2009). Much larger particles, over 
100um in diameter were expired from the oral cavity during both activities. 
Compared to tidal breathing, speaking and coughing put more particles into 
the air, but not as many as heavy breathing did. As far as I am aware the only 
research that attempts to experimentally quantify the size and concentration 
of particles emitted from a human sneeze was published in 1946. Rather than 
using the advanced technology of today, Duguid asked volunteers to place 
dye into their mouth and then sneeze onto a celluloid-surfaced slide. He then 
measured the diameter of the stains left by the droplets under a microscope 
and observed that while the particle size distributions from sneezing and 
coughing were similar, sneezing produced 200-fold more particles compared 
to a cough (Duguid, 1946; Nicas et al., 2005). 
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 Generally, it can be concluded that breathing, talking, coughing, and 
sneezing all create aerosols that are small enough, <3um in diameter, to 
remain suspended in the air indefinitely. The small size of these particles will 
allow about a third of them to penetrate to the lower respiratory tract, leaving 
the other two thirds to penetrate the upper respiratory tract: nasal turbinates, 
pharynx, larynx, and the early bifurcations within the airways. Talking, 
coughing and sneezing also create larger >5um particles that stay in the air 
for shorter than an hour and if they are inhaled they will most likely deposit in 
the upper respiratory tract.  
 
1.7.7 Whether or not breathing, coughing, or sneezing play a 
more important role in transmission is contentious.  
Some groups think sneezing is more important than breathing for spreading 
virus. Bischoff et al. found that coughing and sneezing during air sampling 
was associated with increased virus release into air. This was only detectable 
among patients with the highest nasopharyngeal viral load (Bischoff et al., 
2013). By studying influenza virus transmission within a school Chen et al. 
concluded that sneezing correlated with a higher likelihood of transmission 
than cough (Chen et al., 2009). However, high viral load is usually correlated 
with sneezing, therefore it is difficult to determine which is the cause of 
increased transmisison. In a ferret transmission experiment, Roberts et al. 
showed that the human pandemic H1N1 influenza A/England/195/2009 virus 
transmitted between co-caged ferrets before ferrets displayed fever or 
sneezing by exposing a naïve ferret to an infected one for only 4 hours in the 
morning, the day after inoculation. They also found that 2/3 ferrets exposed 
via RD for 30 hours between days 1 and 2 post infection became productively 
infected while 0/3 ferrets exposed for 30 hours between days 5 and 6 shed 
virus. In this case more transmission occurred at a time marked by low 
numbers of sneezes while lack of transmission occurred at a time where all 
donor animals were observed sneezing. Interestingly, the virus titre detected 
in the NW of ferrets, on days 5 and 6, when RD transmission did not occur, 
was at least one log lower than that when RD transmission did occur (Roberts 
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et al., 2012). Therefore, the amount of virus expired by infected animals was 
probably more important than the route through which it was aerosolised.  
 
1.7.8 Virus particles detected in exhaled air from humans: 
which size particles have the virus in them? 
Measurement of live virus particles in the air is difficult (Tellier, 2009). A 
couple of groups collected air expired by naturally infected humans, but each 
were only able to culture virus from a small minority of volunteers (Lindsley et 
al., 2010b; Milton et al., 2013). Detection of viral RNA in human expired air 
samples has proved easier, but still not every virus positive patient expired air 
samples in which viral RNA could be detected. For example, one study found 
that only 26 (43%) of patients whose nasopharyngeal swabs were RT-PCR 
positive had viral RNA detected in the air around them over a 20-minute 
detection period (Bischoff et al., 2013). Nonetheless, it is thought that viral 
titre in the nose or pharynx correlates with contagiousness (Bell et al., 2006). 
Therefore, in the absence of measurements of virus in the air, the amount of 
virus in the nose of infected individuals can be informative and is more readily 
measured. 
The only human studies in which virus shedding can be exactly related to the 
timing of infection are volunteer challenge studies. A review of the literature by 
Carrat et al. on laboratory controlled human influenza virus infection 
concluded that virus particles in nose or pharyngeal samples (NPS) from 
humans showed an average peak viral titre on day two post infection and the 
average duration of detectable virus was equal to 4.8 days (95% CI: 4.31-
5.29). In these studies, H3N2 infection led to high viral shedding for two days 
longer than (seasonal) H1N1 infection (Carrat et al., 2008). Viral shedding 
patterns observed in non-hospitalised cases after natural human infection with 
seasonal H1N1, seasonal H3N2, and pandemic 2009 H1N1 were very similar 
to the shedding patterns observed during the challenge studies analysed by 
Carrat et al. (Cao et al., 2009; Cowling et al., 2010; Jia et al., 2011; Loeb et al., 
2012; Nilsson et al., 2010; Suryaprasad et al., 2011; Witkop et al., 2010). One 
difficulty faced in longitudinal studies on virus shedding after natural infection 
is determining the day of infection. Therefore, viral shedding is normally 
 115 
related to days post disease onset, which can be subjective. In some 
instances virus was detected in the NPS for much longer than in the human 
challenge studies or non hospitalized cases. For example patients with 
lymphocytopenia (Gooskens et al., 2009), other hospitalised patients (Chin et 
al., 2012; Lee et al., 2009; Meschi et al., 2011; Na et al., 2011) and especially 
those in intensive care (Malato et al., 2011) shed virus for multiple weeks and 
often the strain they were infected with developed drug resistance (Gulland, 
2009; Moore et al., 2011; Weinstock et al., 2003). Another group with 
prolonged shedding is children. One study observed that children had a 
similar amount of virus to infected adults at illness onset, but viral titres in 
NPS endured longer and had a slower rate of decline (Lau et al., 2013). 
Another study observed that otherwise healthy children could shed virus for 
up to two weeks after illness onset and that longer duration of shedding was 
linked with increased rates of influenza like illness within their households 
(Esposito et al., 2011). However, within a school outbreak, the median 
shedding duration was 6 days by RT-PCR and 5 days by culture (Kay et al., 
2011), which is about the same as Carrat et al.’s observation 4.8 days of 
shedding as determined by culture. Loeb et al., who studied a Hutterite 
community, found that asymptomatic infections were infrequent in those that 
shed virus, but they did not look at seroconversion in relation to symptoms or 
viral shedding (Loeb et al., 2012). In summary, Carrat et al.’s viral shedding 
curves are good guidance for the human cases. However, it should be 
acknowledged that a fraction of the population shed virus for longer and they 
are the ones more often sampled in hospital-based studies.  
 
1.7.9 Viral RNA is detected in air expired from naturally 
infected humans.  
A number of different studies collected samples from room air where infected 
people were (Bischoff et al., 2013; Killingley et al., 2010; Lindsley et al., 
2010a), coughing only (Lindsley et al., 2010b), coughing or talking and 
breathing (Milton et al., 2013; Stelzer-Braid et al., 2009), or breathing only 
(Fabian et al., 2008; Stelzer-Braid et al., 2009). As observed with virus in NPS, 
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viral RNA copy numbers fell off with time after symptom onset (Milton et al., 
2013). One study, by Lindsley et al. asked patients who were confirmed to be 
positive for influenza virus infection by qPCR on NPS to cough into an aerosol 
sampler. Influenza RNA was detected in 32 of 38 (84%) subjects. Interestingly, 
40% of the patients who volunteered for this study reported that their 
symptoms had begun three days or more before. This indicates that viral RNA 
could be expired by infected individuals for at least a few days after infection 
(Lindsley et al., 2010b). A study by Bischoff et al. found that five of 26 
“emitters”, who also had high viral loads in their NPS, released on average 32 
times more RNA than other emitters. This difference in aerosolization of viral 
RNA could relate to the time post infection, although all patients had reported 
a fever within the last 12 hours, it was not clear for how long they had the 
fever. Nonetheless, release of high concentrations of influenza viral RNA into 
the air associated with high viral loads in NPS (Bischoff et al., 2013).  
In studies that differentiated between sizes of expired particles, both small 
and large particles were found to carry influenza RNA (Bischoff et al., 2013; 
Milton et al., 2013) although there was not much agreement about which 
particles were more important. Bischoff et al. found that smaller particles, with 
diameters less than 4.7um, were on average 4- to 10-times better at carrying 
viral RNA and Milton et al. found more viral copies were exhaled in fine 
particles compared to coarse particles (Bischoff et al., 2013). One study by 
Lindsley et al. found an equal distribution of viral RNA in small (<4um) and 
large (>4um) particles expired in coughs by infected patients (Lindsley et al., 
2010b) but in another study by the same authors they found less influenza 
RNA in the smaller particles compared to the bigger ones (Milton et al., 2013).  
The concentration of viral RNA copies in the air decreased with further 
distance from the source or less sources. Lindsley et al. detected airborne 
particles with influenza RNA throughout an urgent care medical centre and 
found that the location of samplers that detected influenza RNA correlated 
with the location of influenza virus infected patients (Lindsley et al., 2010a). 
Tseng et al. found that the amount of viral RNA in the air of a paediatric 
emergency room correlated with the number of patients present with lower 
respiratory tract infections (Tseng et al., 2010). Killingley et al. found that viral 
RNA was 1.7-times more likely to be detected at a distance of 3 feet from a 
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patients head than at 7 feet from the same patient (Killingley et al., 2010). 
Bischoff et al., measured viral RNA concentration in the air at one, three, and 
six feet from the head of naturally infected individuals in hospital and found on 
average over 8-fold more RNA copies were detected within three feet from 
patients’ heads than the amount detected six feet away (Bischoff et al., 2013). 
Therefore it is clear that there is a concentration gradient for expired viral RNA 
that decreases with the distance from a patient’s head.  
Most of the experiments reviewed above measured breathing mixed with 
other activities, such as talking or coughing, therefore, it was not clear 
whether or not viral RNA could be expired through breathing alone. However, 
two groups who measured breathing alone, put this question to rest. Fabian et 
al. detected viral RNA in breath-only samples (Fabian et al., 2008). Stelzer-
Braid et al. also detected influenza RNA in the breath of four individuals who 
did not talk or cough during sample collection. One of the four was allowed to 
breath through both nose and mouth during detection, two were only allowed 
to breath through their nose and one only allowed to breath through their 
mouth while samples were collected. One patient, for which virus was 
detected during nose-only breathing, also had virus detected in a sample 
collected when he/she was talking (Stelzer-Braid et al., 2009). These studies 
had a small sample size, but support the likelihood that viral RNA is expired 
during breathing and talking in the absence of coughing, or sneezing.  
A consensus on the median or range of concentration of influenza virus RNA 
expired by infected individuals into the air will require a very large study 
population due to the number of variable factors. Measurements from initial 
studies are as follows. Bischoff et al. reported that over 90 RNA copies/during 
a minute sampling of air within six feet of an emitter’s head from 9 out of 26 
(35%) of their emitting volunteers (Bischoff et al., 2013). From Milton et al. the 
equivalent figure was a median of 20 RNA copies but the range was 
enormous, (min 0.1, max 4,300) (Milton et al., 2013). Fabian et al. found 
expiration rates ranged from <3.2-20 RNA copies/min. Using a ratio of 300 
RNA copies per infectious particle, which was determined using their stock 
virus, they calculated that the highest emitter would expire four infectious 
particles per hour (Fabian et al., 2008). Lindsley et al. reported a median of 51 
RNA copies generated in 3-coughs but the maximum was 3,727 which would 
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correspond to 10 infectious particles by the same conversion rate (Lindsley et 
al., 2010b). However, the conversion rate depends on a single measurement 
and might vary considerably so although the amount of viral RNA in the air 
might shed some light on influenza virus transmission, a better link between 
aerosolised viral RNA and infectious virus still needs to be determined. 
 
1.7.10 Influenza virus in the air from naturally or 
experimentally infected animals  
Making the link between particle size or virus in the air and infection or 
transmission is much easier with controlled infection rather than natural 
infection. Infection of animals is far less costly than infection of humans. 
However, expiration of particles after experimental infection of animals has 
only been looked at in a few experiments. Guinea pig and ferret experiments 
that have measured virus particles in the air after infection with human 
seasonal or pandemic viruses indicate that infectious virions can be detected 
in the air albeit at low concentrations (Gustin et al., 2011).  
Mubareka et al. found that air samples collected from cages showed higher 
concentrations and earlier presence of plaque forming units (pfus) when 
guinea pigs were infected with the human seasonal H3N2 
A/Panama/2007/1999 (Pan99) virus compared to the human seasonal H1N1 
A/Texas/36/1991 (Tx91) and this correlated with more efficient transmission 
achieved by the H3N2 virus. Pfu counts were determined by averaging two air 
samples collected over 10 minutes, but the variation was very high, so 
statistical significance was not reached. The detection method used by 
Mubareka et al. involved concentration by ultra centrifugation before plaque 
assay, which is known to reduce viral infectivity, but they were able to detect 
an average of 40 pfu/100L of air sampled over one day (Mubareka et al., 
2009).  
Lakdawala et al. measured viral RNA copies in the air from cages of ferrets 
that were infected with different reassortant viruses during a respiratory 
droplet transmission experiment. They found that efficient transmission 
correlated with increased detection of viral RNA in particles <1um in diameter. 
For two swine based viruses that transmitted poorly, virus released in the air 
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was predominantly in particles >4um and 1-4um in diameter and minimal in 
the smallest particles <1um. This indicates that the size of particle in which 
virions exist in the air might be more important than the total amount released 
(Lakdawala et al., 2011).  
Gustin et al. analysed particle size, count, and viral pfu in aerosols generated 
from ferrets post infection with the efficiently transmitting human seasonal 
H3N2 virus Pan99. They found that ferrets generated the most respiratory 
particles near the 0.5um diameter size and about 5-fold less around the 
2.5um diameter size during both normal breathing and sneezing. Animals who 
were originally infected via aerosol inoculation shed virus in smaller particles 
(0.7-4.7um diameter), while animals infected by the intranasal route shed 
virus in larger particles (>4.7um). Sneezing increased both the total number of 
particles and the viral pfus within them. The highest number of infectious 
virions detected in the air by Gustin et al. was about 1,200 pfus from five 
minutes of sneezing by a virus positive ferret, whereas less than 25 pfus were 
accumulated over 30 minutes, during ferret breathing.  
Together, these animal experiments support a correlation between the 
amount of virus present in the nasal wash and pfus in the air. However, 
Lakdawala et al. provide evidence that the existence and concentration of 
virions in respirated particles <1um might be most important for transmission. 
Therefore, there is a possibility that the total quantity of viral RNA in the air is 
not directly related to transmission efficiency.   
It is difficult to pinpoint how avian viruses zoonose to humans. Avian influenza 
viruses are often detected in buccal (oropharnygeal) and cloacal samples 
from both wild birds and poultry (Claes et al., 2013; Hulsager et al., 2012; 
Jindal et al., 2010; Löndt et al., 2008; Marché et al., 2012; Morales et al., 
2009; Wasilenko et al., 2011). A few experiments have shown that avian 
viruses can be detected in the air. Chen et al. found virus in air was higher 
during a dust storm compared to quieter weather patterns (P.-S. Chen et al., 
2010). Avian influenza H9N2 virus was detected in the air of chicken houses 
in Shangdong Province, China at a concentration calculated to range from 
1.25x104 to 6.92 x104 copies per litre of air (Lv et al., 2011). The avian 
influenza HPAI H5N1 virus A/turkey/Turkey/1/2005 was observed to transmit 
between chickens over a distance of up to 1 m through the air, albeit at low 
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rates. During these experiments air on top of the cages was collected and 1.3 
and 1.6 log EID50 of virus was detected on days 2 and 3 post infection 
(Spekreijse et al., 2011). Therefore, it can be concluded that both RNA and 
live avian viruses are aerosolised and their inhalation by humans might be a 
key route for influenza virus zoonosis.  
Swine influenza is characterised by an upper respiratory tract infection (Choi 
et al., 2012; Lorusso et al., 2012). Swine influenza virus is detected in nasal 
swabs from swine (Corzo et al., 2013; Zhao et al., 2012) and in the air. Virus 
expired into the air by a single pig is detectable at low levels the day after 
infection and the concentration increases on the second day. When many 
pigs are housed together, the amount of viral RNA in the air increased with 
the number of pigs with virus positive nasal swab samples (Corzo et al., 2014, 
2012).  
 
1.7.11 Virus stability in the environment is dependent 
upon temperature and humidity  
Lowen et al. showed that transmission efficiency of a human seasonal 
influenza virus (H3N2 A/Panama/2007/1999) between guinea pigs is inversely 
correlated with temperature and affected by relative humidity (RH). At the 
lower temperatures of 5°C and 20°C RD transmission between guinea pigs 
was 75-100% efficient at both 20% and 35% RH. While at 30°C and 35% RH 
RD transmission was fully inhibited (Lowen et al., 2007). However, direct 
contact (DC) transmission between guinea pigs at 30°C at all levels of RH 
tested remained high: 75-100% efficient (Lowen et al., 2008). At very low RH, 
the liquid from aerosolised droplets evaporates completely, thus drying out 
virus particles and rendering them dead. Virus stability is at its maximum at 
RH of 20-40% and 60-80%. At 50% RH both virus stability and guinea pig RD 
transmission at 20°C are much reduced. Instability at 50% RH is a feature 
common for enveloped viruses, but not for those without lipid envelopes 
(Tellier, 2006). RD transmission occurred between guinea pigs at 65% RH at 
5°C and 20°C, while transmission at 80% RH and 20°C was fully inhibited. 
Since virus was shown to be stable at this RH it was suggested by Lowen et 
al. that respiratory droplets may not undergo as much desiccation and remain 
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large or even grow bigger at high RH, so that the particles fell to the ground 
more quickly and did not remain airborne long enough to support RD 
transmission (Lowen et al., 2007; Schaffer et al., 1976). These observations 
may account for the seasonality of human influenza virus activity (Tamerius et 
al., 2013).  
Paek et al. found that when stored at the same temperature, different H5N1 
viruses degraded at different rates. They suggested that the improved stability 
of a 2008 virus, over earlier strains, may have accounted for the large number 
of outbreaks that occurred that year (Paek et al., 2010). Stability of many 
individual influenza virus proteins has also been associated with increased 
binding or enzyme activity and increased transmission or epidemiological 
spread (Bloom et al., 2010; Herfst et al., 2012; Imai et al., 2012). 
 
1.7.12 Human Infectious Dose 50 
Many studies have attempted to identify the minimum infectious dose 501 
(MID50) for humans. Infection, in these experiments, is determined to have 
occurred if infectious virus (or sometimes viral RNA) is detected in the lungs, 
nose, or pharynx on at least one day some time from 24 hours up to about a 
week post infection. In humans, a minimum infectious dose experiment using 
virus aerosolised in particles the majority of which were 1-3um in diameter 
was performed once, by Alford et al. in 1966. They determined that the human 
minimum infectious dose inhaled to infect 50% of those exposed, who had 
HAI titres lower than 40 was between 1 and 5 TCID50. They did acknowledge 
that they assumed their impinger collection of aerosolised virus was 100% 
efficient and if this was wrong then the dose could have been larger. 
Interestingly, each subject involved in this study inhaled aerosols for a very 
short period, about a minute, so only took 5-14 inhalations, which was 
calculated to equal 10L of air. Based on previous work, which indicated that 
60% of inhaled particles were deposited in the lung, they assumed that the 
actual amount of virus that initiated infection was between 0.6 and 3 TCID50. 
                                            
1 MID50 is the minimum infectious dose that leads to 50% of people or 
animals becoming infected after challenge. ID50 is the same. 
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Another study, that measured the infectious dose in humans using intranasal 
spray inoculation rather than aerosol found 40% of susceptible volunteers 
became ill after administration of 30 TCID50 (Alford et al., 1966). Using Fabian 
et al.’s calculation of 300 RNA copies per infectious virion, the higher end of 
Alford’s observation (huID50 = 5 TCID50) would translate to indicate that if 
1,500 RNA copies were inhaled 50% of those exposed would become 
infected. Generally it is assumed that adults inhale 10L of air per minute. 
Therefore, using Bishoff et al.’s indication that 35% of emitters expire viral 
RNA at 90 copies or more per 10L of air detected six feet away from their 
head (Bischoff et al., 2013), exposure to one of these individuals within that 
distance, for 17 minutes, would infect 50% of those exposed. To restate the 
risk, these rough calculations indicate that standing within six feet of an 
individual who is expiring influenza virus in respiratory particles for about 20 
minutes gives a person who lacks anti-HA antibodies to the virus a 50% 
chance of becoming infected. The more recent human challenge study that 
used different doses for the inoculum looked for correlations between virus 
shedding and disease, but not dose and infection. The lowest dose they used 
was 1,000 TCID50 and in many cases less than 50% of those challenged 
shed virus (Wilkinson et al., 2012). Therefore, human experiments are 
inconclusive in determining the MID50. 
Animal experiments differ from human experiments because the animals live 
for much shorter periods and a negative serological response usually means 
the experimental animals have never been infected with influenza virus. 
Nevertheless, determination of the MID50 at which 50% of the animals have 
detectable virus in their nose may be useful for determining the 
transmissibility of an influenza virus. Steel et al. determined the guinea pig 
MID50 for the human seasonal H3N2 Pan99 and avian HPAI H5N1 
VN/1203/04 to be 24 and 3 pfu, respectively (Steel et al., 2009). It is 
interesting that the avian virus has a lower MID50 in guinea pigs compared to 
the human virus. This may be due to a higher expression of a2,3-linked SA 
versus a2,6-linked SA in the guinea pig respiratory tract (Y. Sun et al., 2010). 
On a previous occasion, Bouvier et al., working in the same lab, determined 
the guinea pig MID50 for the human seasonal H3N2 Pan99 to be 66 pfu, which 
si of the same order as Steel’s number but indicates variance in the assay 
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(Bouvier et al., 2008). The MID50 for human seasonal viruses in ferrets has 
been determined by a number of groups. Koster et al. calculated that 
exposure of naïve ferrets to 0.02-819 RNA copies of a prototypic 2009 
pandemic H1N1 virus by aerosol led to 50% infectivity. Their calculations 
equated this to 0.1-3.0 infectious particles (Koster et al., 2012). In an earlier 
paper, from the same lab MacInnes et al. determined the ID50 to be between 
1.8 and 186 infectious virions (MacInnes et al., 2011). However, 
measurements of infectious virus by those within this lab do not match those 
of others performing similar experiments. Roberts et al. showed that the ferret 
ID50 was lower than 10 pfu when a human seasonal H3N2 virus was 
delivered by intranasal inoculation (Roberts et al., 2011). Herlocher et al. 
determined the ferret ID50 of a human seasonal H3N2 Wuhan-like virus and 
an H1N1 New Caledonia-like virus to be 1 and 7 TCID50, respectively 
(Herlocher et al., 2004). Lakdawala et al. looked at ferret ID50 of four viruses, 
one that was a prototypic 2009 pandemic H1N1 and others that were swine 
viruses or reassortants. They found that the ferret ID50 was 18 TCID50 for 
three out of four viruses, including the pandemic virus, and less than 10 
TCID50 for the fourth. However, since the pandemic virus transmitted more 
efficiently than the virus with a lower ID50, they concluded that in this case it 
did not correlate with transmission efficiency (Lakdawala et al., 2011). Gustin 
et al. showed that similar amounts of the human seasonal H3N2 influenza 
virus Pan99, 1.1 and 1.9 pfu, were required to infect 50% of ferrets by 
intranasal and aerosol delivery, respectively (Gustin et al., 2011). Therefore, it 
can be concluded that in ferrets the ID50s of human seasonal H1N1 and 
H3N2 viruses are most likely lower than 10pfu and the ID50 of human 
pandemic 2009 H1N1 viruses were likely less than 20 pfu.  
One group has looked into determining a ferret ID50 for H5N1 viruses. 
Lednicky et al. infected ferrets by deposition of 50ul liquid into each nostril or 
as an aerosol. They found that delivery of 49 TCID50 in a liquid to the nose 
led to virus detected in the nasal wash of 2/3 ferrets infected with the clade 1 
H5N1 virus A/Vietnam/1203/2004 (VN/1203/04). When 32 TCID50 of the 
same virus were delivered as an aerosol 3/3 ferrets shed virus in their nasal 
washes. Intranasal instillation of the same dose, 49 TCID50, of two other 
H5N1 viruses of clade 2.2 led to detection of virus in the nasal wash of 3/3 
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ferrets for both (Lednicky et al., 2010). Therefore the ferret ID50 for H5N1 
viruses is less than 49 TCID50 when delivered intranasally and less than 32 
TCID50 when delivered as an aerosol for H5N1 viruses.  
 
1.7.13 Relationship between dose and virus shedding 
(quantity & delivery method) 
There are two common assumptions regarding virus shedding. One is that a 
higher inoculum will lead to a higher peak shedding titre. The other is that all 
influenza viruses can induce the same amount of shedding as long as you 
inoculate with a higher dose of the ‘weaker’ virus. Experiments where virus 
shedding is measured after different viruses and different inoculation doses 
are used show that these assumptions may not always hold true.  
Different viruses induce different peak titres. At doses that led to three of three 
inoculated ferrets shedding virus, Lakdawala et al. found that a higher dose 
led to lower mean peak titres for two out of four viruses. For the “Eurasian” 
virus, which had an ID50 lower than 10 pfu, inoculation with 10 pfu led to a 
higher mean peak titre than inoculation with 100 pfu. For the “6:2 reassortant” 
virus, which had an ID50 of 18 pfu, inoculation with 100pfu led to a higher 
mean peak titre than inoculation with 10,000 pfu. They only measured viral 
titres every other day, so they might have missed the peak (Lakdawala et al., 
2011). However, if they did catch the peaks, then this data indicates that an 
inoculum slightly above the ID50 can reach the highest virus titre possible and 
that excess viral inoculum stimulates stronger host inhibition.  
Reports of viral titres shed over time after delivery of different doses show that 
a peak shedding titre is reached with doses 10-100 fold greater than the 
MID50 and further increases move the peak in time, but not quantity. Roberts 
et al. infected ferrets with different doses of a human seasonal H3N2 virus 
and a receptor-binding mutant. They measured viral titre in the nasal wash 
daily and did not find a difference in the peak titre shed, but found that the 
time between inoculation and peak decreased with increasing dose. 
Specifically, a low dose of 10 pfu led to the peak of virus shedding three days 
post infection, 100 pfu led to peaks on day two and, while the peak after 
infection with 1,000 pfu was also on day two, there was a lot more virus 
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present in the nasal wash on day one, compared to the others, which 
indicates that the peak may have been reached at some point between the 
collection of day one and day two post infection. The mutant virus had a 
slightly less clear pattern, but with 1,000 pfu the peak was on day five and 
100,000 pfu the peak was on day three post infection. At the ID50 of the 
mutant virus the peak titre reached by the infected ferret that shed virus in its 
nasal wash was lower than peaks reached by higher doses (Roberts et al., 
2011).  
The pattern seen by Roberts et al. was also seen by Gustin et al. They 
showed that infection of ferrets via both intranasal and aerosol inoculation 
with about two times more Pan99 virus than its ID50 led to a peak of shedding 
on the fifth day after infection, while a dose that was about five-fold higher led 
the peak of viral shedding to occur on the third day post infection. Oddly, this 
pattern did not hold for the H5N1 A/Thailand/16/2004 virus. The peak titre 
occurred on day five post infection with low/intermediate and high doses 
(Gustin et al., 2011). This phenotypic difference may relate to the reason that 
H5N1 viruses do not transmit between mammals.  
 
1.7.14 Viral shedding and transmission 
Knowing the ID50 and peak amount of virus shed is helpful in determining 
infectivity and replication efficiency of a virus, but continual transmission of a 
virus requires that it is returned to the environment in a quality and at a 
quantity that propagates spread. As Roberts et al. and Lakdawala et al. 
showed inoculation by a dose around or lower than the ID50 can lead to low 
levels of virus replication (Lakdawala et al., 2011; Roberts et al., 2011). Koster 
et al. showed that shorter exposure of naïve ferrets to ones infected with a 
prototypic pandemic 2009 H1N1 virus led to recipients exposed for three 
hours to shed viral RNA for fewer days compared to those exposed for 20 
hours. This indicates that a lower dose can lead to viral shedding over a 
shorter period than the average five days (Koster et al., 2012).  
The best correlate of human-to-human transmission of endemic or pandemic 
influenza viruses is transmission through the air between ferrets or guinea 
pigs housed in cages separated by two perforated panels placed a few 
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centimetres apart (Bouvier and Lowen, 2010; Gustin et al., 2012). 
Transmission in this set-up is referred to as RD or aerosol (aero) transmission. 
These two names can lead to some confusion because the larger respirated 
particles (>5um) are usually called respiratory droplets and the smaller 
respirated particles (<5um) are usually called aerosols. These names were 
assigned to reflect the amount of time the particles are likely to remain 
suspended in the air. Since the cages in RD/aero transmission experiments 
are so close together, it is possible for particles >5um in diameter to travel 
between the two. However, Koster et al. measured the sizes of particles that 
passed between two cages and while they detected many particles of smaller 
diameters, they detected no particles with diameters >5um (Koster et al., 
2012). Therefore, the term aerosol may be more appropriate than RD for 
experiments that allow air to travel through perforated panels between 
animals placed in neighbouring cages.  
The understanding of the DC model of transmission has also improved 
recently. It is now understood that fomite transmission plays a relatively small 
role in overall rates of DC transmission (Mubareka et al., 2009). Furthermore, 
the evidence that virus in the air is more concentrated closer to the source 
can explain why animals that share the same space would be exposed to 
higher doses. Therefore, it is likely that the closer proximity to expired 
particles is responsible for a large part of the higher rates of DC over aerosol 
transmission for some viruses, rather than the fact that co-housed animals 
share water bottles and bedding.  
 The only study that looked at the effect of different inoculation doses and 
transmission was Gustin et al. They found that an inoculum equal to about 
two-times the ID50, about 2 or 4 pfus of virus, delivered to donors via 
intranasal or aerosol administration, respectively, both led to 100% infection 
and DC, but not aerosol transmission. When they increased the dose by 
about five-fold, to 25 or 28-42 pfus, delivered to donors intranasally or via 
aerosol, respectively, they found that virus delivered in an aerosol led to 
aerosol transmission, while delivery in a liquid did not. Transmission in this 
case was defined by detection of viral pfus in the nasal wash of aerosol-
exposed ferrets. It is difficult to draw conclusions as to why they observed this 
difference. They claim that the difference is probably due to the amount of 
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virus shed and the duration over which virus above a certain threshold 
concentration was shed, but since they did not determine the nasal wash titre 
on the second day after donor infection, it seems likely that they missed the 
peak for the donors that were intranasally inoculated. The fact that the 
intranasally inoculated donors shed more viruses than aerosol-inoculated 
donors one day after infection strengthens this possibility. Therefore it seems 
that a difference in dose was not the reason for the difference in aerosol 
transmission. Instead, distribution of the inoculum may be responsible for the 
observed difference in aerosol transmission. By delivering fluorescently 
labelled virus, Gustin et al. showed that intranasal inoculation, which they 
performed using a volume of 1ml, led to a higher percentage of inoculum 
being delivered into the oesophagus (17%) when compared to delivery in an 
aerosol (4%). Delivery of virus in an aerosol showed 70% deposition in the 
trachea, while delivery intranasally led to 26% deposition in the same location. 
Deposition in the nasal turbinates and bronchi only differed by 1 or 2%, 
respectively between the two delivery modes. (They noted that 14% of virions 
deposited in the lungs after aerosol inoculation, but did not state the 
percentage of deposition in the lungs after intranasal inoculation.) If dose, 
peak titre, and time to peak titre could be ruled out, then the higher delivery of 
virions to the digestive tract might be explain why aerosol transmission was 
not achieved with this inoculum dose after intranasal administration. Notably, 
a four-to-five-fold higher inoculum dose (110-250 pfus delivered intranasally 
and 750-1000 pfus delivered via aerosol) led to aerosol transmission via both 
routes of donor infection (Gustin et al., 2011). Overall this shows that the 
delivery mode and dose are both important for transmission of influenza 
viruses. 
Ferret transmission experiments are usually performed by inoculation of donor 
ferrets with 200ul to 1ml of liquid containing a high titre of virus (104-106 pfu). 
High doses insure that a peak of shedding is reached soon after inoculation. 
In mice, installation of radioactive particles delivered in different liquid 
volumes intranasally show different patterns of dissemination. With a small 
volume of 10ul Southam et al. found that 20% of the radioactivity was found in 
the lungs five minutes after installation. By one hour after inoculation, the 
amount in the lung dropped to about 5%. Another study, by Eyles et al. found 
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only 0.17% of delivered radioactivity in the lungs 15 minutes after delivery. At 
one or four hours after inoculation both studies found that the majority of 
radioactivity had moved to the stomach or intestines. When a larger volume of 
inoculum, 25, 50, or 75ul was used 40-60% of radiation was found in the lung 
within the first 15 minutes post inoculation and the percentage of radioactivity 
in the lung remained relatively high for an hour or hours, despite clearance 
through the digestive tract (Eyles et al., 2001; Southam et al., 2002). The 
smallest inoculum, 2.5ul of a bacteria, tested was found to induce an immune 
response in the nose, but not in the lungs with evidence of delivery to the 
digestive tract (Pickett et al., 2000). These results indicate that inoculum 
delivered to the nose is easier to transport to the digestive tract than inoculum 
delivered to the lungs. Both small and larger inoculation volumes led to 30% 
or more of the inoculum to be diverted to the digestive tract within 15 minutes 
of administration. Comparatively, Gustin et al. reported that about 10% of viral 
particles were delivered to the digestive tract when ferrets were inoculated via 
aerosol.  
It is clear that there are more barriers to transmission than there are to 
infection and replication. It follows that an “aerosol transmissible dose 50” 
(ATD50) might be a useful way to characterise viruses when trying to predict 
their probability of causing a pandemic. An ATD50 would be a dose, delivered 
to one animal (nebulized into an aerosol) that leads to transmission to 50% of 
aerosol-exposed animals. The ID50 tells us how many virions have to be 
deposited on the airway epithelium for enough to get through the mucus 
barrier, enter into, survive, and replicate in cells to the point of releasing new 
infectious virions. The ATD50 would add a measurement of barriers that 
prevent transmission, such as release of viable virions into the air at a 
concentration that exposes susceptible animals or individuals to an ID50 dose. 
Furthermore, measurements of time between initial day of virus shedding and 
day of peak virus shedding by aerosol exposed sentinels seems to give a 
good indication as to whether or not a virus could sustain a chain of aerosol 
transmission.  
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1.8 The mucus barrier 
The first barrier that a virion faces when it lands in the respiratory tract is the 
glycocalyx - often less glamorously referred to as mucus. Mucus contains a 
complex milieu of proteins that present decoy receptor and other factors that 
may further inhibit or even enhance influenza virus infectivity. In order to 
further understand possible mechanisms of inhibition, some of the literature 
on mucus is reviewed below. The initial focus is on the physiological aspects 
of mucus. Next, mucins are described in more detail. Finally other inhibitors in 
mucus are described with a focus on factors shown to interact with influenza 
viruses.  
1.8.1 Mucus 
If the directionless journey through the air ends with deposition of a virion in 
the respiratory tract of an animal the next barrier it will face after desiccation, 
changes in temperature, and changes in humidity will be the mucus barrier. 
Mucus lines both the enteric tract of birds and the respiratory epithelium of 
mammals and the respiratory tract of chickens. Mucus contains many 
inhibitory and/or destructive chemicals, proteins, and cells in a ‘resting’ state 
and many more in an inflammatory state. Terminally linked SAs on any glycan 
where viral binding does not lead to a productive cellular infection are called 
decoy receptors of which there are many in mucus (Matrosovich and Klenk, 
2003; Matrosovich et al., 2004; McCrea, 1948). Mucins, due to their high 
concentration of glycosylation, are the main presenters of decoy receptors. 
Mucus also contains soluble pattern recognition molecules (PRMs) that 
recognise pathogen associated molecular patterns (PAMPs). The multivalent 
expression of HA proteins on the envelope of an influenza virion present 
strain and glycosylation dependent PAMPs that can be detected by PRMs. To 
a lesser extent, due to its lower frequency, NA also presents PAMPs. Like 
mucins, some PRMs are glycosylated and have terminal SA that can act as 
decoy receptors.  
Driven by the beat of cilia, the movement of the viscous-elastic gel that is 
mucus creates a mucociliary ladder, which brings the majority of inhaled 
particles from the location where they settle within the respiratory tract to the 
pharynx where they are swallowed and usually destroyed by the acidic 
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environment of the stomach (Evans et al., 2009; Vareille et al., 2011). 
Mucociliary clearance (Reviewed by Voynow and Rubin, 2009) of bacteria 
may take up to six hours (Knowles and Boucher, 2002) while movement of a 
5mg particle of saccharin from the nose to the tongue took between 11 and 15 
minutes in healthy individuals (Antunes and Cohen, 2007). When the 
efficiency of mucociliary clearance is hindered by abnormalities, such as 
those that cause cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and 
chronic rhinosinusitis (CRS) individuals suffer higher morbidity particularly 
after respiratory infections (Antunes and Cohen, 2007).  
The upper and lower respiratory tracts (URT and LRT) are usually referred to 
separately. The URT includes the nasal turbinates, pharynx, and larynx. The 
LRT includes the trachea to the alveoli. Unless ‘large’ volumes of liquid are 
poured down the nose, the two remain separate except that they sample the 
same air. The URT has always been known to harbour commensal bacterial. 
Only recently, the LRT was confirmed to also harbour bacteria. While there is 
some overlap between species, the comparative proportions of each differ 
between the URT and LRT. There are still many unknowns about the effects 
of a local environment on the airway microbiomes and variance between 
internal spaces or over time (Beck et al., 2012; Morris et al., 2013). Due to the 
constant exposure to microbes, like the digestive tract, the respiratory tracts, 
maintain tolerant states until stimulated by multiple danger signals (Hussell 
and Goulding, 2010; Snelgrove et al., 2011; Wissinger et al., 2009). The URT 
and LRT have different mucosal make-ups and separate draining lymph 
nodes (Netter, 2010; Rohen et al., 2010).  
If an initial influenza virus infection at a dose that leads to aerosol 
transmission starts with inhalation of 28-42 pfus (as shown for H3N2 Pan99 
delivered by aerosol in ferrets (Gustin et al., 2012), then perhaps an average 
35 virions are deposited onto the airways. Since aerosol transmission occurs 
mainly through respirated particles that are smaller than 5um in diameter, it 
can be assumed that there is equal deposition along the respiratory tract. A 
small number of particles might land in each of the following six locations: the 
nasal turbinates, pharynx, larynx, trachea, bronchi, bronchioles and alveoli. In 
the URT, each virion has less than 15 minutes to get through the mucus 
barrier and bind to a cell surface receptor or it will be swallowed. In the LRT 
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virions have more distance to travel before they are expelled and thus more 
time, but can succumb to the same destiny.  
1.8.2 Mucins 
In the late 1940s, mucins were identified as the inhibitory factor within serum 
that blocked influenza virus agglutination (McCrea, 1948). Furthermore, 
treatment with receptor destroying enzyme (a bacterial neuraminidase) was 
found to diminish the blocking activity of the mucins within serum (Anderson, 
1948). SA was identified in the early 1950s (Gottschalk, 1956; Saito et al., 
1955; Schmid, 1953; Svennerholm, 1956). The link that this was the receptor 
that HA bound and NA cleaved was made soon after. Altogether, these 
observations led to the understanding that it was the terminal SA on glycans, 
particularly those expressed on mucins, which inhibit infection by acting as 
decoy receptors. 
Mucus consists of approximately 1% NaCl and 1-2% proteins, of which about 
half are mucins and the other half are carrier or signalling proteins (Antunes 
and Cohen, 2007). Therefore, and also because of their size, mucins are the 
major macromolecular constituents of mucus (Thornton et al., 2008). 
Expression of 12 human mucin genes have been detected in tissues from the 
lower respiratory tract of healthy individuals, these include: MUC1, 2, 4, 5AC, 
5B, 7, 8, 11, 13, 15, 16,19, and 20 (Rose and Voynow, 2006). The main 
secreted mucins in human respiratory mucus are MUC5AC and MUC5B. 
They are secreted by goblet cells and cells in the submucosal glands, 
respectively (Rose and Voynow, 2006; Voynow and Rubin, 2009). MUC2, 
MUC7, MUC8, and MUC19 make up a minor portion of airway secreted 
mucins (Voynow and Rubin, 2009). The other mucins (MUC1, MUC4, MUC11, 
MUC13, MUC15, and MUC20) are all membrane expressed (Voynow and 
Rubin, 2009). Both secreted and membrane expressed mucins can inhibit 
influenza virus infection. Some membrane-expressed mucins are found in 
exosomes, which were described in Chapter 4. 
Mucins are large proteins with multiple repeating sequences rich in Serine 
and Threonine that provide sites for O-linked glycans (Rose and Voynow, 
2006). Mucins also have Asparagines and sometimes have the correct 
sequence for N-linked glycans: Asn-X-Ser/Thr (where X is any aa except 
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Proline). Some evidence that N-linked glycans play a role in mucin folding has 
been reported (Bell et al., 2003; Yu et al., 2008). Mucins are 50-90% 
carbohydrate by mass and have dozens to hundreds of possible glycosylation 
sites per molecule (Rose and Voynow, 2006). The interlinking of the 
carbohydrate chains gives mucins their elasticity and physical impenetrability. 
The carbohydrate chains can terminate with blood group determinants, 
sulphate, fucose, or SA (Rose and Voynow, 2006). SA and sulphate termini 
give mucins a negative charge while fucose is hydrophobic. Modification of 
the terminal sugars of mucins, in turn modify their physical and biological 
properties. Alternative modifications can be induced by disease (Rose and 
Voynow, 2006). For example, mucins from the duodenum of cystic fibrosis 
(CF) patients were shown to have increased terminal fucosylation and 
sulfation and less SA (Dische et al., 1959). Analysis of sialation of MUC5B 
from salivary secretions of CF patients demonstrated a shift from a2,6- to 
a2,3-linked SA. Meanwhile, the terminal SAs on MUC7s of non-CF patients 
were predominantly a2,3-linked and that predominance increased further on 
MUC7s from CF patients (Shori et al., 2001). Therefore, despite presenting a 
plethora of glycans, different disease states may affect the number of terminal 
SA and alter their linkage, such that mucins are more or less inhibitory to 
influenza virus infection.  
1.8.3 Proteins (besides mucins) that present decoy receptors 
Inhibitors of influenza virus HA activity and replication were initially identified 
in serum from animals. Many proteins that were initially characterised as 
serum inhibitors are also present in mucus. Early studies on serum inhibitors 
of influenza virus separated them into Francis-, β-, and γ-inhibitors. Francis-
inhibitors were very stable and later identified as antibodies. β-inhibitors were 
characterised as heat lable since exposure to heat led to degradation of their 
activity (Konno, 1958). Later β-inhibitors were characterised as lectins. γ-
inhibitors could be destroyed by receptor destroying enzyme (i.e. NA 
activity)(Styk, 1973), thus it was not a far stretch to understand that they were 
sialated glycoproteins and inhibited infection by presenting decoy receptors. 
SP-A is a surfactant protein that is important for lung function. SP-A 
opsonised a 1989 H3N2 influenza virus and increased its uptake by alveolar 
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macrophages. Removal of the whole carbohydrate on SP-A or cleavage of its 
terminal SA abolished the enhanced phagocytosis (Benne et al., 1997). Gp-
340 is a scavenger receptor found in the lung. It too inhibits influenza in a 
terminal-SA dependent manner (Hartshorn et al., 2003).   
α2-Macroglobulins (A2Ms) of horses, guinea pigs, and swine, can inhibit 
human influenza viruses due to their expression of decoy receptors with 
terminal SA (Hanaoka et al., 1989; Pritchett and Paulson, 1989; Ryan-Poirier 
and Kawaoka, 1993). Recently HA binding of SA on A2M was shown to 
further inhibit influenza virus infection because HA-activated A2M bound and 
de-activated proteases. Thus it reduced the number of proteases available to 
activate newly produced HA0 (C.-H. Chen et al., 2010). 
Serum amyloid P (SAP) and C reactive protein (CRP) are both short 
pentraxins and have similar structures. However, only SAP was found to 
inhibit the mouse-adapted version of the 1968 H3N2 pandemic strain (X31). 
SAP is glycosylated while CRP is not (Köttgen et al., 1992). When grown in 
the presence of SAP influenza virus became resistant to its inhibition after 
acquiring a mutation in the RBS of its HA. Therefore, the inhibitory activity of 
SAP against this virus was achieved via its presentation of decoy SA. The 
decoy SA on SAP was deemed to be a2,6-linked and inhibited 
haemagglutination activity of H3N2 viruses isolated from 1968 to 2010. 
Pentraxin 3 (PTX3) differs from SAP and CRP in that it has a separate N-
terminal domain (Cieślik and Hrycek, 2012). It also has a2,3-linked SA. 
Therefore, it was able to inhibit human inlfuenza viruses isolated from 1968 to 
1973, which retained some ability to bind a2,3-SA (Job et al., 2013a).  
H-Ficolin also inhibits influenza virus by providing a decoy receptor. De-
sialation of H-Ficolin reduced its ability to inhibit flu and addition of oseltamivir 
increased its neutralising activity. In contrast to closely related L-Ficolin, H-
Ficolin was able to inhibit the 2009 pandemic influenza virus. As well as 
preventing virus from binding cellular receptors, binding of H-Ficolin led to 
deposition of complement onto the virus’ surface (Verma et al., 2012). 
The few proteins, reviewed above, that have been identified as carriers of 
glycans with terminal SA that inhibit influenza have two other common 
features. Except for A2M, they are all lectins. Lectins are carbohydrate 
binding proteins and most of these decoy receptor barring proteins were 
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initially hypothesized to inhibit influenza virus by binding to its glycans. The 
second common feature is that all of them (including A2M) can lead to the 
recruitment of complement.  
1.8.3.1 The complement cascade 
The complement cascade is one of the earliest discovered defence 
mechanisms of innate immunity. Complement proteins are found in the blood 
and mucus. The main role of complement is to mark the surface of microbes 
and apoptotic host cells for degradation by lysis or phagocytosis.  
The complement pathway has three modes of recognition: classical, lectin, 
and alternative. The classical pathway relies on antibody recognition of 
pathogens. Shortly, C1q binds to the Fc portion of antibodies and attracts 
other proteins that lead to the formation of the C1-complex, which in turn 
recruits complement component 3 (C3). Lectin binding to carbohydrates on 
the surface of microbial glycoproteins and glycolipids is another recognition 
route that can lead to recruitment and activation of C3. The alternative 
complement pathway is less specific as it begins with C3 binding directly to 
lipids that make up a membrane’s surface. C3 is activated after hydrolytic 
cleavage by convertases. This hydrolysis leads to exposure of a thioester 
group that can covalently attach to membrane surfaces (Janssen and Gros, 
2007; Janssen et al., 2005). Interestingly, C3 is a member of the a2-
macroglobulin (A2M) family (de Bruijn and Fey, 1985) and has two N-linked 
glycans (Welinder and Svendsen, 1986). 
Similarly to C3, the cathelicidin LL-37 binds directly to high-density 
lipoproteins that are found in membranes and causes membrane degradation. 
LL-37 inhibits several influenza viruses in a dose dependent manner (Tripathi 
et al., 2012). 
Recognition of pathogens by antibodies or lectins leads to destruction by lysis 
or phagocytosis. Lysis occurs when C3 activation leads to formation of the 
membrane attack complex (MAC), which destroys pathogens by creating 
destructive pores in their membranes (Janeway et al., 2001)2. As with most 
                                            
2 Activation of C3 on host cells is hindered by Factor H, which is not present in 
the membranes of invading pathogens (Gros, 2011; J. Wu et al., 2009). 
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immune responses it is likely that too much or too little complement can lead 
to enhanced disease post influenza virus infection. Complement is important 
for dendritic cell migration and was found by one group to be protective 
against 2009 pandemic and H5N1 viruses (Kandasamy et al., 2013; O’Brien 
et al., 2011). Another group showed that inhibition of complement reduced 
H5N1 induced lung injury (Sun et al., 2013). A fourth group found that 
pandemic H1N1 associated with higher deposition of C4d in the lung 
compared to a seasonal H1N1 and concluded that enhanced disease was 
due to complement complexes (Monsalvo et al., 2010).  
Phagocytosis of pathogens by macrophages and other cells can be stimulated 
by recognition of the Fc portion of antibodies, the tail ends of soluble lectins or 
by direct binding of cell-anchored PRRs on phagocytic cells. (PRRs on 
macrophages are reviewed by Londrigan et al., 2012 and the immune 
response of macrophages to influenza is reported by Wang et al., 2012).  
Lectins are prevalent in mucus and bind to glycans on HA and NA. The 
glycans on HA and NA are diverse and change according to host and stage of 
adaptation. In order to understand the roles of lectins a clear understanding of 
the glycans on HA and NA is important.  
1.8.3.2 Glycosylation of HA and NA 
HA and NA both have glycans on their head and stalk regions. HA has three 
conserved glycans in its stalk region, which are important in protein folding, 
trimerization, pH stability, fusion, transport, and ultimately replication (Hebert 
et al., 1995; Ohuchi et al., 1997; Roberts et al., 1993; Seidel et al., 1991; 
Wagner et al., 2002a). Oligosaccharides on the head region of HA protect it 
from proteolytic degradation (Schwarz and Klenk, 1974) and allow it to evade 
immune recognition through altering the sequence of, or adding steric 
hindrance near, antibody binding epitopes (Das et al., 2010; Job et al., 2013b; 
Kim and Park, 2012; Kobayashi and Suzuki, 2012; Skehel et al., 1984; Smith 
et al., 2004; Wang et al., 2009). The glycosylation patterns on NA also vary 
both by group, subtype, and with antigenic drift over time. Glycosylation of NA 
can assist in protein folding, regulate catalytic activity, mask antigenic regions, 
and prevent proteolytic cleavage (Chen et al., 2012; Z. L. Wu et al., 2009). 
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Therefore, glycans on HA and NA are always present, but their locations are 
variable. 
HA and NA gain glycans through cellular processes. After transcription, 
influenza mRNA is translated like cellular mRNA in the ER, therefore influenza 
glycoproteins are treated like other extracellular proteins and their glycans are 
added, trimmed, and re-glycosylated along the ER-Golgi pathway. Initial 
glycosylation occurs upon protein synthesis during transport into the ER. 
Further trimming and modification occurs in the endoplasmic reticulum. A 
process in the cis-Golgi determines whether or not a glycan will have the 
possibility of becoming hybrid or complex. Branching is determined in the 
medial-Golgi while elongation and “capping” or “decorating” (adding SA, 
fucose, or sulfate) occur in the trans-Golgi (Varki et al., 2009).  
The mature forms of the two influenza glycoproteins are known to have both 
oligomannose glycans, which naturally terminate in Mannose (Man) and 
complex glycans. Complex glycans often carry terminal SA, but due to the 
activity of the viral NA removing the SA, the terminal sugar of these chains 
would be Galactose (Gal). Other sugars found in high-mannose, hybrid, or 
complex glycans isolated from influenza glycoproteins include Glucose (Glc) 
and N-Acetyl-D-glucosamine (GlcNAc) and they are sometimes found at the 
termini (Functional Glycomics Gateway, n.d.; Karaivanova et al., 1998; Mir-
Shekari et al., 1997). Fucose, which is always terminal, but sometimes buried 
among the branches of a complex glycan, has been found to make up a small 
proportion of the oligosaccharides on influenza glycoproteins (Collins and 
Knight, 1978). Also, in some instances, some sugars on influenza 
glycoproteins are sulphated (Karaivanova and Spiro, 1998). Thus, the 
terminal sugar on HA and NA glycans can vary. 
The size of a glycan was found to associate with its distance from the viral 
membrane. Glycans closer to the membrane were smaller than those at the 
distal tip of HA (Mir-Shekari et al., 1997). The structures of glycans, which are 
created by repeated transferring and trimming, are dictated by cell type and its 
physiological and biochemical state as well as the sequence of the 
glycoprotein. Since a cell that is adding glycans to HA and NA is normally 
infected, the state of the cellular response to infection may play a role in HA 
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and NA glycosylation. Sugar metabolism also affects glycan structure 
heterogeneity.  
HA molecules of influenza viruses from different species differ in their extent 
of glycosylation; swine and avian viruses have less glycans than human 
viruses. Therefore, since pandemic HAs have always recently derived from 
animal sources, it also tends to have less glycosylation sites than human 
seasonal viruses (Sun et al., 2011; Suzuki, 2011; Wei et al., 2010; Zhang et 
al., 2004).  
Similar to the influenza glycoproteins, many extracellular and cell surfaced 
expressed proteins (and lipids) are glycosylated. Glycans expressed on host 
proteins have two main functions: structural modulation and signalling. The 
first role is similar to the role of glycans on influenza proteins, they help in 
protein folding, provide protection from proteases, maintain solubility and 
conformation. The second role is one of signalling, specifically, glycans are 
involved in cell-cell and cell-matrix interactions. Lectins are proteins that bind 
sugars. The human immune system differentiates between self and non-self 
in numerous ways. Glycans on pathogens are displayed in repeating patterns 
with similar spatial orientation, which allows multiple interactions by lectins 
and thus increases their otherwise low binding affinity in the same way that 
influenza virus HA, a viral lectin, binds SA (Varki et al., 2009).  
1.8.3.3 Lectins 
Most lectins bind sugars through a defined carbohydrate recognition domain 
(CRD). Three families of lectins that are known to bind influenza glycoproteins 
are galectins, C-type lectins, and ficolins. Galectins generally bind sugars with 
terminal β-Gal, but also bind those containing three to four repeating poly-N-
acetyllactosamine sequences, regardless of the terminal sugar. C-type lectins 
are Ca2++ dependent. There are over 17 groups of proteins with C-type lectin 
domains and the human genome encodes over 100 proteins that fall into 
these groups. Collectins and endocytic receptors are the main two groups that 
are known to bind to influenza glycoproteins. The CRD of collectins is shallow 
and only makes a few contacts to sugars. Most collectins that bind influenza 
have been shown to detect Man, but collectins can also bind to GlcNAc (Varki 
et al., 2009). Ficolins bind GlcNAc and GalNAc (Matsushita, 2012). These 
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lectins have the ability to recognise an array of glycans that might be 
presented on influenza glycoproteins after de-sialation by NA. Binding 
preferences of these and other lectins, from humans and other animals are 
reviewed by Ng et al. (2012). Siglecs are SA binding lectins that belong to the 
I-type lectin family. They might detect sialated glycans on influenza 
glycorptoeins if NA activity was not complete, but this has not been reported.  
Mannose binding lectin (MBL) and lung surfactant protein D (SP-D) of animals 
and humans inhibit influenza virus by binding surface protein glycans. MBL 
prefers to bind glycans that terminate in L-Fucose then Man and SP-D prefers 
glycans with terminal GlcNAc (Reviewed by Ng et al., 2012). Human MBL can 
opsonise influenza virus (Hartshorn et al., 1993a). Inhibition by MBL can 
follow in either a complement dependent and independent manner (Anders et 
al., 1994, 1990; Hartley et al., 1992; Hartshorn et al., 1993b; Kase et al., 
1999). SP-D inhibits influenza by binding to sugars on HA (Goh et al., 2013; 
White et al., 2005). Binding of HA by SP-D can also inhibit NA activity (Tecle 
et al., 2007). Lack of SP-D inhibition has been linked with infection in the LRT 
(Qi et al., 2011). The 2009 pandemic influenza virus, which has one glycan on 
its head, is resistant to both SP-D and MBL (Job et al., 2010). This is 
supported by the finding that MBL deficiency did not associate with increased 
disease post infection with the 2009 pandemic strain (Eisen et al., 2011). 
Thus it is possible that a lack of glycans on the heads of influenza virus 
glycoproteins – like the lack of antigenic sites that are recognised by 
antibodies in the human population – might make it more likely that a virus 
could cause a pandemic. 
L-Ficolin is similar to MBL and SP-D in that it binds glycans. Its difference lies 
in the fact that it has a fibrinogen-like domain. L-Ficolin prefers Glc-NAc. It 
inhibited the replication of two human H1N1 influenza viruses that have 
multiple glycans on their heads in vitro and in vivo, but its activity against 
pandemic virus has not been measured (Pan et al., 2012). 
Galectins have been shown to interact with influenza virus glycoproteins. 
However, different groups found contrasting effects on virus replication. 
Chernyy et al. showed that chicken galectins CG-1A and -2 and human 
galectins HGal-1 and -8 promoted binding of some influenza viruses to swine 
testi and MDCK cells. Furthermore, they showed that galectins aided 
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internalisation of virions into de-sialated cells (Chernyy et al., 2011). In 
contrast, Yang et al. showed that Gal-1 bound directly to influenza virus, but 
inhibited HA activity and viral infectivity in cells. Furthermore, Gal-1 knockout 
mice were more susceptible to influenza virus infection and intranasal 
treatment of mice with recombinant Gal-1 enhanced survival and reduced viral 
load, inflammation, and apoptosis in the lung (Yang et al., 2011). Therefore, 
Gal-1 is a potent antiviral in mice. Lectins also play a role in immune 
modulation. In contrast with the findings of Chernyy et al., Gal-9 knockout 
mice were less susceptible to influenza infection. In the absence of Gal-9, 
mice mounted a more robust virus specific CD8 T cell and antibody response 
that led to faster viral clearance compared to that achieved in wild type mice 
(Sharma et al., 2011). Therefore, binding of Gal-9 to influenza Gal must inhibit 
rather than stimulate the mouse anti-viral immune response. It would be 
interesting to know which galectins are present in the lungs of humans before 
and during influenza virus infection and the roles that they play in viral 
neutralisation or immune regulation. 
Defensins inhibit influenza virus (Daher et al., 1986). Defensins are classified 
into three groups (α, β, and θ) by their fold and di-sulfide bonds. Their 
structure has a similar fold to a CRD and four of the alpha-defensins are 
lectins (Lehrer et al., 2009). θ-defensin was shown to inhibit influenza virus 
infection by cross-linking HA through binding its glycans so that it could not 
undergo fusion (Leikina et al., 2005). The human gene for θ-defensin is not 
functional, but it is expressed by non-human primates (Lehrer et al., 2012). 
Granulocytes and epithelial cells secrete defensins. Mouse defensin 
expression was shown to vary by anatomical location throughout the 
respiratory tract (Chong et al., 2008). Interestingly, individuals of East Asian 
origin have higher copy numbers of β-defensin, presumably since that is an 
area of high influenza virus zoonotic activity (Hardwick et al., 2011). 
(Defensins are reviewed by Tecle et al., (2010), Wilson et al., (2013) and 
others). 
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1.8.4 Other proteins in mucus 
As mentioned above, half of the proteins in mucus are not mucins. They 
belong to a diverse set of families and play roles in lung function, cell 
maintenance, and protection from microorganisms and polutants. Over 2,000 
proteins have been identified within induced sputum, saliva or nasal brushes 
or washes, or bronchoalveolar lavage (BAL) of healthy and diseased 
individuals (J. Chen et al., 2008; Gharib et al., 2011, 2009; Nicholas et al., 
2006). As a quick overview: Proteins found in the mucus fall into many 
categories: enzymes (proteases, glycolytic enzymes, enzymes involved in 
lipid metabolism, etc.); adhesion proteins (those involved in wound healing, 
thrombosis & blood clotting); carriers/transporters (of haem, hormones, ions, 
metals, etc.); signalling proteins (cytokines, chemokines); lectins (collectins, 
ficollins, galectins, siglecs, etc.); immunoglobulins (antibodies: IgA, IgM, IgG, 
etc.); innate immune proteins (complement, antioxidants); and inhibitors (of 
many of the aforementioned proteins). The extracellular recognition of 
influenza viruses by antibodies and lectins has been well studied and the field 
of decoy receptors is growing. However, there are so many glycosylated 
proteins in the extracellular space, it is a hard to see an end to possible 
influenza virus inhibitors.  
The diverse set of proteins that present decoy receptors clearly play an 
important role as a barrier that prevents most animal or human-animal 
reassortant influenza viruses from being able to cause pandemics. It is likely 
that this barrier along with the need to bind a2,6-linked SA receptors on 
epithelial cells drives selection of HA NA pairs suitable for human-to-human 
transmission. Further research should aim to characterise the glycans 
expressed on specific proteins in specific conditions as well as the 
downstream effects on influenza viruses that bind to them.  
As discussed earlier in the introduction, there must be significant lack of 
immunity in the population to a influenza virus in order for it to cause a 
pandemic. Therefore, the antibody mode of recognition is disarmed by the 
novel antigenicity of the HA. The lectin recognition pathway may act as 
another barrier that must be overcome by an influenza virus before it can 
cause a pandemic. In line with the importance of the lectin barrier, pandemic 
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influenza viruses tend to lack glycans on the surface of the HA head. Avoiding 
the barrier of decoy receptors is slightly more complicated. Since viral 
replication relies on HA binding to target cells that function cannot be 
discarded. It seems instead that the viruses method of overcoming decoy 
receptors is to discard them though the sialidase function of NA and may be 
why HA/NA balance is so important for pandemic viruses.  
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1.9 Characteristics of NA that may relate to the ability 
of viruses to overcome barriers to transmission 
Two characteristics of NA that relate to the ability of viruses to replicate and 
thus may relate to the ability of zoonotic viruses to become transmissible are 
NA stalk length and the presence or absence of a secondary SA binding site.  
 
1.9.1 NA Stalk Truncation  
The stalk regions of avian virus NA proteins are known to vary in length while 
the stalk regions of human virus NA proteins are almost always the same 
length. The stalk region of human influenza viruses’ NAs are about 50 aas 
long (Reid et al., 2000) and hereafter termed a long stalk (LS). The most 
thorough analysis of NA stalk length of avian influenza viruses is by Li et al. 
(2011). Throughout this thesis, any NA that has phylogenetic ancestors with a 
stalk longer than it will be considered a short stalk (SS) NA. Li et al. analysed 
all avian NA gene sequences available on the www.flu.lanl.gov database on 
17 December 2009 that had been sequenced from nt 90 to nt 270, which were 
not duplicates or manipulated in labs. It is important to note that the 
sequences collated by Li et al. are biased due to increased sampling (and 
sequencing) of closely related viruses that arose during outbreaks among 
poultry. This means that the frequency of SS NAs as a total of virus isolates is 
skewed to favour poultry isolates. However, their dataset also includes 
isolates from routine sampling of wild birds. Therefore, one of the strengths of 
Li et al.’s analysis is that it represents a diverse set of viruses (Li et al., 2011). 
Cognizant of these strengths and weaknesses, Li et al.’s data has been 
adjusted (for ease of interpretation) and re-presented here. 
The diversity of NA stalk deletions in different avian viruses analysed by Li et 
al. is depicted in Figure 1.9. The most common HPAI H5N1 lineage is a good 
example that allows interpretation of the information in this figure. The HPAI 
H5N1 viruses are the only avian viruses with a stalk deletion that have been 
isolated in three continents and therefore have three coloured rectangles in 
the right hand column to indicate that they were isolated in Asia (green), 
Europe (teal), and Africa (orange). To the left of the three rectangles, there 
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are over ten adjacent “+” signs, which indicates that H5N1 viruses with this 
particular stalk deletion have been isolated from birds yearly for over a 
decade. Following the grey line further to the left leads to a red bar that 
indicates the location of the aas that were deleted as indicated on the x-axis 
of the graph. These H5N1 viruses have 20 aas deleted from aa 49 through aa 
68. Figure 1.9 provides a qualitative overview of many of the different NA 
stalk-deletions that have been found in nature.  
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Figure 1.9. NA stalk deletions by HA and NA subtype, deletion length, longevity 
and location. This figure was created by merging three figures from Li et al. and 
adding additional labels and connectors. On the right-hand side of the figure, the 
blocks of colour indicate the continent(s) in which an avian influenza virus isolate with 
a specific stalk deletion was found: Asia (green), North America (pink), Europe (teal), 
and Africa (orange). A “+” sign indicates that a virus with the specific NA deletion, 
connected by a grey line, was isolated in that year. Location, by aa position, and 
length of stalk deletion are indicated by the coloured bars. Some lengths of deletions 
are indicated with black numbers. If a black number is followed by a multiplication 
sign, it indicates that the length and aa location of that specific deletion has occurred 
multiple times. Together, the number of bars and multipliers indicate how many 
truncation events have been detected within each NA subtype over the studied 
period. Identified deletions within N1 NAs are indicated in red, deletions in N2 NAs 
are indicated in blue and so on as labelled. HA subtypes have been added in 
separate columns on the left of the figure.   
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Further analysis by Li et al. allows quantification of the number of stalk 
truncation events, the number of isolates that have SS NA, and the frequency 
with which they occur by viral, HA, or NA subtype. Table 1.3 lists the virus 
subtypes from Li et al.’s dataset that have the most NA stalk truncation events. 
They used phylogenetic analysis to determine the number of truncation 
events per NA. The heat-map colouring of Table 1.3 shows that the number of 
truncation events does not correlate with the number or frequency virus 
isolates with SS NAs. Except for H7N7, which has a low number of truncation 
events and a low frequency of isolates with SS NAs, colours of second row of 
Table 1.3 do not line up with colours of third and fourth rows. This analysis 
assumed that the HA was paired with a specific NA when the truncation event 
occurred. However, this could be a misrepresentation if pairing came about 
through reassortment and ancestral associations were not sampled. 
Table 1.4 shows the number of truncation events and Table 1.5 shows the 
frequency of virus isolates that have SS NAs as a percentage of the total 
number of viruses isolated by HA and NA subtype. Table 1.4 shows the 
number of stalk truncations that have been documented for each HA and NA 
subtype. The bottom row, labelled “H1-Hun”, shows the frequency of NA 
truncation by NA subtype. Viruses with N2 NAs have undergone the most 
truncations with 26 and N1 NAs have undergone the second most with 11 
truncation events. Also notable is that truncated N3 NAs have been selected 9 
times and truncated N7 NAs been selected 5 times. The far right column of 
Table 1.4, labelled “N1-N9” highlights differences in the frequency of NA 
truncation in association with different HA subtypes. For example, H5 HAs 
were paired with NAs that arose from 19 separate truncation events: 11 were 
N2 NAs; 6 were N1 NAs; and 2 were N3 NAs. Whereas, H6 HAs were paired 
with NAs that arose from 10 separate truncation events; 5 were N2 NAs, 4 
were N1 NAs, and 1 was an N5 NA.  
Table 1.5 shows the frequency of viruses with a deletion in the NA as a 
percentage of all sequenced viruses of that particular subtype. In total 45% of 
avian influenza viruses with sequenced HA and NA genes have stalk 
deletions (bottom right cell). The bottom row and far right column of this table 
are not as informative as those of Table 1.4 because the bias toward outbreak 
viruses skews the data. However, comparing specific subtypes, such as were 
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picked out for Table 1.3, shows H5N1 viruses are much more likely to have a 
SS NA than H9N2 viruses (92% versus 32%).  
Importantly, after controlling for shared ancestry, Li et al. found a correlation 
between gallinaceous hosts and deletions in the NA stalk. However, this 
correlation was not found in HPAI H5N1 viruses, where 99% of HPAI H5N1 
isolates had a stalk deletion even though many were isolated from wild birds. 
This is likely because the HPAI H5N1 lineage underwent a period of poultry 
adaptation before it spread to other species. 
 
 
Table 1.3. Comparison of NA stalk truncation events with number and 
frequency of SS NA isolates. Data was collected and adapted from Li et al., 2011. 
Heat-map colour scales were applied using “Conditional Formatting” in Microsoft 
Excel for Mac 2011, v14.3.9.   
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Table 1.4. Number of NA stalk truncation events by viral subtype. Red and yellow 
shading indicate subtypes in which 1 or 2 truncation events were detected. Green shading 
indicates that truncation was detected 3 or more times within that subtype. (Adapted from 
data presented in Li et al., 2011.) 
 
 
 
N1 N2 N3 N4 N5 N6 N7 N8 N9 N1-N9
H1 0 0 0 0 0 0 0 0 0 0
H2 0 0 0 0 0 0 0 0 0 0
H3 0 0 0 0 0 0 0 0 0 0
H4 0 0 0 0 0 1 0 0 0 1
H5 6 11 2 0 0 0 0 0 0 19
H6 4 5 0 0 1 0 0 0 0 10
H7 1 3 5 0 0 0 3 0 0 12
H8 0 0 0 0 0 0 0 0 0 0
H9 0 7 0 0 0 0 0 0 0 7
H10 0 0 1 0 0 0 2 0 0 3
H11 0 0 1 0 0 0 0 0 0 1
H12 0 0 0 0 0 0 0 0 0 0
H13 0 0 0 0 0 0 0 0 0 0
H14 0 0 0 0 0 0 0 0 0 0
H15 0 0 0 0 0 0 0 0 0 0
H16 0 0 0 0 0 0 0 0 0 0
Hun 0 0 0 0 0 0 0 0 0 0
H1-Hun 11 26 9 0 1 1 5 0 0 53
N1 N2 N3 N4 N5 N6 N7 N8 N9 N1-N9
H1 0% 0% 0% 0% 0% 0% 0%
H2 0% 9% 0% 0% 0% 0% 0% 0% 0% 1%
H3 0% 1% 0% 0% 0% 0% 0% 0% 0% 0%
H4 0% 5% 0% 0% 0% 0% 0% 0% 0% 1%
H5 92% 46% 5% 0% 0% 0% 0% 0% 0% 83%
H6 61% 16% 0% 0% 12% 0% 0% 0% 35%
H7 69% 88% 24% 0% 0% 0% 7% 0% 0% 53%
H8 0% 0% 0% 0% 0%
H9 0% 32% 0% 0% 0% 0% 0% 32%
H10 0% 0% 63% 0% 0% 0% 3% 0% 0% 10%
H11 0% 0% 13% 0% 0% 0% 0% 0% 1%
H12 0% 0% 0% 0% 0% 0%
H13 0% 0% 0% 0% 0%
H14 0% 0%
H15 0% 0% 0%
H16 0% 0% 0%
Hun 0% 100% 25%
H1-Hun 79% 36% 15% 0% 2% 0% 4% 0% 0% 45%
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Table 1.5. Frequency of short stalk NA in avian viruses. Percentages were calculated by 
dividing the number of influenza virus isolates of each indicated subtype by the number of 
isolates with any length of stalk deletion as described by Li et al. (2011). Green highlighted 
cells show where stalk truncation of the serotype indicated was present at a frequency 
greater than 30% and at least 100 isolates were sequenced. Yellow indicates cells where the 
at least 17 isolates were sequenced and at least 3 were found to have a stalk truncation and 
the stalk truncation frequency was greater than or equal to 5%. Cells were highlighted red to 
indicate that 17 or more isolates were sequenced and detection of NA truncation was at a 
rate of less than 5%. These numbers were chosen arbitrarily post hoc. H1-H16 = HA subtype 
1-16; “Hun” = HA subtype unknown. “H1-Hun” = Viruses of HA subtype H1-H16 plus viruses 
where HA subtype was unknown. (Adapted from Li et al.’s Table 1.)  
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In summary, 53 NA stalk deletions had arisen in nature between the years of Li et 
al.’s analysis and they varied in length (from 1-35 aas) and location (between aas 40 
and 90) within the NA gene. Most viruses with NA stalk deletions are not long-lived. 
However, some viruses with NA stalk deletions, such as H5N1, H6N1, H9N2, H5N2, 
and H7N2 circulated within birds for over five years. Viruses of HA subtypes H2, H4, 
H5, H6, H7, H9, H10, and H11 have all been isolated with an NA that had a stalk 
deletion of 13 or more amino acids. H9N2 viruses have had NAs with shorter stalk 
deletions of 2, 3, 4, and 6 aas. The dominant H9N2 lineage has a 3 aa deletion in the 
stalk of its NA. Therefore, it can be concluded that influenza viruses with NA stalk 
deletions arise and under the right circumstances, which are not yet fully understood, 
can persist in the avian population.  
Before Li et al.’s analysis, others had noted that deletions in the stalk domain of NA 
were associated with viruses isolated from poultry and not from wild birds (Banks et 
al., 2001; Matrosovich et al., 1999; Spackman et al., 2003). Moreover, viruses with 
truncated NA stalks were selected during laboratory passage through gallinaceous 
birds. Passage of duck H7N3 and H9N2 viruses in quail led to selection of viruses 
with more than 20 aas deleted from the stalk of NA (Giannecchini et al., 2010; 
Hossain et al., 2008). Similarly, passage of a duck H3N2 virus isolate in quail led to 
stepwise stalk deletion in NA (Yamada et al., 2012). Another group found that quail-
passage of a duck H2N2 virus did not induce NA stalk truncation, but further 
adaptation of the quail-adapted virus in chickens led to selection of a 27 aa NA stalk 
truncation (Sorrell et al., 2010). The NA of the H7N9 virus that recently zoonosed in 
China has a 5 aa deletion in its stalk domain and the evolutionary pathway of this 
virus indicates that it spent some time adapting to poultry (Bao et al., 2013). 
Therefore, there is mounting evidence that NA stalk truncation is selected within 
terrestrial birds. 
Genetically engineered SS and LS paired viruses have been used to study the effect 
of NA stalk truncation on viral replication and virulence. Influenza virus with SS NA 
was shown to enhance replication and virulence in eggs and chickens when 
compared to virus with LS NA (Hossain et al., 2008; Munier et al., 2010; Sorrell et al., 
2010; Zhou et al., 2009). A short NA stalk had varying effects on replication in cell 
culture; in A549 cells, viruses with short stalk NAs grew to higher titres, while the 
opposite was observed in MDCK cells (Chutinimitkul et al., 2010b; Zhou et al., 2009). 
Both Zhou et al. and Matsuoka et al. found that virulence in mice was enhanced for 
viruses with a truncated NA stalk compared to their equivalents with a long stalk 
(Matsuoka et al., 2009; Zhou et al., 2009).  
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As explained in Section 1.5 of this thesis, there is an evolutionary requirement for a 
balance between the HA binding avidity for SA receptor and the NA enzyme activity 
that destroys the receptor. Mutations in HA or NA often drive compensatory change 
in the other gene in order to conserve this critical balance in activities relative to SA 
expression in the target tissue. NA stalk deletion is often coupled with increased HA 
glycosylation, which has been shown to reduce receptor binding affinity (Baigent and 
McCauley, 2001; Banks et al., 2001; Bender et al., 1999; Matrosovich et al., 1999; 
Matsuoka et al., 2009; Wang et al., 2009). Compensatory changes in HA were also 
observed in vitro in viruses that lacked the NA gene altogether (Richard et al., 2012) 
and in vivo when NA mutations were linked with drug resistance (Ginting et al., 2012; 
Mochalova et al., 2010). 
A few viruses with amino acid deletions within the NA stalk have been isolated from 
humans. One group found that within the quasispecies of viruses found in the 
nasopharyngeal washes of patients there was a 22 aa deletion in the NA stalk 
domain and that virus with stalk deletion could be retained in some cases and 
outcompeted in other cases by viruses with full length NA stalks in culture (Zhirnov et 
al., 2009). A human seasonal H3N2 influenza virus underwent stalk truncation by 4 
aas in an immunocompromised patient after 5 days of oseltamivir treatment. The 
virus with shortened NA stalk transmitted by direct contact to an equal number of 
ferrets as the full length NA stalk parental virus, but RD transmission was not tested 
(Memoli et al., 2010). It remains to be determined whether or not human viruses with 
stalk deletions could transmit between humans or other mammals through the air.  
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1.9.2 NA Haemadsorption 
Haemadsorption (Hd) is the binding by NA of a receptor that is expressed on the 
surface of erythrocytes or red blood cells (RBCs). The receptor is sialic acid and 
there is some evidence that its linkage is nonspecific (Hausmann et al., 1995; 
Uhlendorff et al., 2009). Haemagglutination by HA and Hd by NA were initially difficult 
to distinguish because both viral glycoproteins are expressed at the infected cell 
surface and on the virus particle.  
Hd was first documented by Choppin et al. (Choppin and Tamm, 1960) as a property 
of NA that was retained by the selected clone of a 1957 pandemic H2N2 viral isolate 
named A/RI/5+/57 (RI5+). After finding that RI5+ viruses still agglutinated chicken 
RBCs even after the RBCs had been desialated by NA purified from Vibrio cholera, 
Choppin et al. purified the N2 NA to determine whether or not it would be capable of 
destroying the receptor on the RBCs. Unexpectedly, they found that purified viral NA 
rosettes caused spontaneous RBC agglutination at 4°C. This indicated that NA, like 
HA, had a receptor-binding domain.  
Similarly, using purified N9 NA rossettes from detergent-dissociated virions of 
influenza virus A/tern/Austrailia/G70c/75 (ternAus75), Laver et al. (Laver et al., 1984) 
showed that this NA also agglutinated chicken RBCs. Laver et al. went one step 
further and showed that the sialidase activity of NA could be inhibited by antibodies 
while the Hd activity was retained. Therefore, they suggested that the two activities 
were located at separate sites on the NA protein. The Hd site is sometimes referred 
to as NA’s second sialic acid binding site. After the determination of the ternAus75 
N9 NA sequence (Air et al., 1985) and its three dimensional structure in complex with 
a Fab fragment of a monoclonal antibody (Colman et al., 1987), Webster et al. went 
on to show that several N9 NA antibody escape mutants lost the ability to 
haemagglutinate chicken RBCs. By determining the amino acid sequence of these 
escape mutants, they localized the Hd site to a region including residues 364, 366, 
367, 369, 396, and 432 (H1 numbering throughout) (Webster et al., 1987). A 
sequence alignment through this region of NAs of several different subtypes and their 
Hd+ or Hd- status is shown in Figure 1.10. The aas linked to Hd by Webster et al. 
and others after them are boxed in red. 
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Nuss and Air showed that Hd activity could be transferred from one NA to 
another by a few aa changes. Nuss and Air conferred the Hd+ phenotype to 
the NA of the H2N2 human influenza virus A/Tokyo/3/67 (Tok67), which was 
originally Hd-, by substituting key aas through the Hd domain from the avian 
N9 Hd+ NA. These substitutions of 3 (KDL365-367IAS) and 5 (DSDNR395-
399LNTDW) aas in the 370- and 400-loops, respectively, corresponded to the 
same regions as defined by Webster et al. (Nuss and Air, 1991). Around the 
same time, Hausman et al. showed that the N1 NA of A/FPV/Rostock/34 
(foRos34) also bound to chicken RBCs. Furthermore, they showed that 
mutations S367L or TDW397-399DNR, which were located in the same 
putative Hd domain as identified within N9 and N2, abrogated the N1 NA Hd+ 
phenotype. They also showed that mutation W179S affected the Hd 
phenotype, but since this mutation was not in the Hd binding site the 
mechanism of its action is unclear (Hausmann et al., 1995). The terms 370- 
and 400-loop were originally coined while characterising the Hd domain of N9 
and N2 NAs. Despite the difference between N2 and N1 numbering, the terms 
370- and 400-loop will be used throughout this thesis to describe the first and 
second loops of the Hd domain, but numbering will be according to N1 NA. 
The 400-loop refers to 5 aas 395-399 (N1 numbering), which are on a β-sheet 
while the other loops do not have secondary structure. The aas 429-438 will 
be referred to as the 430-loop. 
When Varghese et al. solved the X-ray crystal structure of ternAus75 N9 NA 
in complex with SA it became clear that several of the amino acid residues of 
the 370-loop, aas 364 to 369, including the serines of the SxxSxS motif, the 
backbone oxygen and the side-chain oxygen of N396, the aromatic face of 
W399 (in the 400-loop), and the nitrogen of K432 were all involved in bonds to 
make a total of 8 interactions with SA that led to the Hd+ phenotype 
(Varghese et al., 1997) (Figure 1.11). Comparison of sequences from 
ternAus75 N9 and foRos34 N1 NAs, which were both Hd positive, showed 
that the N1 NA had I at position 396, rather than N (see alignment, Figure 
1.10). Therefore, it was concluded that an N at 396, and thus the interaction 
between SA and the side-chain oxygen (numbered 4 in Figure 1.11), was not 
necessary for Hd. Varghese et al., referring to the N2 NAs, state in their 
discussion that “This [Hd] signature since has disappeared under antigenic 
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drift in post-1957 human and swine stains”. Since the sequenced viruses with 
N2 NAs isolated from swine between 1957 and the time Varghese et al. 
published were likely of human-origin, this observation may have been due to 
selection during transmission between humans rather than selection 
pressures on viruses that transmitted between swine. Varghese et al. did not 
comment on the presence or absence of the Hd signature in N1 NAs from 
viruses of human- or swine-origin.  
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Figure 1.11. X-ray crystal structure of N9 and N2 NAs with SA in Hd domain. (A) 
The surface of a single NA head region of ternAus75 N9 NA is shown with SA bound 
in the enzyme site (purple sticks) and Hd site (green sticks). Light Blue = Carbons, 
Grey = Hydrogens, Blue = Nitrogens, Red = Oxygens. (B) Atomic interactions 
between ternAus75 N9 NA and SA reproduced from (Varghese et al., 1997). (C) 
Atomic interactions between ternAus75 N9 NA and SA reproduced from (Uhlendorff 
et al., 2009). (D) Hd site of ternAus75 N9 NA with bound SA viewed using Pymol 
from top, 370-loop side, and 400-loop side. Amino acid interactions are indicated with 
dashed black lines, numbered with red numbers and identified by red lines. (E) An 
overlay of two crystal structures using Pymol: ternAus75 N9 NA (bound to SA) and 
Tok67 N2 NA. Residues involved in bonds with SA are coloured yellow for ternAus75 
NA and the equivalent residues for Tok67 NA are coloured in orange. Red arrows in 
(E) show residues of Tok67 that abrogate Hd (Nuss and Air, 1991). Residues of 
ternAus75 and Tok67 that are in the Hd-loops, but not directly involved in interactions 
with SA are coloured Light blue and magenta, respectively. Backbone of ternAus75 
and Tok67 are dark blue and purple, respectively. 
 
In 1997, Kobasa et al. considered whether or not Hd was a host-species 
specific adaptation. They found that avian influenza virus NAs of subtypes 1-3 
and 5-9 haemadsorbed chicken RBCs while human virus NAs of either 
subtype N1 or N2 did not. They did not test an N4 NA. An equine influenza 
virus N8 NA haemadsorbed chicken RBCs strongly. A swine influenza virus 
N1 NA haemadsorbed chicken RBCs with only 5-10% of the Hd activity 
achieved by NAs with maximal activity like the equine N8 and the avian N1 
and N9 NAs.  
The swine NA was from the influenza H1N1 A/swine/Italy/437/76 (swIt76) 
virus. The full sequence of swIt76 NA is not available, but Kobasa et al. 
published the sequence through the 370- and 400-loops (as SisSrS LtdW). 
Thus swIt76 differed by two aas from the N1 NAs of foRos34 and dkAus803 in 
the following residues: T365I/I396L (foRos34/dkAus80 ! swIt76). However, 
swIt76 NA had the same sequence through the Hd defining regions as 
                                            
3 The Hd profile of dkAus80 NA had the same Hd strength as swIt76 NA, 
despite the 2 aa differences in their sequences. 
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A/turkey/Missouri/81 N1 NA4, which was shown by Kobassa et al. to have 
strong Hd binging (Kobasa et al., 1997). Therefore, it is unlikely that these aa 
differences account for the reduced binding affinity of the Hd domain of swIt76 
N1 NA but more likely that sequences outside of the known Hd defining region 
affected this phenotype. Presumably, the swIt76 NA belonged to the classical 
swine lineage and therefore was a descendent of NAs that had been adapting 
to swine since at least 1918 (Nardelli et al., 2010; Smith et al., 2009a).  
Kobasa et al. characterised the growth in vitro and in vivo of a virus with an 
Hd+ wt and Hd- mutant N2 NA. Mutation S367L in the NA from influenza virus 
A/duck/Hong Kong/7/75 H3N2 abrogated Hd and resulted in a 50% reduction 
in cleavage of the small soluble substrate MUNANA. Kobasa et al. suggest 
that the reduction in enzyme activity may be due to a structural perturbation of 
the active site. Virus with the Hd- NA was attenuated at early times after 
infection in chicken embryo fibroblast (CEF) cells, however the mutant virus 
eventually reached the same titre as wild type. The mutation did not affect the 
virus’ thermostability and was considered not to affect infectivity of Peking 
ducks (Kobasa et al., 1997). Thus, despite showing a difference in vitro, 
Kobasa et al. could not identify any effects of loss of Hd activity on the virus 
phenotype in vivo in ducks. 
In summary, Kobasa et al. found that Hd+ phenotype associated with birds, 
horses, and swine, but not human virus NAs.  
 
  
                                            
4 The full-length sequence of A/turkey/Missouri/81 NA is not available.  
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More recently, Uhlendorff et al. analysed the Hd phenotype of NAs of two 
pandemic strains: H2N2 A/Singapore/1/1957 (Sing57) and H1N1 A/Brevig 
Mission/1/1918 (BrevM18) (Uhlendorff et al., 2009). The BrevM18 NA, the 
only 1918 influenza virus isolate with full NA sequence available, had the Hd 
domain sequence: StsSrS(364-369)/ItdW(396-399)/K(432), which suggests it 
should be Hd+. In contrast, the Sing57 N2 NA had a substitution S364N in the 
370-loop, which suggested that Hd had been lost. Of the other N2 NA 
sequences available from 1957 and 1958 human isolates, five isolates 
(including RI5+), retain the Hd+ signature SxxSxS/NxxW/Q whereas about 20 
others have substitutions including S364N, S367L, or N396K/S (Figure 1.12).  
Experimental testing confirmed that Sing57 N2 NA wt was indeed Hd- and the 
single point mutation N364S restored its Hd capacity. Any one of three further 
mutations S367L, N396S, or W399R, which were observed in human virus N2 
NAs, individually reverted the Hd status of Sing57 N364S back to Hd-. 
Reflecting on the H2N2 human virus NA sequences available from 1957 and 
1958 isolates, Uhlendorff et al. made two interesting suggestions about the 
selection pressure toward Hd- NAs in humans. Firstly, the isolation of viruses 
from humans with the Hd+ sequence in NA indicated that a virus with an Hd+ 
NA crossed the species barrier and was transmissible between humans. 
Secondly, although viruses with the Hd+ signature in NA were transmissible, 
viruses with an Hd- signature in NA were naturally selected and this was most 
likely due to a fitness benefit these mutations bestowed onto the virus in the 
human host. The fact that different human H2N2 virus lineages had different 
mutations in the Hd interacting residues supports both of these hypotheses by 
showing that a reduction in Hd binding was independently selected numerous 
times.  
As expected from its intact Hd domain sequence, the 1918 N1 NA from 
BrevM18 displayed substantial ability to Hd human RBCs, but unexpectedly 
its ability to bind chicken RBCs was 5-10 fold lower than that of the two avian 
N1 NAs and the Sing57 N2 N364S Hd+ mutant (Uhlendorff et al., 2009). 
Therefore, BrevM18 N1 NA had a reduced Hd capacity despite retaining the 
signature Hd+ sequence, much like the swIt76 NA. This indicated that before 
emergence of the 1918 pandemic virus, the BrevM18 NA may have 
undergone mutations, in amino acids other than those in the interacting 
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residues, that dampened its ability to Hd from a level achieved by its putative 
avian precursor NA.  
Early studies on Hd hypothesised that the Hd domain may bind to receptors 
that were not cleavable by NA. It was proposed that the Hd domain might bind 
SA in a linkage, such as a2,8-SA or gangliosides, that was not cleaved by the 
enzyme site of the same NA. These hypotheses arose from an observation by 
Air and Laver. They performed HA assays with two reassortant H1N9 viruses, 
one Hd+ and the other that was selected under antibody pressure and had 
become Hd-. Both viruses agglutinated RBCs. However, when they repeated 
the experiment with RBCs that had been desialated by incubation with N9 NA, 
they found that only the Hd+ H1N9 virus retained some ability to agglutinate 
RBCs (Air and Laver, 1995). Hausman et al. and Uhlendorff et al. showed that 
the Hd domains of foRos34 N1 and Tok67 N367S N2 NAs, respectively, 
which were Hd+, bound similarly to α2,3- and α2,6-resialated RBCs 
(Hausmann et al., 1995; Uhlendorff et al., 2009). Furthermore, comparison of 
the RBS of an avian H3 HA and the N9 NA Hd pocket led Uhlendorff et al. to 
conclude that the Hd pocket was very shallow and unlikely to be involved in 
bonds with sugars further down a glycan chain. It is possible that the H1N9 
Hd- virus had acquired reduced HA binding affinity that could account for its 
inability to agglutinate RBCs that had significant amounts of SA removed by 
pre-treatment with NA. 
Early studies on the ability of NA to Hd concluded that receptor binding by N9 
NA did not play a significant role in the initial stages of virus infection. This 
conclusion was made because the inhibitory effects of anti-HA antibodies 
were not overcome by an Hd+ NA (Laver et al., 1984). Yet it took many years 
to identify the function of an Hd+ site on NA. Uhlendorff et al. showed that the 
Hd status of an NA did not affect the efficiency of cleavage of monovalent SA. 
However, when they measured cleavage of α2,3- and α2,6-SA expressed on 
multivalent sialylglcopolymers they found that the ability to Hd associated with 
an increased rate of cleavage of both substrates (Uhlendorff et al., 2009).  
Thus Hd may serve to tether multivalent substrates and facilitate enzyme 
cleavage.   
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2 Chapter 2: The short stalk length of an 
H7N1 avian influenza virus NA protein 
inhibits viral growth in cell culture. 
2.1 H7N1 SSckIt99 Introduction 
A focus on adaptations that an avian NA might have to undertake to support 
efficient human-to-human transmission was stimulated by previous work 
undertaken within the Barclay lab. Scull et al. showed that infection of primary 
human airway epithelial cells (HAEs) with a human influenza virus led to 
efficient replication regardless of whether or not the cells were incubated at 
32°C or 37°C. However, in comparison, two avian viruses grew efficiently in 
the same cells at 37°C, but their growth was inhibited at 32°C. Scull et al. 
went on to compare viral growth of the human seasonal H3N2 virus 
A/Victoria/3/1975 (Vic75) at 32°C and 37°C with an HA mutant, a PB2 mutant, 
and a “7+1” virus that had seven genes from Vic75 and an NA from an avian 
virus. The 7+1 virus with avian origin NA had over a two log reduction in 
growth at two time points compared to the wild type virus when infected cells 
were incubated at 32°C. Furthermore, spread of the 7+1 virus throughout the 
HAE culture was also restricted (Scull et al., 2009). Therefore, it seemed 
important to understand the barriers that prevented this NA of an avian virus 
from supporting efficient replication in human cells. 
Avian influenza viruses replicate optimally at higher temperatures than human 
viruses (Massin et al., 2001). The temperature preference is likely different 
because avian viruses have adapted to maximise replication in the epithelial 
cells of the intestinal tract of birds, which have a core temperature around 41 
or 42°C, depending on their size (Clarke and Rothery, 2007; Marais et al., 
2011; Prozesky, 1963). The core temperature of humans is 37°C and that is 
the temperature of human’s LRT. However, the nasal mucosa, which is 
cooled by inhaled air, has a mean temperature of 32°C (Lindemann et al., 
2002).  
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2.2 H7N1 SSckIt99 Results 
The gene of the avian NA used in Scull et al. was from the highly pathogenic 
avian influenza (HPAI) H7N1 virus A/chicken/Italy/13474/1999 (ckIt99). The 
virus was isolated from a chicken that died during a string of particularly 
devastating outbreaks among poultry farms in Italy in 1999 (Whiteley et al., 
2007). During this outbreak and the culling of birds that followed a small 
number of exposed humans became seropositive for the H7N1 virus. About 
3.8% of poultry workers seroconverted to H7 viruses between 1999 and 2003 
(Puzelli et al., 2005). However, no viruses were isolated from humans.  
2.2.1 Bioinformatics analysis of the ckIt99 NA 
In order to analyse genetic differences that might account for the reduced 
growth phenotype of the 7+1 virus at the cooler temperatures in human airway 
cells, the gene sequence of the ckIt99 N1 NA was compared to that of the 
consensus from human seasonal N1 NA genes (Figure 2.1). The NA of ckIt99 
differed from the human N1 NA consensus sequence by 0 aas in the cytosolic 
domain, 5 aas in the transmembrane domain, and 45 aas in the head domain. 
There was 1 aa deletion in the head domain of SSckIt99 NA compared to the 
human seasonal consensus. It also had a 22 aa deletion along with 12 other 
aa differences in its stalk domain. Due to this 22 aa deletion, we called it a 
short stalk (SS) NA. 
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Figure 2.1. Amino acid alignment of hte consensus sequence from human 
seasonal H1N1 NAs and SSckIt99 NA. 906 complete human seasonal H1N1 NA 
protein sequences were downloaded from the Influenza Research Database on 
03/04/2014 (2009 pandemic, laboratory, and duplicate sequences were excluded). 
Sequences were aligned using Geneious v6.1.6 and the consensus was extracted. It 
was then aligned to SSckIt99 NA, which is shown here. huSeas = consensus 
sequences for human seasonal H1N1 NAs pre 2009 pandemic. The cytoplasmic tail 
domain is underlined in purple. The transmembrane domain is underlined in magenta. 
The stalk domain is underlined in green. The head domain is underlined in orange. 
Amino acids are coloured by polarity: red = negative charge; blue = positive charge; 
green = polar; yellow = nonpolar. 
 
2.2.2 Generation of viruses 
In order to assess whether that the deletion in the stalk of ckIt99 NA was the 
reason that the 7+1 virus from Scull et al. had reduced growth and spread in 
HAE cultures, a NA with a full length stalk, which from this point onward will 
be referred to as long stalk (LS), was engineered. The sequence of ckIt99 NA 
was very similar to other NAs isolated during the Italian H7N1 outbreak in 
1999. One of the viruses, A/chicken/Italy/1082/1999 (ck1082), had an NA with 
a long stalk and thus its sequence was used as a template to insert 66 
nucleotides into the stalk region of the NA gene of ckIt99. An alignment of 
these two sequences shows that they only differ by two aas, ck1082 to ckIt99: 
R173K (coloured blue in Figure 2.2 A) and A397T (coloured yellow and green 
in Figure 2.2 A).  
Three viruses were engineered using reverse genetics, each had seven 
genes from the human seasonal H3N2 virus Vic75 plus one of the following 
NA genes: the matching Vic75 NA; the SSckIt99 NA; or the LSckIt99 NA. The 
coloured bars in Vic75 NA shows that there are many differences between the 
avian N1 NA ckIt99 and a human N2 NA throughout the whole sequence 
(Figure 2.2 A).  
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Figure 2.2. Alignment of NA sequences from Vic75, SSckIt99, ck1082, and 
LSckIt99 viruses. (A) Shows an alignment of the full-length amino acid sequences 
of the NAs used in this study. (B) Shows sequence through the deleted stalk region 
of SSckIt99 NA shows the nucleotides that were engineered into the stalk to make 
LSckIt99 NA. (C) Shows a zoomed in view from the stalk region indicated in A plus 
extra aas in the N and C-terminal directions for each NA. (A and C) Amino acids are 
coloured by polarity. Aas that have a negative charge are coloured red, those with a 
positive charge are blue, green are polar and yellow are nonpolar. (B) Nucleotides 
that are not equal to the consensus of the alignment are backlighted with grey. The 
stalk region is labelled with a green bar below the sequences.  
 
2.2.3 The short stalk length of ckIt99 NA inhibits virus 
replication  
 The experiments reported by Scull et al. describing the difference in 
viral growth conferred by avian virus NA has been performed in HAE cells, 
which present a complex environment. HAE cultures are multi-layered, have 
different populations of polarised cells, some are ciliated, others, in particular 
goblet cells are not and these two cell types express glycans with differentially 
linked SA (Thompson et al., 2006). The goblet cells secrete mucins onto the 
apical surface of the culture, which is exposed to air, so the mucins collect 
together and form a viscous mucus layer on top of the HAE cells. This has 
been proposed previously to act as a barrier for influenza infection which the 
viral NA is able to overcome (Matrosovich et al., 2004).  
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Influenza viruses are often assessed for replication in MDCK cells. MDCK 
cells are a transformed cell line. The cells grow as a monolayer under media, 
so mucins are not concentrated on their surface. MDCKs express both α2,3- 
and α2,6-SAGs and are permissive to most human and avian influenza 
viruses (Matrosovich et al., 2003). To see if there was a difference between 
the replication kinetics of the three viruses in this simple model at 37°C, a 
temperature that is permissive to most influenza viruses, MDCK cells were 
infected with virus at low MOI and virus released into the media was 
measured at different times post infection (Figure 2.3). Virus with LSckIt99 NA 
grew to greater than one log-higher titres compared to virus with SSckIt99 NA 
at both 12 and 24 hpi. Virus with SSckIt99 NA grew to lower titres than virus 
with naturally paired human seasonal HA and NA genes. However, 
unexpectedly, virus with LSckIt99 NA grew to higher titres than the wild type 
human seasonal virus. All differences between viruses at 12 and 24 hpi were 
statistically significant (p<0.0001).  
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Figure 2.3. Growth of 7+1 viruses in MDCK cells. (A) MDCK cells were infected in 
triplicate with MOI 0.01, cells were incubated at 37°C, media was collected at times 
indicated and plaque assay was performed to titre viral concentrations. Key shows 
NA of each virus, the other seven viral genes are from Vic (i.e. 7+1 viruses). Error 
bars represent 95% confidence intervals. (B) Statistical significance for the 
differences between the 95% confidence intervals of each virus at each time point 
was determined by 2-way ANOVA with Tukey post test for one family.  
 
2.2.4 The short stalk length of ckIt99 NA inhibits viral spread 
in MDCK cells 
 The ability of viruses to spread through MDCK cell cultures was 
observed at 32°C. Cells were infected with each virus in triplicate and fixed, 
then stained with anti-NP antibody at 12 and 48 hpi. The viral inoculums used 
for infection were back titrated and plaque assays confirmed that dilutions of 
each virus were within one log of that aimed for and that any variation in titres 
between viruses was less than a log. The LSckIt99 NA virus dose was found 
to be within a log, but nevertheless higher than the inoculum dose of the other 
two viruses, which explains why at 12 hpi two infected cells are visible per 
field of cells infected with Vic NA and SSckIt99 NA viruses while ten infected 
cells are visible per field after cells were infected with LSckIt99 virus (Figure 
2.4 A). At 48 hpi almost all cells in each well exposed to a virus with a long 
stalk NA were infected. However, many uninfected cells remained in wells 
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exposed to the virus with a short stalk NA (Figure 2.4 B). Therefore, even in a 
simple cell culture system the short stalk length of an avian NA inhibited 
spread of virus. This suppression of viral spread resulting from decreased NA 
activity is similar to what others have seen in the presence of an NA inhibitor 
as well as with viruses that lack NA altogether (Mori et al., 2011; Moules et al., 
2010).  
 
 
Figure 2.4. Spread of virus in MDCK cells. MDCK cells were infected at an MOI 
0.01 with each of the viruses indicated in triplicate and incubated at 32°C for (A) 12 
hours or (B) 48 hours then fixed, permeabilised, and stained for NP proteins (green) 
and DNA (blue). Images are representative of all three wells. Yellow scale bars are 
100um long.  
 175 
2.2.5 H7N1 virus with short stalk NA replicates to lower levels 
in HAEs than virus with an NA that has an elongated 
stalk  
Since HA and NA genes normally acquire mutations that balance their activity 
levels, it is likely that the ckIt99 NA stalk truncation was selected in order to 
reduce NA activity so that it matched the avidity of the H7N1 HA for the 
receptor expressed by epithelial cells at the site of replication in chickens. To 
confirm that the attenuating effect of stalk truncation was not merely due to 
the mismatch between HA and NA in the 7+1 RG virus, and to investigate the 
effect of stalk truncation when paired with the cognate HA, two more viruses 
were rescued, which utilized the H7 HA gene. To minimise risk, the vaccine 
strain H7 HA, which had its multibasic site removed (Whiteley et al., 2007), 
was used along with six internal genes from the human vaccine strain 
A/Puerto Rico/8/1934 (PR8). This is an accepted and well used method for 
creating vaccine viruses (Luke and Subbarao, 2006; Stephenson et al., 2004). 
Both RG viruses were tested for replication in HAE cells. Virus with LSckIt99 
NA grew better than virus with SSckIt99 NA in HAE cells incubated at 32°C at 
12, 48, and 72 hpi. The titre of virus with LSckIt99 NA was over half a log 
higher than the titre reached by virus with SSckIt99 NA at 48 and 72 hpi and 
these differences were statistically significant (p≤0.001). Stalk elongation of 
the avian N1 NA increased growth in HAEs of a virus with homologous avian 
H7 HA   
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Figure 2.5. Growth of viruses with HA and NA from ckIt99 in HAE cells. HAE 
cells were infected with MOI of 0.01 and incubated at 32°C for 72 hours. The HA and 
NA genes were from the H7N1 ckIt99 virus (NA either SS or LS) and six internal 
genes were from PR8. Statistical analysis was performed by 2-way ANOVA with 
Sidak posttest. (HAEs infected and supernatant collected by Neeltje van Doremalen.) 
 
2.3 H7N1 SSckIt99 Discussion 
The results presented here showed that the shortened stalk of the NA from a 
chicken-adapted H7N1 influenza virus restricts viral growth in cell culture. 
Virus growth in MDCK cells at 37°C was restricted when SS NA was paired 
with a human seasonal H3 HA. Spread of the same virus in MDCK cells was 
restricted at 32°C. When paired with its cognate avian H7 HA, growth of virus 
with SS NA was restricted at later time points compared to virus with LS NA. 
Restoration of the stalk to a length that is observed in viruses normally 
isolated from humans or waterfowl showed that extension of the NA head to a 
distance from the cell and viral membrane plays an important role in the ability 
of NA to support viral replication in both simple and complex mammalian cell 
culture systems.  
The H7N1 outbreak in Italy was followed by other H7 outbreaks in poultry and 
in some of these it has been documented that some humans became infected. 
NA stalk truncation is frequently but not always seen: The NA of the H7N7 
viruses from the outbreak in the Netherlands in 2003, which transmitted to 
some close contacts of poultry workers, did not have any deletions in the NA 
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stalk. Neither did the two H7N3 viruses that were isolated from one individual 
in Canada in 2004 and another individual in Mexico in 2012. On the other 
hand, the H7N2 virus NY107 that had an extra deletion in the 220-loop of its 
HA had a 16 aa deletion in the stalk of its NA. This virus transmitted efficiently 
between direct contact ferrets when administered intranasally, but not to 
respiratory droplet exposed ferrets (Belser et al., 2008). H7N3 viruses have 
been a major cause of avian influenza virus outbreaks in the Americas over 
the last ten years, but not many humans have been infected (Krauss and 
Webster, 2012). H7N3 viruses with a range of stalk deletions from 16-28 aas 
have been isolated in Asia, Europe, and North America (see Figure 1.9). The 
H7N9 viruses isolated from humans in China this year (2013) have 5 aas 
deleted from the stalk domain of the NA when compared to other avian N9 
NAs. Interestingly, the consensus N9 NA sequence has one more amino acid 
in the region between the cytosolic tail and the head domain compared to the 
consensus for N1 NAs, so the 5 aa deletion is more like a 4 aa deletion, when 
compared to human transmissible NAs. Whether this small truncation in N9 
NA plays any role in limiting the onwards spread of the virus from infected 
people has not yet been determined. 
Comparatively, H5N1 infection of humans has been documented much more 
frequently. This is likely because H5N1 infections of humans induce higher 
morbidity and mortality. Therefore, understanding barriers that prevent H5N1 
viruses from initiating a pandemic are a more pressing concern.   
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3 Chapter 3: The short stalk length of an 
H5N1 avian influenza virus NA protein 
inhibits viral growth and transmission in 
mammalian-based models. 
3.1 H5N1 SStyTy05 Introduction 
3.1.1 Assessing the impact of NA stalk truncation in the 
context of NA from a HPAI H5N1 virus. 
Since the first documented lethal outbreak in humans of highly pathogenic 
avian influenza (HPAI) H5N1 virus in 1997 more than half of the people with 
confirmed infection have died (WHO, 2013). Although the case fatality rate 
may be much lower in a pandemic scenario, there is reason to worry that a 
pandemic caused by an H5N1 influenza virus could be severe. Currently, 
H5N1 viruses that have evolved in nature demonstrate limited transmission 
from person-to-person (Aditama et al., 2012) indicating host range barriers 
have so far prevented an H5N1 pandemic. Understanding the exact nature of 
these host range barriers may aid in the prediction of and preparation for an 
H5 influenza pandemic. 
Panzootic H5N1 influenza viruses that are the agents of recent outbreaks 
emerged from wild birds in Southeast Asia around the turn of the century. 
Influenza A/Goose/Guangdong/1/96 (GsGd96) virus is the lineage defining 
strain for both the HA and NA of currently circulating H5N1 viruses and this 
strain had six basic amino acids (aas) at the HA cleavage site, a genetic 
feature associated with highly pathogenic avian influenza virus (HPAI). 
Sequencing of viruses from the 1997 outbreak of HPAI H5N1 in humans and 
poultry revealed that, compared with the GsGd96 NA, the NA of the 1997 
outbreak viruses had a 19 aa deletion in its stalk region (Bender et al., 1999; 
Matrosovich et al., 1999; Xu et al., 1999). The 1997 H5N1 virus lineage was 
effectively ‘stamped out’, but H5N1 viruses re-emerged in 2003 with a new 
genetic constellation named “genotype Z”. The 2003 H5N1 viruses derived 
their HA and NA gene segments from the GsGd96 lineage, while the internal 
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genes, which originated from other avian influenza viruses, were gained 
through reassortment (Guan et al., 2004). Early isolates of genotype Z 
retained the multibasic cleavage site (MBCS) in HA and possessed a long 
stalk length NA, including the human H5N1 isolate A/HongKong/213/03. 
However, HPAI H5N1 viruses with a 20 aa stalk truncation in NA rapidly 
emerged and subsequently spread across Asia, Europe and Africa (Brown, 
2010; Guan et al., 2002). According to Li et al., 99% of HPAI H5N1 viruses 
isolated between 2003 and 2011 had NA with a short stalk (Li et al., 2011). 
We hypothesised that the deletion in the stalk of H5N1 NAs acted as a barrier 
to transmission between mammals. First, we confirmed that the stalk deletion 
of a NA from the main HPAI H5N1 lineage had the same effect on viral 
replication in cell cultures as was seen with ckIt99 NA. Next, we showed that, 
in the context of an otherwise transmission-competent prototypic pandemic 
H1N1 virus, the same NA reduced transmission via respiratory droplets (RD) 
between ferrets and its short stalk length was a major contributing factor.  
 
3.2 H5N1 SStyTy05 Results 
3.2.1 Bioinformatics study on the NA of H5N1 virus. 
There are a number of differences between the NA of ckIt99 and NAs of 
H5N1 viruses. The deletion in the NAs of most H5N1 viruses are two aas 
shorter and the deleted amino acids are from a section of the stalk that begins 
five aas closer to the transmembrane domain and ends seven additional aas 
away from the head region.  
Influenza A/turkey/Turkey/1/2005 virus (tyTy05), a clade 2.2.1 HPAI H5N1 
virus, is representative of the clade of viruses that caused a panzootic 
outbreak in Turkey from October 2005 and led to 21 confirmed human cases 
of H5N1 influenza by the end of January 2006 (Meijer, 2006; Oncul et al., 
2006). The NA of tyTy05 virus had the same 20 aa deletion that is 
predominant among genotype Z viruses. We aimed to generate an isogenic 
pair of recombinant viruses that differed only in stalk length of N1 NA. To 
elongate the N1 NA stalk, a protein sequence search of tyTy05 NA was 
performed in Geneious. Of the first 100 sequences returned, 34 had full-
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length stalks. To find the genetic sequence with closest identity to tyTy05 NA, 
nucleotide sequences of the seven top matches with a full-length stalk were 
aligned with ty05 NA. The sequence for A/chicken/Jilin/hl/2004 (ck/Jilin04) 
proved to be most similar with 97.2% identity and was used to engineer 
LStyTy05 NA (Figure 3.1).   
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Figure 3.1. Alignment of NA sequences from E195/09, SStyTy05, ck/Jilin04, and 
LStyTy05 viruses. Sequences of N1 NAs shown by (A) full length aa sequence (B) 
nucleotide sequence of region covering stalk deletion and (C) aa sequence of stalk 
region. The first sequence, A/England/195/2009 (E195/09), is the natural full-length 
sequence of a prototypic pandemic NA followed by the natural sequence from 
A/turkey/Turkey/1/05 NA (SStyTy05), from which nucleotides 145-204 are absent. 
The third sequence (ck/Jilin04) is from the N1 NA of A/chicken/Jilin/hl/04 virus, and 
was the sequence, without a stalk deletion, found in Genbank to have the highest 
nucleotide identity with SStyTy05 NA. The final sequence, (LStyTy05 NA) was 
engineered by inserting nucleotides 145-204 from ck/JilinNA into SStyTy05 NA. 
Amino acids are coloured as bars in A and highlighted in C where they differ amongst 
the NA sequences in this set (blue= positively charged; red = negatively charged; 
green = polar; yellow= non-polar). Nucleotides in B are highlighted in grey where 
E195/09 NA differs from ck/Jilin04 NA. The stalk region is labelled with a green bar 
below the sequences.  
 
Using reverse genetics, three viruses were rescued with seven genes from 
the prototypic pandemic strain A/England/195/09 (E195/09) and either its 
cognate or a SS or LS version of tyTy05 NA. E195/09 virus was isolated from 
the nose swab of a sick individual who returned to England from Mexico in 
April 2009 (Ellis et al., 2009). Since they were both N1 NAs, the sequences of 
E195/09 and LStyTy05 NA are much closer than the Vic N2 NA was to 
LSckIt99 NA. Nevertheless, they differed by 56 aas: 8 in the transmembrane 
domain; 14 in the stalk domain; and 34 in the head domain. 
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3.2.2 The short stalk length of a NA from H5N1 is responsible 
for reduced viral growth in cell cultures and in ex vivo 
tissue 
Virus growth was measured under multicycle conditions at 32°C in MDCKs, 
primary human nasal epithelial cells (HNE), primary ferret tracheal epithelial 
cells (FTE), and in ex vivo tissue from ferret nasal turbinates (FNT). The only 
difference between HAE and HNE cells is that the location of cell source has 
been specified as nasal for HNE cells, whereas cells used to make HAEs 
could have originated from the nose, trachea, bronchi, or lungs (Fulcher et al., 
2005). FTE cells were produced in our laboratory following protocols similar to 
those utilized for generating HAE cultures. The FTE cultures were similarly 
multi-layered, differentiated, polarized, with ciliated and non-ciliated cells, and 
secreted mucus onto their apical surface, which was exposed to air. They 
may differ from human cells due to inherent differences in the presence or 
form of cellular proteins and glycans but are currently largely uncharacterized. 
Only one other group has described the generation of FTE cells and they 
reported an opposite lectin staining pattern to what has been observed with 
HAEs. They showed that SNA stained ciliated cells while MAAI and MAAII 
stained non-ciliated cells. Furthermore, they found that human influenza 
viruses infected ciliated cells while an avian H5N1 virus replicated in non-
ciliated cells (Zeng et al., 2013). The process of creating HAEs or FTEs 
involves pronase treatment to make a single cell suspension then removal of 
fibroblasts and other cells that stick to a tissue culture dish, such as 
monocytes. Presumably lymphocytes remain in cell suspension and thus may 
be co-cultured with the epithelial cells, but it is not known if they survive for 
any significant period of time. The epithelial cells are cultured for weeks to 
give them time to reform into multi-layered differentiated tissue before an 
experiment commences. In contrast, ex vivo tissue sections are infected 
within hours of extraction from a living animal and retain the local environment 
including all immune cells located interstitially and in the airways. However, in 
the experiments here, the air interface is lost through submersion of the 
tissues in media.   
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In MDCK cells, the virus with LStyTy05 NA showed increased replication over 
the virus with SStyTy05 NA by a log mean difference of 0.66 (95%CI: 0.09-
1.23) and 0.89 (95%CI: 0.32-1.46) at 24 and 48 hpi, respectively (Figure 3.2). 
Interestingly, virus with SStyTy05 NA grew at the same rate as human 
pandemic virus E195/09 with its cognate NA, while in this same culture 
system, but at 37°C, virus with SSckIt99 NA grew less well compared to the 
human seasonal H3N2 virus with its cognate NA (Figure 2.3). The higher 
titres of virus with LStyTy05 NA compared to E195/09 virus were statistically 
significant at both 24 and 48 hpi in MDCK cells.  
In HNE cells both E195/09 wt NA and LStyTy05 NA viruses grew to higher 
titres than SStyTy05 NA virus, with a log mean difference between LStyTy05 
NA and SStyTy05 NA of 1.41 (95%CI: 0.56-2.25) at 24 hpi. The difference 
between E195/09 and SStyTy05 NA viruses was statistically significant at 48 
and 72 hpi. The difference between growth of LStyTy05 NA and E195/09 virus 
was not statistically significant in HAEs (Figure 3.2).  
Again in FTE cells both E195/09 and LStyTy05 NA viruses grew to higher 
titres compared to SStyTy05 NA virus at 24 and 48 hpi. The viral growth 
between SStyTy05 and LStyTy05 NA viruses differed by a log mean 
difference of 1.30 (95%CI: 0.80-1.79) at 24 hpi in FTEs. Interestingly, in FTEs, 
the LStyTy05 NA virus grew less well compared to E195/09 virus at 24 hpi 
and this difference was statistically significant (Figure 3.2).  
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Figure 3.2. Multicycle virus replication of viruses with different NAs. Multicycle 
virus replication was assessed in MDCK, HNE, or FTE cells at 32°C. Cells were 
infected with viruses at MOI of 0.01. The mean viral titre of each virus (N=3) is 
indicated with a symbol and error bars represent 95% confidence intervals (CIs). 
Note the 95% CIs for LStyTy05 NA at 48 and 72 hpi in MDCKs and at 72 hpi in HNEs 
do not show because they were very small. Stars indicate to the p-values for the 
differences between viruses with SStyTy05 and LStyTy05 NA. Statistical significance 
was determined using a Two-way ANOVA with Tukey’s multiple comparison post test. 
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
3.2.3 Respiratory droplet transmission in ferrets is limited by 
a short stalk NA 
A ferret transmission experiment performed within the Barclay group showed 
that that a recombinant E195/09 virus with its cognate NA transmitted to 3/3 
ferrets via respiratory droplet (RD) (van Doremalen et al., 2011). Others have 
reported a RD transmission rate of 66% to 100% using similar prototypic 
pandemic viruses in ferrets (Imai et al., 2012; Itoh et al., 2009; Lakdawala et 
al., 2011; Maines et al., 2009; Munster et al., 2009). To determine whether or 
not introduction of the avian N1 NA would affect transmission and if stalk 
length would influence this, four ferrets were inoculated intranasally with 
1x106 pfu of either SStyTy05 or LStyTy05 NA viruses in 200ul PBS and 24 
hours later a direct contact (DC) ferret was co-housed with each donor and a 
RD exposed ferret was housed in an adjacent cage, which was separated by 
perforated panels (Figure 3.3). Ferrets were nasal washed daily and plaque 
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assays performed to determine the viral titre shed in the nasal wash (Figure 
3.4).  
 
Figure 3.3. Ferret transmission cage setup. Donor ferrets were inoculated with 106 
pfu virus in 200ul PBS on day zero and housed in separate cages. The day after 
inoculation one DC ferret was co-housed with each donor and one RD ferret was 
housed in an adjacent cage separated by two perforated panels. 
 
Both SStyTy05 and LStyTy05 NA viruses were shed by all inoculated donors 
and all DC exposed animals. Ferrets inoculated with SStyTy05 or LStyTy05 
NA virus shed similar amounts of infectious virus, as determined by 
calculating the mean area under the curve (AUC), 5.0x105 (pfu x d)/ml for 
SStyTy05 NA or 6.3x105 (pfu x d)/ml for LStyTy05 NA, over 6 or 6.3 days, 
respectively. Figure 3.4 A shows the amount of virus detected daily in the NW 
from individual ferrets and Table 3.1 shows the mean differences with 95% 
CIs and p-values. Ferrets exposed via DC to the SStyTy05 NA virus shed 
fewer virions, and shed virus for a shorter period of time, than animals 
exposed via DC to LStyTy05 NA virus. SStyTy05 NA DC animals shed on 
average, 8.1x105 (pfu x d)/ml for a mean of 4 days, while DC ferrets infected 
with the LStyTy05 NA virus shed, on average, 1.7x107 (pfu x d)/ml for a mean 
of 5.3 days. Although these differences were not statistically significant, they 
showed a trend that related a shorter NA stalk length to reduced viral 
shedding by ferrets infected through DC transmission. Additionally, the first 
day of shedding by DC ferrets exposed to the SStyTy05 NA virus was delayed 
by an average of 2.75 days compared to the DC ferrets exposed to the 
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LStyTy05 NA virus and this difference was statistically significant. 
Furthermore, while three of the four ferrets exposed by RD to the LStyTy05 
NA virus shed virus in their nasal wash, no virus was detected in the nasal 
wash of any of the ferrets similarly exposed to the SStyTy05 NA virus (Figure 
3.4, bottom panels).  
 
 
Figure 3.4. Viral shedding and weight loss by ferrets inoculated or exposed to 
virus. (A) Viral titre from nasal wash was determined daily by plaque assay from 
Donor, DC, and RD ferrets. SStyTy05 NA virus is shown in red and LStyTy05 NA 
virus is shown in blue. (B) Change in weight of Donor, DC, and RD ferrets over time. 
Weight change was calculated as the percentage difference in weight on the 
indicated day in comparison to day zero. pfu = plaque forming units; ml = milliliters; 
dpi = days post infection; G = a “group” consisting of one donor ferret plus one DC 
and one RD exposed ferret in shared or adjoining cages, respectively. 
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Viral infection with SStyTy05 NA versus LStyTy05 NA viruses did not lead to 
significant differences in the mean weight gain or loss within inoculated donor 
or exposed DC ferrets (Figure 3.4 B, means not shown). The mean difference 
in weight between ferrets exposed via RD to the two viruses did reach 
significance on numerous days, including days 1, 7, and 10-14. The DC 
exposed ferret in group 4, depicted with a light blue line received 4ml of saline 
solution subcutaneously at 9 dpi, which may account for its slight increase in 
weight. The RD exposed ferret of group 4, depicted with a pink line in the 
bottom panel, is the one that seroconverted after RD exposure to SStyTy05 
NA virus. 
 
Exposure 
Route 
Log (AUC (pfu x d/ml)) 
(95% CI) 
1st day (95% CI) Total days (95% CI) 
Inoculation -0.06 (-2.63 to 2.52) -0.25 (-1.23 to 0.73) 0.25 (-2.06 to 2.56) 
DC   2.06 (-0.50 to 4.64)  2.75 (1.77 to 3.73) **** 1.25 (-1.06 to 3.56) 
RD  3.76 (1.19 to 6.33) **  n/a 3.00 (0.69 to 5.31) ** 
Table 3.1. Mean difference between amounts of virus shed, day virus was first, 
and number of days that virus was shed from ferrets after exposure to 
LStyTy05 NA virus in comparison to SStyTy05 NA virus.  
AUC = Area under the curve 
pfu x d/ml = plaque forming units multiplied by days per ml averaged per group (N=4) 
1st day = first day virus was shed post inoculation or exposure, averaged by group 
Total days = total number of days that virus was detected in the nasal wash, 
averaged by group 
n/a = not applicable 
95% CI = 95% confidence interval, ** p<0.01, **** p<0.0001 
 
Microneutralisation (MN) assays performed on serum collected pre-exposure 
showed that all ferrets were seronegative (MN<10) for the challenge virus 
before the experiment. A second serum sample was collected 21 days after 
the first day of exposure. All ferrets that were virally positive by nasal wash 
were found to seroconvert (MN≥320). Although none of the ferrets that were 
exposed via RD to the SStyTy05 NA virus became virologically positive, one 
seroconverted, but it had a low MN titre (MN=20). The three ferrets that shed 
virus following exposure via RD to the LStyTy05 NA virus were seropositive 
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(MN>1,280), and the one ferret that did not shed virus remained seronegative 
(MN<10) (Table 3.2).  
 
Virus NA Inoculated Ferrets DC Ferrets RD Ferrets 
SStyTy05 (ND) 2/2 (1♯ MN=320, 1♯ MN=640) 1/4 (3♯ MN<10, 1♯ MN=20) 
LStyTy05 4/4 (4♯ MN>1,280) 4/4 (4♯ MN>1,280) 3/4 (3♯ MN>1,280, 1♯ MN<10) 
Table 3.2. Seroconversion of ferrets upon exposure to virus with short or long 
stalk NA. 
Sera were collected both before and 21 days after inoculation or exposure. All ferrets 
were serologically negative (MN<10) by microneutralisation assay before the 
experiment. 
♯ Number of ferrets to which the following MN titre applies. 
ND = not done 
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3.2.5 Long stalk HPAI H5N1 NAs are rare 
It was already clear that the overwhelming majority of H5N1 viruses were 
paired with SS NAs (Li et al., 2011), but it was unclear which H5N1 clades 
contained the LS NAs. Analysis focused on HPAI H5N1 influenza viruses 
showed that short stalk NA genes predominate (96%) within this dataset. Only 
4% of HPAI H5N1 viruses in this dataset were found to have long stalk NA 
genes (Table 3.3). 
 
Host 
Avian- 
Anser-
iformes 
Avian-
Gall-
iformes 
Avian-
Other Human Swine 
Mammal
- 
Other 
Total 
H5N1 
w/MBCS 425 404 105 159 20 14 1,127 
SS NA 
(%) 
395    
(93%) 
396   
(98%) 
101   
(96%) 
157   
(99%) 
16     
(80%) 
14   
(100%) 
1,079  
(96%) 
LS NA 
(%) 
30        
(7%) 
8       
(2%) 
4         
(4%) 
2         
(1%) 
4       
(20%) 
0         
(0%) 
48         
(4%) 
Table 3.3. Stalk length of NAs from HPAI H5N1 influenza viruses isolated after 
1995 for which paired HA and NA sequences were available.  
SS = Short Stalk; LS = Long Stalk 
 “Avian-Other” for LS NA = 2 Ciconiiformes, 1 Passeriform, 1 Falconiform; MBCS = 
multibasic cleavage site (2 or more, usually 5 or 6 basic aas);  
“Avian-Other” for SS NA = (in descending frequency) 38 Ciconiiformes (herens, 
egrets, storks), 31 Passeriformes (songbirds), 15 Falconiformes, 7 Accipitriformes 
(birds of prey: hawks, eagles, vultures), 5 Pelecaniforms, 2 Charadriiformes, 2 
Struthioniformes (ostrich), 1 Gruiform (crane-like) 
 
Maximum likelihood phylogenetic trees of paired H5N1 HA and NA sequences 
were generated and HA clades were labelled (light blue vertical lines) (Figure 
3.5). Many of the LS NAs were from the European and North American LPAI 
H5N1 clades (shown in gold). This dataset showed a total of five truncation 
events (labelled with black or grey text on the NA tree). One of the stalk 
truncation events associated with a LPAI H5N1 virus (shown in grey). The 
others associated with HPAI H5N1 viruses (shown in black). The difference 
between our findings and those of Li et al., who reported six separate 
truncations within H5N1 viruses, may be because our analysis only included 
sequences that were full length, while Li et al.’s analysis considered any 
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sequence that had information for nucleotides through the stalk region. The 
NA tree reinforced the idea that stalk truncation events are infrequent, but can 
lead to persistent lineages. Notably, the SStyTy05 N1 NA used in this study 
had the 20 aa deletion that dominates contemporary HPAI H5N1 viruses. 
Stalk elongation was not observed. 
Most of the HPAI H5N1 viruses with a LS NA (shown in red) were paired with 
HAs that belong to the early clades (0, 3, 4, 5, 6, 7, 8, 9). The early clades 
represent viruses that were isolated in Asia through 2004. H5N1 viruses of 
clade 2 are those with increased host range and wide geographical spread. 
The only clade 2 HPAI H5N1 virus with a LS NA was isolated from a domestic 
duck in 2011 in Zhejiang Provence, China. The NA tree showed that the origin 
of the LS NA found in dk/Zhejiang/2245/2011 was from the otherwise LPAI 
European clade (see Figure 3.5 insert). This finding indicates that this virus 
resulted through reassortment of an HPAI and LPAI H5N1 virus. Although 
isolation of HPAI H5N1 viruses with a LS NA has been incredibly rare since 
2004, the singular instance shows that it can occur.  
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Figure 3.5. NA and HA maximum likelihood phylogenetic trees. Maximum 
likelihood phylogenetic trees were constructed from 1,150 paired H5N1 full-length 
sequences. The HA tree is on the left and the NA tree is on the right. Stalk truncation 
events are each annotated in grey or black with the year of the earliest virus isolate 
and the number of aas that were deleted. Taxa names have been removed for clarity 
(see supplementary material of Blumenkrantz et al., 2013 for full names). The insert 
is a magnified view of the area around the branch dedicated to the LS NA of 
dk/Zhejiang/2245/2011, which is indicated by a red dot on both the HA and NA trees. 
Branch colours are: red = avian HPAI LSNA, pink = mammalian HPAI LSNA, gold = 
avian LPAI LSNA, black = avian and mammal HPAI SSNA, grey = avian LPAI SSNA. 
Years indicate the date of virus isolates indicated by a bracket or line. Insert nodes 
are labelled with bootstrap values. Virus names of interest and HA clades are noted 
in light blue.   
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3.2.6 Some HPAI H5N1 viruses with long stalk NA had HA 
genes with mammalian adaptations but all retained PB2 
627E.  
It is clear that genes other than NA also play an important role in controlling 
influenza virus transmission such as HA and PB2. Therefore, sequences of 
HA and PB2 from H5N1 viruses with LS NAs were searched for genetic traits 
that had previously been shown to associate with mammalian adaptation 
(Chutinimitkul et al., 2010b; Gambaryan et al., 2006; Herfst et al., 2012; Imai 
et al., 2012). Lack of the glycosylation site at residue 158 (H3 numbering) in 
HA due to a N158D or T160A mutation has been shown to increase 
replication and transmission of H5N1 viruses in guinea pigs (Gao et al., 2009) 
and ferrets (Imai et al., 2012; W. Wang et al., 2010) when H5 mutations that 
alter the receptor binding preference toward α2,6-linked SA are also present. 
Accordingly, an H5N1 virus with a long stalk NA and lacking this glycosylation 
site might be two steps closer to a mammalian transmissible phenotype. 
Interestingly, and perhaps of some concern, we found that most 94% (45/48) 
of the H5N1 viruses that had long stalk NA also lacked the HA-158:160 
glycosylation site.  
The only virus with a LS NA and an HA mutation associated with increased 
α2,6-SAG receptor binding was the A/Hong Kong/213/03 (HK213/03) virus, 
which had the mutation S227N (Gambaryan et al., 2006; Shinya et al., 2005). 
This virus was isolated from a young boy who had two family members die 
from a similar disease and one was confirmed to have an H5N1 infection 
(Peiris et al., 2004), but serology was not analysed to see if other family 
members or carers had seroconverted. One study found that this virus did not 
transmit from infected to RD exposed ferrets, indicating that other barriers 
prevented it from achieving aerosol transmission (Maines et al., 2006). 
Examination of the 44 PB2 gene sequences available for viruses with long 
stalk NA, including HK213/03 and A/duck/Zhejiang/bj/2002, found that all had 
PB2 627E, rather than K, and therefore might show compromised virus 
replication and transmission in mammals (Subbarao et al., 1993; Van Hoeven 
et al., 2009). Indeed, observers noted that the HK213/03 had low levels of 
replication (Maines et al., 2006; Peiris et al., 2004).  
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3.3 H5N1 tyTy05 Discussion 
This study was designed to determine whether the truncated NA from a HPAI 
H5N1 virus limits RD transmission of an otherwise human H1N1 influenza 
virus in a ferret model. We found that a recombinant virus, SStyTy05 NA, with 
an avian virus NA that has a short stalk combined with seven other gene 
segments from a transmissible prototypic 2009 pandemic virus had reduced 
growth in cell culture at 32°C. This was apparent in MDCKs and particularly 
pronounced in differentiated human and ferret nasal or tracheal epithelial cell 
cultures that expressed mucus. These findings recapitulated our previous 
observations that surface glycoproteins of avian influenza viruses limit virus 
spread in complex cultures at temperatures of the upper airways (Scull et al., 
2009 and Chapter 2). A trend that showed attenuated replication of virus with 
SS NA in MDCK cells incubated at 37°C was also observed (data not shown), 
but the difference was greater when cells were incubated at the cooler 
temperature shown here. It is likely that this is due to the slowing of enzyme 
kinetics. 
We also found that SStyTy05 NA virus was compromised in its transmission 
to exposed ferrets. SStyTy05 NA virus was transmitted to only one out of four 
RD exposed ferrets. We attribute the defect in transmission largely to the 
shortened stalk length of NA because a second recombinant virus, LStyTy05 
NA, that differed only by a 20 aa insertion into the stalk of its NA, transmitted 
to three of four similarly exposed ferrets. Moreover, the one RD exposed 
ferret that seroconverted following exposure to SStyTy05 NA infected animals 
did not shed detectable virus in nasal wash, suggesting that a chain of RD 
transmission would not be supported for the SStyTy05 NA virus. Although 
SStyTy05 NA virus did transmit to co-housed animals, the amount of virus 
shed by recipient DC ferrets was lower than that of ferrets exposed in the 
same way to LStyTy05 NA virus. Also, time of shedding was both delayed and 
shortened. All of these observations indicate that a short NA stalk length is a 
significant factor that can limit viral growth and transmission. 
Binding by HA to α2,6-linked SA receptors, HA stability, and internal genes 
competent for efficient replication in mammalian cells in vivo are deemed 
crucial for RD transmission of influenza virus in mammals (Mitnaul et al., 
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2000; Van Hoeven et al., 2009; Wagner et al., 2002b). Since RD transmission 
of a H5N1 virus was not achieved despite numerous attempts (Chen et al., 
2011a; Chutinimitkul et al., 2010b; Jackson et al., 2009; Maines et al., 2006; 
Yen et al., 2007) until recently (Herfst et al., 2012; Imai et al., 2012), we 
studied the effect of NA stalk length in the context of seven genes, all but the 
NA gene, from a prototypic pandemic H1N1. We considered the pandemic H1 
to be a reasonable HA partner for the avian N1 NA because it had recently 
crossed the species barrier into humans. Indeed, initial reports showed that 
the 2009 pandemic H1 HA bound α2,6 SA strongly while retaining some 
residual binding to α2,3 SA (Belser et al., 2011b; Bradley et al., 2011; Childs 
et al., 2009; Y. Liu et al., 2010). The six internal genes from the pandemic 
virus were also well suited for transmission studies as they had been proven 
to support RD transmission in the ferret model (Itoh et al., 2009; Maines et al., 
2009; Munster et al., 2009; van Doremalen et al., 2011). 
Two papers recently described ferret RD transmissible H5N1 viruses (Herfst 
et al., 2012; Imai et al., 2012). The NA gene in the transmissible H5 virus 
generated by Imai et al. was derived from pH1N1 2009 virus and therefore 
had a full length stalk. Herfst et al. generated their transmissible H5 virus with 
a short stalk NA. This virus had numerous additional mutations engineered 
into HA or PB2 and acquired during ferret passage. However, this virus was 
less efficiently transmitted compared to human seasonal and pandemic 
influenza strains (Herfst et al., 2012). It would be interesting to see if NA stalk 
elongation would improve the transmission efficiency of this virus. 
A role for NA in viral infectivity and transmissibility in mammals has been 
noted previously. Data from Matsuoka et al. showed NA stalk length had 
varying effects on viral infectivity in mice (Matsuoka et al., 2009). Other 
studies have shown a link between NA enzymatic activity and RD 
transmission in guinea pigs and ferrets. In the context of a 2009 H1N1 
pandemic precursor virus, Yen et al. showed that replacing a swine N2 NA by 
the pandemic N1 NA, which had much higher sialidase activity, improved 
transmission efficiency from 1/3 to 3/3 RD exposed ferrets (Yen et al., 2011). 
This improved transmission efficiency correlated with reduced aggregation at 
the surface of MDCK cells (Yen et al., 2011). Lakdawala et al. showed that, 
compared to a virus with classical swine N1 NA, virus with pandemic N1 NA 
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had higher NA enzyme activity and increased number of viral genome copies 
in small respirated particles, which also associated with increased 
transmission efficiency (Lakdawala et al., 2011). Conversely, viruses with 
reduced NA enzyme kinetics, as a result of mutations that confer NA drug 
resistance, often show reduced transmission (Bouvier et al., 2008). In cases 
where drug resistance does not compromise transmission, equal or improved 
RD transmission was dependent on compensatory aa mutations in NA that 
restore good expression of NA enzyme activity at the infected cell surface and 
on the virion (Bloom et al., 2010; Bouvier et al., 2012).  
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4 Chapter 4: Molecular mechanisms of short 
NA stalk inhibition 
4.1 Molecular Mechanisms – Introduction 
In Chapter 2 and 3 viruses with short NA stalk lengths were restricted in their 
ability to grow in tissue culture and transmit through the air between ferrets 
compared to viruses that differed only by a longer NA stalk length. Several 
groups have used reverse genetics to demonstrate that NA stalk length 
affects the biological properties of influenza viruses. NAs with different stalk 
lengths had similar enzyme kinetics when cleaving single-valent substrates 
(Matsuoka et al., 2009; Munier et al., 2010; Zhang et al., 2011). In contrast, 
when the substrate was multivalent, such as when it is presented on red blood 
cells (RBCs), a short stalk length reduced the rate of viral elution (Castrucci 
and Kawaoka, 1993; Matsuoka et al., 2009; Munier et al., 2010; Zhang et al., 
2011; Zhou et al., 2009). Therefore experiments were designed to measure 
the restricted release of SS NA viruses from physiological substrates and 
show that restriction was due to reduced sialidase activity.   
4.2 Molecular mechanisms of SS inhibition - Results 
4.2.1.1 Exogenous NA improves growth of a virus with SSckIt99 NA  
Although there is a possibility that deletion of the stalk domain in NA has other 
effects on the virus-host interaction, we hypothesised that the deletions within 
the stalk domains studied here led to a deficiency in the ability of NA to cleave 
SA. To test this, we asked whether the defect in virus replication could be 
rescued by supplementing growth medium with exogenous neuraminidase. 
Sialidases are found in many organisms from bacteria to vertebrates and 
some bacterial sialidases are commercially available in a purified form. Since 
avian NAs have a preference for α2,3-SAGs (Kobasa et al., 1999) the NA 
from Clostridium perfringens was chosen to determine whether or not it could 
substitute for the activity lost with stalk truncation. C. perfringens cleaves 
α2,3-SAGs at approximately twice the rate it cleaves α2,6-SAGs (Cassidy et 
al., 1965). Indeed, exogenous NA was found to enhance growth of the 
SSckIt99 NA virus at 24hpi when added to the media at 1mU/ml. Exogenous 
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NA did not significantly improve the ability of Vic virus with its cognate NA or 
LSckIt99 NA virus to grow in MDCKs. Excessive amounts of exogenous NA 
led to reduced viral growth (Figure 4.1), which is in line with the requirements 
for HA:NA balance and the concept that sialidases might have antiviral 
potential.  
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Figure 4.1. Multicycle viral growth in the presence of exogeneous NA. MDCK 
cells were infected with virus at an MOI of 0.01 then incubated in the presence or 
absence of purified bacterial neuraminidase in the concentrations indicated for 24 hpi 
at 37°C. Released virus was titrated by plaque assay in MDCK cells. 
 
4.2.2 Ability to cleave a small soluble substrate with a single 
SA is not affected by NA stalk length 
Pairs of NAs with full length stalks and deletions have been shown to have 
similar enzyme kinetics when cleaving a small soluble substrate with a single 
linked SA (Matsuoka et al., 2009; Munier et al., 2010; Zhang et al., 2011). To 
compare the sialidase kinetics of SStyTy05, LStyTy05 and E195/09 NA 
viruses, an enzyme assay was performed using the small soluble substrate 
MUNANA. First the amount of virus to input into the assay was standardised. 
To achieve this, viruses were serially diluted in 5-fold steps and incubated 
with the highest concentration of substrate for 30 minutes at 32°C. The E159 
NA virus, at its stock concentration, cleaved the least amount of substrate. 
Therefore, the other two virus stocks were diluted by the dilution factor that 
brought them closest to having cleaved the same amount of substrate as 
E195/09 NA virus over 30 minutes. Using this method of standardization 
required almost 10-fold more pfu per well E195/09 NA virus than of either 
virus with tyTy05 NA (p<0.05), (Table 4.1). E195/09 NA virus displayed a 
slightly higher Km and Vmax compared to that of either virus with tyTy05 NA 
but only the Km difference was statistically significant between E195/09 and 
SStyTy05 NA viruses (p<0.05). Importantly, there was no significant 
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difference between the Km or Vmax of viruses with SS and LS tyTy05 NA 
enzymes indicating that stalk length did not directly affect enzyme activity 
(Table 4.1).  
 
Virus NA Km (µM)∞ Vmax (FU/s)∞ Virus (pfu/well)∞ 
SStyTy05  60 ± 14 * 96 ± 17 2.7x10
5
 ± 1.7x10
5
 ** 
LStyTy05  86 ± 23 108 ± 38 3.0x10
5
 ± 2.0x10
5
 * 
E195/09 139 ± 31 133 ± 25 2.5x10
6
 ± 4.0x10
5
  
Table 4.1. Cleavage of a small soluble substrate (MUNANA) by viral NA. Input of 
virus to achieve equivalent conversion of substrate was standardized by viral dilution 
after preliminary determination of NA activity.  
∞Results are given as the mean ± standard deviation from three independent 
determinations on triplicate samples where R2 > 0.98. When the difference between 
a E195/09 NA virus value and a value for SStyTy05 NA or LStyTy05 NA viruses 
reached statistical significance it is indicated by stars next to the SStyTy05 NA or 
LStyTy05 NA value. The differences between SStyTy05 NA and LStyTy05 NA 
viruses were not statistically significant in any comparison. * p<0.05, ** p<0.01. uM = 
micromolar; FU= Fluorescent Units; s = seconds; pfu = plaque forming units. 
 
4.2.3 The ability of NA to cleave complex substrates is limited 
by a short stalk length 
Many groups have shown that when the substrate is multivalent, such as 
when it is presented on red blood cells (RBCs), a short stalk length reduces 
the rate of viral elution (Castrucci and Kawaoka, 1993; Matsuoka et al., 2009; 
Munier et al., 2010; Zhang et al., 2011; Zhou et al., 2009). To confirm that the 
SS and LS tyTy05 NA viruses from this study also differed in their abilities of 
cleave SA from a more complex substrate, we performed an erythrocyte 
elution assay. This involved incubating viruses with red blood cells (RBCs) for 
one hour on ice, which allowed the HA to bind sialated glycans, followed by 
incubation at 32°C, which allowed the NA to cleave SA and promote virion 
elution from the RBCs, resulting in a loss of haemagglutination. The 
haemagglutination reactions were programmed with 16 HA units (HAU) of 
each virus. This equated to 2.57 x 106 pfu SStyTy05 NA virus, 2.93 x 106 pfu 
 201 
LStyTy05 NA virus and 2.25 x 106 pfu E195/09 virus. E195/09 and LStyTy05 
NA viruses, which have long NA stalks, fully eluted from the chicken RBCs 
after one or 24 hours, respectively, while viruses with SStyTy05 NA did not 
fully elute from chicken RBCs even after 24 hours (Figure 4.2 A). The elution 
assay was repeated using human RBCs. All three viruses were able to fully 
reverse the haemagglutination reaction, however, full RBC elution of virus 
with SStyTy05 NA took longer than its long stalk equivalent (Figure 4.2 B). 
Thus, LStyTy05 NA virus completely eluted from a starting point of 16HAU in 
20 minutes, while for SStyTy05 NA virus 8HAU remained at the first time point. 
Not until after 60 minutes incubation at 32°C did SStyTy05 NA virus fully elute. 
 
Figure 4.2. Viral elution from erythrocytes. Viruses were diluted to equal HA units 
and then mixed with RBCs at 4°C to promote haemagglutination. After HA was 
established, the plate was moved to 32°C to promote NA enzyme activity. The loss of 
HA was assessed every 20 minutes and determined by the appearance of a RBC 
pellet. Experiments were performed three times with different batches of virus and 
these graphs are representative of the pattern seen with either chicken (A) or human 
(B) RBCs. 
 
Normally, human influenza viruses are not in contact with RBCs, but the 
airways are full of sialated molecules that can act as decoy receptors. In 
addition the viral glycoproteins themselves contain SA and NA plays a role in 
the release and dispersal of virus particles by disaggregating virions through 
cleaving SA from the glycoproteins on the virion surface, which HA would 
otherwise bind. To compare the efficiency by which viruses with SStyTy05 NA 
and LStyTy05 NA achieved this, virus particles released following infection of 
HNE cultures were visualized by electron microscopy (Figure 4.3 A). Some 
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filamentous virions were present for viruses of both NA lengths. The majority 
of virions from both viruses were spherical. The mean of three wells showed 
that SStyTy05 NA virions tended to aggregate in clumps. Only 25% (95% CI: 
37-14%) of the particles with SStyTy05 NA were singlets while the majority, 
61% (95% CI: 73-50%) of the particles with LStyTy05 NA were observed as 
discrete virions. Observations of over 450 particles per virus from three 
separately infected cell cultures over 10 fields of view indicated that the 
difference in the percentage aggregation of released particles was statistically 
significant (p<0.001) (Figure 4.3 B). 
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Figure 4.3. Virion aggregation. HNE cells were infected with either SStyTy05 NA or 
LStyTy05 NA virus (MOI 20) and incubated at 32°C. Twenty-four hours later released 
virions were collected in a small volume and negatively stained with uranyl acetate 
then visualized using an electron microscope. Virions were considered aggregated if 
two or more were clearly touching. (A) Representative EM images of SStyTy05 NA 
virions (left panel) and LStyTy05 NA virions (right panel). Supernatant from 
uninfected wells lacked virions (not shown). (B) The average percentage of virions 
aggregated determined by counting over 150 virions per well from three separate 
wells for each virus. Symbols represent individual wells, middle line is the mean and 
error bars denote 95% confidence intervals. MOI = multiplicity of infection. *** 
p<0.001. 
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Exosomes are small-secreted vesicles (30-100nm diameter) released by 
many cell types including respiratory epithelial cells (Kapsogeorgou et al., 
2005). Characterisation of exosomes from human treacheobronchial epithelial 
cells (HTBEs) showed that they express numerous glycoproteins on their 
surface and can inhibit infection by a human influenza virus (Kesimer et al., 
2009). The above analysis of virion aggregation counted virions as being 
singlets if they were not touching any other virions. Therefore, it did not 
account for the number of virions that were bound to exosomes. Exosomes 
were found in the supernatant of all HNEs, regardless of whether or not they 
were infected or uninfected. Although not quantified, it was noted that 
SStyTy05 NA virions tended to have more exosomes bound to both single 
virions (Figure 4.4 SS) and aggregated virions (not shown), whereas 
LStyTy05 NA virions had very few or no exosomes bound (Figure 4.4 LS). 
Their adherence to SStyTy05 NA virions may play a role in reducing the virus’ 
ability to transmit to RD exposed ferrets. 
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Figure 4.4. EM images of exosomes in supernatant from infected or uninfected 
HNE cells. These images are from the same HNE supernatant as Figure 4.3 
collected at 24 hpi. The top three images are of exosomes, which were present in the 
supernatant from uninfected (un) HNEs. The four images on the left are of virions 
with exosomes bound to their surfaces, which were found in the supernatant taken 
from HNE cells 24 hpi with SStyTy05 NA virus (SS). The three images on the right, 
labelled LS, are from the supernatant of HNE cells 24 hpi with LStyTy05 NA virus 
either without any exosomes, with a very small exosome, or with a large exosome 
that was not touching the virion. The black bar signifies 50nm in length. 
 
4.2.4 Inhibition of viral infectivity by mucus is more 
pronounced when virus has a truncated NA stalk 
 Mucus contains many complex sialated glycans and has been 
proposed to act as an innate barrier to influenza virus infection by impeding 
viral access to the target epithelial cell layer. Previously we showed that 
incubating influenza viruses with mucus harvested from uninfected ferret 
nasal wash or from uninfected HNE cell cultures inhibited virus infectivity of 
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MDCK cells (Roberts et al., 2011). Those experiments were performed with 
virus and mucus at 4°C to prevent the NA enzyme digesting away the 
inhibitory sialic acid moieties. In the present study we wished to assess the 
ability of different viral NA enzymes to overcome the inhibition of infectivity by 
mucus and to ask whether the stalk length of NA affected this phenotype.  
Mucus was collected from the apical surface of HNE cultures. Mixing virus 
with mucus led to an initial dilution of 75% and two further 100-fold dilutions 
(to 0.75% and 0.0075%) were used to determine the amount of mucus 
required to block infection of MDCK cells by E195/09 virus (Figure 4.5). 
Depending on where a virion lands along the respiratory tract it may have 
anywhere from seconds to hours to cleave its way through mucus before it is 
transported by the mucociliary ladder to the pharynx and swallowed (Evans et 
al., 2009; Vareille et al., 2011). A 5mg particle of saccharin deposited in the 
nose of healthy adults took between 11 and 15 minutes to be detected by the 
tongue of healthy individuals (Antunes and Cohen, 2007). Therefore, in the 
first instance, infectivity was measured after 20 and 40 minutes. Infectivity 
was normalized to that in the absence of mucus. The highest concentration of 
mucus completely abrogated infection of MDCK cells by E195/09 virus after 
both 20 and 40 minutes of incubation at 32°C. The mid-range dilution also 
significantly inhibited infection within both incubation periods, while the lowest 
dilution did not have a consistent effect. Oseltamivir, a small molecule inhibitor 
that binds to the active site of NA, inhibits viral infection in the absence of 
mucus, but can be diluted so that it is only partially obstructive. A 
concentration of 31uM was used here because it partially inhibited infection in 
the absence of mucus. Interestingly, with the 20-minute incubation, infectivity 
was inhibited to a further extent in the presence of both oseltamivir and the 
lowest dilution of mucus. This trend was continued with 40-minute incubation, 
but the difference was not statistically significant (Figure 4.5). This shows that 
when NA activity is inhibited, decoy receptors in mucus are not cleaved at an 
efficient rate.  
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Figure 4.5. Viral infectivity in the presence of mucus alone or in conjunction 
with oseltamivir. Black circles show infectivity of virus with 8 genes from E195/09 in 
the presence of increasing concentrations of mucus (without oseltamivir) as a 
percentage of infectivity in the absence of mucus. Grey circles show infectivity of the 
same virus in the presence of oseltamivir alone or oseltamivir with increasing 
concentrations of mucus as a percentage of viral infectivity in the absence of both 
mucus and oseltamivir. Virus was incubated with cells at 32°C for (A) 20 minutes and 
(B) 40 minutes before cells were washed and plaque assays were performed. 
Oseltamivir was used at a final concentration of 31uM. P values were determined 
using a one-way ANOVA followed by a Tukey post-test for all possible comparisons. 
Only some p values are shown for simplicity and ease of interpretation.  
 
To determine the effect of mucus on infectivity of SS and LS tyTy05 NA 
viruses, each were incubated at 32°C in the presence or absence of mucus 
and assayed for infectivity on MDCK cells. Even after two hours incubation, 
only a very low amount, 11%, of SStyTy05 NA viruses were able to initiate 
infection in the presence of mucus (Figure 4.6). In contrast viruses with long 
NA stalks more readily overcame mucus inhibition: E195/09 virus recovered 
54% and LStyTy05 NA virus recovered 40% infectivity. The difference in 
infectivity recovered by both viruses with full-length stalks compared to 
SStyTy05 NA virus was statistically significant (p<0.0001). This experiment 
was also performed with shorter incubation times and the same pattern was 
observed (see Figure 5.5).  
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Figure 4.6. Infectivity of virus with SS and LS NA in the presence of mucus. 
100% infectivity was determined by diluting virus so that about 50 plaques formed 
per well of a 6-well plate after 2 hours of incubation in a small volume of serum-free 
buffer followed by 3-day incubation with overlay and plaque development with 
antibody detection. Percentage infectivity was determined as the ratio of the number 
of plaques that formed in the presence of mucus compared to the number that 
formed in the absence of mucus. Virus was diluted, mixed with buffer or mucus, then 
added to wells of MDCK cells in triplicate to allow infection for 2 hours at 32°C. Cells 
were washed 3 times and plaque assays were performed to detect pfus. This 
experiment was performed twice, so N=6. Error bars denote 95% confidence 
intervals. ** p<0.01, **** p<0.0001; MOI 0.00001. 
 
4.3 Molecular Mechanisms – Discussion 
This study was designed to explore the effect of stalk length on NA activity in 
relation to functions that counter human innate barriers to infection. We found 
that a short NA stalk length, which is present in over 60% of H7N1 and over 
90% of H5N1 viruses was responsible for reduced release from decoy 
receptors. The ability to cleave multivalent substrates was clearly reduced for 
virus with SS NA compared to virus with LS NA. Virus with SS NA eluted 
more slowly from erythrocytes, aggregated more often, and bound more 
exosomes. Furthermore, virus with SS NA was severely inhibited by mucus. 
Exosomes can inhibit viral growth and transmission in multiple ways. 
Exosome preparations separated by density gradient from other secreted 
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constituents of HTBE cells carried MUC1 and other smaller glycoproteins 
(including CD59, CD63, and CD133). MUC4 and MUC16 were also found in 
the exosome fractions from some preparations. Exosome preparations from 
HTBE cells stained strongly for α2,6-linked SA and very little α2,3-linked SA 
was detected. Isolated exosomes were shown to inhibit infection by a human 
influenza virus (Kesimer et al., 2009). If bound to a virion, an exosome could 
sterically block incoming virus from reaching the receptor on the epithelial 
cells of a new host. Exosomes can also carry miRNA that activate innate 
immune responses (Mobergslien and Sioud, 2013). Thus, a cell that 
endocytosed a virus with an attached exosome may quickly become 
refractory to replication. In contrast, exosomes were recently implicated in the 
enhanced spread of a picornavirus, HAV (Feng et al., 2013). Therefore, their 
role in virus infections and host responses remains unclear. 
The reduction in viral release from decoy receptors that was observed here 
was due to reduced NA activity. The reduction in NA activity was not apparent 
when cleavage of a small soluble substrate (MUNANA) was measured. This 
indicates that the enzymatic domain was not responsible for reduced NA 
activity. The ability of exogeneous NA to significantly improve growth of virus 
with SS NA supports the theory that stalk truncation reduces NA activity. 
Furthermore, the additive inhibitory effect of Oseltamivir in the presence of 
mucus supports the theory that decoy SA receptors present in mucus are the 
block to viral infectivity. Therefore, we conclude that reduction in NA stalk 
length inhibits sialidase activity in a manner that severely reduces viral fitness 
in models that represent barriers faced during replication in mammals.  
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5 Chapter 5: Characteristics of the pandemic 
N1 NA differentiate it from avian and swine 
influenza virus NAs of the same and 
separate lineages.  
5.1 Haemadsorption – Introduction  
In 2009 an influenza virus of which all eight gene segments shared MRCAs 
with swine influenza viruses caused a pandemic. Within the first year of the 
new virus circulating among humans it is estimated to have caused 105,700-
395,600 deaths worldwide with a case fatality rate (CFR) of 0.012-0.327% in 
18-65 year olds. The CFR was estimated to be up to five times higher in parts 
of the world that lack a developed healthcare infrastructure (Dawood et al., 
2012). In the UK alone, over 16,000 individuals were admitted to hospital due 
to swine-origin H1N1 infection and over 800 died within the first two years of 
the pandemic (Mytton et al., 2012). Therefore, it is important to understand 
the characteristics that allowed this virus to transmit from person-to-person in 
order to predict or prepare for future “swine-flu” pandemics. 
The H1N1 virus that caused the 2009 pandemic was a reassortant with genes 
from many origins. The HA, NP, and NS genes came from the classical (CL) 
swine lineage that has transmitted between swine since at least 1918. The 
PB2 and PA genes came from an avian influenza virus that zoonosed from 
birds to swine in the late 1990’s in North America. The PB1 gene came from a 
human seasonal H3N2 virus that also zoonosed into swine in the late 1990’s 
and was incorporated into what is called the triple reassortant internal genome 
(TRIG) that predominated among swine influenza viruses in North America 
since 1998 (Choi et al., 2012; Lorusso et al., 2012; Smith et al., 2009b). The 
NA and M genes came from a Eurasian (EA) swine lineage virus with all 
genes derived from closely related avian influenza viruses (Dunham et al., 
2009; Schultz et al., 1991). Swine viruses with genes of this lineage were first 
detected in Belgium and Germany in 1979 (Pensaert et al., 1981; Scholtissek 
et al., 1983). Then they were detected in Italy in 1985 (Donatelli et al., 1991), 
in the UK in 1992 (Brown et al., 1997) and in China in 1993 (Guan et al., 
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1996). The EA swine lineage became the dominant lineage in Europe, but 
some reassortant viruses with genes from CL swine and human seasonal 
viruses are also detected on occasion (Brown, 2011; Lycett et al., 2012). No 
swine influenza virus lineage dominates in Asia, instead, there is a mixture of 
many lineages from North America, Europe, or only found in Asia (Choi et al., 
2012).  
Prior to the 2009 pandemic, viruses has clearly been circulating in Asia that 
shared seven out of eight genomic segments from the same lineage as the 
pandemic virus, for example A/sw/Hong Kong/915/04 H1N2 virus (Smith et al., 
2009b). The one gene of the pandemic virus, which was from a totally 
different lineage, was the NA. Therefore, we, and others hypothesised that the 
pandemic N1 NA of EA swine lineage was, for some reason, important in the 
genesis of the 2009 pandemic.  
As described in section 1.5, influenza virus NA protein possess an ability to 
haemadsorb (bind to red blood cells) which varies between strains and is 
often lost upon adaptation of viruses to humans. Since genes of the EA swine 
lineage clearly had an avian origin, but had adapted to swine for many years, 
we hypothesised that the NA would have a swine-like Hd+ phenotype. 
However, alignment of the NA from E195/09, a prototypic 2009 N1 NA, with 
other NAs that were Hd+ showed that E195/09 NA had an Asparagine (N) at 
position 369, rather than a Serine (S) like all other Hd+ NAs. Residue 369 was 
designated as a SA-interacting residue according to the crystal structure by 
Varghese et al. (Varghese et al., 1992) and Webster et al. had shown that the 
mutation S369Y abrogated Hd in the ternAus75 N9 NA (Webster et al., 1987) 
(See alignment Figure 1.10 and 3D structures Figure 1.11). This lay open the 
prospect that the prototypic 2009 pandemic NA might be Hd-.  
Indeed, the possibility that the pandemic NA was Hd- would fit with the 
observations by Kobasa et al. that human influenza NAs were Hd- and with 
the observations of Uhlendorff et al. that the Hd domain of recent pandemic 
strains had either lost (in the case of 1957 N2 NA) or lowered (in the case of 
1918 N1 NA) affinity for SA. Therefore, we hypothesised that the 2009 
pandemic NA had lost Hd activity by the single amino acid mutation at residue 
369, a testable hypothesis by reversion of that sequence change. The ability 
to alter a phenotype by a single aa usually indicates a recent loss of function 
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and might support the notion that the pandemic NA had lost this function to 
improve its transmissibility between humans. Once we had a mutated version 
of E195/09 NA that was Hd+, we planned to determine the effect of gain of Hd 
on transmission of the 2009 pandemic virus in the ferret model.  
 
5.2 Haemadsorbtion – Results  
5.2.1 Pandemic 2009 N1 NA did not haemadsorb RBCs and Hd 
activity was not bestowed upon it through the N369S 
mutation 
NA from the virus A/England/195/2009 was used to study the haemadsorption 
properties of a prototypic pandemic H1N1 NA. NA from the avian virus ckIt99 
(H7N1) was selected as a positive control for these studies because it had an 
identical amino acid sequence to A/ostrich/Italy/984/00 (osIt00), which had 
been shown to be Hd+ (Uhlendorff et al., 2009) and because a cDNA clone of 
this NA gene was available in our laboratory (Whiteley et al., 2007). The other 
N1 NA that was shown to be Hd+, that of A/FPV/Rostock/1934 (foRos34), 
differed from ckIt99 NA by 16 aas in the head domain, which begins at aa 82, 
but these differences did not fall in the 370- and 400-loops of the Hd domain. 
Both NAs of ckIt99 and foRos34 had the sequence StsSrS ItdW in their 370- 
and 400-loops. CkIt99 and foRos43 NAs differed at position 432, which was 
shown to vary in other NAs that retained the ability to haemadsorb: ckIt99 has 
K432 while foRos34 NA has N432. The amino acids in the head region of 
ckIt99 NA and the pandemic E195/09 NA differed by 29 aas (Figure 5.1).  
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Figure 5.1. Alignment of wt NAs from foRos34, LSckIt99, and E195/09. The 370-loop, 400-
loop, and 432 residues of the Hd domain are outlined by black boxes.  
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Each of the NA genes of interest was cloned into a pCAGGS expression 
plasmid to allow exogenous expression in cultured cells, enabling NA to be 
studied separately from HA. The cloned NA genes were tagged with an 
epitope tag in the stalk region, which allowed confirmation that the NA was 
expressed in transfected cells. Hd assays were performed as described in the 
methods section. Briefly, NA expression plasmids were transiently transfected 
into triplicate wells of Vero cells in suspension. The next day, after cells had 
settled as a monolayer, chicken RBCs were allowed to bind at 4°C. Cells were 
washed gently three times to remove unbound RBCs and then either fixed, 
stained, and visualised under a microscope, or lysed and absorbance was 
measured using a photometer. The presence or absence of haemadsorption 
was observed visually on five separate occasions in the presence of a positive 
and negative control.  
The positive control was produced using cDNA encoding the nucleotides that 
dictated the aa sequence for ckIt99 NA in an unaltered “wild type” (wt) form. 
Since plasmids with short and long stalk (SS & LS) equivalents were 
generated for the previous chapter, they were also used here, with a tag that 
replaced natural or engineered aas, so that the total number of aas in each 
stalk was not altered. The positive controls are labelled SSckIt99 wt or 
LSckIt99 wt. A plasmid that lacked coding cDNA, termed “Empty Vector” was 
transfected into cells as a negative control. The negative control had no green 
staining, indicating the absence of NA, and no haemadsorbed RBCs. To 
ensure that antibody detection of the tag was specific, cells were transfected 
with SSckIt99 wt (NF) that lacked the tag in its stalk and stained with antibody. 
These cells were Hd+, but did not fluoresce and thus confirmed the anti-Flag 
antibody was specific for the inserted tag (Figure 5.2 A, B and C). 
On all occasions the NA of ckIt99 was clearly Hd+ although the degree of 
RBC adherence varied. This did not vary between the LS or SS genotype. 
Figure 5.2 B top panels show many RBCs bound to Vero cells expressing 
SSckIt99 wt NA whereas the density of red cell binding to the same NA 
expressed in Figure 5.2 A and C is somewhat less. A number of reasons 
could account for these differences including; slight variation in time between 
transfection and incubation with RBCs, which may have led to a difference in 
NA expression levels; slight variation in temperature during the experiment; 
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cells were washed with cold PBS and kept on ice, but may have warmed 
slightly and allowed some release of RBCs; or difference in washing vigour 
that may have affected the number of RBCs bound by Hd+ NAs and those 
RBCs that would have otherwise remained in the well despite not being bound. 
Regardless of the minor differences on each occasion, ckIt99 wt NA was 
clearly Hd+ and either none or very few chicken RBCs bound to E195/09 wt 
NA. Therefore, we concluded that ckIt99 wt NA was Hd+ and E195/09 wt NA 
was Hd-. 
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Figure 5.2. Haemadsorption phenotype of wild type and mutant avian, swine, 
and human influenza virus NAs. Vero cells were transfected with pCAGGS 
plasmids that express NA with a FLAG tag inserted into the stalk. At 16-24 hours 
after transfection cells were washed and probed with chicken RBCs on ice, then 
washed again. Cells were fixed with 4% paraformaldehyde. NA expression was 
monitored by staining with anti-Flag antibody (1:500) followed by anti-mouse FITC 
conjugate (1:1000).. Nuclei of both Vero cells and RBCs were stained with DAPI 
(blue). Visualization of haemadsorption was performed five times, photos presented 
in A, B, and C were from three separate experiments that show the variation in levels 
of haemadsorption observed. The Masters student Lukus Roberts collected images 
in A, under my supervision and I collected the images for B and C. Images in A and B 
were collected using 400x magnification and those in C were collected using 200x 
magnification with an Axiovert 40 microscope (Zeiss). 
 
The Hd experiment was also performed using human RBCs. Again ckIt99 wt 
NA was Hd+ while E195/09 wt NA was Hd- (data not shown). 
To quantify the extent of Hd, absorbance by haemoglobin released from lysed 
RBCs that bound NA was measured in two separate experiments, (Figure 5.2 
A and B). In both experiments absorbance in wells where Vero cells 
expressed E195/09 wt NA was always significantly less than those expressing 
SSckIt99 NA and not statistically different from background levels.  
After establishing that E195/09 wt NA was indeed Hd-, the possibility to confer 
an Hd+ phenotype by a single point mutation was tested. In addition, as a 
reciprocal test of whether or not S369N abrogated Hd in the avian N1 NA, the 
mutation was introduced into ckIt99 NA. Expression of both NAs with 369 
mutations were detectable by anti-Flag antibody (Figure 5.2 A rows 3 and 6, C 
rows 2 and 4) and did not differ in expression staining pattern from their wild 
type NA. Mutation S369N in ckIt99 NA did indeed reduce its Hd activity 
(Figure 5.2 A row 3, C row 2). However, the mutation N369S did not bestow 
Hd activity to E195/09 NA (Figure 5.2 A row 6 and C row 4). More chicken 
RBCs, as measured by presence of haemoglobin in cell lysate, bound to 
SSckit99 wt NA than to SSckIt99 S369N and E195/09 wt or mutant NAs. 
Quantification of the extent of Hd using the absorbance method revealed that 
Hd activity by ckIt99 S369N mutant NA was about 50% or less than that of 
 218 
ckIt99 wt NA and this difference was statistically significant (p<0.001) (Figure 
5.3). A similar reduction in Hd activity was observed by Hausmann et al. 
studying two single amino acid mutants of foRos34 NA that lowered the 
percentage of RBCs bound to 20% of that bound by the wild type NA. 
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Figure 5.3. Quantification of haemadsorption by different influenza A virus NA 
proteins. Absorbance of haemoglobin released from lysed RBCs bound to NA 
expressing cells was measured by photometer. Background absorbance, from wells 
where Vero cells were transfected with empty vector, was subtracted from the 
absorbance of each well of NA expressing cells. The average absorbance of wells 
expressing SSckIt99 wt NA wt was set to 100% and the percentages of absorbance 
for all other wells were calculated accordingly. Data in A was collected from triplicate 
wells and samples were not stored on ice; data in B was collected in quadruplicate 
wells and samples were stored on ice. The first time the experiment was performed 
total absorbance levels were lower. Negative values indicate that wells with cells 
transfected by empty vector had a higher background binding of RBCs compared to 
the wells with cells transfected by E195/09 wt NA, but the difference was not 
statistically significant. The numbers of Vero cells present in all Hd- wells were 
deemed equal by microscopic investigation of similarly treated cells. Error bars 
indicate 95% CIs. Statistical analysis was performed using One-way ANOVA with a 
Tukey posttest. **p<0.01, ***p<0.001, ****p<0.0001 
5.2.2 Further mutations did not bestow haemadsorption 
activity to the pandemic 2009 N1 NA.  
Since a single point mutation did not make E195/09 NA Hd+, other changes to 
aa residues in the Hd domain were introduced. In addition to the aa residue at 
position 369, there were three other aa differences in the Hd domain and one 
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more just outside of it between E195/09 NA wt and the N1 NAs that were Hd+. 
The four other aas were I365T, G395A, N397T, and E398D (Figure 5.1). 
Therefore, much in the way that Nus and Air made Tok67 N2 NA Hd+ by 
replacing all of the residues of the 370- and 400-loops with the avian Hd+ 
sequence, an E195/09 NA mutant “5 mu” was engineered with the changes 
listed above plus N369S from the single mutant. The sequence of E195/09 
5mu was StsSrS aItdW K through the Hd domain. This NA was expressed in 
Vero cells as before and probed with chicken RBCs to test for and quantify Hd. 
The additional 4 mutations did not confer Hd activity to the E195/09 NA 
(Figure 5.2 C, row 5). Confirming this, there was no increase in absorbance 
signal for E195/09 5mu NA above that seen for E195/09 NA wt (Figure 5.3 B).  
Further sequence comparison between E195/09 NA and the other N1 NAs 
with known Hd+ profiles showed 4 more aa differences within the 26 aa span 
between the 370- and 400-loops of the Hd domain (Figure 5.1). The 
consensus sequence of avian influenza virus N1 NAs including ckIt99 and 
foRos34 NAs, was 382-EtdSSfsV-389 (Figure 1.10 and Figure 5.1). Therefore, 
the 4 aas that differed between E195/09 NA wt and the Hd+ N1 NAs 
(capitalised here) were engineered into E195/09 5mu NA, to make E195/09 
9mu NA. This mutant NA was expressed in transfected cells with the same 
pattern as wild type E195/09 NA, but still did not show any signs of increased 
haemadsorption (data not shown).   
In a final attempt to recreate an Hd+ site within the E195/09 NA gene, four 
more mutations were added to 9mu to make E195/09 13mu NA, which had 
the same sequence as the Hd+ N1 avian virus NAs from aa 312 through to 
the C-terminus (except for a single difference at aa 418). The additional 
mutations were I321V, K331G, V338M, and N344Y. Aa 344 faced toward the 
enzyme active site and mutation Y344N was previously associated with 
mammalian adaptation of influenza viruses (Reid et al., 2000). Moreover 
mutation D344N was shown to dramatically affect NA activity in the context of 
human seasonal H1N1 NA (Rameix-Welti et al., 2011). The E195/09 13mu 
NA was expressed in Vero cells but like the other E195/09 NA based proteins, 
E195/09 NA 13mu also showed no increased Hd activity over E195/09 NA wt 
either when chicken RBCs were used (Figure 5.2 B row 3) or when human 
RBCs were used (data not shown).  
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5.2.3 N1 NAs of 2009 pandemic lineage were haemadsorbtion 
positive 
The 2009 pandemic N1 NA was derived from a swine influenza virus of 
Eurasian lineage and thus the NA gene had adapted to swine for about 30 
years after zoonosis from an avian host. The H1N1 influenza virus 
A/duck/Bavaria/1/77 (dkBav77) is a “lineage defining strain”, a putative 
precursor of the H1N1 Eurasian avian-origin swine lineage viruses (Ottis and 
Bachmann, 1980; Scholtissek, 1995; Scholtissek et al., 1983). The swine 
influenza virus A/swine/England/453/2006 (swEng06) is a prototypic swine 
H1N1 virus of the Eurasian avian-origin swine lineage that circulated in pigs in 
Europe in 2006. SwEng06 can experimentally infect and transmit between 
pigs (Lloyd et al., 2011). We aimed to trace the Hd phenotype and genotype 
in the NAs of these viruses as they moved between species from birds to 
swine to humans, in particular to ask when the Hd phenotype might have 
been lost within the pandemic 2009 N1 NA lineage. Sequence analysis of the 
three NAs revealed that they had many aa differences (Figure 5.4). In the 
head domain, starting from aa S82, the pandemic NA E195/09 varied from the 
sequence of dkBav77 NA by 36 aas. SwEng06 NA varied from dkBav77 NA 
by 34 aas and E195/09 and swEng06 NAs varied from each other by 26 aas. 
The Hd domain sequence of dkBav77 and swEng06, SxxSxS IxxW K, 
suggested they would both be Hd+. Therefore, we hypothesised that the 
precursor avian virus dkBav77 NA would be typical of other avian NAs and be 
Hd+. However, since it had not been possible through multiple mutations to 
make E195/09 NA Hd+, we hypothesised that the ability to Hd was lost during 
circulation in swine and that other mutations contributed to the lack of Hd 
activity.    
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Figure 5.4. Amino acid alignment of dkBav77, swE06, and E195/09 wild type 
NAs. The 370-loop, 400-loop, and 432 residues of the Hd domain are outlined by 
black boxes. 
 
The NA cDNA cloned from the avian virus dkBav77 and obtained from Dr. 
Jurgen Stech happened to have the sequence of a minority of the 
quasispecies rather than the consensus sequence. The consensus sequence 
indicated residue 364 should have aa S, but the clone had 364N and this aa is 
the first interacting residue of the Hd 370-loop. The mutant S364N was 
selected by the N9 NA of ternAus75 under antibody pressure and was Hd- 
(Webster et al., 1987). The Hd- N2 NA of the 1957 pandemic virus Sing57 
had 364N and the mutation N364S made it Hd+ (Uhlendorff et al., 2009). 
Therefore, we hypothesised that the dkBav77 NA clone with 364N would also 
be Hd- and a restored wt 364S would be Hd+. As before, dkBav77 wt, 
dkBav77 364N, and swEng06 wt NAs were cloned into expression vectors 
with tags in their stalks.   
A first screen, not including dkBav77 wt or 364N, found swEng06 wt NA to be 
Hd- (Figure 5.2 B, row 4). Then later, when dkBav77 wt and 364N NAs were 
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both available, a second screen for haemadsorption capabilities of a larger 
number of NAs was performed. In the later screen, swEng06 wt NA was found 
to be Hd+ (Figure 5.2 A, row 7). Haemadsorption by the positive control NA, 
ckIt99 wt NA in the first screen was numerous (Figure 5.2 B, row 1), but in the 
second screen Hd by ckIt99 wt NAs was not (Figure 5.2 A, rows 1 and 2). 
Thus these differences did not explain the lack of Hd activity for swEng06 NA 
in the first screen, but did suggest that swEng06 NA was indeed Hd+. In the 
later screen, dkBav77 wt was Hd+ and dkBav77 364N Hd- (Figure 5.2 A, rows 
8 and 9).  
In order to be sure that swEng06 wt NA was truly Hd+, wells used for images 
in Figure 3.2A were scored visually in a systematic manner. A100x 
magnification was chosen for this analysis because many NA expressing cells 
could be analysed in one field of view and RBCs were still easy to detect. The 
Hd assay was performed in triplicate for each NA. Within each of the three 
wells, four fields of view were analysed. If chicken RBCs were seen anywhere 
within the field of view then the field was considered Hd+. The difference 
between Hd+ and Hd- was stark, chicken RBCs were observed in either all 12 
fields of view or none depending on the expressed NA (Table 5.1). 
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Plasmid No. Hd+ FoV 
in well 1 
No. Hd+ FoV 
in well 2 
No. Hd+ FoV 
in well 3 
No. Hd+ FoV 
in all wells 
Empty vector 0 0 0 0 
SSckIt99 wt 4 4 4 12 
LSckIt99 wt 4 4 4 12 
LSckIt99 S369N 0 0 0 0 
LStyTy05 wt 0 0 0 0 
dkBav77 wt 4 4 4 12 
dkBav77 364N 0 0 0 0 
swEng06 wt 4 4 4 12 
E195/09 wt 0 0 0 0 
E195/09 N369S 0 0 0 0 
Table 5.1. Observational analysis of Hd status of NAs. Hd ratings were 
determined by observation of 4 fields of view per well, under 100x magnification. If 
chicken RBCs were seen within the field of view then the field was considered Hd+. 
The number of Hd+ fields of view in each well and their sum are shown. This work 
was performed by Mr. Roberts. No. Hd+ FoV = number of Hd+ fields of view. 
 
Kobasa et al. concluded that swIt76 NA had a lower Hd activity compared to 
that which was achieved by a equine virus NA and some avian virus NAs 
(Kobasa et al., 1997). Therefore, we hypothesised that swEng06 wt NA would 
have lower Hd activity compared to the avian strain with which it shared a 
lineage. Since the low number of RBCs per well was below the level of 
haemoglobin detectable by absorbance, the number of NA expressing cells 
with RBCs bound and the number of RBCs bound to Hd+ cells were counted 
for dkBav77 wt and swEng06 wt NAs. NA expressing cells were counted and 
characterised as either having RBCs bound or not. On average 10.9% (SD 
1.1%) of swEng06 wt NA and 5.8% (SD 0.6%) of dkBav77 wt NA expressing 
cells had RBCs bound and this difference was significant (t-test, p<0.01). It 
was also found that swEng06 wt and dkBav77 wt NA expressing cells with 
RBCs on the surface had an average of 4.0 (SD 0.5) and 3.1 (SD 0.4) RBCs 
bound, respectively, and this difference was not significant (t-test, p=0.11). 
Thus the Hd activity of the swine virus NA was more than that of the avian 
virus NA in this case.  
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5.2.4 An avian NA from an H5N1 virus does not haemadsorb 
RBCs. 
 Many avian NAs studied thus far have proven to be Hd+.  However, at 
the end of the 20th century a small number of avian H9N2 influenza virus 
infections were detected in humans and Matrosovich et al. made the 
observation that a branch of avian N2 NAs had lost the Hd+ signature 
sequence by substitution of the S at aa 364 for N or K (Matrosovich et al., 
2001). As more H9N2 NA sequences from China, the United Arab Emirates, 
and Tunisia were analysed, this Hd signature loss due to acquisition of 
additional changes to the predicted SA interacting residues was corroborated 
(Aamir et al., 2007; Liu et al., 2003; Tombari et al., 2011).  
The avian virus tyTy05 was introduced in the preceding chapter. It is from 
H5N1 clade 2.2, which has a wide host range and broad geographical spread. 
The NA of tyTy05 NA has the sequence StnSrS ItdW K through its Hd domain, 
thus it bears a change at a key position previously shown to affect Hd, 366N. 
The mutant A366D was selected in the N9 NA of ternAus75 under antibody 
pressure and was Hd- (Webster et al., 1987). Indeed, after expression of 
tyTy05 wt NA in Veros, it did not bind chicken RBCs and was thus Hd- 
perhaps suggesting that adaptation to terrestrial birds can also select for loss 
of this function (Figure 5.2 A, row 4 and B, row 5)(Table 5.1). 
 
5.2.5 Virus infectivity in the presence of mucus correlates 
with Hd phenotype 
To initiate infection in the airway, influenza virus needs to penetrate through 
mucus using NA to cleave decoy receptors and release HA so that it can 
access cell surface expressed receptors. If NA activity is low, in relation to HA 
avidity, virus will take longer to penetrate through mucus. This is likely 
because less viral particles will diffuse toward the cells over a set period of 
time.  
To test the effect of haemadsorption on the virus’ ability to overcome inhibition 
by mucus, assays were performed in the context of infectious virus. A series 
of isogenic viruses based on E195/09 (pH1N1 2009) were generated, which 
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differed only in their NA. Infectivity of viruses with avian, swine, and pandemic 
virus NAs – each paired with E195/09 HA plus six internal genes from 
E195/09 – were measured in the presence or absence of human mucus 
(Figure 5.5). Human mucus was collected from the surface of HNE cells. This 
mucus has both α2,3- and α2,6-linked SA. Viruses were mixed with a small 
volume of mucus or PBS then the mixture was overlaid on MDCK cells and 
incubated at 32°C for the times indicated. Afterward cells were washed and 
plaque assays were performed to determine the number of virions that 
successfully infected cells and formed a plaque. The results are presented as 
a percentage of infectivity that remained in the presence of mucus compared 
to infectivity achieved in the absence of mucus. Experiments were performed 
in triplicate on one, two, or three occasions and data was pooled.  
Viruses with an Hd+ NA were found to have higher levels of infectivity in the 
presence of mucus compared to viruses with NAs that were mutated in a way 
that abrogated haemadsorption. Abrogation of the Hd+ phenotype with a 
mutation such as ckIt99 S369N (Figure 5.5 :Hd+: dark green vs Hd-: light 
green) or dkBav77 S364N (Hd+: darker yellow vs Hd-: brighter yellow) 
decreased the ability of the mutant viruses to penetrate human mucus and 
thus create plaques. The mutation N369S in E195/09 NA, which was 
hypothesised to re-instate haemadsorption, but did not, did not significantly 
affect the ability of its virus to penetrate mucus (Figure 5.5: black vs grey 
symbols).  
Earlier results from this chapter (Figure 5.2 A) showed that the avian NA 
tyTy05 was Hd-. A mutant that conferred the Hd+ phenotype to this NA was 
not attempted. However, since they are both of avian origin, it is interesting to 
compare infectivity in the presence of mucus achieved by virus with Hd- 
tyTy05 NA to virus with Hd+ ckIt99 NA of similar stalk length. Viruses with 
Hd+ ckIt99 wt NA were found to recover higher infectivity than viruses with 
Hd- tyTy05 wt NA (SS: orange vs red and LS: dark green versus blue). This 
difference was statistically significant for some comparisons as shown with 
stars on the graphs in Figure 5.5. These results show that there was a general 
correlation between the Hd+ phenotype and enhanced mucus cleavage.  
Comparison of viruses with swine-origin NA to those with avian-origin NA 
show a trend toward better ability to penetrate through human mucus. The 
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virus A/Ohio/1/07 (Oh07) is of swine-origin, but was isolated from a human 
after direct exposure to pigs (Shinde et al., 2009). The HA and NA are both of 
the Classical swine lineage and the NA has the sequence through the Hd 
domain SisSrS aLtdW K, which is the same sequence of the swIt76 NA that 
was shown to Hd chicken RBCs at a low level (Kobasa et al., 1997). The Hd 
phenotype of Oh07 NA was not confirmed here. SwEng06 NA, which is from 
the EA avian-origin swine lineage was shown to be Hd+ in Figure 5.2 A. 
Despite being from different lineages, the two NA genes retained an equally 
high percentage of infectivity in the presence of human mucus.  
Viruses with these two swine NAs, overcame the inhibition of infectivity by 
human mucus more efficiently compared to viruses with NAs that were Hd- 
including SS or LS avian ckIt99 S369N and tyTy05 wt NA, Hd- dkBav77 364N 
NA, and Hd- early pandemic E195/09 NA. Viruses with swine-origin NAs were 
also more efficient at cleaving human mucus compared to virus with the Hd+ 
LSckIt99 wt NA (Figure 5.5: compare pink and violet to all colours and black, 
but not yellow triangles). To retain clarity, only some of the statistically 
significant differences are indicated in Figure 5.5. 
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Figure 5.5. Infectivity of viruses with different NA Hd phenotypes in the presence of mucus. 
Viruses were incubated with mucus on MDCK cells at 32°C for the indicated amount of time, 
washed, and plaque assays were performed. All viruses shown here have seven genes from the 
pandemic strain E195/09 and NAs as indicated on the x-axis. The ability of viruses to penetrate 
through human mucus is shown as the percentage of infectivity that remained in the presence of 
mucus compared to infectivity achieved in the absence of mucus. The NAs of the two viruses on 
the left hand side of each graph (orange and red) have short stalks. The NAs of the rest of the 
viruses have long stalks. All p values were determined using a one-way ANOVA followed by Tukey 
posttest to compare all means at each time point, stars of significance are shown above black bars 
that link datasets selected for clarity. N=6 for all viruses incubated for 30 and 120 minutes, N=9 for 
all viruses with 60 minute incubation, except N=3 for viruses with dkBav77 wt and dkBav77 364N 
NAs; and N=6 for OhO7 NA. Error bars indicate the 95% CI. Lukus Roberts performed one 
experiment in triplicate, incubated for 60 minutes, with all NAs shown in the 60 minute graph 
except Oh07. Under the x-axis labels, along the bottom of the figure, Hd+, -, or ? means Hd 
positive, negative or untested. Min = minute, ns = not significant, *p<0.05, **p<0.01, ***p<0.001, 
***p<0.0001. 
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5.2.6 Cleavage of decoy SA in mucus increases infectivity of 
viruses with Hd+ and Hd- NAs 
To ascertain that the inhibitory effect of mucus on virus infectivity was due to 
the presence of decoy receptors and not another factor that is secreted by 
HNE cells, mucus was incubated for one hour at 37°C with a bacterial 
sialidase from C. perfringens that cleaves both α2,6- and α2,3-linked SA. 
Infectivity of virus with LSckIt99 NA wt (Hd+) or S369N (Hd-) mutant was 
measured in the presence of de-sialated mucus. Cleavage of SA with 
bacterial NA reduced the blocking efficacy of mucus on the virus with the Hd- 
mutant NA and also decreased the extent to which mucus blocked infectivity 
of virus with the Hd+ ckIt99 wt NA (Figure 5.6). However, these differences 
were not statistically significant by One-way ANOVA. The trend toward 
increased infectivity when mucus is pre-treated with exogeneous NA confirms 
that part of the block within mucus is from decoy SA receptors. 
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Figure 5.6. The effect of exogeneous NA from bacteria on inhibition of virus 
infectivity by airway mucus. Mucus was incubated with either PBS or bacterial NA 
diluted to 1 mU/ml in PBS for one hour at 37°C before it was mixed with virus. Virus 
plus mucus (+/-bcNA) was then allowed to incubate with cells for one hour at 32°C 
before cells were washed and plaque assay was performed. Infectivity in the 
presence of mucus (+/- bcNA) is shown as a percentage of infectivity in the absence 
of mucus. Error bars indicated standard deviation from the mean. Infectivity by 
viruses with or without bcNA was not statistically significant from any other by one-
way ANOVA. This experiment was performed by Lukus Roberts. 
5.2.7 Viruses with swine or human-adapted NAs grow to 
higher titres in MDCK cells than viruses with pandemic 
or avian NAs 
With the aim to understand the consequence of Hd activity on virus replication, 
we measured the growth characteristics of viruses that differed only by their 
NAs. As in the mucus infectivity assay, all viruses had 7 genes from E195/09 
and the NA gene indicated in the key. At 15 hours post infection, virus with the 
homologous E195/09 NA grew to the lowest average titre, 6.8 x 105 ± 2.9 x 
105 pfu/ml. Growth in MDCK cells was improved for viruses with avian NAs, 
which attained titres one log higher, although the differences were not 
statistically significant. For example, virus with dkBav77 364N NA grew to an 
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average titre of 5.0 x 106 ± 1.8 x 106 pfu/ml, similarly virus with LSckIt99 wt 
NA reached an average titre of 4.8 x 106 ± 2.5 x 106 pfu/ml. Virus with 
swEng06 wt grew to even higher titres, attaining a titre of 3.9 x 107 ± 2.3 x 107 
pfu/ml. The improved growth of virus with swEng06 NA was not statistically 
significant compared to viruses with avian NAs, but the difference was 
statistically significant when compared to viruses with the pandemic E195/09 
NA (Figure 5.7). MDCK cells do not secrete mucus, so the NA activity 
measured here is most likely related to NA’s ability to cleave cellular receptors 
or to disaggregate virions by desialating HA. 
 
                              
Figure 5.7. Replication of recombinant influenza viruses with swine and 
human-adapted NAs in MDCK cells. All viruses had seven genes from the 
prototypic pandemic strain E195/09 with NAs as indicated in the key. MDCK cells 
were infected with MOI of 0.05 and incubated at 37°C for 15 hours, then viral 
supernatant was collected and plaqued. Error bars indicate 95% CIs. P-values 
determined using One-way ANOVA with Tukey posttest. **p<0.01; ns = not 
significant. 
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5.2.8 Haemadsorption by NA improves viral growth in human 
differentiated primary airway cell culture when paired 
with a human HA 
Multicycle replication of viruses with seven genes from the pandemic 2009 
virus and an avian NA gene (ckIt99) with a long stalk that was Hd+ or Hd- 
showed that virus with an NA that could Hd (Figure 5.2) and cleave through 
mucus more efficiently (Figure 5.5) grew to higher titres in primary HNE cells. 
The difference between viruses with LSckIt99 Hd- and Hd+ NAs was 1.8 logs 
(95%CI: 0.8-2.8) at 24 hpi and 1.3 (95%CI: 0.3-2.3) at 48 hpi. The differences 
between virus with E195/09 wt NA and either of the other two viruses were 
not significant (Figure 5.8). The improved growth of virus with Hd+ NA over 
Hd- NA in HNEs, but not in MDCKs, may be due to the presence of mucus 
secreted by goblet cells onto the apical surface of HNEs.  
 
     
Figure 5.8. Replication in human airway epithelial cultures of recombinant 
influenza viruses that vary in Hd phenotype. All viruses had seven genes from 
E195/09 and either the cognate NA or NA from LSckIt99 wt (Hd+) or S369N (Hd-). 
Cells were infected with an MOI of 0.01. Statistical significance is shown for the 
difference between means of viruses with Hd+ or Hd- ckIt99 NA. Error bars indicate 
95% CIs. P-values determined using Two-way ANOVA and Tukey posttest.  **p<0.01, 
***p<0.0001. 
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5.2.9 Avian influenza viruses can regulate HA:NA balance 
though stalk deletion or haemadsorption 
 To assess the effect of Hd genotype in a pair of viruses that had a 
natural match in HA and NA, four RG viruses with six internal genes from PR8 
and the ckIt99 HA plus SS or LS Hd+ and Hd- NA were generated. Their 
replication in HAE cells was compared. Loss of Hd activity through the S369N 
mutation led to decreased growth when the NA had a short stalk (Figure 5.9 A, 
light orange), but when the NA had a long stalk, reduction in NA activity by 
loss of Hd+ phenotype led to higher viral titres (Figure 5.9 B, light green). The 
log mean difference between SS viruses with Hd+ and Hd- NAs was 0.8 logs 
(95%CI: 0.4-1.2) at 24 hpi. The log mean difference between LS viruses was 
0.7 logs (95%CI: 0.4-1.0) at 12 hpi and 0.4 logs (95%CI: 0.1-0.7) at 24 hpi. 
This reinforces the importance of HA:NA balance and shows that an 
overactive NA can lead to a reduction in viral growth and that NA activity can 
be regulated both by stalk length as well as Hd phenotype to affect this 
balance.  
 
      
Figure 5.9. Growth of haemadsorption positive and negative viruses with 
cognate HA in HAE cell culture. HNE cells were infected at MOI 0.01. All viruses 
had six internal genes from PR8 virus and the HA of ckIt99 virus H7N1 plus a SS or 
LS ckIt99 wt (Hd+) or S369N  (Hd-) NA. Statistical significance is shown for the 
difference between means of viruses with Hd+ or Hd- ckIt99 NA. Error bars indicated 
standard deviation. P-values determined using Two-way ANOVA and Sidak posttest. 
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5.2.10 Viruses with swine NAs and human pandemic HA 
grew to higher titres in HNEs, but not in ex-vivo ferret 
tracheal tissue 
 Differences in ability to cleave mucus and grow in MDCK cells were 
detected for viruses with swine NAs compared to virus with pandemic NA 
(Figure 5.5 and Figure 5.7). The same sets of viruses were compared for viral 
growth in HAEs and also in a novel ex vivo culture system using pieces of 
ferret trachea. Viruses with swEng06 and Oh07 NAs both replicated better 
than virus with the pandemic NA in human primary differentiated nasal cells 
that secrete mucus. The difference in growth between the two viruses with 
swine NAs was not statistically significant at any time point. At 48 hpi, the 
mean titre of virus with Oh07 NA was 2.4 logs (95%CI: 0.6-4.1) higher and the 
mean titre of virus with swEng06 NA was 1.8 logs (95%CI: 0.01-3.6) higher 
than that of E195/09 (Figure 5.10 A). However, in ferret trachea, virus with 
swEng06 NA grew to titres on average 2-logs lower than virus with E195/09 
NA and this difference was statistically significant (Figure 5.10 B). In ferret ex-
vivo trachea sections virus with E195/09 wt and 13mu NA grew to titres on 
average over 2-3 logs higher than viruses with swEng06 and SStyTy05 NAs. 
At 48 hpi the mean log difference between virus with E195/09 NA and the two 
that hardly grew was between 0.9 and 6.0 (95%CI).   
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Figure 5.10. Replication in HNEs and in ex-vivo ferret tissue of recombinant 
influenza viruses with NA gene segment derived from swine influenza virus 
strains. All viruses had seven genes from E195/09 and NA as indicated in the key. 
(A) HNE cells were infected with MOI 0.01 and incubated at 32°C (B) Ferret trachea 
was sectioned into small discs and distributed into 3 wells, so that each virus infected 
a section from different parts of the trachea. Tissue sections were inoculated with 
high titres (1x106 pfu in 750ul for one hour) of virus then washed and incubated 
submerged in media for the indicated time period. The colour of the stars indicates 
that they relate to the difference between virus with the matching colour NA and the 
prototypic 2009 pandemic virus. Error bars in A indicate 95% CIs and in B they 
indicate standard error of the mean. P-values determined using Two-way ANOVA 
and Tukey posttest. *p<0.05, **p<0.01, ***p<0.0001. 
 
5.3 Haemadsorbtion – Discussion   
In summary, two natural avian NAs and one natural swine NA were shown to 
be Hd+, whereas one natural avian (H5N1) NA and one natural human 
(recent pandemic) NA were shown to be Hd-. This is the first time that S-to-N 
mutations at positions 364 and 369 of an N1 NA were shown to affect the Hd 
phenotype. As far as I am aware, this is also the first time that an N1 NA of 
the Eurasian H5N1 lineage has been characterised as Hd-. Poultry play a 
significant role in perpetuation of both H9N2 and H5N1 viruses (Pepin et al., 
2013), thus it is possible that loss of the Hd phenotype was selected in poultry 
in these viruses.  
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5.3.1 The Hd domain 
Visualisation of the Hd domain of ternAus75 N9 NA in comparison to the Hd 
domains of BrevM18 N1 NA and CA/04/09 N1 NA (both wild type and in silico 
mutants) can shed some light on why haemadsorption by E195/09 NA was 
not achieved despite numerous mutations (Figure 5.2). Figure 5.11 A shows 
the surface view of ternAus75 N9 NA with SA bound to the Hd site and Figure 
5.11 B shows the same NA without SA.  
The orange arrows point to the red surface area representative of the terminal 
oxygen of aa residue 369 for each NA in the figure. In the Hd site of BrevM18 
NA (Figure 5.11 C) the red patch is slightly higher and more to the left than 
then the red patch of ternAus75 (Figure 5.11 B). CA/04/09 NA wt has an 
asparagine at position 369; therefore it presents an oxygen and a nitrogen at 
the surface of the Hd pocket. The oxygen is further to the right, compared to 
the oxygen of both ternAus75 and BrevM18. The blue patch in the middle of 
the Hd site of CA/04/09 marks the location of the nitrogen. The oxygen of the 
N369S CA/04/09 mutant NA (Figure 5.11 E) is predicted (using Pymol) to be 
in a location more similar to that seen in the BrevM18 NA than ternAus75 NA. 
The green arrow points to the backbone hydroxyl group of aa residue 396. 
Varghese et al. (1997) showed that this oxygen interacts with the 4-hydroxyl 
oxygen and the nitrogen of the 5-acetamido group of SA (Figure 1.11 D, 
bonds 5 and 6). A large red coloured area shows the oxygen is exposed at 
the surface of the N9 NA. In contrast, the green arrow in Figure 5.11 D shows 
that access to the backbone hydroxyl of E195/09 NA is obstructed, as it lies 
underneath the asparagine at position 397. The 397-threonines of BrevM18 
and CA/04/09 5mu NAs (Figure 5.11 C and F) sit further to the right than 397-
asparagine of CA/04/09 wt NA and likely would induce less steric hindrance to 
bonds involving the backbone hydroxyl of residue 396.  
The magenta arrow pointing to the red surface area indicates the location of 
the oxygen of the 367-serine residue of ternAus75 NA (Figure 5.11 A and B). 
This oxygen interacts with the 8-hydroxyl of the glycerol substituent of SA 
(Varghese et al., 1997). The black arrow points to the oxygen of the 364-
serine residue. In the ternAus75 NA this oxygen has a hydrogen bond 
interaction with one of the oxygens of the carboxylate group of SA (Varghese 
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et al., 1997). The distance between the 364 and 367 oxygens of BrevM18 NA 
is much further than the distance between the two oxygens in the N9 NA 
(compare C to B in Figure 5.11). The oxygen of serine-367 in CA/04/09 NA is 
shielded from surface exposure (Figure 5.11 D) due to the orientation of its 
hydrogen, which is oriented upward in wt CA/04/09 NA (H) rather than 
downward, as it is in ternAus75 NA (G) and BrevM18 (I).  
Given these differences in charge distribution around the Hd pocket, it is not 
surprising that BrevM18 NA bound only weakly to SA presented on chicken 
RBCs and no binding was detected with E195/09 wt NA. However, it is difficult 
to say why BrevM18 NA bound to human RBCs (Uhlendorff et al., 2009) and 
the E195/09 5mu NA did not. Along with the difference in the orientation of 
serine-369, the orientation of the hydroxyl group of serine-366 differs between 
CA/04/09 and BrevM18 NAs (Figure 5.11: purple arrows in H and I). 
Furthermore, the Hd pocket of CA/04/09 NA is wider than that of BrevM18 NA 
due to tyrosine-399 sitting further back and exposing more of the hydrophobic 
arch at the top of the Hd pocket, where lysine-432 extends from the 430-loop 
(Figure 5.11: blue arrows, compare C with F). It may be that mutations outside 
of the Hd pocket are responsible for these conformational differences 
between CA/04/09 and BrevM18 NAs.  
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Figure 5.11. 3D structures of NA Hd domains. 3D images of wild type or mutant 
NAs from the indicated viruses were created using Pymol. N9 NA ternAus75 is 
shown with SA bound in the Hd site. PDB files for: CA04 A/California/04/2009 NA 
3NSS (Q. Li et al., 2010); ternAus75 A/tern/Austrailia/G70C/75 NA 1MWE (Varghese 
et al., 1997), BrevM18 A/Brevig Mission/1/1918 NA 3BEQ (Xu et al., 2008).   
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5.3.2 Loss of Hd reduced viral infectivity in the presence of 
mucus 
Although an Hd+ phenotype could not be bestowed upon the pandemic NA, 
despite numerous mutations, an Hd- phenotype was conferred to two Hd+ 
avian N1 NAs through single amino acid mutations in interacting residues 
within the 370-loop of the Hd domain. 
Hd+ and Hd- viruses that only differed by a single amino acid, showed 
different abilities to infect in the presence of mucus. De-sialation of mucus 
with exogenous NA showed that part of the inhibitory effect of mucus was due 
to decoy receptors that Hd+ NAs were better at destroying. Loss of Hd activity 
reduced the ability of virions to penetrate through mucus and infect MDCK 
cells.  
5.3.3 Mucus cleavage and specificity of sialidase activity for 
α2,3- vs α2,6-SA 
The differences in the ability of NAs from viruses adapted to different hosts to 
cleave through HNE mucus may relate to the linkage of terminal SA in human 
mucus. One study found that the NA of a swine virus preferred to cleave SA 
from α2,3-SAGs over α2,6-SAGs with a 20:1 ratio, while an NA from a human 
virus showed a lower preference (5:1) and an avian virus NA showed a higher 
preference (50:1) (Mochalova et al., 2007). More recently, Gerlach et al. 
showed that NAs from some swine viruses and a 2009 pandemic virus were 
2-10-fold more efficient at cleaving α2,6-SAG when compared to NAs from 
avian and human seasonal viruses isolated before 2009 (Gerlach et al., 2012). 
In our mucus cleavage assay, virus with E195/09 NA had an intermediate 
phenotype. Infectivity in the presence of HNE mucus was inhibited more than 
infectivity of viruses with swine NAs and the E195/09 virus achieved infectivity 
about equal to the virus that had an NA that was Hd+ and had a long stalk 
(LSckIt99 wt NA). This difference in our observations and those of Gerlach et 
al. may be due to the higher complexity of glycans present in mucus 
compared to synthetic glycans, even when the synthetic glycans are 
presented on chains of GlcNAc. We stained HNE mucus with both SNA and 
MAA lectins and found both present in large quantities (data not shown). 
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Furthermore, mucus was stained with SNA and MAA lectins post incubation 
with virus, but the effect of virus was not significant enough to detect a 
reduction in the presence of either specifically linked SA. This shows that the 
plaque reduction assay was particularly sensitive for measuring local NA 
activity. 
5.3.4 The effect of Hd on viral growth in HNEs depends on HA 
affinity for the human receptor 
Loss of Hd activity reduced the ability of a virus with avian NA paired with a 
recent pandemic HA to grow in HNE cells. This observation makes one 
wonder why loss of Hd activity was selected in humans after the introduction 
of the 1957 pandemic strain. One major difference between the 1957 
pandemic HA and the 2009 pandemic HA are their pre-pandemic hosts, either 
avian or swine respectively. Due to their difference in preference for α2,3- 
versus α2,6-linked SA an avian-origin zoonotic HA is likely to have lower 
binding affinity for human receptors than that of a swine-origin zoonotic HA. 
Indeed, when the avian NA had a long stalk, as did the NA of the 1957 
pandemic and was paired with an avian HA, the Hd- virus grew to higher titres 
at early time points in HAEs compared to the Hd+ virus. This indicates that 
excessive sialidase activity can be detrimental to virus growth and reduced 
NA activity through loss of the ability to Hd efficiently balanced an HA that had 
low binding affinity for the cellular receptor of the system in question.  
In Chapter 2 (Section 2.2.5), viruses with HA and NA from ckIt99, with NA 
either SS or LS, were compared (Figure 2.5). In that situation, reduction of NA 
activity, through stalk truncation, led to lower viral titres at late time points in 
HAEs. In contrast, when NA activity was reduced through loss of Hd in this 
chapter (Figure 5.9), the benefit was apparent at early time points in HAEs. 
This indicates that reduction in Hd activity improves receptor binding while 
reduction in NA stalk length allows receptor binding, but reduces virion 
release.  
Studying this group of viruses made a third comparison possible: that of 
viruses with an Hd- or Hd+ phenotype on a SS NA. On a short stalk, the ability 
to Hd conferred a growth benefit at 24 hpi. Therefore, an avian-origin virus 
with a SS NA, but increased ability to cleave mucus due to an Hd+ phenotype 
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may be more supportive of avian influenza virus replication in humans than 
the Hd- tyTy05 NA and thus may be better suited to support aerosol 
transmission between mammals.  
5.3.5 The restriction on viral growth in ex vivo ferret trachea 
requires further exploration 
The final findings of this chapter (Figure 5.10) portray two conflicting 
messages. In line with earlier observations, viruses with swine NAs that 
retained the highest level of infectivity in the presence of mucus grew better in 
HNEs than virus with the 2009 pandemic NA. However, in ferret tracheal 
sections replication of virus with swEng06 NA was about 2-logs lower than 
that of virus with its cognate 2009 pandemic NA over a three day period.  
It is interesting to note that growth in ferret trachea of virus with swEng06 NA 
was similar to that achieved by virus with SStyTy05 NA, which did not transmit 
via RD between ferrets in Chapter 3Error! Reference source not found.. 
The inhibition faced by virus with swine NA in tracheal sections is in line with 
observations by Yen et al. and Lakdawala et al. who found that ferret 
transmission of pandemic precursor and reassortant viruses with swine NAs 
was lower than that achieved by the pandemic virus in full (Lakdawala et al., 
2011; Yen et al., 2011). Therefore, it is important for future work to address 
the reason for the difference observed here. 
5.3.6 Other methods used to detect Hd  
There are many drawbacks to the Hd assay. Here we screened chicken and 
human RBCs to see if E195/09 NA bound to them, but we could not detect 
increased binding over baseline with wild type or mutant NAs. This could be 
because the assay is not very sensitive; indeed we almost missed the Hd+ 
phenotype of swEng06 NA. Therefore, methods to detect and quantify binding 
to receptors with low binding affinity are needed. Two groups have quantified 
low affinity binding to the Hd domain.  
Sung et al. used Brownian dynamic simulations to compare the binding of SA 
to NAs from pH1N1, human Tok67 N2 NA and NA from the avian H5N1 virus 
A/Vietnam/1203/2004 (VN1203/04). They concluded that there was some 
residual binding of SA at the Hd site for both human pandemic and endemic 
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NAs. For the binding of SA to the Hd domain they found that the on rate was 
fastest for the avian H5N1 NA, and slowest for the human N2 NA with the new 
pH1N1 NA sitting midway between. Intriguingly, they discovered that the Kon 
rate of SA to the Hd site for all three NAs was faster than the Kon rate of SA 
to the enzymatic site, and that the Kon rate of SA to the avian VN1203/04 NA 
enzymatic site was much slower than the Kon rate for the human NAs (Sung 
et al., 2010). This finding indicates that SA binding to the Hd site on an avian 
NA is much more important for enzyme activity than it is with human NAs, but 
that the human NAs still bound SA.  
 Lai et al. used saturation-transfer difference (STD) NMR spectroscopy 
to study binding of α2,3-linked SA to virus like particles expressing NAs from 
CA04/09, the H5N1 A/Cambodia/JP52a/2005 (Camb05), and the human 
seasonal H1N1 A/Gansu/Chenguan/1129/2007 (Gansu07) in the presence of 
oseltamivir which allowed them to only look at the Hd binding since the 
enzyme site was blocked by the drug. Again they found the SA binding to the 
Hd site by avian H5N1 NA was much stronger than that shown by human 
adapted N1 NAs of pH1N1 or seasonal virus, but that binding to these NAs 
was still present (Lai et al., 2012). 
5.3.7 Conclusion 
In conclusion, analysis of NA activity of influenza viruses should first confirm 
the presence or absence of binding in the secondary sialic acid binding site. 
Here we have shown that the ability to bind SA by the Hd domain can have a 
substantial impact on viral replication in locations where mucus is plentiful, 
such as the respiratory tract. Recent NA inhibitors are designed to 
recapitulate the multivalent tethered substrate of the natural physiological 
environment (Papp et al., 2011). These may be more efficient than older 
single-valent inhibitors, like oseltamivir, in inhibiting zoonotic avian or swine 
viruses that are Hd+. Further exploration of the reasons for the variability of 
the Hd domain in NAs of swine influenza viruses may inform our 
understanding of the role that pigs play in generating pandemic viruses and 
the host range barriers that are encountered in different mammalian species.  
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6 Overall Discussion 
6.1 Short stalk 
6.1.1 Short stalk length of NA inhibits viral fitness in 
mammalian models 
Here we showed that the SS length of NA from two avian influenza viruses 
was a reason for restricted viral growth and transmission in mammalian 
systems. The fist deletion studied here was of 22 aas that arose in the stalk of 
NA during an H7N1 influenza virus outbreak in poultry in Italy in 1999. When 
paired with the human seasonal Vic75 HA, virus with a 22 aa deletion in the 
stalk of ckIt99 NA grew to lower titres and spread less well in MDCK cells 
compared to an otherwise isogenic virus with LS NA. When paired with its 
cognate HA, virus with SS ckIt99 NA grew to lower titres in HAE cells at later 
time points than virus with LS NA. 
The second deletion studied was of 20 aa that arose in the stalk of NA of 
H5N1 viruses around 2003, soon after H5N1 viruses gained the internal gene 
cassette “Genotype Z”. When paired with the human pandemic E195/09 HA, 
virus with a 20 aa deletion in the stalk of tyTy05 NA grew to lower titres in 
MDCK, HNE, and FTE cells. The restriction on viral growth was more 
pronounced in primary epithelial cells than in MDCK cells. Primary 
differentiated airway cells are considered to be a good model for studying 
restrictions that avian influenza viruses might face after zoonosis into a 
human host. Primary cells do not have altered gene expression as do 
immortalised cell lines (Czekanska et al., 2014; Hou et al., 2013; Tommasi et 
al., 2013). Cellular differentiation means that both ciliated and goblet cells are 
present in these cultures. The fact that the apical layer is exposed to air 
means that mucus collects in a concentrated manner on the surface of the 
cells. 
The results in Chapter 3 showed that virus with a 20 aa deletion in its NA stalk 
was restricted in its ability to transmit between ferrets through the air in 
comparison to a virus that was otherwise isogenic except that it had a LS NA. 
Ferrets are the gold standard laboratory models for the study of influenza 
virus transmission. As discussed in the introduction (Section 1.6.1 “Different 
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hosts have differentially linked SA…”), ferrets and humans have similar 
patterns of expression of a2,6-linked SA in their airways. Table 1.2 of the 
introduction shows that human pandemic and seasonal viruses transmit 
through the air between ferrets while most avian influenza viruses do not.  
The results presented in Chapter 4 showed that the restriction responsible for 
reduced replication and lack of aerosol transmission of viruses with SS NA 
was inefficient release of virions from inhibitory receptors. In the transmission 
experiment, similar amounts of infectious particles were shed from both 
groups of inoculated donor animals. However, when we looked at the 
characteristics of virus shed from HNEs we found that SStyTy05 NA virions 
aggregated more than LStyTy05 NA virions. It is possible that aggregated 
virions are less able to be incorporated into the appropriately sized respiratory 
droplets for transmission through the air (Milton et al., 2013) or that they are 
compromised in their ability to initiate infection in the recipient animal. Indeed, 
we showed that virus with a short stalk NA had a reduced ability to initiate 
infection of MDCK cells in the presence of mucus, perhaps because it was 
compromised in its ability to cleave tethered multivalent sialic acid substrates. 
Neutralization of virus by mucus was significantly reduced through extending 
the NA stalk length. Together, these observations suggest that cleavage of 
SA from viral glycoproteins and mucins was compromised by NA’s short stalk 
length  
We did not test the virus’ ability to overcome inhibition of infectivity by ferret 
mucus and so we cannot categorically say that the in vitro measurement 
accounted for the difference in transmissibility between the two viruses. 
However, ferret nasal wash was scored for viscosity and found to increase at 
the same time that the ferret’s nasal wash sample became positive for virus 
(data not shown). This serves as a reminder that virus not only faces mucus 
when it initiates infection in a new host, but that the concentration of mucins 
and other inhibitors in the mucus increase with stimulation by PAMPs (Tadaki 
et al., 2008 and reviewed in Evans et al., 2010; Parker and Prince, 2011; 
Voynow and Rubin, 2009). 
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6.1.2 Implications for a pandemic with an H5 NA 
The findings presented here have implications in regard to the characteristics 
of HA and NA if an H5 pandemic was to arise. The barriers to transmission 
observed in our experiments could be overcome in three ways: (1) A short 
stalk HPAI H5N1 NA could enhance its activity through compensatory 
mutations that counteract its steric hindrance; (2) An H5 HA with low avidity 
for its receptor could balance the low activity of a short stalk NA; or (3) 
Reassortment in birds, swine, or humans could lead to the pairing of an H5 
HA with a long stalk NA. 
Although a virus with a short stalk NA has not supported transmission of a 
human influenza virus in the past, enzyme activity of a short stalk NA could be 
enhanced in several ways that might overcome this genetic barrier. Mutations 
that improve NA protein expression density on the virion surface (Bloom et al., 
2010) or substrate affinity and/or reaction velocity (Abed et al., 2011; 
Mountford et al., 1982; Rameix-Welti et al., 2008) have been associated with 
improved influenza virus replication or transmission. Moreover, it is likely that 
different short stalk NAs naturally vary in enzyme activity and therefore start 
out from a different baseline in this adaptive pathway. Figure 5.5 shows all 
viruses tested in the mucus infectivity assay. Both SS and LS pairs of viruses 
with tyTy05 and ckIt99 NAs showed that stalk elongation increased infectivity 
in the presence of mucus. However, mucus inhibited SStyTy05 NA virus much 
more than it inhibited virus with SSckIt99 NA virus at all time points. This 
suggests that the head region of ckIt99 NA was more efficient at destroying 
mucus decoys than the head region of tyTy05 NA. This suggests that viruses 
with some short stalk NAs, but not others, might support transmission 
between mammals.  
Viruses with a short stalk NA might gain fitness through HA mutations that 
reduce affinity or alter specificity of SA binding and make the receptor decoys 
in mucus less able to inhibit virus infectivity. For example, the HA of seasonal 
H1N1 strains acquired mutations near the receptor binding site that were 
associated with improved replication when paired with a 2008 drug resistant 
NA (Ginting et al., 2012). Similarly, a change in HA receptor binding of 
influenza B viruses was observed in virus isolates that carried NA mutations 
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conferring resistance to neuraminidase inhibitors following treatment 
(Mochalova et al., 2010). We previously showed that the inhibitory effect of 
mucus on virus infectivity was reduced by mutations in the HA that altered its 
receptor binding specificity (Roberts et al., 2011). Thus, a virus with a short 
stalk NA might reduce the SA avidity of its HA, for example by accumulation 
of HA glycosylation sites as seen in gallinaceous hosts (Banks et al., 2001; 
Matrosovich et al., 1999; Sorrell et al., 2010). According to Xu et al. the HA 
from the 2009 pandemic has the lowest avidity of the four most recent human 
pandemic virus HAs (Xu et al., 2012b). Therefore the pandemic H1 HA used 
here might have been the most likely to balance an NA with a substantially 
reduced activity due to stalk truncation, and yet we still found that this HA:NA 
combination showed compromised transmission.  
The possibility of reassortment to restore NA stalk length prompted us to look 
at the frequency of long stalk NAs in H5N1 influenza viruses generated by 
reassortment in nature. In line with the findings of Li et al. (Li et al., 2011), we 
found that the majority of avian HPAI H5N1 viruses have short stalks (Figure 
3.5 and Table 3.3). However, some HPAI H5N1 viruses isolated from birds, 
swine, and humans did have a long stalk NA (Table 3.3). Therefore, it seems 
prudent to determine the NA stalk length for all new H5N1 viral isolates since, 
according to our findings, viruses with a long stalk NA have a lower barrier to 
overcome in order to become mammalian transmissible. A virus with H5 HA 
could gain an NA with a longer stalk from any of the nine NA subtypes. 
Influenza viruses with long stalk NA genes are more common in anseriformes 
(Li et al., 2011) so domestic ducks and geese may act as a mixing vessel for 
generating HPAI H5 HA with long stalk NA. However, all of the HPAI H5 HA 
genes with long stalk NA genes from these avian hosts so far retained amino 
acids 224N, 226Q, and 228G, which confer avian-like receptor binding 
preference to α2,3 SA. Therefore, these hosts are unlikely to transmit virus 
with pandemic potential directly to humans. Using reverse genetics, 
introduction of a long stalk NA from a human influenza virus has been shown 
to increase H5 virus transmission. Chen et al. showed that a virus with an H5 
HA, which was mutated so that it bound α2,6-linked SA, did not support RD 
transmission between ferrets with its cognate NA, but when paired with the 
long stalk N2 NA of a human seasonal H3N2 virus, RD transmission was 
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achieved (Chen et al., 2011a). Imai et al. also reported that RD transmission 
was achieved in ferrets with a modified H5 HA paired with seven other 
influenza genes from a pandemic H1N1 strain, including the long stalk NA 
(Imai et al., 2012). Transmission of some H5N1/pH1N1 reassortants without 
further adaptation was achieved in guinea pigs (Y. Zhang et al., 2013). 
Interestingly the NA of the H5N1 virus used in this study was not truncated. 
Taken together, these observations support our hypothesis, that RD 
transmission of virus with a short stalk NA in mammals might be increased by 
acquisition of a long stalk.  
In summary, the results presented in Chapters 2-5 showed that the short stalk 
length of an avian virus NA led to reduced transmission of a virus, which was 
otherwise more efficiently transmitted. These findings suggest that a fully 
poultry-adapted H5N1 virus may be less likely to initiate the next human 
pandemic than previously thought without substantial mutation or 
reassortment of the NA gene. Furthermore our data reinforce the idea that 
multigenic adaptation (Russell et al., 2012) may be needed for an animal 
influenza virus to jump the host species barrier and become a pandemic strain.  
6.1.3 Why does stalk truncation arise in poultry? 
The finding that low NA activity leads to reduced release and thus inhibited 
viral replication and transmission in mammalian systems is reassuring in that 
this barrier reduces the probability of SS NA viruses causing pandemics. The 
question of how and why stalk truncation arises in birds has not been fully 
answered. The association between stalk truncation and adaptation to poultry 
relies on observations made soon after viruses have become enzootic in 
poultry after introduction from wild birds. Stalk truncation has also been 
selected by serial passage of viruses in gallinaceous hosts (Giannecchini et 
al., 2010; Hossain et al., 2008; J. Li et al., 2010; Sorrell and Perez, 2007; 
Yamada et al., 2012).  
Although none of the systems studied here favoured virus with a SS NA, 
viruses with SS NAs have clearly conferred a growth benefit in the respiratory 
tract of chickens. Virus with the same stalk deletion as the ckIt99 NA studied 
here replicated to higher titres in the oropharyngeal cavity of chickens 
compared to virus engineered to have LS NA (Hoffmann et al., 2012). 
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Similarly, a virus engineered to have a 19 aa stalk deletion in an N1 that had 
95% homology with GsGd965 NA grew to higher titres than virus with the 
natural LS form of the NA in the lungs of chickens (Munier et al., 2010). These 
two SS NA viruses also seemed to confer a growth benefit in the caecum or 
cloaca. However, viral titres shed from the airways exceeded and preceded 
those shed from the cloaca by at least a day and over two logs (Hoffmann et 
al., 2012). Replication of a wild bird influenza virus in quail was also much 
higher in buccal, rather than cloacal samples even before adaptation through 
serial passage (Sorrell and Perez, 2007).  
A driving factor for influenza virus adaptation to a new host is the need to 
balance HA binding affinity with NA sialidase activity in an environment where 
sialic acid density and presentation is different. Interestingly, only 10-20% of 
N-linked glycans from 10-day-old embryonated chicken eggs have terminal 
SA (Sriwilaijaroen et al., 2009). Whereas 47% of N-linked glycans from Gull 
egg white have mono- or di-sialated termini (Suzuki et al., 2009). This 
suggests that decoy receptors may be less prevalent in chickens compared to 
waterfowl. Lower levels of terminal SA would also mean fewer receptors for 
HA to bind. Therefore, a dramatic reduction in sialidase activity may be 
selected during viral adaptation to chickens in order to prevent NA from 
cleaving the few receptors available for entry and fusion. 
Furthermore, reduced HA affinity for the entry receptor in the airways of 
poultry may drive the selection of viruses with reduced NA activity. The HA of 
viruses isolated from poultry and humans during the zoonotic outbreak of 
H5N1 in 1997 had lower affinity for α2,3-linked SA than closely related viruses 
isolated from ducks (Matrosovich et al., 1999). H9N2 viruses of the Eurasian 
poultry lineage also showed lower α2,3-SA binding affinity (Matrosovich et al., 
2001) and reduced ability to haemagglutinate cow, horse and pig RBCs (Saito 
et al., 2001) compared to H9 viruses of the wild bird lineage. While influenza 
viruses from both Anseriformes and Galliformes prefer α2,3-linked SA, they 
differ in their ability to recognise different subterminal sugars. Duck viruses 
prefer α2,3-1,3GlcNAc-linked sugars over α2,3-1,4GlcNAc-linked sugars. 
Binding by duck viruses is not affected by sulfation and some duck viruses 
                                            
5 GsGd96 is the lineage defining ancestor of H5N1 viruses. 
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prefer non-fucosylated subterminal GlcNAc. Gull viruses prefer fucosylated 
over non-fucosylated sugars. Poultry viruses prefer α2,3-1,4GlcNAc-linked 
sugars over α2,3-1,3GlcNAc-linked sugars and prefer sulfated over non-
sulfated subterminal GlcNAc (Gambaryan et al., 2004, 2005, 2008)(and 
reviewed by Gambaryan et al., 2012 and Nicholls et al., 2008). It is possible 
that stalk truncation occurs to balance weak binding of a wild bird virus before 
it adapts to the receptors that are prominent in terrestrial poultry. 
From the 1999-2000 outbreak of H7N1 influenza viruses in birds in Italy 118 
unique nucleotide sequences for NA are accessible through the IRD database 
and six more only through the GISAID database (as of 05/09/2014). Three of 
the sequenced NA genes had long stalks (A/chicken/Italy/1082/1999; 
A/chicken/Italy/1391/1999; A/turkey/Italy/604/2000)(determined by alignment 
using Geneious v6.1.6). Interestingly, the paired HAs of the three LS NA 
isolates had V186 (H3 numbering)(196 by H7 numbering) and of 192 unique 
HA nucleotide sequences accessible through the IRD database and six more 
only through the GISAID database (as of 05/09/2014) that had SS NAs about 
16% had V186 while the rest had G186. About three times as many viruses 
were isolated from turkeys as were from chickens. Of those viruses with SS 
NA 23% of the HAs isolated from turkeys had V186 while only 2% of the HAs 
isolated from chickens had V186. Few viruses were isolated from guinea fowl, 
ostrich, quail, duck, and goose and all had G186. Residue 186 is right at the 
tip of the β-sheet that points up into the left side of the RBS, just under the 
190-helix. Interestingly, H7N9 HAs have V186 as do some wild bird and some 
other terrestrial bird H7 HAs. A few groups have suggested that other 
terrestrial birds act as intermediates that allow wild bird viruses to adapt to 
chickens (Cilloni et al., 2010; Giannecchini et al., 2010; Perez et al., 2003; 
Sorrell and Perez, 2007; Sorrell et al., 2010; Yamada et al., 2012). However, 
since turkeys were the main host of the 1999-2000 epizootic (Capua et al., 
2002), it is not clear if this was the case for this outbreak.  
Also interestingly, despite achieving higher levels of replication in the lungs of 
chickens, SS NA virus from the 1999 outbreak stimulated lower levels of 
inflammatory cytokines than virus engineered to have LS NA (Hoffmann et al., 
2012). Stacey Shultz-Cherry and her group showed that cleavage of SA from 
the inactive form of latent TGFb by influenza virus NA activated it. The 
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downstream effect was an increased inflammatory response, lower viral 
replication and delayed mortality in mice. They found that many H5N1 viruses 
with SS NA had low activation of TGFb and that delivery of exogeneous TGFb 
improved outcome post H5N1 infection in mice (Carlson et al., 2010; Schultz-
Cherry and Hinshaw, 1996). Therefore, reduction in stimulating an innate 
antiviral immune response may support the selection of virus with SS NA in 
poultry at the same time as improving the ability of virus to replicate.  
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6.2 Haemadsorption 
6.2.1 Summary of findings 
Here we showed that the recent pandemic N1 NA was Hd negative. However, 
unexpectedly, we were unable to restore its ability to Hd, despite numerous 
mutant NAs being made (Sections 5.2.1, p212 and 5.2.2, p219). Therefore, 
we looked back at other NAs of the same lineage to see when the ability to Hd 
had been lost. We found that the avian lineage defining NA was Hd+, as was 
an NA from a swine virus of the avian-origin EA swine lineage that descended 
from the same introduction of avian H1N1 into swine as the pandemic NA. 
Therefore, it seems as though loss of haemadsorption occurred during 
transmission between swine.  
By comparing avian virus NAs that were naturally Hd+ with mutants that were 
Hd-, we showed that loss of haemadsorption activity led to a reduced ability of 
virions to penetrate through human mucus (Section 5.2.5, p225). Experiments 
in the presence or absence of exogeneous NA showed that the inhibitory 
effect of mucus could be reduced by additional sialidase activity (Section 5.2.6, 
p230). Viruses with E195/09 HA and Hd- NAs showed a trend toward lower 
growth in MDCKs compared to their Hd+ counterparts and the difference was 
statistically significant in HNE cells (Section 5.2.7, p231 and Section 5.2.8, 
p233). However, when paired with an avian HA, Hd+ virus with LS NA showed 
that too much sialidase activity could lead to lower growth in HAE cells 
(Section 5.2.9, p234). This finding may explain why, after the 1957 
introduction of H2N2 strain, viruses that had lost the ability to haemadsorb 
were selected in humans (Uhlendorff et al., 2009).  
The contrast between the results at the end of the haemadsorption chapter is 
striking (Figure 5.10 A versus B): virus with swine NA retained a higher 
percentage of infectivity in the presence of mucus and grew to higher titres in 
HNE cells, but faced a barrier to growth in sections of ex vivo ferret trachea. 
There are a number of possible ways to interpret these findings. One could 
argue that since ferret tracheal sections are submerged in media and mucus 
is diluted, growth of virus with swEng06 NA may not have had such an 
advantage in ferret trachea as it did in HNEs. We did not perform transmission 
experiments with viruses that contained swEng06 NA gene. Thus it is difficult 
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to understand the significance of the attenuated replication in the ferret 
tracheal explants. 
The Oh07 and swEng06 NAs share 92% identity with the classical and 
Eurasian-avian origin NAs that were used in virus transmission experiments 
by Lakdwala et al. and Yen et al. They presented evidence that transmission 
of pH1N1 2009 viruses in ferrets was better with its cognate NA than with 
other swine origin NAs (Lakdawala et al., 2011; Yen et al., 2011). Their 
transmission experiments and our findings in ferret tracheal tissue indicate 
that a virus with seven genes from Eng195 and swEng06 NA may not transmit 
as well as wild type. If that were the case, the reason may be tracked to the 
difference in host response between HNEs and ex vivo tissue culture. 
Therefore, further investigation of the differences between these two models 
would be worth pursuing in the future.  
6.2.2 What happens to the haemadsorption ability of avian 
NAs in swine?  
The results presented here and by Kobasa et al., (1997) prove that the NAs of 
at least two swine viruses were Hd+. However, the two pandemic NAs that 
arose from swine had either a reduced (1918) or absent (2009) ability to 
haemadsorb chicken RBCs. The fact that the 1918 pandemic NA retained the 
aa sequence signatory of the ability to haemadsorb, but was shown to have 
much reduced affinity for chicken RBCs in comparison to other Hd+ NAs (See 
figure 6 of Uhlendorff et al., 2009) indicates that a mutation (or mutations) 
other than those of interacting residues can affect the ability of a NA to Hd.  
A mechanism for the reduction in Hd activity through mutations that are not 
involved in interacting residues is suggested by the findings here that the Hd 
domains of 1918 and more so of 2009 NAs were wider than that of ternAus75 
N9 NA, which has been crystallised with SA bound in its Hd domain. A wider 
RBS of human H3 and swine H9 HAs associates with prefererence for a2,6-
linked SA in comparison to the RBS of H5 HA, which binds more strongly to 
a2,3-linked SA (Chandrasekaran et al., 2008; Ha et al., 2001). 
Since the ability to Hd chicken RBCs seems to be lost in swine at some point 
before a pandemic, it is interesting to know how frequently this may occur. 
Therefore, we analysed swine NA sequences to determine how many were 
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likely to be Hd+ and how many were likely to be Hd- in comparison to avian 
and human NAs. Since aas responsible for the widening of the NA Hd domain 
have not been identified, we cannot identify the point of initial reduction of Hd. 
However, since we know that mutations in the Hd interacting residues indicate 
that the ability to Hd had likely been lost prior to their selection, we can 
identify the lower boundary of swine sequences that are most likely Hd-. With 
this flaw in the analysis in mind, the presence of all different sequences of 
swine, avian, and human N1 NAs, through the 370-loop, were counted and 
displayed as a percentage of total (Table 6.1). Like viruses endemic in 
humans, only viruses with N1 and N2 NAs are enzootic in swine. N2 NAs 
were excluded from this analysis, leaving it to focus on N1 NAs because it 
was assumed that all swine N2 NAs were of human origin from the 
introduction of human endemic H3N2 into the swine population after the 1968 
pandemic.  
NAs of avian virus isolates clearly retained the Hd positive consensus 
sequence 364 – SxxSrS6 – 369 (N1 numbering) and NAs of human virus 
isolates had a clear dominance of the sequence SxxLrK. In contrast, NAs of 
swine virus isolates had a more diverse set of sequences. About 54% of 
swine isolates retained the avian consensus sequence with 21% having the 
sequences SxxSrN and 15% having SxxSrR. Analysis of the interacting 
residues within the 370-loop showed that aa 369 has the most variability and 
can be used as a signal of alteration within the Hd domain. Therefore, 
characterisation by lineage was undertaken with a focus on the amino acid 
residues present at position 369. This analysis showed that many more swine 
isolates from the Eurasian avian-origin swine lineage had lost the Hd+ 
signature compared to swine isolates of the Classical lineage (Table 6.2). If 
loss of haemadsorption by swine NAs is a prerequisite for a human pandemic 
                                            
6 Capitalisation of aas indicates that their side chains were involved in direct 
interactions with SA in the Hd binding site according to Varghese et al. (1997). 
The lowercase aas indicate that their side chain points away from the Hd 
pocket. In the case of the ‘r’, it is an active site residue that is conserved 
between all NAs (Colman et al., 1983; Xu et al., 2008), whereas ‘x’ indicates 
that many aas are found at these two locations in NA sequences. 
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virus, then once the mutations responsible for the widening the Hd domain 
that lead to loss of Hd are identified, information presented like this on a 
yearly basis may help identify how many swine NAs in circulation have 
pandemic potential. 
The reason that loss of Hd is selected in swine is still unknown. However, the 
frequencies with which Hd- sequences are present in swine indicate that 
swine transmission of Hd- viruses is supported. Transmission of Hd- viruses 
between swine was further supported by preliminary phylogenetic analysis 
(data not shown).  
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Table 6.1. Frequency of HxN1 virus isolates by host species and specific amino 
acid residues present in the Hd domain 370-loop of NA. Residues deemed to be 
SA-interacting amino acids according to the crystal structure with ternAus75 N9 NA 
are focused on to reduce complexity. The majority of avian virus isolates have the 
Hd+ signature sequence: SxxSrS. About 54% of swine virus isolates retain the Hd+ 
signature sequence in the 370-loop, whereas in humans over 76% of isolates have 
the sequence SxxLrK.  
aa"364&369 Avian"(%) Swine"(%) Human"(%) Pandemic"(Human)"(%)
SxxSrS 97.3 53.5 11.4 0.6
SxxSrN 0.3 21.2 0.1 87.4
SxxSrR 0.1 15.0 0.6 0.0
SxxSrK 0.0 4.0 3.7 11.6
SxxSrM 0.0 3.1 0.0 0.0
NxxSrS 1.3 0.6 0.0 0.0
SxxLrR 0.0 0.6 0.1 0.0
SxxLrK 0.1 0.5 76.8 0.0
SxxIrK 0.0 0.5 4.6 0.0
SxxLrS 0.0 0.5 0.0 0.0
SxxTrS 0.0 0.3 0.0 0.0
NxxSrN 0.0 0.2 0.0 0.0
SxxFrS 0.1 0.1 0.0 0.0
SxxSrH 0.0 0.0 1.3 0.1
SxxSrT 0.1 0.0 0.0 0.1
SxxSrX 0.1 0.0 0.0 0.1
SxxLrN 0.0 0.0 0.0 0.1
GxxSrN 0.0 0.0 0.0 0.0
NxxSrK 0.0 0.0 0.0 0.0
NxxSrR 0.2 0.0 0.0 0.0
TxxSrS 0.1 0.0 0.0 0.0
DxxSrS 0.1 0.0 0.0 0.0
NxxSrG 0.1 0.0 0.0 0.0
SxxArS 0.1 0.0 0.0 0.0
SxxFrK 0.1 0.0 0.2 0.0
SxxSrG 0.1 0.0 0.0 0.0
SxxSrI 0.1 0.0 0.0 0.0
SxxYrS 0.1 0.0 0.0 0.0
CxxLrK 0.0 0.0 0.0 0.0
GxxSrS 0.0 0.0 0.0 0.0
NxxLrK 0.0 0.0 0.2 0.0
SxxSrQ 0.0 0.0 0.6 0.0
TxxSrK 0.0 0.0 0.0 0.0
SxxSkS 0.1 0.0 0.0 0.0
SxxLiK 0.0 0.0 0.0 0.0
#"of"
sequences 1819 1007 2024 3005
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Table 6.2. Frequency of mutation at NA-369 by viral lineage. Red highlights in 
each column are shaded darker for large percentages and lighter for lower 
percentages. All instances of 0.0% are shaded blue. 
 
6.2.3 Possibility of another receptor 
The observation that BrevM18 NA haemadsorbed human RBCs more strongly 
than chicken RBCs indicates that its Hd domain likely bound a receptor that 
was slightly different from that bound by NAs of avian viruses. Although 
E195/09 NA did not bind human RBCs it may bind a receptor present on other 
RBCs. Kobasa et al. showed that three N2 NAs from viruses isolated in 1967 
and 1968 had relatively high sialidase activity against NeuGc (Kobasa et al., 
1999). Swine express NeuGc. Since the 2009 pandemic arose in swine, 
where NeuGc is present, the NA might have developed an ability to cleave 
this receptor as it could have acted as a decoy receptor in swine. RBCs from 
horses, swine, and cows express varying levels of NeuGc (Ito et al., 1997) 
and future Hd analysis should screen these to see if they are bound by the Hd 
domain of E195/09 NA or other NAs of swine viruses. 
 
6.2.4 Change in NA post introduction into humans in 2009  
6.2.4.1 The NA Hd domain mutation N369K was selected in 
descendants of the 2009 pandemic virus  
All (100%) of sequences isolated during the first wave of the pandemic 
(through September 2009) and posted on Genbank had 369N in the 
aa369
Other avian NorthAm 
avian
Eurasian 
avian
H5N1 Classical 
swine
Eurasian 
swine
Pandemic Human 
seasonal
G 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0%
H 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 1.1%
I 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0%
K 0.0% 0.0% 0.0% 0.0% 0.6% 3.6% 11.9% 97.0%
M 0.0% 0.0% 0.0% 0.0% 0.0% 12.3% 0.0% 0.0%
N 0.0% 0.0% 0.0% 0.1% 9.9% 0.8% 87.0% 0.2%
Q 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.6%
R 0.0% 0.0% 1.4% 0.1% 7.0% 47.4% 0.0% 0.8%
S 100.0% 100.0% 97.5% 99.7% 82.5% 36.0% 0.8% 0.3%
T 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.1% 0.0%
X 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.1% 0.0%
# of 
Sequences
17 284 285 1419 543 253 3189 1755
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haemadsorption domain. By the third wave of the pandemic (July 2010 – June 
2011) 63% of viruses from the 2009 lineage H1N1 had 369K rather than 369N, 
which was still present in 35% of viruses isolated during the third wave. By the 
2011-2012 flu season 97% of NAs had 369K. Therefore, the mutation N369K 
was clearly selected during human transmission of 2009 pandemic lineage 
viruses. Since we found that neither wild type (369N) or N369S mutant 
E195/09 NA haemadsorbed chicken or human RBCs, it seemed odd that a 
mutation at residue 369 was under selective pressure. 
6.2.4.2 Visualisation of how 369K altered to the Hd pocket 
Since the mutation 369K was located in the centre of the Hd domain, in case 
there was another receptor that bound to the pandemic NA, it seemed worth 
visualising how this mutation would alter the space. 3D images of ternAus75 
N9 NA with and without SA bound to the Hd domain and CA/04/09 NA wt from 
Figure 5.11 were placed alongside a predicted image of what CA/04/09 NA 
369K might look like. This image was generated using Pymol mutagenesis 
and selecting the conformation with the least charge interference. The orange 
arrow points to the residue at position 369 in each picture. Long amino acids 
like Lysine and Arginine are sometimes associated with altered antigenicity, 
since they can stretch across a large surface area. However, the Lysine at 
369 is predicted to stick straight upward completely filling what was previously 
a negatively charged crevice with a carbon chain topped by a positive charge 
and three hydrogens (Figure 6.1). If the Hd pocket of E195/09 NA bound to a 
receptor that was not detected by our Hd assay, then the N369K mutation 
would likely have abrogated that interaction.  
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Figure 6.1. 3D structures of Hd domain from first and third wave pandemic 
strains. 3D images of wild type or predicted mutant NAs from the indicated viruses 
were created using PyMol. (A, B, & C) N9 NA of ternAus75 (A) with SA bound in the 
Hd site; (D & E) N1 NA of CA/04/09; (F & G) N1 NA of CA/04/09 with N369K mutant 
created in silico. (A, B, D, & F) surface view; (C, E, & G) stick view. The orange 
arrow points to residue 369 in each image. Images A through E are known from X-
ray crystallography, images F and G were predicted using PyMol. PDB files: 
ternAus75-1MWE and CA04-3NSS. 
 
 261 
6.2.4.3 Generation of virus with a pandemic related NA that had 
369K 
It would have been interesting to compare the activity of an E195/09 N369K 
mutant NA to the wild type with N369. If virus with the wild type E195/09 NA 
retained more infectivity in the presence of mucus or grew to higher titres than 
a virus with mutant 369K then it would indicate that the Hd domain of E195/09 
played a role in NA activity. However, this mutant was not available and there 
was no time to make it. 
Instead, the NA of a virus from the third wave of the pandemic, 
A/England/687/2010 (E687/10), which had 369K and three other mutations 
that differentiated it from E195/09 NA was available, as it had been created in 
our lab for other purposes. Since mutation from S to N in ckIt99 (Figure 5.2) 
and S to Y in ternAus75 (Webster et al., 1987) reduced haemadsorption in 
their respective NAs, K was not hypothesised to make E195/09 NA Hd+. 
When a pol1 plasmid that encoded E687/10 NA was transfected into Vero 
cells with four ‘helper’ plasmids no binding of chicken RBCs was detected 
(experiment performed by Lukus Roberts, data not shown). However, this 
plasmid did not have a flag tag in its stalk and therefore NA expression was 
not confirmed. To investigate how the third wave NA compared to the NA of 
E195/09, virus with seven genes from E195/09 and the NA of gene of 
E687/10 was generated.  
6.2.4.4 Virus with NA from the third pandemic wave retained more 
infectivity in the presence of mucus compared to virus with 
NA from the first wave 
The ability to penetrate mucus by virus with E687/10 NA was compared to 
virus with E195/09 NA. Virus with the 3rd wave 2009 pandemic NA retained 
about 2-fold more infectivity in the presence of mucus over 60 minutes than 
virus with the NA from the 1st wave (Figure 6.2).  
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Figure 6.2. Infectivity in the presence of mucus of viruses with NA from first 
and third pandemic waves. Viruses were incubated with mucus on MDCK cells at 
32°C for 60 minutes, washed, and plaque assays were performed. The two viruses 
shown here have seven genes from the pandemic strain E195/09 and NAs as 
indicated on the x-axis. The ability of viruses to penetrate through human mucus is 
shown as the percentage of infectivity that remained in the presence of mucus 
compared to infectivity achieved in the absence of mucus. The p value was 
determined using a one-way ANOVA followed by Tukey posttest to compare all 
means at each time point including the 60 minute measurements shown in Figure 5.5. 
Stars of significance are shown above the black bar. N=9 for virus with E195/09 wt 
NA and N=3 for virus with E687/10 wt NA. Error bars indicate the standard deviation. 
Lukus Roberts performed one experiment in triplicate that included virus with each 
NA shown here. ****p<0.0001. 
 
6.2.4.5 Virus with NA from the third pandemic wave grew to higher 
titres than virus with NA from the first wave 
Growth of viruses that only differed by their NA was measured in MDCK cells. 
At 15 hours post infection, virus with its cognate E195/09 NA grew to an 
average of 6.8 x 105 ± 2.9 x 105 pfu/ml, while virus with E687/10 NA grew to 
an average of 2.2 x 108 ± 3.3 x 108 pfu/ml (Figure 6.3). Thus, in a cell-based 
system, the 3rd wave NA led to more efficient viral growth.   
 
 263 
 
Figure 6.3. Replication of recombinant influenza viruses with NA from the first 
and third pandemic waves. Both viruses had seven genes from the prototypic 
pandemic strain E195/09 with NAs as indicated on the x-axis. MDCK cells were 
infected with MOI of 0.05 and incubated at 37°C for 15 hours, then viral supernatant 
was collected and plaqued. Error bars indicate 95% CIs. P-value determined using 
one-way ANOVA followed by Tukey posttest to compare the means of growth for the 
viruses shown here and in Figure 5.7.  **p<0.01. 
 
6.2.4.6 Other NA mutations that may have reduced mucus 
inhibition and enhanced virus growth 
If the mutation N369K destroyed an interaction between NA and a receptor, 
then, in line with the results presented in Chapter 5, a reduction in NA activity 
was expected. Instead virus with a third wave NA had improved infectivity in 
the presence of mucus and viral growth in MDCK cell culture. Since N369K 
was not tested alone, it could be that the other three mutations of E687/10 NA 
accounted for its improved activity. The three other mutations were V106I, 
V241I, and N248D.  
By the 2011-2012 influenza season the other mutations present in E687/10 
were much more common than their precursors: 94% of isolates had 106I; 
97% had 241I; and 98% had 248D. The aa changes V106I (primarily) and 
N248D were shown to increase the stability of NA and its ability to cleave SA 
at lower pH. V106I is at the interface between two NA subunits and therefore 
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was hypothesised to stabilise the tetramer (Takahashi et al., 2013). Increased 
stability and NA activity may have led to the improved fitness of virus with 
E687/10 NA observed here.  
The effect, if any, of aa changes V241I and N369K remain to be functionally 
characterised. It is possible that N369K was a random mutation that was 
carried with the other mutations that improved viral fitness and transmission 
thus leading it to be included in the dominant circulating strain (Rambaut et al., 
2008). Alternatively, if the Hd pocket of E195/09 NA did bind to an undetected 
receptor and its loss alone led to reduced NA activity, then it would be 
interesting to know the order in which the mutations of E687/10 were acquired. 
This knowledge would add to the understanding of what changes zoonotic 
viruses undertake during their adaptation to humans and would help us 
predict the possibility of emergence of mutations that could be troublesome, 
such as mutations that make viruses drug resistant.   
 
6.2.5 Implications of Hd findings for future pandemics 
At the beginning of this project, it was not clear whether or not a virus with an 
Hd+ NA could cause a pandemic. Delving deeply into the natural history of the 
1957 pandemic virus suggests that the NA that started that pandemic was 
likely Hd+. The work presented here offers the possibility that, like stalk 
truncation in poultry, in order to balance low HA avidity of an avian virus in a 
new host, viruses without the ability to Hd were selected in humans by 1958 
because they had a better HA/NA balance that improved growth and 
transmission. Furthermore, we suggest that when paired with an avian HA, a 
SS avian NA that was Hd+ would lead to higher viral titres in HAEs than an 
Hd- NA, like tyTy05.  
HA NA balance of swine or avian-human reassortant viruses that is sufficient 
for human-to-human transmission is required before a novel virus can cause a 
pandemic (Xu et al., 2012b). Therefore, it is important to fully understand and 
account for the factors that affect NA activity, such as its ability to bind 
receptors in its second SA binding site. 
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6.3 Summary of NA alterations that might allow a new 
enzootic or pandemic virus to arise 
The research presented here supports previous findings that NA activity is 
malleable and shows that it can be reduced by stalk truncation or loss of 
binding by the Hd domain. Stalk truncation seems to sometimes occur when a 
wild aquatic bird virus transmits between terrestrial birds. Loss of Hd binding 
capacity (at least for the receptor on chicken RBCs) seems to possibly occur 
in three scenarios: during enzootic transmission of a swine virus among swine 
(e.g. pre-pandemic 1918 & 2009); during enzootic transmission of an avian 
virus among poultry (e.g. H9N2 & tyTy05 NA of H5N1); and during human 
transmission of a reassortant virus with an avian-origin HA, NA, and PB1 (e.g. 
1957 pandemic).  
Reduction in NA activity through stalk truncation may be driven by a number 
of factors. Transmission via the faecal-oral route versus the aerosol route may 
play a role. Avoidance of activating inflammatory immune responses, such as 
TNFα, may be a factor. A major reason may be the lower levels of SA present 
in the respiratory tract of terrestrial birds compared to the enteric tract of wild 
aquatic birds. Lower levels of SA in mucus would mean that strong NA activity 
is not needed to cleave decoy receptors and allow virus to penetrate through 
mucus. Lower levels of SA on cellular glycoproteins would mean that 
excessive NA cleavage could be detrimental to infection. Finally, lower levels 
of terminal SA on viral glycoproteins would mean less aggregation and less 
sticking to cells post budding, again indicating that there would be a lower 
requirement for NA cleavage during release. In the face of low levels of SA 
receptor, low NA activity would be tolerated for two of its main activities and 
selected for by the reduction in receptor destruction.   
Reasons for loss of Hd activity in swine and humans may differ. Loss of Hd 
activity by viruses that descended from the 1957 pandemic virus may have 
been driven by similar drivers as those for stalk truncation: lower levels of HA 
receptors and reduced stimulation of inflammatory responses. Loss of Hd 
activity in swine, before the 1918 and 2009 pandemics may be driven by 
adaptation to cleave NeuGc, which may be a prominent decoy receptor in 
pigs. Alternatively, reduction of Hd activity may reduce NA activity after other 
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mutations increase it in order to re-adjust HA/NA balance. These phenomena 
are summarised in Figure 6.4. 
This thesis has taken a few steps to further define the outcome of changes in 
NA stalk length or Hd binding, but more research is needed to determine the 
drivers that lead to selection of these traits. 
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7 Chapter 7: Materials and Methods 
7.1 Materials 
7.1.1 Vectors 
Name Description Supplier 
pCI Used for “Victoria helper” plasmids. 
These plasmids induce expression 
of the protein encoded by an 
inserted gene. pCI is a mammalian 
expression vector with a CMV 
promoter, which drives  human 
polymerase II transcription. pCI 
encodes the Ampicillin resistance 
and SV40 genes. 
Life Technologies 
pCAGGS Used to express high levels of 
mRNA, which is translated into 
protein in mammalian cells. Driven 
by the CAG promoter, which 
consists of the CMV early enhancer 
element, the first exon and intron of 
the chicken β-Actin gene (the 
promoter), and the splice acceptor 
of the rabbit β-Globin gene. 
Designed by Miyazaki 
et al., Gene, 1989. 
Obtained from the 
Belgian Co-ordinated 
Collections of 
Microorganisms 
(BCCM)/ Laboratory 
Medicine Best 
Practices (LMBP).  
pPol1 (aka 
pPRG made 
from pUC19) 
Used for “Pol1” plasmids for 
A/Victoria/3/1975, 
A/PuertoRico/8/1934 and 
A/chicken/Italy/13474/1999. Has the 
human polymerase I promoter at the 
5’ terminus and the hepatitis delta 
virus antigenomic ribozyme at the 3’ 
terminus of the gene of interest. 
Dr. Thomas Zurcher, 
GlaxoSmithKline 
pMK Used for “Pol1” plasmids for 
E195/09 HA and NA. 
Life Technologies 
pMA Used for “Pol1” plasmids for 
E195/09 (PB2, PB1, PA, NP, M and 
NS) and swOh07 NA 
Life Technologies 
pHW2000/Pol1 
Pol2 
Used for “Pol1” plasmids for 
A/duck/Bavaria/1/1977 
Jurgen Stech, 
Friedrich-Loeffler-
Institut 
Undetermined Used for “Pol1” plasmids for 
A/swine/England/453/2006 NA 
Hongbo Zhou, 
FLUPIG 
Undetermined Used for “Pol1” plasmids for 
A/turkey/Turkey/1/2005 NA 
Ron Fouchier, 
Erasmus 
Table 7.1. Vectors used for the research presented here. 
pPRG and pCI described in (Jackson et al., 2002)  
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pCAGGS vector designed by (Miyazaki et al., 1989) 
 
7.1.2 Plasmids 
Name Description Origin 
pCI-Vic-PB2  “Helper” plasmid: PB2 protein of Vic virus  
Thomas 
Zurcher, 
GlaxoSmithKline 
pCI-Vic-PB1 “Helper” plasmid: PB1 protein of Vic virus 
pCI-Vic-PA “Helper” plasmid: PA protein of Vic virus 
pCI-Vic-NP “Helper” plasmid: NP protein of Vic virus 
pPol1-Vic-PB2 “Rescue” plasmid of Vic virus seg 1 
Thomas 
Zurcher, 
GlaxoSmithKline 
pPol1-Vic-PB1 “Rescue” plasmid of Vic virus seg 2 
pPol1-Vic-PA “Rescue” plasmid of Vic virus seg 3 
pPol1-Vic-HA “Rescue” plasmid of Vic virus seg 4 
pPol1-Vic-NP “Rescue” plasmid of Vic virus seg 5 
pPol1-Vic-NA “Rescue” plasmid of Vic virus seg 6 
pPol1-Vic-M “Rescue” plasmid of Vic virus seg 7 
pPol1-Vic-NS “Rescue” plasmid of Vic virus seg 8 
pPol1-E195/09-PB2 “Rescue” plasmid of E195/09 virus seg 1 
Designed by 
Lorian 
Hartgroves and 
Wendy Barclay, 
synthesised by 
Life 
Technologies 
pPol1-E195/09-PB1 “Rescue” plasmid of E195/09 virus seg 2 
pPol1-E195/09-PA “Rescue” plasmid of E195/09 virus seg 3 
pPol1-E195/09-HA “Rescue” plasmid of E195/09 virus seg 4 
pPol1-E195/09-NP “Rescue” plasmid of E195/09 virus seg 5 
pPol1-E195/09-NA “Rescue” plasmid of E195/09 virus seg 6 
pPol1-E195/09-M “Rescue” plasmid of E195/09 virus seg 7 
pPol1-E195/09-NS “Rescue” plasmid of E195/09 virus seg 8 
pPol1-E195/09-NA-Flg Flag tag added to stalk of E195/09 NA This project 
pCAG-E195/09-NA-Flg “Expression” plasmid with Flag This project 
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tag  
pPol1-E195/09-NA-369S 1
st attempt to make E195/09 
NA Hd+ This project 
pPol1-E195/09-NA-369S-
Flg 
1st attempt to make E195/09 
NA Hd+ This project 
pCAG- E195/09-NA-369S-
Flg 
“Expression” plasmid: 1st 
attempt to make E195/09 NA 
Hd+ 
This project 
pPol1-E195/09-NA-5mu-Flg 2
nd attempt to make E195/09 
NA Hd+ This project 
pCAG E195/09-NA-5mu-Flg 
“Expression” plasmid: 2nd 
attempt to make E195/09 NA 
Hd+ 
This project 
pPol1-E195/09-NA-9mu-Flg 3
rd attempt to make E195/09 
NA Hd+ This project 
pCAG-E195/09-NA 9mu-Flg 
“Expression” plasmid: 3rd 
attempt to make E195/09 NA 
Hd+ 
This project 
pPol1-E195/09-NA 13mu-
Flg 
4th attempt to make E195/09 
NA Hd+ This project 
pCAG- E195/09-NA 13mu-
Flg 
“Expression” plasmid: 4th 
attempt to make E195/09 NA 
Hd+ 
This project 
pPol1-PR8-PB2 “Rescue” plasmid of PR8 virus seg 1 
Cloned from 
cDNA and 
inserted into 
pPRG plasmid 
by Alison 
Whiteley 
pPol1-PR8-PB1 “Rescue” plasmid of PR8 virus seg 2 
pPol1-PR8-PA “Rescue” plasmid of PR8 virus seg 3 
pPol1-PR8-NP “Rescue” plasmid of PR8 virus seg 4 
pPol1-PR8-M “Rescue” plasmid of PR8 virus seg 7 
pPol1-PR8-NS “Rescue” plasmid of PR8 virus seg 8 
pPol1-ckIt99-HA “Rescue” plasmid of ckIt99 virus seg 4 Alison Whiteley 
pPol1-SSckIt99 NA “Rescue” plasmid of SSckIt99 virus seg 6, aka wt Alison Whiteley 
pCAG-SSckIt99-NA “Expression” plasmid of SSckIt99 NA This project 
pPol1-SSckIt99-NA-Flg “Rescue” plasmid: Flag tag in short stalk of SSckIt99 wt NA This project 
pCAG- SSckIt99-NA-Flg 
“Expression” plasmid wt head 
sequence Flag tag in stalk, with 
length maintained 
This project 
pPol1-SSckIt99-NA-369N 
“Rescue” plasmid: Mutation 
S369N significantly reduced 
haemadsorbtion by ckIt99 NA 
This project 
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pPol1-SSckIt99-NA-369N-
Flg 
“Rescue” plasmid: Hd- mutant 
with Flag tag in short stalk This project 
pCAG-SSckIt99-NA-369N-
Flg 
“Expression” plasmid: Hd- 
mutant with Flag in short stalk This project 
pPol1-LSckIt99-NA “Rescue” plasmid: Elongated stalk of ckIt99 wt NA This project 
pPol1-LSckIt99-NA-Flg “Rescue” plasmid: ckIt99 NA wt, with Flag tag in long stalk This project 
pCAG-LSckIt99-NA-Flg 
“Expression” plasmid: ckIt99 
NA wt with Flag tag in long 
stalk 
This project 
pPol1-LSckIt99-NA-369N 
“Rescue” plasmid: Added Hd- 
mutation, S369N, to LSckIt99 
NA 
This project 
pPol1-LSckIt99-NA-369N-
Flg 
“Rescue” plasmid: ckIt99 NA 
Hd- mutant, with Flag tag in 
long stalk 
This project 
pCAG-LSckIt99-NA-369N-
Flg 
“Expression” plasmid: ckIt99 
NA Hd- mutant with Flag tag in 
long stalk 
This project 
pPol1-SStyTy05-NA “Rescue” plasmid of SStyTy05 virus seg 6 with short stalk (wt) 
Ron Fouchier, 
Erasmus  
pPol1-MStyTy05-NA 
“Rescue” plasmid of seg 6 
MStyTy05 with medium length 
stalk 
This project 
pPol1-LStyTy05-NA “Rescue” plasmid of seg 6 LStyTy05 with long stalk This project 
pPol1-LStyTy05-NA-Flg 
“Rescue” plasmid of seg 6 
LStyTy05 with long stalk with 
Flag tag 
This project 
pPol1-dkBav77-NA “Rescue” plasmid of dkBav77 virus seg 6, wt 
Jurgen Stech, 
Friedrich-
Loeffler-Institut 
pPol1-dkBav77-NA-Flg 
“Rescue” plasmid of dkBav77 
virus seg 6, wt with Flag tag in 
stalk 
This project, 
Lukus Roberts 
pCAG-dkBav77-NA-Flg 
“Expression” plasmid: dkBav77 
virus seg 6, wt with Flag tag in 
stalk 
This project, 
Lukus Roberts 
pPol1-dkBav77-364N-NA “Rescue” plasmid of dkBav77 virus seg 6, Hd- 
This project, 
Lukus Roberts 
pPol1-dkBav77-364N-NA-
Flg 
“Rescue” plasmid of dkBav77 
virus seg 6, Hd- mutant with 
Flag tag in stalk 
This project, 
Lukus Roberts 
pCAG-dkBav77-364N-NA-
Flg 
“Expression” plasmid: dkBav77 
virus seg 6, Hd- mutant with 
Flag tag in stalk 
This project, 
Lukus Roberts 
pPol1-swEng06-NA “Rescue” plasmid of swEng06 virus seg 6 
Hongbo Zhou, 
FLUPIG  
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pPol1-swEng06-NA-Flg 
“Rescue” plasmid of swEng06 
virus seg 6 with Flag tag in 
stalk 
This project 
pCAG-swEng06-NA-Flg 
“Expression” plasmid of 
swEng06 NA with Flag tag in 
stalk 
This project 
pPol1-swOh07-NA “Rescue” plasmid of swOh07 virus seg 6 
Designed for 
this project; 
sequence from 
Colin Russell, 
synthesised by 
GeneArt 
Table 7.2 Plasmids used for the research presented here. 
“Helper” and “Expression” plasmids express mRNA that gets translated into the 
encoded protein. 
“Rescue” plasmids express negative sense viral RNA. 
Seg = Gene segment 
A/Victoria/3/1975 “Pol1” and “Helper” plasmids described in (Elleman and Barclay, 
2004). 
A/England/195/2009 Pol1 plasmids described in (Brookes et al., 2011) 
A/PuertoRico/8/1934 and A/chicken/Italy/13474/1999 Pol1 plasmids described in 
(Whiteley et al., 2007) 
A/turkey/Turkey/1/2005 Pol1 plasmids were sequenced by Ron Fouchier as 
described in (de Wit et al., 2007). 
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7.1.3 Viruses 
Virus Name HA NA Internal Comment 
Vic Vic Vic Vic Wild type hu seas H3N2 from 1975 
SSckIt99 NA+7Vic Vic SSckIt99 Vic 
hu seas H3 + av N1 
(of H7N1) 
reassortant + hu 
seas internals 
LSckIt99 NA+7Vic Vic LSckIt99 Vic 
hu seas H3 + long 
stalk av N1 (of 
H7N1) reassortant + 
hu seas internals 
SSckIt99 
NA/HA+6PR8 ckIt99 SSckIt99 PR8 
av H7 and wt N1 
HDpos (of H7N1) 
with vaccine strain 
internals  
SSckIt99 S369N 
NA/HA+6PR8 ckIt99 SSckIt99 PR8 
av H7 and wt N1 
HDneg (of H7N1) 
with vaccine strain 
internals  
LSckIt99 
NA/HA+6PR8 ckIt99 LSckIt99 PR8 
av H7 and long stalk 
N1 HDpos (of 
H7N1) with vaccine 
strain internals  
LSckIt99 S369N 
NA/HA+6PR8 ckIt99 LSckIt99 PR8 
av H7 and long stalk 
N1 HDneg (of 
H7N1) with vaccine 
strain internals  
SStyTy05 
NA+7E195/09 E195/09 SStyTy05 E195/09 
pn H1 + hu zoo av 
N1 (of H5N1) 
reassortant + pn 
internals 
LStyTy05 
NA+7E195/09 E195/09 LStyTy05 E195/09 
pn H1 + hu zoo av 
N1 (of H5N1) long 
stalk reassortant + 
pn internals 
E195/09 (aka 
E195/09) E195/09 E195/09 E195/09 
Wild type 2009 pn 
H1N1 
E195/09 N369S 
NA+7E195/09 E195/09 
E195/09 
N369S E195/09 
2009 pn H1 and N1 
with mutation in Hd 
domain 
E687/10 
NA+7E195/09* E195/09 E687/10 E195/09 
1st wave pn H1 
(from 2009) + 3rd 
wave pn N1 (from 
2010) + pn09 
internals  
swEng06 
NA+7E195/09 E195/09 swEng06 E195/09 
pn H1+ sw EA N1 + 
pn internals 
swOh07 E195/09 swOh07 E195/09 pn H1+ sw CL N1 + 
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NA+7E195/09 pn internals 
dkBav77 
NA+7E195/09* E195/09 dkBav77 E195/09 
pn H1 + av N1 
HDpos + pn 
internals 
dkBav77 S364N 
NA+7E195/09* E195/09 
dkBav77 
S364N E195/09 
pn H1 + av N1 
HDneg + pn 
internals 
 
Table 7.3 Viruses used for the research presented here. 
All viruses for this project were generated using the 12 plasmid reverse genetic 
method (Fodor et al., 1999; Neumann et al., 1999). Vic helper plasmids were used in 
all cases. * = viruses generated by Lukus Roberts.  
hu seas = human seasonal; av = avian; hu zoo av = an avian-origin virus isolated 
from a human; pn = pandemic; sw = swine (CL = classical swine lineage; EA = 
Eurasian swine lineage); internal = gene segments 1, 2, 3, 5, 7 and 8; HDpos/neg = 
haemadsorption positive/negative.  
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7.1.4 Primers 
Primer Name Purpose Sequence (5'-3') 
Fin_stalk_ckIt Insert 66nt from 
stalk region of 
NA from 
influenza isolate 
A/ck/It/1082/99 
into SSckIt99 NA 
CATTACTTATGAAAACAACACCTG
GGTAAATCAGACGTATGTCAACAT
TAGCAATACCAATTTTCTTACTGAA
CAGGCTGTAACTTCGGTGACATTA
G Underlined nts indicate those 
inserted. 
R_stalk_ckIt Primer used to 
clone the 
reverse DNA for 
inserting 66nt 
into SSckIt99 NA 
ATGCTTTGGTTGCATGGTTCAGGC
TG 
F_fix_stalk_ckIt Add extra nts 
within 27nt 
region 
encorporating 
missing nts for 
stalk insertion 
CATTACTTATGAAAACAACACCTG
GGTAAATCAGACGTATGTCAACAT
TAGC The underlined sequence 
indicates the nts that were missing 
from the first attempt at stalk 
insertion. 
Flu_specific_NA_F Sequence 5' end 
of NA 
TATTGGTCTCAGGGAGCAAAAGCA
GGAGT The underlined sequence 
binds to the 3' noncoding region of 
NA vRNA. 
Flu_specific_NA_
R 
Sequence 3' end 
of NA 
ATATGGTCTCGTATTAGTAGAAAC
AAGGAGTTTTTT The underlined 
sequence binds to the 5' noncoding 
region of NA cRNA. 
Fin_FLst_ckIt Insert into 
SSckIt99 NA 
66nt, 24 of which 
encode the flag 
tag and the 
others from the 
stalk region of 
A/ck/It/1082/99  
CGATTACAAGGACGACGATGACA
AGGTAAATCAGACGTATGTCAACA
TTAGCAATACCAATTTTCTTACTGA
ACAGGCTGTAACTTCGGTGACATT
AG Underlined nts indicate those 
inserted. Bold nts indicate those that 
encode the Flag tag.  
R_stalk_ckIt Primer used to 
clone the 
reverse DNA for 
inserting 66nt 
including Flag 
tag into SSckIt99 
NA 
ATGCTTTGGTTGCATGGTTCAGGC
TG (same sequence as R_stalk_ckIt 
above) 
F_FlagLS_ckIt_fix Primer used to 
fix LSckIt99 Flag 
containing stalk 
CAAGGTAAATCAGACGTATGTCAA
CATTAGC Underlined nts are those 
added during fix 
R_FlagLS_ckIt_fix Primer used to 
fix LSckIt99 Flag 
containing stalk 
TCATCGTCGTCCTTGTAATCGATG
C Underlined nts are those added 
during fix 
Fin_FLAG_ckIt Insert Flag tag GATTACAAGGACGACGATGACAA
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into stalk of 
SSckIt99 NA 
GATTACTGAACAGGCTGTAACTTC
GGTGACATTAG The bold sequence 
encodes the Flag tag. The underlined 
sequence are 2 extra nts, needed to 
keep the sequence in the correct 
frame 
R_FLAG_ckIt Reverse for 
insert Flag tag 
into stalk of 
SSckIt99 NA 
CTGGTACTGGTTCCCTGTCTGAAT
TGAATGG 
Fin_FLAG_E195/0
9 
Replace nts of 
E195/09 NA 
stalk with nts 
that encode a 
Flag tag  
GATTACAAGGACGACGATGACAA
GGTAAATCAGACATATGTTAACAT
CAGCAAC Bold text encodes the 
Flag tag. 
R_FLAG_E195/09 Replace nts of 
E195/09 NA 
stalk with nts 
that encode a 
Flag tag 
GACGCTTTGATTGCATGTTTCAAT
CTG 
Fp_ckIt_NA_S369
N 
Change amino 
acid 369 from an 
S to an N in 
order to test 
effect on the 
ability of ckIt NA 
to haemadsorb 
ACGGCTTTGAGATGATTTGGGATC
CG The underlined base replaced a 
G at position 1,040 with an A.  This 
changed the amino acid from an S to 
an N at position 369. 
Rp_ckIt_NA_S369
N 
see above CGGAAGAACAAAAAGCACTAGTTC
CAGAA 
Fp_E195/09NA_N
369S 
Change amino 
acid 369 from an 
N to an S in 
order to test 
effect on the 
ability of 
E195/09 NA to 
haemadsorb 
GGGAGAACTAAAAGCATTAGTTCA
AGAAGCGGTTTTGAGATGATTTGG
GATCCG The underlined base 
replaced an A at position 1,106 with a 
G. This changed the amino acid at 
position 369 from an N to an S. 
Rp_E195/09NA_N
369S 
see above CGGATCCCAAATCATCTCAAAACC
GCTTCTTGAACTAATGCTTTTAGTT
CTCCC 
Fp_E195/09NA_I3
65T 
Make E195/09 
NA 5mu: mutate 
E195/09 NA 
N369S to 
contain 
additional 
change: I365T 
GGGAGAACTAAAAGCACTAGTTCA
AGAAGCGG 
Rp_E195/09NA_I3
65T 
Same as above CCGCTTCTTGAACTAGTGCTTTTA
GTTCTCCC 
F_E195/09NA_3m Make E195/09 GCAAGATATCGTAGCAATAACTGA
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u_400-loop NA 5mu: mutate 
E195/09 NA 
N369S to 
contain 
additional 
changes: 
G395A, N397T, 
E398D 
TTGGTCAGGATATAGCGG 
R_E195/09NA_3m
u_400-loop 
Make E195/09 
NA 5mu: mutate 
E195/09 NA 
N369S to 
contain 
additional 
changes: I365T, 
G395A, N397T, 
E398D 
CCGCTATATCCTGACCAATCAGTT
ATTGCTACGATATCTTGC 
F_E195/09NA_38
5loop4 
Make E195/09 
NA 9mu: mutate 
G382E, N385S, 
N386S, I389V 
AGACAGACAGTAGCTTCTCAGTAA
AGCAAGATATCGTAG 
R_E195/09NA_38
5loop 
Make E195/09 
NA 9mu: mutate 
G382E, N385S, 
N386S, I389V 
CAGTCCATCCGTTCGGATCCCAAA
TC 
F_E195/09NA_38
8MY 
Make E195/09 
NA13mu: mutate 
V338M, N344Y 
GGCAGTTGTGGTCCAATGTCGTCT
AATGGAGCATATGGAGTAAAAGGG
TTTTCATTCAAATACGGC 
R_E195/09NA_32
1VG 
Make E195/09 
NA 13mu: 
mutate I321V, 
K331G, 
TGTCCCATCATTAGGGCGTGGATT
GTCTCCGAAAACTCCACTGCATAT
GTATCC 
F_ty05NA_ms_7a
a 
Make an 
intermediate 
stalk length for 
ty05 NA 
ATCAGCAATACTAAATTTCTTACTG
AGAAAGCTGTGGC 
R_ty05NA_ms_w7
aa 
Make an 
intermediate 
stalk length for 
ty05 NA 
GTTGACATATGTCTGATTTACTGG
TTCAGCTTGGCATTGATTCCCTGT
C (Underlined bases are those that 
were added) 
F_ty05NA_ls_13a
a 
Add the extra nts 
to make medium 
stalk length ty05 
NA into LS 
GTAAATCAGACATATGTCAACATC
AGCAATACTAAATTTC  
R_ty05NA_ls_w13
a 
Add the extra nts 
to make medium 
stalk length ty05 
NA into LS 
CCAGGTGTTGTTTTCATAAGTAATA
ATGCTTTGATTGCATGGTTCAGCT
TGGCATTGATTCCCTG(Underlined 
bases are those that were added) 
R_ty05NA_ls_wFL
G 
Add the extra nts 
to make medium 
CTTGTCATCGTCGTCCTTGTAATC
AATGCTTTGATTGCATGGTTCAGC
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stalk length ty05 
NA into LS NA 
with a Flag tag 
TTGGCATTGATTCCCTG(Underlined 
bases are those that were added) 
F_swE06_NA_wFl
ag 
Insert Flag tag 
into swEng06 
NA 
GATTACAAGGACGACGATGACAAG
GTAAATCAGACATATGTTAACATCA
ACAATAC (Underlined bases are the 
Flag tag) 
R_swE06_NA_Fla
g 
Insert Flag tag 
into swEng06 
NA 
TACGCTTTGACTGCATGTTTCAGA
TTG 
Fp_ckIt_NA_pCA
G 
Clone insert into 
pCAGGS 
TATATATAAAGCGGCCGCGCCACC
ATGAATCCAAATCAGAAGATAATA
ACCATTGG The underlined bases 
indicate the NotI restriction enzyme 
site.  Bold text is used to highlight the 
Kozak sequence. 
Rp_ckIt_NA_pCA
G 
Clone insert into 
pCAGGS 
The Rp_E195/09_NA-pCAGG primer 
was used for ckIt as it did not 
introduce any amino acid differences. 
Fp_E195/09_NA_
pCAG 
Clone insert into 
pCAGGS 
TATATATAAAGCGGCCGCGCCACC
ATGAATCCAAACCAAAAGATAATA
ACCATTGG The underlined bases 
indicate the NotI restriction enzyme 
site.  Bold text is used to highlight the 
Kozak sequence. 
Rp_E195/09_NA_
pCAG 
Clone insert into 
pCAGGS 
TTAATTAATTACGCGTTTACTTGTC
AATGGTAAATGGCAACTC The 
underlined indicates bases where the 
restriction enzyme MluI cuts. 
F_ty05NA_pCAG Clone insert into 
pCAGGS 
ATATATATATATGCGGCCGCGCCA
CCATGAATCCAAATCAGAAGATAA
TAACCATCGG 
R_ty05NA_pCAG Clone insert into 
pCAGGS 
AATTAATTAATTACGCGTCTACTTG
TCAATGGTGAATGGCAACTCAGC 
Fp_swE06_NA_p
CAG 
Clone insert into 
pCAGGS 
ATATATATATATGCGGCCGCGCCA
CCATGAATCCAAATCAGAAGATAA
TAACCATTGG 
Rp_swE06_NA_p
CAG 
Clone insert into 
pCAGGS 
AATTAATTAATTACGCGTTTATTTG
TCAATGGTAAATGGCAACTCAG 
M13F Sequencing 
primer  
GTAAAACGACGGCCAGT 
M13R Sequencing 
primer  
GGAAACAGCTATGACCATG 
F pCAGGS (4715)  Sequencing 
primer  
GCTAACCATGTTCATGCCTTC 
R pCAGGS (85)  Sequencing 
primer  
GGTATTTGTGAGCCAGGGCATTG 
F E195/09NA 
Seq260  
Sequencing 
primer  
GTCAGTGGTTTCCGTGAAATTAGC
GGG 
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F E195/09NA 
Seq1080 
Sequencing 
primer  
CGGCAATGGTGTTTGGATAGGG 
R E195/09NA 
Seq402 
Sequencing 
primer  
GTTTGTCATTTAGCAAGGCCCCTT
GAGTC 
R E195/09NA 
Seq1201 
Sequencing 
primer  
GGATGCTGAACAAAACTCCCGCTA
TATCC 
F ty05NA Seq263 Sequencing 
primer  
GCTGTGGCTTCAGTAACATTAGCG
GG 
F ty05 NA 
Seq1082 
Sequencing 
primer  
GGCAATGGTGTTTGGATCGG 
R ty05NA Seq405 Sequencing 
primer  
GCTTGTCATTCAGCAAGGCTCCCT
GAGTC 
R ty05NA 
Seq1204 
Sequencing 
primer  
GGATGCTGGACAAAACTCCCGCTA
TATCC 
F ckItNA Seq260 Sequencing 
primer 
GCTGTAACTTCGGTGACATTAGCG
GG 
R ckItNA Seq402 Sequencing 
primer 
GCTTGTCATTCAACAGAGCTCCCT
GAGTC 
F ckItNA Seq1082 Sequencing 
primer 
Use F ty05NA Seq1082 
R ckItNA Seq1204 Sequencing 
primer 
Use R ty05NA Seq1204 
F swE06NA 
Seq260 
Sequencing 
primer 
GACAGTAGTTTCAGTGAAATTGGC
GGG 
F swE06NA 
Seq1083 
Sequencing 
primer 
CGGTAATGGTGTTTGGATAGGGA
GG 
R swE06NA 
Seq406 
Sequencing 
primer 
GTTTGTCATTCAGCAGGGCCCCTT
G 
R swE06NA 
Seq1201 
Sequencing 
primer 
Use R E195/09NA Seq1201 
Table 7.4 Primers used for the research presented here. 
All ordered from Eurofins/MWG/Operon. Sequencing primers were ordered with 
basic salt purity, while mutagenesis primers were ordered with HPLC purification and 
when Albriton cloning method was used primers had 5’ phosphorylation. F = Forward 
primer; R = Reverse primer 
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7.1.5 Antibodies and Lectins 
Name Activity Supplier 
Murine anti-influenza 
nucleoprotein (NP) IgG  
Used to visualise 
plaques in blue-cell 
plaque assays 
Clone H7 MAB 2F6-C9, 
generously donated by 
HPA, Collindale (Dhan 
Samuel) 
or bought from AbD 
Serotec (MCA400) 
Goat anti-murine 
polyclonal IgG:BGAL 
Secondary antibody 
conjugated to β-
galactose, used to 
visualise blue-cells in 
plaque assay 
AbD Serotec (103006) 
Murine anti-FLAG 
monoclonal antibody  
Used to detected flag-
tagged NAs expressed 
by Vero cells after 
transfection 
Sigma-Aldrich (F3165) 
Goat anti-mouse 
polyclonal IgG antibody 
conjugated to FITC 
Secondary antibody, 
used to detect mouse 
primary antibody 
AbD Serotec 
(STAR117F) 
Anti-Flag murine mAb 
conjugated to FITC 
Used to consolidate 
primary and secondary 
antibody staining into a 
single step  
Sigma-Aldrich (F4049) 
DAPI (4’,6-Diamidino-2-
phenylindole 
dihydrochloride) 
Binds to DNA in nucleus 
of eukaryotic cells and 
also in chicken RBCs 
Sigma-Aldrich (D8417) 
Table 7.5 Antibodies used in the research presented here. 
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7.1.6 Reagents (incl Kits, Media, buffers, enzymes, substrates) 
Name Application Supplier 
QuikChange Lightning 
Site-Directed 
Mutagenesis Kit [old 
name: QuikChange® II 
XL Site-Directed 
Mutagenesis Kit] 
(contains a Pfu Fusion-
based DNA polymerase, 
that performs high 
fidelity DNA synthesis) 
Used to mutate genes of 
interests within Pol1 
plasmids 
Agilent Technologies 
(210518) 
SOC media Incubate bacterial cells 
post transformation 
Life Technologies 
(15544-034) 
PfuTurbo Hotstart 
polymerase  
PCR DNA to be inserted 
into pCAGG vectors 
Stratagene (600320) 
1x PfuTurbo Reaction 
Buffer 
PCR buffer Stratagene (600153-82) 
PfuTurbo Quick Solution PCR buffer Stratagene (200516-51) 
GoTaq Green Master 
Mix (2X) 
PCR polymerase in 
buffer with gel loading 
dye 
Promega (M7113) 
KOD DNA Polymerase  PCR polymerase 
enzyme used to make 
dsDNA from cDNA 
EMD Millipore (71086-3) 
Vent Polymerase PCR polymerase 
enzyme used to make 
dsDNA from cDNA 
NEB (M0254S) 
ThermoPol Rxn Buffer 
(10x) 
PCR buffer NEB (B9004S) 
 
Superscript III Reverse 
Transcriptase 
Reverse transcription Life Technologies 
(18080085) 
RNaseOUT Inhibits ribonucleases 
from degrading RNA 
Life Technologies 
(10777-019) 
dNTPs PCR  BioLine (BIO-39049) or 
Agilent Technologies 
(200415) 
NotI Restriction 
Endonuclease 
Used to digest gene 
segments post PCR pre 
insert into pCAGGS 
vector 
NEB (R0189S) 
Mlu1 Restriction 
Endonuclease 
Used to digest gene 
segments post PCR pre 
insert into pCAGGS 
vector 
NEB (R0198S) 
Restriction 
Endonuclease Buffer 3  
RE buffer NEB (B7003S) 
BSA For restriction enzyme 
reaction 
NEB (B900IS) 
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T4 Ligase Aneal blunt ends from 
Albriton cloning method 
Life Technologies 
(15224) or EMD 
Millipore (69839)  
Clonables™ 2X Ligation 
Premix 
Buffer including T4 
ligase 
EMD Millipore (70573) 
Dpn1 Digest parental non-
mutated supercoiled 
dsDNA during cloning 
New England BioLabs 
(R0176S) 
XL10-Gold® 
Ultracompetent Cells 
Transformed with 
plasmids for mini and 
maxi-preps 
Agilent Technologies 
(200315) 
Glycerol  Used for storage of 
antibody aliquots and 
transformed bacterial 
cells 
Fisher Scientific 
(G/06/17) 
DNA loading dye (6X) Weigh down DNA so 
that it runs through 
agarose gel and shows 
leading band indicating 
distance of travel 
Thermo Scientific 
(R0611)  
[or make in house with: 
Glycerol (Fisher 
Scientific, G/0650/17), 
EDTA (BDH, AnalR, 
100935V), SDS (Fisher 
Scientific, S/P530/53), 
Bromophenol Blue 
(BDH AnalR, 100935V)] 
Ultrapure agarose  Dissolved in TAE and 
microwaved to make 1% 
agarose gels used to 
separate DNA after 
PCR or RE digestion 
Life Technologies 
(16500500) 
[Or made in house (Tris 
(AnalR NORMAPUR, 
103156X), Acetic Acid 
(BDH AnalR, 10001BT), 
EDTA)] 
TAE Agarose gel running 
buffer 
Life Technologies 
(AM9870) 
Gel Red Visualise DNA in 
agarose gel 
Molecular Probes 
(41003) 
Reporter Lysis Buffer  Lyse RBCs before 
measuring absorbance 
Promega (E397A) 
Ampicilin (final 
concentration: 
100ug/ml) 
Select transformed 
bacteria 
Sigma-Aldrich (A-9518) 
Kanamycin (final 
concentration: 50ug/ml) 
Select transformed 
bacteria 
Life Technologies 
(11815024) 
LB Agar, powder Plate and pick 
transformed bacteria 
Life Technologies 
(22700-041) 
LB Broth (10g/L 
tryptone; 5 g/L yeast 
extract; 5 g/L NaCl) 
Used to culture 
transformed bacterial 
cells 
Sigma-Aldrich (L3022-
1KG) 
HiSpeed Plasmid Maxi 
Kit 
Purify plasmids from 
large cultures of 
Qiagen (12663) 
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transformed bacteria 
Plasmid Maxi Kit Purify plasmids from 
large cultures of 
transformed bacteria 
Qiagen (12163) 
QIAprep Spin Miniprep 
Kit 
Purify plasmids from 
small cultures of 
transformed bacteria 
Qiagen (27106) 
MinElute PCR 
Purification Kit 
Used to elute small PCR 
products in small 
volume (5ug DNA; 
70bp-4kb)  
Qiagen (28004) 
QIAquick PCR 
Purification Kit 
Used to purify PCR 
products from buffer 
(10ug DNA; 100bp-10kb 
long) 
Qiagen (28104) 
QIAquick Gel Extraction 
Kit  
Used to elute RE 
digested DNA after 
running on a gel 
Qiagen (28706) 
QIAamp Viral RNA Mini 
Kit 
Extract viral RNA for 
reverse transcription 
and sequencing 
Qiagen (52906) 
poly-L-lysine  Added to cell culture 
wells before 
haemadsorption assay, 
final concentration: 
0.01% w/v 
Sigma-Aldrich (P4707) 
Fugene 6 Transfect cells with 
plasmids 
Promega (E2691) 
Lipofectamine 2000 Transfect cells with 
plasmid 
Life Technologies 
(11668027) 
Opti-MEM Transfection media 
without phenol red 
Life Technologies 
(11058021) 
Round bottom 
polystyrene 5ml tube 
Non-stick tubes for 
transfection reagent  
Fisher (14-959-6) 
0.05% Trypsin-EDTA 
(1X), phenol red 
remove cells from tissue 
culture flasks 
Life Technologies 
(25300062) 
2.5% Trypsin (10X), no 
phenol red 
remove cells from tissue 
culture flasks 
Life Technologies 
(15090046) 
EDTA (UltraPure™ 
0.5M EDTA, pH 8.0) 
Used with trypsin to 
remove cells from tissue 
culture flasks 
LifeTechologies 
(15575020) 
PBS Wash cells before 
splitting or infecting 
them 
Life Technologies 
(10010-023) 
MucilAir™ Culture 
Medium 
Basal culture media for 
HNE cells 
Epithelix Sarl  
DMEM (Dulbecco’s 
Modified Eagle Medium)  
Cell culture (includes L-
Glutamine) 
Life Technologies 
(41966) 
FBS Cell culture: 10% final Biosera (S181C) 
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concentration for cell 
culture, other 
concentrations used as 
indicated 
penicillin/streptomycin Cell culture: 1% final 
concentration (100U/ml 
each), 
Life Technologies 
(15140-122) 
MEM Non-Essential 
Amino Acid solution 
(100x) 
Cell culture and plaque 
overlay 
Life Technologies 
(11140050) 
10x MEM Plaque overlay Life Technologies 
(21430020) 
L-Glutamine (200mM) Plaque overlay Life Technologies 
(25030024) 
Sodium Bicarbonate 
7.5% solution 
Plaque overlay Life Technologies 
(25080094) 
Bovine Albumin Fraction 
V (7.5% solution; BSA 
V) 
Plaque overlay Life Technologies 
(15260037) 
Dextran (DEAE) Plaque overlay Sigma-Aldrich (D9885) 
Trypsin  Activates HA of virus 
grown in culture by 
cleaving HA0 into HA1 
and HA2 
Lorne Laboratories  
(Worthington 
biochemical corp - 
TRTPCK-LS003740) 
Ham’s F12 Nutrient Mix Initial growth edia for 
FTE cells 
Life Technologies 
(21765-029) 
Antibiotic/Antimycotic 
(100X) 
Prevent bacterial and 
fungal growth in primary 
cells or mucus; contains 
10,000 units/mL of 
penicillin, 10,000 µg/mL 
of streptomycin, and 25 
µg/mL of Fungizone®  
Life Technologies 
(15240-062) 
Pronase Degrades proteins Roche (10165921001) 
DNase I An endonuclease that 
nonspecifically cleaves 
single and double-
stranded DNA 
NEB (M0303S) 
CnT-17 Isolation and 
proliferation media for 
airway epithelial cells 
Cell-N-Tech (CnT-17) 
Transwells Polyester membrane 
cell culture inserts made 
by Corning, tissue 
culture treated, 0.4 µm 
pore size; for FTE cells 
Sigma-Aldrich 
(CLS3470-48EA) 
MycoAlert Detection Kit Test cells for 
mycoplasma 
contamination 
Lonza (LT07) 
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Oxoid Used at 2% for overlay 
during incubation of 
plaque assay 
Thermo-Scientific 
(LP0028) 
Avicel  For plaque assays 
instead of oxoid 
FMC Corporation 
Crystal Violet  Stains cells, leaving 
plaques where there 
was CPE 
Sigma-Aldrich (HT901-
8F0Z) 
CN buffer (10X) (30mM 
K Ferricyanide; 30mM K 
Ferrocyanide; 10mM 
MgCl2; PBS) 
Blue cell plaque assay 
development buffer 
Sigma-Aldrich (P4066;  
CDS001589; M8266) 
X-gal substrate Blue cell plaque assay 
substrate 
Fisher (BPE1615-1) 
Dimethylformamide 
(DMF) 
Blue cell plaque assay 
substrate solvent 
Sigma-Aldrich (319937) 
Methanol Cell fixation VWR (20847.360) 
Acetone Cell fixation VWR (20065.362) 
4% paraformaldehyde Fix cells before 
microscopy 
Electron Microscopy 
Sciences (15710-S) 
Hepes (1M) Paraformaldehyde 
buffer and plaque 
overlay 
Life Technologies 
(15630080) 
Saponin  Permeabilise cells 
before and while 
staining with some 
antibodies 
Calbiochem (558255) 
BSA  Used for cell 
permeabilisation and 
antibody staining buffers 
Sigma-Aldrich (A2153) 
Chicken RBCs (CRBCs) Used for HA, RBCE and 
haemadsorbtion assays 
Sera Laboratories (B-
606-D) or VLA Scientific 
(RBD0757) 
Turkey RBCs Used for HA, RBCE and 
haemadsorbtion assay 
Sera Laboratories (BAS-
130-S) 
Guineapig RBCs Used for HA, RBCE and 
haemadsorbtion assay 
Donated by Imperial 
CBS  
Human RBCs Used for HA, RBCE and 
haemadsorbtion assay 
Donated by volunteers 
Neuraminidase from 
Clostridium perfringens  
Exogeneous bacterial 
NA 
Sigma-Aldrich (N2876) 
Neuraminidase from 
Vibrio cholerae 
Exogeneous bacterial 
NA 
Sigma-Aldrich (N6514) 
   
Table 7.6 Reagents used in the research presented here. 
MDCK cells and 293T cells were grown in DMEM with 1% pen/strep (100U/ml each), 
10% FBS, and 100mM Non-essential amino acids (NEAA). All cells were incubated 
in 5% CO2 at 37°C.   
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7.1.7 Cells 
Name  Description Supplier 
293T Human embryonic kidney cells that 
were transformed by adenovirus and 
contain the Simianvirus 40 large T-
antigen that allows for replication of 
transfected plasmids containing the 
SV40 origin of replication 
ATCC 
MDCKs Madin Darby Canine Kidney cells, 
from kidney of normal female adult 
Cocker Spaniel in 1958 by SH Madin 
and NB Darby 
ATCC via 
GlaxoSmithKline or 
collaborators in 
Scotland 
VEROs African green monkey kidney 
epithelial cells 
ATCC 
HAE Primary human airway epithelial cells, 
multi-layered and polarised so that 
they have a basal layer exposed to 
media and an apical layer exposed to 
air where some cells are ciliated and 
mucus is secreted 
Ray Pickles Lab, 
University of North 
Carolina 
HNE Primary human airway epithelial cells 
of nasal origin, multi-layered and 
polarised so that they have a basal 
layer exposed to media and an apical 
layer exposed to air where some cells 
are ciliated and mucus is secreted 
Epithelix Sarl, 
Switzerland 
Table 7.7 Cells used for the research presented here. 
 
 
7.1.8 Animals 
Species Sex Age Weight 
Ferret female 20-24 weeks old 650-110g 
Table 7.8 Animals used for the research presented here. 
 
 
 
 290 
7.2 Methods 
7.2.1 Molecular biology 
7.2.1.1 Standard Polymerase Chain Reaction (PCR)  
PCR was performed using Vent polymerase (1-2 units; NEB) in 
ThermoPol Rxn Buffer (1x; NEB) with dNTPs (200nM of each NTP; Bioline), 
1uM of each primer, no MgSO4 and 1 ng of template (Pol1 plasmid with gene 
of interest) in 100ul total volume per reaction. All PCR cycling was performed 
on a Mastercycler (personal or gradient; Eppendorf). The cycling parameters 
shown in Table 7.9 were used.   
 
# of cycles Temp (°C) Time Action 
1x 95 2’ Polymerase activation 
30x 
95 30” Denaturation 
60 30” Anneal Primers 
72 1’45” Extension 
1x 72 5’ Final Elongation 
Hold 4 Up to 60 hrs Cool 
Table 7.9. Standard PCR cycling parameters. 
7.2.1.2 Standard and Albriton method of site directed mutagenesis 
PCR 
Standard site directed mutagenesis with the QuikChange® II XL Site-
Directed Mutagenesis Kit (Agilent Technologies) was performed to alter a 
small number of nucleotides (<4) when they were located close together in 
plasmids. However, when larger alterations were required, such as for the 
elongation of stalks or addition of a Flag Tags, Albriton’s cloning method was 
used. Albriton’s cloning method utilizes the buffers and methods 
encompassed in the QuikChange® II XL Site-Directed Mutagenesis Kit with 5’ 
phosphorylated primers and an additional ligation step, using T4 ligase, 
before digestion.  
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To summarise, PCR was performed in a total volume of 25 ul per 
reaction with the desired forward and reverse primers (10pmol/ul of each) plus 
template plasmid (10 ng/ul) mixed with QuickChange Lightning reaction buffer 
(1x), dNTPs (10 mM/ul; BioLine or Agilent Technologies), QuikSolution 
reagent (0.5ul/reaction) and QuickChange DNA polymerase (0.5ul/reaction). 
Cycling parameters shown in Table 7.10 were followed. 
 
# of cycles Temp (°C) Time Action 
1x 95 2’ Polymerase activation 
18x 
95 20” Denaturation 
60 10” Anneal Primers 
68 2.5 min (30 sec/kb) Extension 
1x 68 5’ Final Elongation 
Hold 4 Up to 60 hrs Cool 
Table 7.10. PCR cycling parameters for site directed mutagenesis. 
7.2.1.3 Ligation of ends of DNA  
Ligation was performed by adding 10ul of T4 ligase in pre-made buffer 
(EMD Millipore) to equal volume of PCR product and incubating for 20 
minutes at room temperature or 4°C overnight. 
Alternatively, 10 ul of PCR product was mixed with 5ul of 5x ligase 
buffer, 1.25 ul T4 DNA ligase (4 U/ul; Life Technologies), and water in a total 
volume of 25 ul. This mixture was incubated 30 minutes at room temperature. 
7.2.1.4 Digestion of parental DNA plasmids 
To digest parental plasmid DNA 0.5ul Dpn1 (10U/ul, New England 
BioLabs (NEB)) was added to 10 ul ligation mixture and incubated at 37°C for 
10 minutes. 
7.2.1.5 DNA purification post PCR 
PCR products with restriction endonuclease sites cloned into them, 
which were about 1,500 base pairs (bp) long, were purified with a MinElute 
PCR Purification Kit (Qiagen). 
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7.2.1.6 Restriction Enzyme digestion 
Both PCR fragments and the empty pCAGGS vector were digested 
with Not1 (10 U/ul; NEB) and Mlu1 (10 U/ul; NEB) in the presence of Buffer 3 
(NEB) and 0.1mg/ml BSA (NEB). 10ug of DNA was digested by 10 units of 
each restriction enzyme in a final volume was 50ul for three hours at 37°C. 
7.2.1.7 DNA agarose gel electrophoresis 
DNA gels were made of 1% Ultrapure Agarose (Life Technologies) 
dissolved in TAE buffer (Life Technologies). The gel solution was heated 
shortly in a microwave and poured onto Gel Red (1ul/ml; Molecular Probes) 
then left for 30 minutes to an hour to solidify. If gels were stored for longer 
they were placed in TAE buffer (1-2 hrs) or wrapped in cling film and stored at 
4C (up to 18 hrs) to avoid drying. 1ul of 6X DNA loading dye (Thermo 
Scientific) for every 5ul of a PCR reaction was mixed together then pipetted 
into a well on a gel. Gels were run with 80-100 voltz of electricity in an 
Advance Mupid-One gel tank for 30 minutes to an hour, depending on size. 
Small volumes (5 ul) of PCR reactions were run on gels to determine whether 
or not a gene of the appropriate size had been cloned. Large volumes (30 ul) 
of restriction enzyme digested DNA were run on gels before gel purification 
and ligation. 
7.2.1.8 Gel-extraction and purification of DNA 
After restriction enzyme digestion, bands of the appropriate size were 
excised from DNA gels and purified using a QIAquick Gel Extraction Kit 
(Qiagen). 
7.2.1.9 Bacterial cell transformation and growth of colonies 
Newly generated plasmids were transformed into XL10-Gold® 
Ultracompetent Cells (Agilent Technologies). In brief, 3ul of Dpn1 treated PCR 
product was added to 50ul of bacterial cells, they were allowed to rest on ice 
for 30 minutes with occasional agitation, then heat pulsed for 30 seconds in a 
water bath at 42°C. Bacterial cells were incubated on ice for 2 minutes, then 
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added to 0.5 ml SOC media (Life Technologies) and incubated for 1 hour at 
37°C with shaking at 225-250rpm. The media was split in half and spread 
onto agar plates (Life Technologies) with ampicillin (100ug/ml; Sigma-Aldrich) 
or kanamycin (50ug/ml; Life Technologies) and colonies were grown during 
incubation at 37°C overnight. Colonies were picked and placed into LB broth 
(Sigma-Aldrich) with ampicillin or kanamycin and allowed to expand during 
further incubation at 37°C with shaking for 10-16 hours. 
7.2.1.10 Plasmid purification post bacterial expansion 
Plasmids were isolated from small volumes (5 ml) of bacteria culture 
using a QIAprep Spin Miniprep Kit. Plasmids grown in large volumes were 
isolated with Plasmid Maxi Kit or HiSpeed Plasmid Maxi Kit. All kits from 
Qiagen. 
7.2.1.11 Screen plasmids post bacterial transformation 
Plasmids from pCAGG cloning were screened for inserts of the 
appropriate length (~2 kb) by dabbing the tip used to collect a colony from an 
LB plate into a PCR tube before placing the tip into LB broth. PCR was 
performed in a total volume of 15 ul with M13F and M13R or F_ and 
R_pCAGGS sequencing primers (0.1uM each) and 7.5 ul GoTaq Master Mix 
(Promega). PCR cycling parameters shown in Table 7.11 were used. 
 
# of cycles Temp (°C) Time Action 
1x 95 2’ Polymerase activation 
30x 
95 30” Denaturation 
60 30” Anneal Primers 
72 1’45” Extension 
1x 72 5’ Final Elongation 
Hold 4 Up to 60 hrs Cool 
Table 7.11. GoTaq PCR cycling parameters. 
 
Plasmids from site directed mutagenesis were screened by sequencing 
using either Flu_specific_NA_F, Flu_specific_NA_R (Hoffmann et al., 2001) or 
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a sequencing primer that read through the section where the mutation of 
interest was located. Sequencing primers were designed for this project with 
the aim of spanning the length of the NA gene of interest in 500 nt sections 
and listed at the end of Table 7.4. Sequencing results were analysed using 
Geneious (v4-6).  
7.2.1.12 Extraction of viral RNA 
Viral RNA was extracted from virus containing supernatant using an 
RNA extraction kit (Qiagen). First AVL buffer with carrier RNA were mixed and 
incubated with virus containing supernatant for 10 minutes at room 
temperature. Then RNA was precipitated on a column, washed and eluted in 
water.  
7.2.1.13 Synthesis of cDNA 
To make cDNA from vRNA 10ul of extracted vRNA was mixed with 
3.2uM Flu_specific_NA_F, 10mM dNTPs (BioLine) and double deionized 
water for a total volume of 13ul and heated for 5 minutes at 65°C. This 
mixture was cooled for a minute on ice. A 7ul mixture of 5x first strand buffer, 
DTT (0.1M), RNaseOut (40U; Life Technologies) and Superscript III RT (Life 
Technologies) were added to the vRNA and primer mix and incubated for 60 
minutes at 55°C. The reaction was inactivated by heating the mixture to 70°C 
for 15 minutes. 
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7.2.1.14 PCR of full length double stranded DNA from cDNA  
KOD DNA polymerase (EMD Millipore) was used to synthesise double 
stranded DNA from cDNA. 20ul of cDNA synthesis reaction was mixed in 10X 
buffer with KOD (2.5 units/rxn), dNTPs (150uM each; EMD Millipore), 
Flu_specific_NA_F and Flu_specific_NA_R primers (1uM each) and water for 
a total volume of 50 ul. Cycling conditions were as shown in Table 7.12. 
 
# of cycles Temp (°C) Time Action 
1x 95 5’ Polymerase activation 
30x 
95 30” Denaturation 
52 45” Anneal Primers 
68 3’ Extension 
1x 68 10’ Final Elongation 
Hold 4 up to 60 hours Cool 
Table 7.12. KOD PCR cycling parameters. 
7.2.1.15 Primer Design  
Primer design was performed in silico. When primers were between 25 
and 45 nts they were ordered with purification by de-salting. Primers that were 
longer were ordered with purification by liquid chromatography (HPLC/FPLC). 
Primers were ordered from MWG Operon. Primer sequences with possible 
secondary structure were avoided where possible. A melting temperature of 
78°C was targeted in the design of primers. The melting temperature of the 
primers was calculated in multiple ways. The equation from the Agilent 
Technologies kit is as follows: Tm =  81.5 + 0.41*(%GC) - (675/N) - % 
mismatch; Tm is melting temperature; N is number of primers in length of the 
primer; % mismatch is the per cent of nts that are not the same as the 
sequence to which a primer is designed to anneal, this was not included for 
insertions or deletions. Geneious was also used to determine primer melting 
temperatures, as was the Eurofins online calculator. 
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7.2.1.16 Sequences 
Gene sequences of interest were obtained either from the same source 
as a plasmid as listed in Table 7.1 and Table 7.2 or from the public database 
Genbank (Benson et al., 2013) via the Influenza Virus Resource database 
(Bao et al., 2008) or the Influenza Research Database (Squires et al., 2012). 
All in silico sequences were verified by sequencing. Sequencing was 
performed on a Applied Biosystems 3730xl DNA Analyzer by the MRC CSC 
Genomics Core Laboratory of Imperial College London upon provision of 
plasmid mixed with primer: 3.2 pmol of sequencing primer were mixed with 
400 to 600 ng of plasmid in a total reaction volume of 10 µL. Sequences of 
genes of interest, vectors, and primers were imported or designed and aligned 
or assembled in silico using Geneious software (Biomatters Ltd., v4-6).  
The influenza virus A/England/195/09 (E195/09) is typical of H1N1 
2009 pandemic strains (Ellis et al., 2009).  The virus was isolated from the 
nose swab of a sick individual who returned to England from Mexico in April 
2009. E195/09 was sequenced by the HPA, Genbank (GQ166654-
GQ166661). Gene sequences were designed in silico using Geneious v5.5 
according to methods published previously (Fodor et al., 1999), so that each 
segment of influenza viral genome was flanked by a human RNA polymerase 
promoter I and a ribozyme. Sequences were synthesized by 
(LifeTechnologies), and inserted into the plasmid pMA or pMK.  
Influenza A/turkey/Turkey/1/2005 virus (tyTy05), a clade 2.2.1 HPAI 
H5N1 virus, is representative of the clade of viruses that caused a panzootic 
H5N1 outbreak in Europe in 2005. The rescue plasmid for ty05 NA (Genbank 
EF619973) was a kind gift from Professor Ron Fouchier (Erasmus University). 
Influenza A/chicken/Italy/13474/1999 virus (ckIt99) was isolated during 
a HPAI H7N1 outbreak in poultry in Italy. Thousands of birds were killed either 
from infection or culling. A few veterinarians seroconverted, but no humans 
became sick. The rescue plasmids were made by Alison Whiteley (Whiteley et 
al., 2007). 
This thesis focuses on the manipulation of two regions of the influenza 
virus NA gene: the stalk and the haemadsorbtion domains. The NA stalk 
domain was considered to begin at aa 39, which is the first variable aa after 
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the transmembrane domain ends, and end at aa 91 (N1 numbering), just 
before a conserved cysteine that forms a di-sulfide bond with another cysteine 
in the head domain to make a large loop (Basler et al., 1999). Therefore, the 
most frequent stalk length of a human influenza virus NA is 53 aas. The stalk 
length of NA of the H5N1 influenza virus A/turkey/Turkey/1/2005, which has a 
20 aa deletion is 33 aas, while the stalk length of the NA of the H7N1 
influenza virus A/chicken/Italy/13474/1999, which has a 22 aa deletion is 31 
aas long. Amino acids previously shown to be involved in hemadsorption 
include residues 364-369, 395-399, and 432 (N1 numbering) (Figure 1.9).  
7.2.1.17 Design of mutants and primers 
7.2.1.17.1 Primers and plasmids for stalk alterations of ckIt99 NA  
The stalk of NA is very tolerant of changes introduced into it (Castrucci 
and Kawaoka, 1993; Dolan et al., 2010; Luo et al., 1993). The H7N1 influenza 
A/chicken/Italy/13474/1999 virus is a representative of the HPAI viruses that 
caused a widespread enzootic among poultry, but no disease in humans in 
Italy in 1999. The NA from A/ck/Italy/13474/1999 (SSckIt99 NA) cloned into 
the rescue plasmid pUC19 (aka pPRG, aka Pol1) (Jackson et al., 2002) was 
inherited from Allison Whiteley (Whiteley et al., 2007). The pUC19 vector has 
the human polymerase I promoter at the 5’ terminus and the hepatitis delta 
virus antigenomic ribozyme at the 3’ terminus of the gene of interest as well 
as ampicillin resistance and a lac promoter. It is most similar to the shuttle 
vector pBHad-CMV, but pUC19 has a three-nucleotide deletion (GGA) from 
1,993 to 1,995. The sequence of ckIt99 NA is very similar to other NAs 
isolated during the Italian H7N1 outbreak in 1999. One of the viruses, 
A/chicken/Italy/1082/1999, had an NA with a long stalk and its sequence was 
used as a template to insert 66 nts into the stalk region of the NA gene of 
ckIt99. The new NA, with a long stalk, was named LSckIt99 NA (Fig 2.1).  
To make pPol1-LSckIt99-NA from pPol1-SSckIt99-NA plasmid, the 
Albriton cloning method (see below) was undertaken using the forward primer 
Fin_stalk_ckIt and the reverse primer R_stalk_ckIt. However, none of the 
selected clones had all 66 nts inserted, instead, they had partial insertions. 
Clone 8 had the most nts inserted, but had two short areas of missing 
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nucleotides. Therefore, a second forward primer, F_fix_stalk_ckIt, was 
designed and used in conjunction with the reverse primer R_stalk_ckIt and 
clone 8 to make pPol1-LSckIt99-NA.  
The Albriton cloning method was also used to make pPol1-LSckIt99-
NA-Flg, which encodes an NA with a long stalk that has a Flag tag from nt 2-
24 with the rest of the 66 additional nts from A/chicken/Italy/1082/1999 NA. 
The primers used for this mutagenesis were Fin_FLst_ckIt and R_stalk_ckIt. 
These primers were designed so that the Flag tag would be in the same 
position as the Flag tag added to NA of H11N9 A/ tern/Austrailia /G70c/75 by 
Goto et al. (Goto et al., 1997). However, as before none of the clones had all 
of the desired nts inserted. Again the closest clone was selected and 
corrected using F_FlagLS_ckIt_fix and R_FlagLS_ckIt_fix primers. Addition of 
a Flag tag into the plasmid pPol1-SSckIt99-NA to make the plasmid pPol1-
ckIt99-NA-Flg only required one set of primers (Fin_FLAG_ckIt and 
R_FLAG_ckIt) as a clone with the desired nt changes was selected in the first 
round of cloning. Both primers were phosphorylated on the 5’ end. The Flag 
tag was inserted in place of bases 136-162. The reverse primer R_FLAG_ckIt 
bound to nucleotides 108-138. I aimed to maintain the short stalk length of 
SSckIt99 NA by replacing an equal number of nts in the stalk with nts that 
encode a Flag tag. Primers were designed to insert the sequence that 
encodes the Flag tag into the same location as where Zurcher et al. inserted a 
Flag tag into the NA of human seasonal N2 NAs. Their Flag tag sequence 
was inserted between aas 45 and 54 (Zürcher et al., 2006). In error, I 
designed primers that inserted the Flag tag between aas 45 and 53 of 
SSckIt99 NA Flg, therefore an extra residue in length was added to the stalk 
length of the protein. As a point of interest in relation to spatial distribution, the 
Flag tag in the N2 NAs of Zurcher et al. and in SSckIt99 NA both began 8 
residues from the beginning of the NA stalk, whereas the Flag tag in LSckIt99 
NA began 16 aas from the beginning of the NA stalk, when the stalk is 
considered to start with the 39th aa. Also, as a point of interest, the Flag tag 
added by Zurcher et al. was placed directly after a proline residue, where as 
the ckIt99 NA sequence encoded glutamine residue in position 45 and two 
prolines of the SSckIt99 NA sequence were replaced by the Flag tag 
sequence.  
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7.2.1.17.2 Primers and plasmids for stalk alterations of tyTy05 NA 
Influenza A/turkey/Turkey/1/2005 virus (ty05), a clade 2.2.1 HPAI 
H5N1 virus, is representative of the clade of viruses that caused a panzootic 
H5N1 outbreak and induced human death in Europe in 2005. The plasmid 
pPol1-SStyTy05-NA was a kind gift from Ron Fouchier (Erasmus University). 
The plasmid encoded the SStyTy05 NA gene, which had naturally become 
truncated by 20aas (Genbank EF619973). In order to design a plasmid with 
an elongated stalk, a “Standard” protein “Sequence Search” of ty05 NA was 
performed in Geneious. Of the 100 sequences returned, 34 had full-length 
stalks. To find the genetic sequence with closest nt identity to ty05 NA, the nt 
sequences of the seven top amino acid sequence matches with a full-length 
stalk were aligned with the nt sequence of SStyTy05 NA. The sequence for 
A/chicken/Jilin/hl/2004 (ck/Jilin/04) (Genbank DQ997333) proved to be most 
similar with 97% identity through the coding region (excluding the area where 
the stalk was deleted from SStyTy05 NA).  
To avoid the difficulties experienced during inserting 66 nts into the 
stalk of pPol1-SSckIt99-NA, primers were designed to create plasmid pPol1-
MStyTy05-NA with a medium-length stalk as an intermediate from which a 
plasmid that encoded the long stalk protein LStyTy05 NA (pPol1-LStyTy05-
NA) and a plasmid that encoded the long stalk protein with a Flag tag in the 
stalk (pPol1-LStyTy05-NA-Flg) were cloned. The primers used to make pPol1-
MStyTy05-NA were F_ty05NA_ms_7aa and R_ty05NA_ms_w7aa. The 
plasmid pPol1-MStyTy05-NA encoded an NA with a stalk length of 40 aas. 
The primers F_ty05NA_ls_13aa and R_ty05NA_ls_w13aa were used to clone 
pPol1-LStyTy05-NA. The same forward primer was, in conjunction with the 
primer R_ty05NA_ls_wFLG, used to clone pPol1-LSTyty05-NA-Flg. The flag 
tag is located in the same place as the tag inserted by Goto et al. (1997).  
7.2.1.17.3 Primers and plasmids for Hd mutants and stalk alterations 
of other NAs  
Flag tags were also inserted into the stalk regions of other NAs. The 
primers used to make pPol1-E195/09-NA-Flg and pPol1-swE06-NA-Flg are 
included in Table 7.4. Lukus Roberts designed the primers and cloned pPol1-
dkBav77-NA-Flg.  
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Point mutations were made in the haemadsorption domains of ckIt ss 
NA and E195/09 NA. The Albriton method was used to replace an A with a G 
at base 1,040 of ckIt ss NA. The more traditional site directed mutagenesis 
method was used to replace the G with an A at nucleotide 1,106 of E195/09 
NA. See Table 7.4 for specific sequences used to make these changes. 
Further haemadsorption related mutations were generated with either the 
Albriton cloning method, used whenever an added nt was located at the 5’ 
end of a primer, or standard site directed mutagenesis. The nucleotide 
mutations were introduced using the primers in Table 7.4 to achieve the 
amino acid mutations shown in Figure 7.1. 
 
 
Figure 7.1. Amino acid alignment of E195/09 mutants designed to restore 
haemadsorption.  Residues boxed in magenta show amino acids present in the 
mutants as labelled: N369S, 5mu, 9mu and 13mu. 
7.2.1.17.4 Primers to transfer gene of interest to expression vector  
Since genes for influenza viruses were inherited in Pol1 plasmids and 
the ultimate aim of this project was to test the effect of any functionally altered 
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mutants on virus replication and transmission, all mutants were initially 
introduced into the gene in their original Pol1 plasmid. However, in order to 
measure haemadsorption by NA, it needed to be expressed on its own, in the 
absence of HA. Therefore, NAs were cloned into the expression vector 
pCAGGS7.  
Genes of interest were inserted into the pCAGGS vector using the 
methods that follow. PCR was performed using “_pCAG” primers (Table 7.4) 
to create gene segments, which included the open reading frames (ORF) of 
targeted wild type or mutated NA genes with a NotI restriction enzyme 
cleavage site followed by a Kozak sequence on the 3’ end and the restriction 
enzyme site Mlu1 on the 5’ end. Each “_pCAG” primer included 10-12 extra 
nucleotides, rich in A and T so that they had low melting temperatures, but 
with mixed sequences to minimised primer dimerization to allow the 
endonuclease to bind to the PCR fragment and cleave it.  
7.2.2 Cellular and in vivo virology 
7.2.2.1 Cells  
All cell lines were maintained in DMEM (LifeTechnologies) 
supplemented with 10% fetal bovine serum (FBS; Biosera), 1% 
penicillin/streptomycin (pen/strep; Sigma-Aldrich) and 1% non-essential aas 
(NEAAs; Sigma-Aldrich). Madin-Darby Canine Kidney (MDCK) cells (ATCC®) 
were used for growth curves and to grow virus after initial transfection of 293T 
cells. African green monkey kidney epithelial (Vero) cells (ATCC®) were used 
for haemadsorption experiments. Vero cells were chosen due to high 
transfection frequency, flat morphology, and low autofluorescence. The 
                                            
7 Incidentally, the CAG promoter, which drives the high level of expression 
achieved for genes expressed by the pCAGGS vector, has an area with high 
GC content and therefore is refractory to PCR amplification. Therefore, if I had 
wanted to make mutations to genes in this vector, I would have used 
overlapping PCR to create a mutated gene segment and re-inserted the 
mutated gene by restriction enzyme digestion and ligation. 
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laboratory of Raymond Pickles at the University of North Carolina, Chapel Hill, 
provided HAEs. HNEs were obtained from Epithelix Sarl and cultured 
following the manufacturer’s protocol.  
Ferret tracheal epithelial cells (FTEs) were prepared, expanded and 
maintained by Peter Stilwell before they were infected with SS and LStyTy05 
NA +7E195/09 viruses for this thesis. Ferret trachea was surgically removed 
after euthanasia, cut into 4 sections, then incubated overnight (18 hrs) on a 
rocker at 4C in 10 ml Ham’s F12 Nutrient Mix (Life Technologies) with 
antimycotic/antibiotic (Life Technologies) and Pronase (1.2mg/ml; Roche). 
Pronase was inactivated by addition of 1.1 ml FBS (10%; Biosera). 
Supernatant with cells was decanted to a new tube, leaving cartilage behind. 
The cartilidge was washed in 10ml Ham’s F12 twice and supernatant pooled. 
Cells were centrifuged at 600g for 10 minutes, supernatant decanted and cells 
resuspended in 2ml F12 and 200ul DNAse1 (0.5mg/ml; NEB). Cells were 
incubated on ice, then centrifuged at 600g, both for 5 minutes. Cells were re-
suspended in CNT-17+ media (Cell-N-Tech) plus antimitotic/antibiotic (1X) 
and FBS (10%; not heat in-activated) then plated in fibroblast selective plates 
and incubated for 4 hours at 37°C. Non-adherent cells were collected from 
supernatant and 1 wash of the dish with CNT-17+ media. Cells were 
centrifuged at 600g for 5 minutes, re-suspended in CNT-17+ and counted. 
Cells were plated at 100,000 cells per Transwell (Sigma-Aldrich) in 500 ul in a 
48-well plate with 1ml of CNT-17+ media in the basal layer and incubated at 
37°C. Media was changed every 2-3 days. When transepithelial resistance 
was greater than 1,000 Ohms!cm2 the apical media was removed. Basal 
media was retained and changed regularly until infection.  
All cells were incubated in 5% CO2 at either 37°C or 32°C. Cell 
supernatant was tested regularly for mycoplasma with MycoAlert Detection Kit 
(Lonza). Cell lines were harvested by the following steps: cells were washed 
twice with PBS; suspended in 1 ml of 0.05% Trypsin-EDTA (Life technologies) 
per 10cm2 surface area after incubation for 10-45 minutes at 37°C; 
centrifuged 1500 rpm for 5 minutes and re-suspended in DMEM with 10% 
FBS and 1% pen/strep.  
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7.2.2.2 Transfection of cells 
7.2.2.2.1 Transfection of Vero cells with expression plasmids 
 Vero cells were transfected with pCAGGS plasmids containing NAs to 
be tested for their ability to haemadsorb red blood cells (RBCs). To increase 
cellular adhesion the surface of 12-well tissue culture plates (Falcon) were 
coated with poly-L-lysine (0.01% w/v in ddH2O; Sigma-Aldrich) by adding 500 
ul of solution to each well and incubating for 5 minutes at room temperature. 
Plates were washed 3 times with PBS before addition of cells in suspension 
with transfection reagent and expression vector. Transfection reagent 
Lipofectamine 2000 (Life Technologies) was diluted 1:10 in Opti-MEM media 
(Life Technologies) in polystyrene tubes (Fisher) and incubated at room 
temperature for 5-25 minutes. 1.6ug of pCAGGs DNA that expressed the NA 
of choice was used per well and diluted 1:10 in Opti-MEM in ependorf tubes. 
The DNA (in Opti-MEM) was added to the Lipofectamine (in Opti-MEM) at a 
ratio of 2 ul of Lipofectamine per 1 ug of DNA. The transfection mixture was 
agitated gently and incubated for 20 minutes at room temperature then added 
with Vero cells suspended in media (DMEM with 10% FBS, without antibotics) 
to wells of a 12-well tissue culture plate and incubated at 37°C. Media was 
changed to fresh DMEM with 10% FBS 4-6 hours later and incubated 1-2 
days at 37°C. 
7.2.2.2.2 Transfection of 293T cells for generation of recombinant 
viruses 
Recombinant viruses were generated using the 12-plasmid reverse 
genetics technique described previously (Elleman and Barclay, 2004; Fodor et 
al., 1999). 293T cells were plated into wells of a 12-well Falcon tissue culture 
plate (Fisher) the day before so that they were 80% confluent upon 
transfection. On the day, 2 hours before transfection, the media on 293T cells 
was changed to 0.5 ml DMEM with 3% FBS. 3 pCI-Vic- Helper plasmids (PB2, 
PB1, NP) and 8 pPol1 Rescue plasmids for the virus segments desired were 
each diluted to 500ng/ul in ddH20. The PA helper plasmid pCI-Vic-PA was 
diluted to 50ng/ul. 1 ul of each plasmid was added to an Epindorf tube for a 
total of 12 plasmids per tube in 50 ul Opti-MEM. 20 ul of Fugene 6 
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transfection reagent (Promega) was added to 200 ul Opti-MEM in a 
polystyrene tube and incubated for 5 minutes at room temperature. DNA was 
added to Fugene 6 Opti-MEM mixture and incubated for 15 minutes at room 
temperature. The DNA in Fugene 6 mixture was added drop-wise to 293T 
cells and incubated overnight at 37°C.  
7.2.2.3 Virology 
7.2.2.3.1 Co-culture for virus propagation 
Recombinant viruses were generated by transfecting 293T cells as 
described above with 12-plasmids. The next day, MDCK cells were harvested 
and diluted 1:6 in serum-free DMEM with 1% pen/strep. Transfected 293T 
cells were washed once with PBS and once with serum-free DMEM then 
suspended by repeat pipetting in 1ml serum-free DMEM with 1% pen/strep 
that contained MDCK cells and transferred to a 25cm2 tissue culture flask with 
4 mls of MDCK cells. Co-cultures were incubated for 3-5 days, when 70% 
CPE was achieved.  
7.2.2.3.2 Expansion of viral stock  
When virus harvested from co-culture had a positive HA titre 5-20ul of 
virus in 5ml serum free DMEM with 1% pen/strep were used to infect large 
flasks (175mm2 surface area; Life Technologies). Cells were exposed to 
diluted virus harvested from co-culture for 1 hour at 37°C, then the media was 
removed and 24ml of serum free DMEM with 1% pen/strep and about 1ug/ml 
TPCK treated trypsin (Lorne Labs). Each trypsin batch was titrated as activity 
per weight varied from batch to batch.  
7.2.2.3.3 HA Assay 
50ul of PBS was distributed to each well of a 96- well, V-bottomed, 
microtitre plate (Greiner). Twofold serial dilutions of virus were distributed 
down the plate in 50 ul volumes. 50 ul of chicken (VLA scientific), human 
(donated by volunteers) or turkey (Sera Labs) RBCs at 0.5% concentration 
diluted in PBS were added to each well and the plate was incubated for 1 
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hour at 4°C to allow agglutination of RBCs without NA activity. HA titre was 
determined as the lowest viral dilution where RBCs agglutinated. 
7.2.2.3.4 Plaque assay  
MDCK cells were plated in a 12-well plate and grown to 90% 
confluence before infection. Virus was serially diluted 10-fold in duplicate and 
allowed to bind MDCK cells for 1 hour at 37°C. The inoculum was removed 
and Avicel (RMC BioPolymer Corp) (Matrosovich et al., 2006) in overlay 
media with final concentrations of 1x MEM, 0.21% BSA V, 1mM L-Glutimate, 
0.15% Sodium Bicarbonate, 10mM Hepes, 1x Penicillin/Streptomycin (all Life 
Technologies) and 0.01% Dextran DEAE (Sigma) plus 1.4ug/ml TPCK 
Trypsin (Lorne Laboratories) was added on top of the cells. Cells were then 
incubated for three days at 37°C to allow plaque formation 
7.2.2.3.5 TCID50  
MDCK cells were plated in 100ul per well of a 96-well tissue culture 
dish in cell culture media a day prior to use, so that they were 70% confluent. 
Cells were washed twice with PBS and once with serum free DMEM. Serum 
free DMEM (100ul) was added to all but the first column of wells. 146ul of 
neat virus was added to wells in the first column of cells in quadruplicate then 
diluted in half-Log10 serial dilutions down 12 columns of a 96-well plate by 
transferring 46 ul of media containing virus into each well with 100 ul serum 
free DMEM. Virus was allowed to bind for 1 hour during incubation at 37°C. 
Inoculation media was removed and 150ul fresh serum-free DMEM with 
pen/strep and a pre-determined amount of trypsin (~1ug/ml; Lorne Labs) was 
added. Cells were incubated at 37°C for 4 days, when cytopathic effect 
became clear. Media was removed and cells stained with crystal violet. Log 
TCID50 was calculated using the Spearman-Karber formula below (OIE, 
2007)8.  
                                            
8 An alternative method of calculating the TCID50 is the Reed and 
Muench method (Reed and Muench, 1938). 
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Log TCID50 = Xp1 + (r/n)*d - 0.5*d  
Xp1 = The dilution where the proportion of CPE positive wells to 
number of wells per dilution is one (i.e. the highest dilution with CPE in 
all wells, eg. 4.5) 
d = Log10(dilution factor) (e.g. 0.5 for half-log dilutions, where the 
dilution factor is 0.316; 1 for 10-fold dilutions, where dilution factor is 
0.1)  
r = The sum of the number of wells that have CPE, starting with and 
including the Xp1 column, then wells from other dilutions with less CPE 
until there is no CPE left in any wells at a particular dilution 
n = number of wells per dilution 
7.2.2.3.6 Microneutralisation assay 
Sera were heat inactivated for 30 min at 56°C. MN assay was 
performed on MDCK cells that were plated in 96-well tissue culture plates 
(Greiner) and challenged in triplicate, by incubating overnight (37°C, 5% CO2) 
with 5x104 pfu/well of virus in the presence of 2-fold dilutions of sera from 1/10 
to 1/1,280 in viral diluent (DMEM (Gibco) plus 10mM penicillin/streptomycin 
(Invitrogen) plus 0.35% BSA V (Invitrogen). Cells were fixed and stained as 
described above. Ferrets were considered seronegative if all three wells with 
1/10 diluted serum were positive for infected cells. A ferret was considered 
seropositive when no infected cells were found in the any of the three wells 
with serum diluted 1/20 or further, indicating that seroreactivity had increased 
from MN<10 to MN≥20.  
7.2.2.3.7 Viral growth and spread in MDCKs  
For both multistep growth curves and viral spread, MDCK cells at 70% 
confluence in 12-well plates were inoculated in triplicate with each reported 
virus at a multiplicity of infection (MOI) of 0.01. After 1 hour of incubation with 
100 ul of inoculum, cells were washed with acidic (pH 5) PBS and then 
cultured for 12, 24 or 48 hours in 1ml of DMEM (Life Technologies) with 10% 
FBS (Biosera) 1ug/ml Trypsin (Lorne Labs) and 0, 1, 10 or 100mU/ml 
Neuraminidase from Clostridium perfringens (Sigma-Aldrich). Supernatant 
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with virus was collected at each time point, frozen for plaque titration and 
replaced with fresh media. 
7.2.2.3.8 Infection of HAEs, HNEs, and FAEs; viral growth and viral 
aggregation 
For growth curves in HAE cells, accumulated mucus was washed from 
the apical surface by twice adding 200 ul DMEM and incubating for 30 
minutes before removal. After mucus removal, triplicate wells of cells were 
inoculated with each virus at an MOI of 0.01 in 100ul and incubated for one 
hour. Cells were washed twice before re-incubation at 32°C. Samples were 
collected at pre-determined time points in 300ul DMEM (without FBS or 
antibiotics), after incubation for 30 minutes. All samples were stored at -80°C 
with 0.35% BSA V (Life Technologies) until titration. 
To visualize virion aggregation, HNE cells were infected, in triplicate, at 
an MOI of 20 of either SStyNA or LStyNA virus, while three negative control 
wells were left uninfected. Twenty-four hours post infection released virions 
were harvested from the apical surface of the cells by incubation with 50 ul 
DMEM (Life Technologies) for 15 minutes.   
7.2.2.4 Detection 
7.2.2.4.1 Detection of cell spread 
MDCK cells were fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences) in 250mM Hepes (Life Technologies) and deionized 
water. Cells were permeabilised for 20 minutes at room temperature with 
0.2% Saponin (Calbiochem, 558255) in PBS and 1% BSA (Sigma), then 
probed with a mouse anti-nucleoprotein (NP) antibody (1:300; HPA) for one 
hour in the same buffer. Cells were washed three times, nuclei were detected 
using DAPI (4’,6-Diamidino-2-phenylindole dihydrochloride) (Sigma) and 
immunoreactivity was detected after probing with a secondary anti-mouse Ig 
antibody conjugated to fluorescein isothiocyanate (FITC) (1:1000; AbD 
Serotec) for one hour.  
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7.2.2.4.2 Detection of Flag-tag and CRBCs 
For the haemadsorption assay NA expressing cells were differentiated 
from non-expressing cells by immunofluorescence as was the presence of 
bound chicken red blood cells (CRBCs). Cells were washed with cold PBS 
three times then fixed on ice with 4% paraformaldehyde (Electron Microscopy 
Sciences) diluted in Hepes (250mM; Life Technologies). Fixed cells were 
probed for 1 hour at room temperature in PBS/BSA/Azide with a murine anti-
FLAG monoclonal antibody (1:500; Sigma), which was previously diluted 1:1 
with glycerol (Fisher Scientific). Cells were washed 3 times with PBS. Then 
probed for another hour in the same buffer with a goat anti-murine IgG1 
antibody conjugated to FITC (1:1000; AbD Serotec) and DAPI (1:1000; 
Sigma), which bound to the nuclei of Vero cells and CRBCs.   
7.2.2.4.3 Detection of virus antigen positive cells 
Cells from plaque assay were fixed with 50:50 Methanol:Acetone (both 
VWR) for 10 minutes, washed and stained with primary antibody raised 
against influenza NP (1:300; clone H7 MAB 2F6-C9, HPA) in PBS BSA Azide 
for 1 hour. Wells were washed and probed with secondary antibody: goat anti-
murine polyclonal IgG:BGAL (1:1000; AbD Serotec). Blue stain was 
developed by adding 1X cyanide buffer and X-gal substrate (Fisher) dissolved 
in DMF (Sigma-Aldrich).  
7.2.2.4.4 Detection of plaques by crystal violet stain  
Cells from plaque assay or TCID50 were fixed with 50:50 
Methanol:Acetone and stained for 10 minutes with crystal violet (Sigma-
Aldrich, working concentration 5% v/v) diluted in Ethanol (6.7% v/v) and water 
then washed with running water and allowed to air dry overnight. 
7.2.2.4.5 Phase, brightfield and fluorescent microscopy 
Phase, brightfield and fluorescent images were captured en face using 
an Axiovert 40 inverted microscope with appropriate filters for FITC and DAPI 
with an AxioCam MRc Cooled Microscope digital camera (Zeiss Ltd.). 
Objectives of 10x, 40x and 60x were used.  
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7.2.2.4.6 Electron Microscopy 
 Electron microscopy was performed using standard methods as 
described previously (Hollinshead et al., 1999). In brief, virions from a 5 ul 
drop of apically exposed DMEM were adhered to a freshly glow discharged 
400 mesh hexagonal grid coated with a formvar film, washed in water then 
negatively stained for two minutes with uranyl acetate buffer. The uranyl 
acetate buffer had 1% uranyl acetate dihydrate (UO2(OCOCH3)2!2H2O; MW 
424.15; TAAB laboratories, U008) in water, pH 4.5 (Mollenhauer, 1974; Olson 
and Linck, 1977). The depleted uranium had activity less than 0.078 
gigabecquerels.  
Virions were identified by the presence of an array of spike proteins on 
spherical or filamentous shaped objects. Virus particles were counted as 
either aggregated (when clearly touching another virus particle) or in singlet 
(when a particle was not touching any other virus particles). Virus particles in 
over 10 fields of view at 11,500x magnification were counted per well, viewed 
using an FEI Tecnai G2 electron microscope (FEI) with a Soft Imaging 
System Megaview III charge-coupled device camera. Images were collected 
at 120,000x magnification, using ANALYSIS version DOCU software and 
Olympus SI Viewer (both Olympus Soft Imaging Solutions) and prepared for 
publication using Graphic Converter X (Lemkesoft, v6.7.7). 
7.2.2.5 NA assays 
7.2.2.5.1 Haemadsorption assay 
 NA expressing Vero cells were placed on ice and washed twice with 
PBS. Haemadsorption was performed by probing the cells with 1% CRBCs in 
1ml PBS.  After three hours of incubation with CRBCs at 4°C, cells were 
washed 3x with PBS and fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences) and stained. The ability of different exogenously 
expressed NAs to bind RBCs was observed microscopically (Harvey et al., 
2004; Uhlendorff et al., 2009) or by absorbance.  
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7.2.2.5.2 Absorbance  
After haemadsorption cells were lysed and absorbance due to 
haemaglobin content was measured. One millilitre of Reporter Lysis Buffer 
(Promega) diluted to 1x in water was added to each well and incubated for 
three minutes. Vero cell lysates were scraped from the bottom of the wells 
using a cell scrapper and then pipetted into 1.5ml microtubes. Lysates were 
centrifuged at 13,000 rpm for five minutes and each supernatant was 
transferred to a cuvette.  Absorbance of supernatants were measured at the 
wavelength of 540nm on a Genesys 10 UV Scanning spectrophometer 
(Thermo Scientific) 
7.2.2.5.3 MuNANA assay  
NA enzyme activity was measured using the small soluble substrate 2’-
(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA, Sigma) as 
previously described (WHO Global Influenza Surveillance Network, 2011). 
Viruses were first diluted in the presence of a standard amount of substrate in 
order to determine a viral dilution that would yield approximately equal 
amounts of product per reaction over one hour. To assay the reaction rate the 
substrate was serially diluted in triplicate two-fold in MES (Sigma) assay 
buffer over seven wells, so that the most concentrated well had 50ul of 150uM 
MUNANA and the eighth well only had buffer, used as a baseline. Equivalent 
volumes of diluted virus were added to each well.  The assay was performed 
in black, flat bottom, 96-well Matrix Microplates (Thermo). A test was deemed 
successful if the R2 value was >0.9.  A Fluostar Omega (BMG Labtech) was 
used to measure ultraviolet fluorescence emission every 4 minutes, for 60 
minutes, with a 355 nm excitation filter and 460 nm emission filter. Omega 
MARS software (BMG Labtech) was used to calculate the Km and Vmax of 
each virus using the Michaelis-Menton equation. Three different preparations 
of each virus were tested in three different experimental runs to determine the 
mean values and standard deviations. Statistical significance was determined 
using t-test followed by Bonferroni correction for multiple measurements 
 311 
7.2.2.5.4 Erythrocyte elution assay 
The speed with which NAs could elute virus from RBCs was gauged as 
previously described (Castrucci and Kawaoka, 1993; Zhou et al., 2009). First, 
haemagglutinin (HA) titration was performed on each virus, then each was 
diluted to 64 HA units and HA assay repeated. Plates were then incubated at 
37°C and the reduction in HA titres was recorded every 20 minutes. The 
percentage of HA titre remaining at each time point compared to the start is 
plotted. Data shown is representative of three experiments. 
7.2.2.5.5 Inhibition of virus growth by oseltamivir or mucus 
To measure the effect of mucus on viral infectivity, mucus was 
collected from the surface of HNEs and stored at 4°C. Virus was incubated at 
4°C for one hour with oseltamivir (31uM), mucus (diluted 70-fold in virus 
diluent (PBS+0.35% BSA V; Life Technologies)), both, or virus diluent without 
mucus. The cool incubation temperature was used to allow viral HA to bind 
terminally sialated glycans, while preventing viral NA from cleaving them. The 
mix of virus with or without mucus was then added to MDCK cells and 
incubated for the indicated amount of time at 32°C. At the end of the 
incubation, cells were thoroughly washed with PBS and plaques were 
developed. Mucus inhibition of viral infectivity was performed in triplicate and 
normalized to virus infectivity in the absence of mucus. The triplicate 
experiment was repeated on separate dates and the data was aggregated.  
 
7.2.2.6 Ferret Transmission 
Animal studies were performed as described previously (Roberts et al., 
2011; van Doremalen et al., 2011). Female ferrets (20-24 weeks old) weighing 
650-1100g were obtained from a designated supplier. After acclimatization, 
sera were obtained and tested by microneutralisation (MN) assay against the 
7+1 viruses used in the study, all of which had the HA of A/Eng/195/2009, the 
predominant circulating human influenza virus at the time of experimentation. 
All ferrets were negative for pH1N1 2009 influenza antibodies at the start of 
the experiments (MN<10).  
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In each experiment, four donor ferrets were inoculated intranasally, 
under light aneasthesia using ketamine (22 mg/kg) and xylazine (0.9 mg/kg), 
with 1x106 plaque forming units (pfu) virus in 200 ul, on day zero. Twenty-four 
hours after inoculation, one direct contact (DC) ferret was co-housed with 
each donor and one respiratory droplet (RD) exposed ferret was housed in a 
cage adjacent to each donor cage, separated by two dividers, 10 cm apart 
with holes 3 mm in diameter. All animals were weighed and nasal washed 
daily either until four consecutive days of no virus shedding or for 15 days in 
total after the first exposure day, by which time no virus was detected. Nasal 
wash was plaqued on the same day of collection in MDCK cells as described 
above. The limit of viral detection was 10 pfu/ml of nasal wash. Strict 
protocols were followed to prevent cross-contamination between animals 
during all procedures, as previously described (Roberts et al., 2011). Terminal 
blood samples, collected 21 days post exposure, were tested for 
seroconversion by MN assay using the respective challenge virus for each 
experiment.  
 
7.2.3 Mathematical analysis 
7.2.3.1 Bioinformatics and Phylogenetics  
Full length coding of HA and NA H5N1 nucleotide sequences from any 
host, location and year were downloaded from the NCBI influenza virus 
resource database (Bao et al., 2008).  Duplicate isolates, isolates from 
environmental samples, unknown avian (and blowfly) samples, and poor 
quality isolates (multiple ambiguities) were removed, leaving a total of 1150 
matched HA and NA sequences. Alignments were performed in MUSCLE in 
MEGA 5.05 (Tamura et al., 2011), with manual adjustments. After alignment 
the sequence data was processed in R utilizing packages ape and seqinr.  
Phylogenetic trees were estimated using RAxML (Stamatakis, 2006) with 
GTR+Γ substitution model (general time reversible plus discretized γ-
distribution of rates over sites) and 100 bootstraps. Trees were displayed and 
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coloured according to pathogenicity and stalk length annotations using 
FigTree (Rambaut, n.d.). 
7.2.3.2 Statistical analysis  
All statistical analyses were performed using Prism 6 software (Graph 
Pad). Viral titres from growth curves were normalised by taking the log10 of 
each measurement then comparisons were made using a Repeated 
Measures Two-way analysis of variance (ANOVA) with Tukey’s multiple 
comparisons test. The data was considered as one family and each of the 
three viral titres were compared at each time point for a total of twelve 
comparisons. Samples collected from the same well were considered 
matched.  AUC comparisons from NW titres were also made on log10-
normalised values using a Repeated Measures Two-way ANOVA recognising 
that virus shed from ferrets of the same group were matched. All AUC values 
were considered as one family and three comparisons were made between 
SStyNA and LStyNA, one for each exposure route: inoculation; DC; RD. 
Bonferroni’s multiple comparisons test was used to determine p-values for 
each comparison. Comparisons for first day and total days of virus shed were 
also made using the method used for AUC comparisons, except for the first 
day of shedding where a comparison for RD ferrets could not be made. 
Comparisons between Km, Vmax, and viral input into MUNANA assay as well 
as mucus inhibition of infectivity were made by One-way ANOVA with Tukey’s 
multiple comparisons test. Statistical comparison of virion aggregation was 
made using an unpaired t-test assuming equal standard deviation. 
 
7.2.4 Ethics, Safety and Biosecurity 
All work performed at biosafety level II and was approved by the local 
GM safety committee of Imperial College London, St. Mary’s Campus (Centre 
number GM77) and the Health and Safety Executive of the UK. All animal 
research described in this study was carried out under a UK Home Office 
License, PPL/70/6643.  Human nasal airway epithelial cells were obtained 
from patients undergoing surgical nasal polypectomy and turned into cell 
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cultures (HNEs) by Epithelix Sarl following the guidelines set out in the 
Declaration of Helsinki on biomedical research (Hong Kong amendment, 
1989). Epithelix also follow ethical guidelines in accordance with French 
Biobanks, which are governed by a ‘non-property’ principle and require 
approval by a local ethics committee at each collection centre, plus written 
informed consent from each donor and maintenance of data confidentiality.  
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8 Appendix 
8.1 Amino Acids 
 
Table 8.1. Amino acids. The names, three and one letter codes and chemical make-
up of backbone and side chains for the twenty amino acids. 
!
Gly!/!G! Ala!/A! Val!/!V!
Leu!/!L! Met!/!M! Ile!/!I!
Phe!/!F! Tyr!/!Y! Trp!/!W!
Ser!/!S! Thr!/!T! Cys!/!C!
Pro!/!P! Asn!/!N! Gln!/!Q!
Lys!/!K! Arg!/!R!
His!/!H!
Asp!/!D!
Glu!/!E!
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8.2 Acronyms and Abbreviations 
Acronym or Abbreviation Long Form 
- negative 
+ plus or positive 
3'-SLNLN Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc 
3PNP  PB1, PB2, PA, & NP 
6'-SLNLN Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAc 
A Adenine base of DNA or RNA 
A2M a2-macroglobulin 
A549 See Materials and Methods (Table 7.7) 
Aas Amino acids 
Akt Protein Kinase B 
ANOVA analysis of variance  
ATD50 aerosol transmissible dose 50 
ATF-2  Activating transcription factor-2 
AUC Area Under Curve  
BAL bronchoalveolar lavage 
BCE Before the Common Era 
Bp Base pairs 
BrevM18 A/Brevig Mission/1/1918  (H1N1) 
BSA Bovine Serum Albumin 
C Cytosine base of DNA or RNA 
c-Jun part of a transcription factor 
C1q Complement component 1q 
C3 Complement component 3 
CA/04/09 or CA04 A/California/04/2009 (H1N1) 
Camb05 A/Cambodia/JP52a/2005 (H5N1) 
Cav-1 caveolin-1 
CBC Cap binding complex protein 
CD8, CD59, CD63, and 
CD133 Cluster of Differentiation Antigen # 
CDS Coding sequence (the sequence that encodes aas) 
CE Common Era 
CEF chicken embryo fibroblast 
CF cystic fibrosis 
CFR case fatality ratio 
CHO Chinese hamster ovary cells 
CIs Confidence Intervals 
ck/Jilin04 A/chicken/Jilin/hl/2004 (H7N1) 
ckIt99 A/chicken/Italy/14384/1999 (H7N1)  
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CL Chicken Lectin 
COS a fibroblast cell line from monkey kidney 
CPE Cytopathic effect 
CPSF30 Cleavage and polyadenylation specificity factor 30 
CPSF6 Cleavage and polyadenylation specificity factor 6 
CRAC cholesterol recognition amino acid consensus  
CRD carbohydrate recognition domain 
CRM1 chromosome region maintenance 1; exportin 1; Xpo1; part of importin-beta family  
cRNA RNA complementary to vRNA 
CRP Complement reactive protein 
CRS chronic rhinosinusitis 
CTD c-terminal domain  
DAPI 4',6-diamidino-2-phenylindole  
DC Direct contact 
dkBav77 A/duck/Bavaria/1/77 (H1N1) 
DMEM Dulbecco's Modified Eagle's Medium 
Dsh disheveled protein 
dsRNA double stranded RNA  
E195 or E195/09 A/England/195/2009 (H1N1) 
E3 Enzyme 3 
E687/10 A/England/687/2010 (H1N1) 
EA Eurasian 
eIF4E Elongation Initiation Factor 4E  
EJC exon junction complex 
ELISA  enzyme-linked immunosorbent assay 
EM Electron microscopy 
ER Endoplasmic reticulum 
Fc fragment crystallizable, or tail region of an antibody 
FG phenylalanine-glycine 
FITC Fluorescein isothiocyanate 
FLAG-tag N'-DYKDDDDK-C' 
FNT ferret nasal turbinates p46 
foRos34 A/FPV/Rostock/1934 (H7N1) 
FoV Field of View p88 
FTE ferret tracheal epithelial cells p46 
FU Fluorescent Units 
G guanine base of DNA or RNA 
Gal Galactose 
Gansu07 A/Gansu/Chenguan/1129/2007 
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GFP Green fluorescent protein 
Glc Glucose 
GlcNAc N-Acetyl-D-glucosamine 
GPI glycosylphosphatidylinositol 
GsGd96 A/Goose/Guangdong/1/96 (H5N1) 
GTP Guanosine triphosphate 
HA haemagglutinin 
HAE Human ariway epithelial cells 
Hd Haemadsorption 
HK213/03 A/Hong Kong/213/03 (H5N1) 
HNE Human nasal epithelial cells 
HPAI highly pathogenic avian influenza 
Hpi hours post infection 
HTBEs human treacheobronchial epithelial cells 
ID50 Infectious dose 50 
IFNa Interferon alpha 
IRF-3 Interferon regulatory factor-3 
ISA Infectious salmon anaemia 
Km Michaelis–Menten substrate concentration at which the reaction rate is half of Vmax 
LacNAcs N-Acetyl-D-Lactosamine 
LPAI Low pathogenic avian influenza 
LRT lower respiratory tract 
LS Long stalk 
LSTa 
N-Acetylneuraminyllacto-N-tetraose a; 
Sialyllacto-N-tetraose a; a-NeuNAc-(2-3)-b-
Gal-(1-3)-b-GlcNAc-(1-3]-b-Gal-(1-4)-Glc 
LSTb 
N-Acetylneuramin-lacto-N-tetraose b;  α-
NeuNAc-(2→6)-(β-D-Gal-[1→3])-β-D-
GlcNAc-(1→3)-β-D-Gal-(1→4)-Glc 
LSTc 
N-Acetylneuraminyl-lacto-N-neo-tetraose c; 
α-Neu5Ac-(2→6)-β-Gal-(1→4)-β-GlcNAc-
(1→3)-β-Gal-(1→4)-Glc 
M1 Matrix protein 1 
M2 Matrix protien 2  
MAA Lectin from Maackia amurensis 
MAC membrane attack complex 
MAGI-1 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 
Man Mannose 
MAPK Mitogen-activated protein kinases  
MBCS multibasic cleavage site 
MBL Mannose binding lectin 
MDCK cells Madin Darby Canine Kidney cells, see Materials and Methods (Table 7.7) 
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MES 2-ethanesulfonic acid 
MID50 minimum infectious dose 50   
miRNA microRNA 
MN Microneutralisation 
MOI Muliplicity of infection 
MRCA Most recent common ancestor 
mRNA messanger RNA 
mu Mutant 
MUC1, MUC4, MUC16, etc. Mucin protein-1, 4, 16, etc. 
MUNANA 2'-(4-Methylumbelliferyl)-alpha-D-N-acetylneuraminic acid 
MxA myxovirus resistance protein A 
mya million years ago 
NA Neuraminidase 
NA neuraminidase 
Ncrs Non coding regions 
ND Not done 
NEB New England BioLabs 
NeuAc N-Acetylneuraminic acid 
NFkb nuclear factor kappa-light-chain-enhancer of activated B cells 
NK Natural killer cells 
NL602 A/Netherlands/602/2009 (pH1N1) 
NLS Nuclear localization signal 
NMR Nuclear magnetic resonance spectroscopy 
NP Nucleoprotein 
NPC nuclear pore complex  
NPS nose or pharyngeal sample 
nt(s) Nucleotide(s) 
Nups Nucleoporins 
NW Nasal Wash 
NXF1 Nuclear eXport Factor 1  
NY New York 
OAS oligoadenylate synthetase  
Oh07 A/Ohio/1/07 (H1N1) 
osIt00 A/ostrich/Italy/984/00 (H7N1) 
P-bodies cellular processing bodies 
PA Polyacidic protein 
PABII or PABPII or PABP2 poly(A)-binding protein II  
PAMPs pathogen associated molecular patterns 
Pan99 A/Panama/2007/1999 (H3N2) 
PB1 polymerase basic protein 1 
PB1-F2 polymerase basic protein 1 - frame 2 
PB2 polymerase basic protein 2 
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PBS Phosphate buffered saline 
pCAGGS An expression vector, See table 7.1 
PCD primary ciliary dyskinesia 
PCR Polymerase Chain Reaction  
PD1 Protectin 1 
PDM PDZ-domain binding motif 
PDZ  a binding domain 
Pfu Plaque forming units  
pH1N1, pH2N2, pH3N2 pandemic H1N1, H2N2, or H3N2 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKR protein kinase receptor  
Pol II RNA polymerase II 
polyA poly-adenine 
PR8 A/Puerto Rico/8/1934 (H1N1) 
PRMs pattern recognition molecules 
PRRs pattern recognition receptors 
PSD-95 postsynaptic density protein 95  
PTX3 Pentraxin 3 
R15+ A/RI/5+/57  (H2N2) 
Rab GTPase proteins that regulate membrane traffic 
RAP55 RNA-associated protein 55 
RBCs Red Blood Cells  
RD respiratory droplet 
RdRp RNA dependent RNA polymerase 
RG Reverse genetics 
RH Relative humidity 
RIG-I Retinoic acid inducible gene I  
RNA ribonucleic acid 
Ro Rate of transmission 
RSV respiratory syncial virus 
S Serine 
SA Sialic Acid 
SAGs sialyated glycans 
SAP Serum amyloid P protein 
SF2/ASF a human splicing factor 
SFPQ/PSF  a human splicing factor 
Sing57 A/Singapore/1/1957 (H2N2) 
SLBP Stem-Loop Binding Protein 
SNA Sambucus Nigra Lectin 
SP-D surfactant protein D  
SR serine/arginine-rich 
SS Short stalk 
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SSckIt99 Short stalk ckIt99 
STD saturation-transfer difference 
SUMO small ubiquitin-like modifier 
swEng06 A/swine/England/453/2006 (H1N1) 
swIt76 A/swine/Italy/437/76 (H1N1) 
T thymine base of DNA 
Tat-SF1 HIV-trans-activating protein-specific factor 1 
TCID50 Tissue culture infectious dose 50% 
ternAus75 A/tern/Austrailia/G70c/75 (H1N9) 
TGFb Transforming growth factor beta 
TLR Toll-like receptor 
Tok67 A/Tokyo/3/67 (H2N2) 
TREX TRanscription EXport complexes  
TRIG triple reassortant internal genome 
TRIM Tripartite motif family of proteins 
Tsg101 Tumor susceptibility gene 101 
Tx91 A/Texas/36/1991 (H1N1) 
Tx91  A/Texas/36/91 (H1N1) 
tyTy05 A/turkey/Turkey/1/2005 (H5N1) 
U uracil base of RNA 
UAP56 U2AF65 Associated Protein 56 kDa 
Ud72 A/Udorn/72 (H3N2) 
UIF UAP56-interacting factor 
uM Mircromolar p64 and before 
URT Upper respiratory tract 
UTR untranslated region 
Vic NA A/Victoria/3/1975 (H3N2) 
VLPs virus like particles  
Vmax Michaelis–Menten maximum velocity of an enzyme 
VN1203/04 A/Vietnam/1203/2004 (H5N1) 
vPol viral polymerase 
vRNP viral ribonucleoprotein 
WHO World Health Organisation 
WSN Wilson Smith's Nose 
WSN33 A/WSN/33 (H1N1) 
wt wild type  
X31 HA and NA of A/Aichi/2/1968 (pH3N2) + 6 PR8 internal genes 
Table 8.2. Table of acronyms and abbreviations. 
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